Introducing PHARMAC

Alimentary Tract & Metabolism 25

September 2009

Volume 16 Number 2

Editors

Kaye Wilson & Scott Brydon email: schedule@pharmac.govt.nz Telephone +64 4 460 4990 Facsimile +64 4 460 4995 Level 9, Cigna House 40 Mercer Street PO Box 10 254 Wellington

Freephone Information Line 0800 66 00 50 (9am - 5pm weekdays)

Circulation

Published each April, August and December. Changes to the contents are published in monthly updates. Annual subscription includes three Pharmaceutical Schedule books, 12 updates and occasional information on rule changes and news items. The Schedule is distributed free of charge to over 9,000 health professionals, and is also available on an annual subscription.

Prices

\$22.22 One Schedule book \$4.44 One Update \$120.00 Annual subscription

All prices include postage and exclude GST.

Production

Typeset automatically from XML and TEX. Source XML suitable for database import available on request.

Programmers

Peter Ericson & John Geering email: texschedule@pharmac.govt.nz

http://www.pharmac.govt.nz

ISSN 1172 - 9376

Copyright (c) 1994 Pharmaceutical Management Agency. No part may be reproduced in any form or by any process without written permission, nor be used in any form of advertising, sales, promotion or publicity. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising therefrom.


Section A

General Rules 12

2

Section B

Blood & Blood Forming Organs 39 Cardiovascular System 48 Dermatologicals 58 Genito Urinary System 69 Hormone Preparations – Systemic 75 Infections – Agents For Systemic Use 83 Musculoskeletal System 99 Nervous System 108 Oncology Agents & Immunosuppressants 133 Respiratory System & Allergies 147 Sensory Organs 154 Various 159



Introducing PHARMAC

PHARMAC, the Pharmaceutical Management Agency, is a Crown entity established pursuant to the New Zealand Public Health and Disability Act 2000 (The Act). The primary objective of PHARMAC is to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided.

The PHARMAC Board consists of up to six members appointed by the Minister of Health. All decisions relating to PHARMAC's operation are made by or under the authority of the Board. In particular, Board members decide on the strategic direction of PHARMAC and may decide which community pharmaceuticals should be subsidised and at what levels, and determine national prices for some pharmaceuticals to be purchased by and used in DHB Hospitals, and whether or not special conditions are to be applied to such purchases.

Members of the PHARMAC Board

Richard Waddel Kura Denness David Kerr David Moore Adrienne von Tunzelmann Decisions taken by the PHARMAC Board members, or made under the authority of the Board, incorporate a balanced view of the needs of prescribers and patients. The aim is to achieve long-term gains and efficient ways of making pharmaceuticals available to the community and for DHB Hospitals to purchase them.

Murray Georgel, CE MidCentral DHB, attends PHARMAC's Board meetings as an observer.

The functions of PHARMAC are to perform the following, within the amount of funding provided to it in the Pharmaceutical Budget or to DHBs from their own budgets for the use of pharmaceuticals in their hospitals, as applicable, and in accordance with its annual plan and any directions given by the Minister (Section 103 of the Crown Entities Act):

- a) to maintain and manage a pharmaceutical schedule that applies consistently throughout New Zealand, including determining eligibility and criteria for the provision of subsidies;
- b) to manage incidental matters arising out of (a), including in exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the pharmaceutical schedule;
- c) to engage as it sees fit, but within its operational budget, in research to meet its objectives as set out in Section 47(a) of the Act;
- d) to promote the responsible use of pharmaceuticals;
- e) to manage the purchasing of any or all pharmaceuticals, whether used either in a hospital or outside it, on behalf of DHBs;
- f) any other functions given to PHARMAC by or under any enactment or authorised by the Minister.

The policies and criteria set out in the Pharmaceutical Schedule and PHARMAC's Operating Policies and Procedures arise out of, and are designed to help PHARMAC achieve and perform, PHARMAC's objective and functions under the Act.

However PHARMAC may, having regard to its public law obligations, depart from the strict application of those policies and criteria in certain exceptional cases where it considers this necessary or appropriate in the proper exercise of its statutory discretion and to give effect to its objective and functions, particularly with respect to:

- Determining eligibility and criteria for the provision of subsidies; and
- In exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the Pharmaceutical Schedule.

Decision Criteria

PHARMAC updates the Pharmaceutical Schedule at regular intervals to notify prescribers, pharmacists, hospital managers and patients of changes to Community Pharmaceutical subsidies and the prices for Hospital Pharmaceuticals. In making decisions about amendments to the Pharmaceutical Schedule, PHARMAC is guided by its Operating Policies and Procedures, as amended or supplemented from time to time. PHARMAC takes into account the following criteria when making decisions about Community Pharmaceuticals:

- the health needs of all eligible people within New Zealand (eligible defined by the Government's then current rules of eligibility);
- the particular health needs of Māori and Pacific peoples;
- the availability and suitability of existing medicines, therapeutic medical devices and related products and related things;
- the clinical benefits and risks of pharmaceuticals;
- the cost-effectiveness of meeting health needs by funding pharmaceuticals rather than using other publicly funded health and disability support services;
- the budgetary impact (in terms of the pharmaceutical budget and the Government's overall health budget) of any changes to the Pharmaceutical Schedule;
- the direct cost to health service users;
- the Government's priorities for health funding, as set out in any objectives notified by the Crown to PHARMAC, or in PHARMAC's Funding Agreement, or elsewhere; and
- such other criteria as PHARMAC thinks fit. PHARMAC will carry out appropriate consultation when it intends to take any such "other criteria" into account.

The Operating Policies and Procedures, including any supplements, also describe the way in which PHARMAC determines the level of subsidy or purchase price payable for each Community Pharmaceutical or Hospital Pharmaceutical, respectively.

The decision criteria for Hospital Pharmaceuticals are set out in the hospital supplement to the Operating Policies and Procedures and in the introductory part of Section H of the Pharmaceutical Schedule.

Copies of PHARMAC's Operating Policies and Procedures and of any applicable supplements are available on the PHARMAC website (www.pharmac.govt.nz), or on request.

PHARMAC and the Pharmaceutical Schedule:

PHARMAC manages the national Pharmaceutical Schedule, which lists:

- Pharmaceuticals available in the community and subsidised by the Government with funding from the Pharmaceutical Budget; and
- some Pharmaceuticals purchased by DHBs for use in their hospitals, and includes those Hospital Pharmaceuticals for which national prices have been negotiated by PHARMAC.

In the community approximately 1848 Pharmaceuticals are subsidised by the Government. Most are available to all eligible people within New Zealand on prescription by a medical doctor. Some are listed with guidelines or conditions such as 'only if prescribed for a dialysis patient' or 'Special Authority - Retail Pharmacy', to ensure that Pharmaceuticals are used by those people who are most likely to benefit from them. Pharmaceuticals provided to patients for use while in DHB hospitals are not covered by Sections A to G of the Pharmaceutical Schedule.

Section H of the Pharmaceutical Schedule is not a comprehensive list of Pharmaceuticals that are used within the DHB Hospitals. Section H of the Pharmaceutical Schedule includes Pharmaceuticals that can be purchased at a national price by DHBs for use in their hospitals. These are referred to as National Contract Pharmaceuticals.

Section H of the Pharmaceutical Schedule also identifies new Pharmaceuticals used in hospitals, which have been or are being assessed by PHARMAC, the results of that analysis being available to DHB Hospitals via PHARMAC's website.

A list of Discretionary Community Supply Pharmaceuticals, in Section H of the Pharmaceutical Schedule, identifies those products that currently are not subsidised from the Pharmaceutical Budget as Community Pharmaceuticals in Sections A to G of the Pharmaceutical Schedule but which DHBs can at their discretion fund for use in the community from their own budgets without specific Hospital Exceptional Circumstances approval.

PHARMAC's clinical advisors

Pharmacology and Therapeutics Advisory Committee (PTAC)

PHARMAC works closely with the Pharmacology and Therapeutics Advisory Committee (PTAC), an expert medical committee which provides independent advice to PHARMAC on health needs and the clinical benefits of particular pharmaceuticals for use in the community and/or in DHB Hospitals.

The committee members are all senior, practising clinicians. The chair of PTAC sits with the PHARMAC Board in an advisory capacity.

PTAC helps decide which community pharmaceuticals are to be subsidised from public monies by making recommendations to PHARMAC. Part of the role of PTAC is to review whether Community Pharmaceuticals already listed on the Schedule should continue to receive Government funds. The resources freed up can be used to subsidise other community pharmaceuticals with a greater therapeutic worth.

PHARMAC may obtain clinical advice from PTAC in relation to national purchasing strategies for Hospital Pharmaceuticals. There may be additional specialist hospital representatives on PTAC subcommittees, or additional PTAC subcommittees, where PHARMAC considers this necessary.

PTAC members are:

Carl Burgess Ian Hosford Sisira Jayathissa George Laking	MBChB, MD, MRCP (UK), FRACP, FRCP, physician/clinical pharmacologist, Chair MBChB, FRANZCP, psychiatrist MBBS, MD, MRCP, FAFPHM, FRCP, FRACP, physician PhD, MB, B.Med.Sci, MD, FRACP
Jim Lello	BHB, MBChB, DCH, FRNZCGP, general practitioner
Graham Mills	MBChB, MTropHlth, MD, FRACP, infectious disease specialist
Peter Pillans	MBBCh, MD, FCP, FRACP, clinical pharmacologist
Paul Tomlinson	MBChB, MD, MRCP, FRACP, BSc, paediatrician, Deputy Chair
Mark Weatherall	BA, MBChB, MApplStats, FRACP
Howard Wilson	BSc, PhD, MB, BS, Dip Obst, FRNZCGP, general practitioner

Contact PTAC C/-Advisory Committee Manager , Pharmaceutical Management Agency, PO Box 10 254, WELLINGTON, Email: PTAC@pharmac.govt.nz

The PHARMAC Team

The PHARMAC team has a wide range of expertise in health, medicine, economics, commerce, critical analysis, and policy development and implementation.

Matthew Brougham Kate Adams Paul Alexander Peter Alsop

Jason Arnold Diana Beswethrick Mike Bignall Stephen Boxall Scott Brydon Davina Carpenter Christine Chapman Yvonne Chen Mary Chesterfield

Steffan Crausaz

Andrew Davies

Rachelle Davies Jessica Dougherty

Sean Dougherty Anrik Drenth Kim Ellis

Simon England Andy Erceg

Jackie Evans John Geering Rachel Grocott

Susan Haniel David Harland Karen Jacobs Cherie Jacobson Richard Jaine Geoff Lawn Geraldine MacGibbon Janet Mackay Rachel Mackay

Contracts

Chief Executive Health Economist Health Economist Manager, Corporate and External Relations Senior Analyst HR Contractor Therapeutic Group Manager Creative Director Schedule Analyst **Records Manager** Contract Manager Tender Analyst High Cost Medicines Co-ordinator Manager, Funding and Procurement Procurement Initiatives Manager Senior Receptionist Funding and Procurement Assistant Therapeutic Group Manager Web Developer Access & Optimal Use Co-ordinator Communications Manager Senior Network and System Administrator Therapeutic Group Manager Systems Architect Health Economist / Team Leader Assessment Advisory Committee Manager Health Economist Access & Optimal Use Manager Corporate Assistant Public Health Registrar Applications Developer Therapeutic Group Manager Access & Optimal Use Manager Manager. Schedule and

Trish Mahoney Adam McRae

Scott Metcalfe

Peter Moodie Christina Newman

Deborah Nisbet Leigh Parish Marama Parore

Chris Peck Melanie Pemberton Fisher Sharon Ponniah

Matthew Poynton Rachel Pratt

Jan Quin Dilky Rasiah Kyle Reid

Brian Roulston Fiona Rutherford Rico Schoeler

Merryn Simmons

Liz Skelley Moana Tane Jayne Watkins

Greg Williams Lisa Williams Kaye Wilson Stephen Woodruffe Contract Manager Team Leader, Access & Optimal Use Chief Advisor Population Medicine / Public Health Physician Medical Director Executive Assistant to Chief Executive/Office Manager Receptionist PA to Medical Director Manager, Access & Optimal Use & Māori Health Analyst Communications Advisor Access and Optimal Use Manager Analyst/Health Economist Hospital Exceptional Circumstances Panel Co-ordinator Team Leader, Medical Team Deputy Medical Director High Cost Medicines Panel Co-ordinator / Growth Hormone Analyst Senior Policy Analyst Manager, Analysis and Assessment PHARMAC Seminar Series Co-ordinator Finance Manager Māori Health Manager Community Exceptional **Circumstances Panel** Co-ordinator Therapeutic Group Manager Legal Counsel Schedule Analyst Therapeutic Group Manager

Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price (if it differs from the Subsidy) and any access conditions that may apply; and
- some Hospital Pharmaceuticals that are purchased and used by DHB Hospitals, including those for which national prices have been negotiated by PHARMAC.

The purpose of the Schedule is not to show the final cost to Government of subsidising each Community Pharmaceutical or to DHBs in purchasing each Hospital Pharmaceutical since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for some Hospital Pharmaceuticals, on any logistics arrangements put in place by individual DHB Hospitals.

Finding Information in the Pharmaceutical Schedule

Community Pharmaceuticals

For Community Pharmaceuticals, the Schedule is organised in a way to help the reader find Community Pharmaceuticals, which may be used to treat similar conditions. To do this, Community Pharmaceuticals are first classified anatomically, originally based on the Anatomical Therapeutic Chemical (ATC) system, and then further classified under section headings structured for the New Zealand medical system.

- Section A lists the General Rules in relation to Community Pharmaceuticals and related products.
- Section **B** lists Community Pharmaceuticals and related products by anatomical classification, which are further divided into one or more therapeutic headings. Community Pharmaceuticals used to treat similar conditions are grouped together.
- Section C lists the rules in relation to Extemporaneously Compounded Products (ECPs) and Community Pharmaceuticals that will be subsidised when extemporaneously compounded.
- Section D lists the rules in relation to Special Foods and the Special Foods that are subsidised.
- Section E Part I lists the Community Pharmaceuticals that are subsidised on a Practitioner's Supply Order (PSO) and Wholesale Supply Order (WSO).
- Section E Part II lists rural areas for the purpose of PSOs.
- Section F lists the Community Pharmaceuticals dispensing period exemptions.
- Section G lists the Community Pharmaceuticals eligible for reimbursement of safety cap and related rules.

The listings are displayed alphabetically (where practical) within each level of the classification system. Each anatomical section contains a series of therapeutic headings, some of which may contain a further classification level. Where a Community Pharmaceutical is used in more than one therapeutic area, they may be cross-referenced.

The therapeutic headings in the Pharmaceutical Schedule do not necessarily correspond to the therapeutic groups and therapeutic subgroups, which PHARMAC establishes for the separate purpose of determining the level of subsidy to be paid for each Community Pharmaceutical.

The index located at the back of the book in which Sections A-G of the Pharmaceutical Schedule are published can be used to find page numbers for generic chemical entities, or product brand names.

Hospital Pharmaceuticals

Section H lists Pharmaceuticals that DHBs fund from their own budgets. The Hospital Pharmaceuticals are grouped into the following Parts in Section H:


- Part I lists the rules in relation to Hospital Pharmaceuticals.
- Part II lists Hospital Pharmaceuticals for which national contracts exist (National Contract Pharmaceuticals). These are
 listed alphabetically by generic chemical entity name and line item, the relevant Price negotiated by PHARMAC and, if
 applicable, an indication of whether it has Hospital Supply Status (HSS) and any associated Discretionary Variance (DV)
 Pharmaceuticals and DV Limit.
- Part III lists Assessed Pharmaceuticals, which have been or are being assessed by PHARMAC and, where such assessment
 is available, PHARMAC's opinion regarding the use of the Assessed Pharmaceuticals in hospitals. DHB Hospitals are not
 obliged to implement those recommendations.
- Part IV lists Discretionary Community Supply Pharmaceuticals, which are not Community Pharmaceuticals, but which a DHB Hospital can, in its discretion, fund for use in the community from its own budget.

The index located at the back of the Section H supplement can be used to find page numbers for generic chemical entities, or product brand names, for Hospital Pharmaceuticals.

Explaining drug entries

The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the amount of that subsidy paid to contractors, the supplier's price and the access conditions that may apply.

Example



Glossary

Units of Measure

gramg	microgramµg
kilogramkg	milligrammg
international unitiu	millilitreml

millimole	mmol
unit	u

Abbreviations

Ampoule	Amp	Granules	Gran	Suppository	Supp
Capsule	Сар	Infusion	Inf	Tablet	Tab
Cream	Crm	Injection	Inj	Tincture	Tinc
Device	Dev	Linctus	Linc	Trans Dermal Delivery	
Dispersible	Disp	Liquid	Liq	System	TDDS
Effervescent	Eff	Long Acting	LA		
Emulsion	Emul	Ointment	Oint		
Enteric Coated	EC	Sachet	Sach		
Gelatinous	Gel	Solution	Soln		

BSO Bulk Supply Order.

- CBS Cost Brand Source. There is no set manufacturer's price, and the Government subsidises the product at the price it is obtained by the pharmacy.
- CE Compounded Extemporaneously.
- CPD Cost Per Dose. The Funder (as defined in Part I of the General Rules) cost of a standard dose, without mark-ups or fees and excluding GST.
- ECP Extemporaneously Compounded Preparation.
- HSS Hospital Supply Status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.
- OP Original Pack subsidy is rounded up to a multiple at whole packs.
- PSO Practitioner's Supply Order.

Sole Subsidised

Supplier Only brand of this medicine subsidised.

WSO Wholesale Supply Order.

XPharm Pharmacies cannot claim subsidy because PHARMAC has made alternative distribution arrangements.

- ▲ Three months supply may be dispensed at one time if the exempted medicine is endorsed 'certified exemption' by the practitioner.
- * Three months dispensed all-at-once or, in the case of oral contraceptives, six months dispensed all-at-once, unless medicine is endorsed "close control" or "cc" and the endorsement is initialled by the prescriber.

\$ Safety cap required and subsidised for oral liquid formulations, including extemporaneously compounded preparations.

- Fully subsidised brand of a given medicine. Brands without the tick are not fully subsidised and may cost the patient a
 manufacturer's surcharge.
- S29 This medicine is an unapproved medication supplied under Section 29 of the Medicines Act 1981. Practitioners prescribing this medication should:
 - a) be aware of and comply with their obligations under Section 29 of the Medicines Act 1981 and otherwise under that Act and the Medicines Regulations 1984;
 - b) be aware of and comply with their obligations under the Health and disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
 - c) exercise their own skill, judgement, expertise and discretions, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an indication for which it is not approved.

Note: Where medicines supplied under Section 29 that are used for emergency situations, patient details required under Section 29 of the Medicines Act may be retrospectively provided to the supplier.

	Definitions						
Abbrev.	Pharmacy Services Agreement	All other Pharmacy Agreements					
[HP1]	Subsidised when dispensed from pharmacies that have the Complex Medicines Variation of the Phar- macy Services Agreement	Available from selected pharmacies that have an ex- clusive contract to dispense 'Hospital Pharmacy' [HP1] pharmaceuticals.					
[HP3]	Subsidised when dispensed from pharmacies that have the Pharmacy Services Agreement. A Special Food with [HP3] annotation is subsidised when dis- pensed by a pharmacy that has a Special Foods Ser- vice appended to their Pharmacy Services Agreement by their DHB.	Available from selected pharmacies that have an ex- clusive contract to dispense 'Hospital Pharmacy' [HP3] pharmaceuticals.					
[HP4]	Subsidised when dispensed from pharmacies that have the Monitored Therapy Variation (for Clozapine Services)	Avaliable from selected pharmacies that have an ex- clusive contract to dispense 'Hospital Pharmacy' [HP4] pharmaceuticals.					

Patient costs

Community Pharmaceuitical costs met by the Government

Most of the cost of a subsidised prescription Community Pharmaceutical is met by the Government through the Pharmaceutical Budget. The Government pays a subsidy for the Community Pharmaceutical to Contractors, and a fee covering distribution and pharmacy dispensing services. The subsidy paid to Contractors does not necessarily represent the final cost to Government of subsidising a particular Community Pharmaceutical. The final cost will depend on the nature of PHARMAC's contractual arrangements with the supplier. Fully subsidised medicines are identified with a \checkmark in the product's Schedule listing.

SALBUTAMOL		
Aerosol inhaler 100 µg per dose		Fully subsidised brand
	(6.00)	Higher priced brand

Pharmaceutical Co-Payments

Some Community Pharmaceutical costs are met by the patient. Generally a patient pays a prescription charge. In addition a patient will sometimes pay a manufacturer's surcharge, after hours service fee and any special packaging fee.

PRESCRIPTION CHARGE

From 1 September 2008, everyone who is eligible for publicly funded health and disability services should in most circumstances pay only \$3 for subsidised medicines.

All prescriptions from a public hospital, a midwife and a Family Planning Clinic are covered for \$3 co-payments.

Prescriptions from the following providers are approved for \$3 co-payments on subsidised medicines if they meet the specified criteria:

- After Hours Accident and Medical Services with a DHB or a PHO contract.
- Youth Health Clinics with a DHB or a PHO contract.
- Dentists who write a prescription that relates to a service being provided under a DHB contract.
- Private specialists (for example, opthalmologists and orthopaedics) who write a prescription for a patient receiving a publicly funded service contracted by the DHB.
- General practitioners who write a prescription during normal business hours to a person who is not enrolled in the general
 practice provided the person is eligible for publicly funded health and disability services and the general practice is part of a
 PHO.
- Hospices that have a contract with a DHB.

Patients can check whether they are eligible for publicly funded health and disability services by referring to the Eligibility Direction on the Ministry of Health's website.

To check if a medicine is fully subsidised, refer to the Pharmaceutical Schedule on PHARMAC's website or ask your pharmacist or general practitioner.

DHBs have a list of eligible providers in their respective regions. Any provider/prescriber not specifically listed by a DHB as an approved provider/prescriber should be regarded as not approved.

NOTE: Information sourced from Ministry of Health Website, for more information please visit www.moh.govt.nz

MANUFACTURER'S SURCHARGE

Not all Community Pharmaceuticals are fully subsidised. Although PHARMAC endeavours to fully subsidise at least one Community Pharmaceutical in each therapeutic group, and has contracts with some suppliers to maintain the price of a particular product, manufacturers are able to set their own price to pharmacies. When these prices exceed the subsidy, the pharmacist may recoup the difference from the patient.

To estimate the amount a patient will pay on top of the prescription charge, take the difference between the manufacturer's price

and the subsidy, and multiply this by 1.86. The 1.86 factor represents the pharmacy mark-up on the surcharge plus other costs such as GST. Pharmacies charge different mark-ups so this may vary.

Manufacturer's surchage to patient = (price - subsidy) \times 1.86

For example, a Community Pharmaceutical with a supplier (ex-manufacturer) cost of \$11.00 per pack with a \$10.00 subsidy will cost the patient a surchage of \$1.86 on top of the prescription charge. The most a patient should pay is therefore \$16.86 - being \$15.00 maximum prescription charge, plus \$1.86.

Hospital Pharmaceutical and Pharmaceutical Cancer Treatment Costs

The cost of purchasing Hospital Pharmaceuticals and Pharmaceutical Cancer Treatments (for use in DHB hospitals and/or in association with Outpatient services provided in DHB hospitals) is met by the Funder (in particular, the relevant DHB) from its own budget. As required by section 23(7) of the Act, in performing any of their functions in relation to the supply of Pharmaceuticals including Pharmaceutical Cancer Treatments, DHBs must not act inconsistently with the Pharmaceutical Schedule.

PHARMAC web site

PHARMAC has set up an interactive Schedule on the Internet. It can be used to calculate the cost of a prescribed Community Pharmaceutical. This site at *http://www.pharmac.govt.nz* takes into account the quantity of Community Pharmaceutical prescribed as well as the patient's age, whether the patient has a community services card, high use health card or prescription subsidy card, the fee for pharmacy services and prescription charges.

Other information about PHARMAC is also available on our website. This includes copies of the Annual Review, Annual Report and Annual Plan, as well as information such as the Pharmaceutical Schedule, Pharmaceutical Schedule Updates, National Hospital Pharmaceutical Strategy, other publications and recent press releases.

Special Authority Applications

Special Authority is an application process in which a prescriber requests government subsidy on a Community Pharmaceutical for a particular person. Applications must be submitted to the Ministry of Health by the prescriber for the request to be processed.

Subsidy

Once approved, the presciber will be provided a Special Authority number which must appear on the prescription. Specialists who make an application must communicate the valid authority number to the prescriber who will be writing the prescriptions.

The authority number can provide access to subsidy, increased subsidy, or waive certain restrictions otherwise present on the Community Pharmaceutical.

Some approvals are dependent on the availability of funding from the Pharmaceutical Budget.

Criteria

The criteria for approval of Special Authority applications are included below each Community Pharmaceutical listing, and on the application forms available on PHARMAC's website.

For some Special Authority Community Pharmaceuticals, not all indications that have been approved by Medsafe are subsidised. Criteria for each Special Authority Community Pharmaceutical are updated regularly, based on the decision criteria of PHARMAC. The appropriateness of the listing of a Community Pharmaceutical in the Special Authority category will also be regularly reviewed. Applications for inclusion of further Community Pharmaceuticals in the Special Authority category will generally be made by a pharmaceutical supplier.

Special Authority Applications

Application forms can be found at www.pharmac.govt.nz. Requests for fax copies should be made to PHARMAC, phone 04 460 4990. Applications are processed by the Ministry of Health, and should be sent to:

Ministry of Health Sector Services, Private Bag 3015, WANGANUI 4540 Fax: (06) 349 1983 or free fax 0800 100 131

For enquiries, phone the Ministry of Health Sector Services Call Centre, free phone 0800 243 666

Note: The Ministry of Health can only provide information on Special Authority applications to prescribers and pharmacists.

Each application must:

- Include the patients name, date of birth and NHI number (codes for AIDS patients' applications)
- Include the practitioner's name, address and Medical Council registration number
- Clearly indicate that the relevant criteria, have been met.
- Be signed by the practitioner.

Exceptional Circumstances policies

The purpose of the Exceptional Circumstances policies are to provide:

- funding from the Community Exceptional Circumstances budget for medication, to be used in the community, in circumstances where the provision of a funded community medication is appropriate, but funding from the Pharmaceutical Budget is not able to be provided through the Pharmaceutical Schedule ("Community Exceptional Circumstances"); or
- an assessment process for the DHB Hospitals to determine whether they can fund medication, to be used in the community, in circumstances where the medication is neither a Community Pharmaceutical nor a Discretionary Community Supply Pharmaceutical and where the patient does not meet the criteria for Community Exceptional Circumstances ("Hospital Exceptional Circumstances"); or
- an assessment process for DHB Hospitals to determine whether they can fund pharmaceuticals for the treatment of cancer in their DHB Hospital, or in association with Outpatient services provided in their DHB hospital, in circumstances where the pharmaceutical is not identified as a Pharmaceutical Cancer Treatment ("Cancer Exceptional Circumstances") in Sections A-H of the Pharmaceutical Schedule.

Upon receipt of an application for approval for Community Exceptional Circumstances or Hospital Exceptional Circumstances, the Exceptional Circumstances Panel first decides whether an application will be assessed initially under the Community Exceptional Circumstances criteria or the Hospital Exceptional Circumstances criteria. Cancer Exceptional Circumstances is a separate process.

Hospital Exceptional Circumstances

If the application is first assessed but not approved under the Community Exceptional Circumstances criteria, the Exceptional Circumstances Panel may recommend the funding of the pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget under Hospital Exceptional Circumstances.

If the application is first assessed under the Hospital Exceptional Circumstances criteria, the Exceptional Circumstances Panel may:

- a) recommend against the funding of the pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget, in which case a DHB Hospital must not fund the pharmaceutical from its own budget;
- b) recommend the funding of the pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget under Hospital Exceptional Circumstances, in which case a DHB Hospital may, but is not obliged to, fund the pharmaceutical from its own budget;
- c) defer its decision until further assessment under the Community Exceptional Circumstances criteria can undertaken; or
- d) recommend interim funding of the pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget under Hospital Exceptional Circumstances until further assessment under the Community Exceptional Circumstances criteria can be undertaken.

Permission to fund a pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget under Hospital Exceptional Circumstances will only be granted by PHARMAC where it has been demonstrated that such funding is cost-effective for the relevant DHB in the region in which the patient resides.

If the patient being treated with a pharmaceutical under Hospital Exceptional Circumstances usually resides in a district other than that within the jurisdiction of the DHB initiating the treatment, then the DHB initiating the treatment must either agree to fund any on-going treatment required once the patient has returned to his/her usual DHB, or obtain written consent from the DHB or DHBs in which the patient will reside following the commencement of treatment.

Applications for Hospital Exceptional Circumstances should be made on the standard application form available from the PHARMAC website www.pharmac.govt.nz or the address below:

The Coordinator, Hospital Exceptional Circumstances Panel PHARMAC, PO Box 10 254 Wellington

Phone: (04) 916 7521 or fax (09) 523 6870 Email: ecpanel@pharmac.govt.nz

Cancer Exceptional Circumstances

Permission to fund a pharmaceutical for the treatment of cancer from the Hospital's own budget under Cancer Exceptional Circumstances will only be granted by PHARMAC where it has been demonstated that the proposed use meets the criteria.

If the patient being treated with a pharmaceutical under Cancer Exceptional Circumstances usually resides in a district other than that within the jurisdiction of the DHB initiating the treatment, then the DHB initiating the treatment must either agree to fund any on-going treatment required once the patient has returned to his/her usual DHB, or obtain written consent from the DHB or DHBs in which the patient will reside following the commencement of treatment.

Community Exceptional Circumstances

In order to qualify for Community Exceptional Circumstances approval one of the following criteria must be met:

- a) the condition must be rare; or
- b) the reaction to alternative funded treatment must be unusual; or
- c) an unusual combination of circumstances applies.

Rare and unusual are considered to be in the order of less than 10 people nationally.

Where one of the above Community Exceptional Circumstances entry criteria is met, the application may then be further examined under supplementary criteria, assessing suitability of the pharmaceutical, clinical benefit, the cost effectiveness of the treatment, and the patient's ability to pay for the treatment. Where these documented criteria are met, a subsidy sufficient to fully fund the pharmaceutical will be made available to the specific patient on whose behalf the application was made.

Community Exceptional Circumstances funding is only available where the criteria are met and is not available for financial reasons alone.

Applications for Community Exceptional Circumstances, Hospital Exceptional Circumstances and Cancer Exceptional Circumstances should be made on the standard application form available from the PHARMAC website www.pharmac.govt.nz or the address below:

The Coordinator, Community Exceptional Circumstances Panel PO Box 10 254 Wellington Phone (04) 916 7553 or fax (09) 523 6870 Email: ecpanel@pharmac.govt.nz

INTRODUCTION

Section A contains the restrictions and other general rules that apply to Subsidies on Community Pharmaceuticals. The amounts payable by the Funder to Contractors are currently determined by:

- the quantities, forms, and strengths, of subsidised Community Pharmaceuticals dispensed under valid prescription by each Contractor;
- the amount of the Subsidy on the Manufacturer's Price payable for each unit of the Community Pharmaceuticals dispensed by each Contractor and;
- the contractual arrangements between the Contractor and the Funder for the payment of the Contractor's dispensing services.

The Pharmaceutical Schedule shows the level of subsidy payable in respect of each Community Pharmaceutical so that the amount payable by the Government to Contractors, for each Community Pharmaceutical, can be calculated. The Pharmaceutical Schedule also shows the standard price (exclusive of GST) at which a Community Pharmaceutical is supplied ex-manufacturer to wholesalers if it differs from the subsidy. The manufacturer's surcharge to patients can be estimated using the subsidy and the standard manufacturer's price as set out in this Schedule.

The cost to Government of subsidising each Community Pharmaceutical and the manufacturer's prices may vary, in that suppliers may provide rebates to other stakeholders in the primary health care sector, including dispensers, wholesalers, and the Government. Rebates are not specified in the Pharmaceutical Schedule.

This Schedule is dated 1 September 2009 and is to be referred to as the Pharmaceutical Schedule Volume 16 Number 2, 2009. Distribution will be from 20 September 2009. This Schedule comes into force on 1 September 2009.

PART I

INTERPRETATIONS AND DEFINITIONS

1.1 In this Schedule, unless the context otherwise requires:

"90 Day Lot" means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 90 consecutive days' treatment;

"180 Day Lot" means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 180 consecutive days' treatment;

"Access Exemption Criteria" means the criteria under which patients may receive greater than one Month's supply of a Community Pharmaceutical covered by Section F Part II (b) subsidised in one Lot. The specifics of these criteria are conveyed in the Ministry of Health guidelines, which are issued from time to time. The criteria the patient must meet are that they:

a) have limited physical mobility;

- b) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
- c) are relocating to another area;
- d) are travelling extensively and will be out of town when the repeat prescriptions are due.

"Act" means the New Zealand Public Health and Disability Act 2000.

"Advisory Committee" means the Pharmaceutical Services Advisory Committee convened by the Ministry of Health under the terms of the Advice Notice issued to Contractors pursuant to Section 88 of the Act.

"Alternate Subsidy" means a higher level of subsidy that the Government will pay contractors for a particular community Pharmaceutical dispensed to a person who has either been granted a Special Authority for that pharmaceutical, or where the prescription is endorsed in accordance with the requirements of this Pharmaceutical Schedule.

"Assessed Pharmaceuticals" means the list of Pharmaceuticals set out in Section H Part III of the Schedule, that have been or are being assessed by PHARMAC.

"Authority to Substitute" means an authority for the dispensing pharmacist to change a prescribed medicine in accordance with regulation 42(4) of the Medicines Regulations 1984. An authority to substitute letter, which may be used by Practitioners, is available on the final page of the Schedule.

"Bulk Supply Order" means a written order, on a form supplied by the Ministry of Health, or approved by the Ministry of Health, made by the licensee or manager of an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 for the supply of such Community Pharmaceuticals as are expected to be required for the treatment of persons who are under the medical or dental supervision of such a Private Hospital or institution.

"Cancer Exceptional Circumstances" means the policies and criteria administered by PHARMAC relating to the ability to fund, from a DHB hospital's own budget, pharmaceuticals for the treatment of cancer that are not identified as Pharmaceutical

Cancer Treatments in Sections A-H of the Pharmaceutical Schedule.

"Class B Controlled Drug" means a Class B controlled drug within the meaning of the Misuse of Drugs Act 1975.

"Close Control" means the dispensing of a Community Pharmaceutical, in accordance with a Prescription, in quantities less than one 90 Day Lot (or for oral contraceptives, less than one 180 Day Lot) for a Community Pharmaceutical referred to in Section F Part I, or in quantities less than a Monthly Lot for any other Community Pharmaceutical, where any of a), b) or c) apply.

- a) All of the following conditions are met:
 - i) the Community Pharmaceutical has been prescribed for a patient who:
 - 1) is not a resident in a Penal Institution, Rest Home or Residential Disability Care Institution; and
 - 2) either of the following:
 - i) in the opinion of the prescribing Practitioner is:
 - a) frail; or
 - b) infirm; or
 - c) unable to manage their medication without additional support; or
 - d) intellectually impaired; or
 - e) requires close monitoring due to recent initiation onto, or dose change for, the Community Pharmaceutical (applicable to the patient's first changed Prescription only); and
 - f) requires that Community Pharmaceutical to be dispensed in a smaller quantity than that for which it is currently funded, or
 - ii) the Community Pharmaceutical is any of the following:
 - a) a tri-cyclic antidepressant; or
 - b) an antipsychotic; or
 - c) a benzodiazepine; or
 - d) a Class B Controlled Drug; and
 - ii) the prescribing Practitioner has:
 - A) endorsed each Community Pharmaceutical on the Prescription clearly with the words "Close Control" or "CC"; and
 - B) initialled the endorsement in their own handwriting; and
 - C) specified the maximum quantity or period of supply to be dispensed at any one time.
- b) All of the following conditions are met:
 - i) The Community Pharmaceutical is prescribed for a patient who is a resident in a Rest Home or Residential Disability Care Institution; and
 - A) the quantity or period of supply to be dispensed at any one time is not less than 28 days' supply; and
 - B) the prescriber or pharmacist has written the name of the Rest Home or Residential Disability Care Institution on the prescription; and
 - C) the prescriber or pharmacist has:
 - written on the Prescription the words "Close Control" or "CC" (this applies to all medicines prescribed on the prescription), and
 - 2) initialled the endorsement/annotation in their own handwriting; and
 - 3) specified the maximum quantity or period of supply to be dispensed at any one time.
- c) All of the following conditions are met:
 - i) where PHARMAC has approved and notified pharmacists to annotate prescriptions for a specified Com-
 - munity Pharmaceutical(s) "Close Control" without prescriber endorsement for a specified time; and
 - ii) the dispensing pharmacist has:
 - A) clearly annotated each of the approved Community Pharmaceuticals that appear on the prescription with the words "Close Control" or "CC"; and
 - B) initialled the annotation in their own handwriting; and
 - C) specified the maximum quantity or period of supply to be dispensed at any one time, as specified by PHARMAC at the time of notification.

"Community Exceptional Circumstances" means the policies and criteria administered by the Exceptional Circumstances Panel relating to funding from the Community Exceptional Circumstances budget for medication, to be used in the community, in circumstances where the provision of a funded community medication is appropriate, but funding from the Pharmaceutical Budget is not able to be provided through the Pharmaceutical Schedule.

"Community Pharmaceutical" means a Pharmaceutical listed in Sections A to G of the Pharmaceutical Schedule that is subsidised by the Funder from the Pharmaceutical Budget for use in the community.

"Contractor" means a person who is entitled to receive a payment from the Crown or a DHB under a notice issued by the Crown or a DHB under Section 88 of the Act or under a contract with the Ministry of Health or a DHB for the supply of Community Pharmaceuticals.

"Controlled Drug" means a controlled drug within the meaning of the Misuse of Drugs Act 1975 (other than a controlled drug specified in Part VI of the Third Schedule to that Act).

"Cost, Brand, Source of Supply" means that the Community Pharmaceutical is eligible for Subsidy on the basis of the Contractor's annotated purchase price, brand, and source of supply.

"Dentist" means a person registered with the Dental Council, and who holds a current annual practising certificate, under the HPCA Act 2003.

"DHB" means an organisation established as a District Health Board by or under Section 19 of the Act.

"DHB Hospital" means a DHB, including its hospital or associated provider unit that the DHB purchases Hospital Pharmaceuticals for.

"Discretionary Community Supply Pharmaceutical" means the list of Pharmaceuticals set out in Section H Part IV of the Schedule, which may be funded by a DHB Hospital from its own budget for use in the community.

"Doctor" means a medical Practitioner registered with the Medical Council of New Zealand and, who holds a current annual practising certificate under the HPCA Act 2003.

"DV Limit" means, for a particular Hospital Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit.

"DV Pharmaceutical" means a discretionary variance Pharmaceutical, that does not have HSS and which:

- a) is either listed in Section H Part II of the Schedule as being a DV Pharmaceutical in association with the relevant Hospital Pharmaceutical with HSS; or
- b) is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant Hospital Pharmaceutical with HSS, but which is not yet listed as being a DV Pharmaceutical.

"Endorsements" - unless otherwise specified, endorsements should be either handwritten or computer generated by the practitioner prescribing the medication. The endorsement can be written as "certified condition", or state the condition of the patient, where that condition is specified for the Community Pharmaceutical in Section B of the Pharmaceutical Schedule. Where the practitioner writes "certified condition" as the endorsement, he/she is making a declaration that the patient meets the criteria as set out in Section B of the Pharmaceutical Schedule.

"Exceptional Circumstances Panel" means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for administering policies in relation to Community Exceptional Circumstances and Hospital Exceptional Circumstances.

"Funder" means the body or bodies responsible, pursuant to the Act, for the funding of pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors.

"GST" means goods and services tax under the Goods and Services Tax Act 1985.

"Hospital Care Operator" means a person for the time being in charge of providing hospital care, in accordance with the Health and Disability Services (Safety) Act 2001.

"Hospital Exceptional Circumstances" means the policies and criteria administered by the Exceptional Circumstances Panel relating to the ability to fund, from a DHB Hospital's own budget, pharmaceuticals for use in the community by a specific patient where a subsidy is not available from the Pharmaceutical Budget or under Community Exceptional Circumstances.

"Hospital Pharmaceuticals" means National Contract Pharmaceuticals, DV Pharmaceuticals, Discretionary Community Supply Pharmaceuticals and Assessed Pharmaceuticals.

"Hospital Pharmacy" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an person on the Prescription of a Practitioner. "Hospital Pharmacy-Specialist" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy:

- a) to an Outpatient; and
- b) on a Prescription signed by a Specialist; or

if the treatment of an Outpatient with the Community Pharmaceutical has been recommended by a Specialist, on the Prescription of a Practitioner endorsed with the words "recommended by [name of specialist and year of authorisation]" and signed by the Practitioner.

"As recommended by a Specialist" to be interpreted as:

- a) follows a substantive consultation with an appropriate Specialist;
- b) the consultation to relate to the Patient for whom the Prescription is written;

c) consultation to mean communication by referral, telephone, letter, facsimile or email;

d) except in emergencies consultation to precede annotation of the Prescription; and

e) both the specialist and the General Practitioner must keep a written record of the consultation.

For the purposes of the definition it makes no difference whether or not the Specialist is employed by a hospital.

"Hospital Pharmacy-Specialist Prescription" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy:

a) to an Outpatient; and

b) on a Prescription signed by a Specialist.

For the purposes of this definition, a "specialist" means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

"HSS" means hospital supply status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.

"In Combination" means that the Community Pharmaceutical is only subsidised when prescribed in combination with another subsidised pharmaceutical as specified in Section B or C of the Pharmaceutical Schedule.

"Individual DV Limit" means, for a particular Hospital Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the specified percentage of that DHB Hospital's Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

"Licensed Hospital" means a place or institution that is certified to provide hospital care within the meaning of the Health and Disability Services (Safety) Act 2001.

"Lot" means a quantity of a Community Pharmaceutical supplied in one dispensing.

"Manufacturer's Price" means the standard price at which a Community Pharmaceutical is supplied to wholesalers (excluding GST), as notified to PHARMAC by the supplier.

"Maternity hospital" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied pursuant to a Bulk Supply Order to a maternity hospital certified under the Health and Disability Services (Safety) Act 2001.

"Midwife" means a person registered as a midwife with the Midwifery Council, and who holds a current annual practising certificate under the HPCA Act 2003.

"Month" means a period of 30 consecutive days.

"Month restriction" means that no Subsidy is available:

- a) unless the Community Pharmaceutical is dispensed on the Prescription of a Practitioner; and
- b) for any quantity of that Community Pharmaceutical dispensed on the Prescription (whether or not dispensed as a repeat) in excess of a Monthly Lot.

"Monthly Lot" means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 30 consecutive days' treatment;

"National Contract Pharmaceutical" means a Hospital Pharmaceutical for which PHARMAC has negotiated a national contract and the Price.

"National DV Limit" means, for a particular Hospital Pharmaceutical with HSS, the discretionary variance limit, being the specified percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

"Not In Combination" means that no Subsidy is available for any Prescription containing the Community Pharmaceutical in combination with other ingredients unless the particular combination of ingredients is separately specified in Section B or C of the Schedule, and then only to the extent specified.

"Nurse Prescriber" means a nurse registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003 and who is approved by the Nursing Council, to prescribe specified prescription medicines relating to his/her scope of practice.

"Optometrist" means a person registered as an optometrist with the Optometrists and Dispensing Opticians Board, who holds a current annual practising certificate under the HPCA Act 2003, and who is authorised by regulations under the Medicines Act 1981 and approved by the Optometrists and Dispensing Opticians Board to prescribe specified medicines.

"Outpatient" , in relation to a Community Pharmaceutical, means a person who, as part of treatment at a hospital or other institution under the control of a DHB, is prescribed the Community Pharmaceutical for consumption or use in the person's home.

"PCT" means Pharmaceutical Cancer Treatment in respect of which DHB hospital pharmacies and other Contractors can claim Subsidies.

"PCT only" means Pharmaceutical Cancer Treatment in respect of which only DHB hospital pharmacies can claim Subsi-

dies.

"Penal Institution" means a penal institution, as that term is defined in The Penal Institutions Act 1954;

"PHARMAC" means the Pharmaceutical Management Agency established by Section 46 of the Act (PHARMAC).

"Pharmaceutical" means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to H of the Schedule.

"Pharmaceutical Benefits" means the right of:

- a) a person; and
- b) any member under 16 years of age of that person's family, to have made by the Government on his or her behalf, subject to any conditions for the time being specified in the Schedule, such payment in respect of any Community Pharmaceutical supplied to that person or family member under the order of a Practitioner in the course of his or her practice.

"Pharmaceutical Budget" means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals.

"Pharmaceutical Cancer Treatment" means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a "PCT" or "PCT only" Pharmaceutical that DHBs must fund, from their own budgets, for use in their hospitals, and/or in association with Outpatient services provided in their DHB Hospitals, in relation to the treatment of cancers.

"Practitioner" means a Doctor, a Dentist, a Midwife, a Nurse Prescriber or an Optometrist as those terms are defined in the Pharmaceutical Schedule.

"Practitioner's Supply Order" means a written order made by a Practitioner on a form supplied by the Ministry of Health, or approved by the Ministry of Health, for the supply of Community Pharmaceuticals to the Practitioner, which the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.

"Prescription" means a quantity of a Community Pharmaceutical prescribed for a named person on a document signed by a Practitioner.

"Private Hospital" means a hospital certified under the Health and Disability Services (Safety) Act 2001 that is not owned or operated by a DHB.

"Residential Disability Care Institution" means premises used to provide residential disability care in accordance with the Health and Disability Services (Safety) Act 2001.

"Rest Home" means premises used to provide rest home care in accordance with the Health and Disability Services (Safety) Act 2001.

"Retail Pharmacy-Specialist" means that the Community Pharmaceutical is only eligible for Subsidy if it is supplied on a Prescription or Practitioner's Supply Order signed by a Specialist, or, in the case of treatment recommended by a Specialist, a Prescription or Practitioner's Supply Order and endorsed with the words "recommended by [name of Specialist and year of authorisation]" and signed by the Practitioner.

"As recommended by a Specialist" to be interpreted as:

- a) follows a substantive consultation with an appropriate Specialist;
- b) the consultation to relate to the Patient for whom the Prescription is written;
- c) consultation to mean communication by referral, telephone, letter, facsimile or email;
- d) except in emergencies consultation to precede annotation of the Prescription; and

e) both the Specialist and the General Practitioner must keep a written record of consultation.

"Retail Pharmacy-Specialist Prescription" means that the Community Pharmaceutical is only eligible for Subsidy if it is supplied on a Prescription, or Practitioner's Supply Order, signed by a Specialist. For the purposes of this definition, a "specialist" means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

"Schedule" means this Pharmaceutical Schedule and all its sections and appendices.

"Section B" of this Pharmaceutical Schedule means the list of Community Pharmaceuticals eligible for Subsidies included in the Schedule.

"Section C" of this Pharmaceutical Schedule means the list of community extemporaneously compounded preparations and galenicals eligible for Subsidies included in the Schedule.

"Section D" of this Pharmaceutical Schedule means the list of community special foods eligible for Subsidies included in the Schedule.

"Section E Part I" of this Pharmaceutical Schedule means the list of Community Pharmaceuticals eligible for Subsidies and available on a Practitioner's Supply Order or a Wholesale Supply Order included in the Schedule.

"Section E Part II" of this Pharmaceutical Schedule means the list of rural areas for the purpose of community Practitioner's Supply Orders included in the Schedule.

"Section F Part I" of this Pharmaceutical Schedule means the part of Section F relating to the exemption from dispensing in Monthly Lots, and requirement to dispense in 90 Day Lots or 180 Day Lots, as applicable, in respect of the Community Pharmaceuticals referred to in this part of Section F;

"Section F Part II" of this Pharmaceutical Schedule means the part of Section F relating to the exemption from dispensing in Monthly Lots in respect of the Community Pharmaceuticals referred to in this part of Section F;

"Section G" of this Pharmaceutical Schedule means the list of Community Pharmaceuticals eligible for reimbursement of safety caps.

"Section H" of this Pharmaceutical Schedule means the general rules for Hospital Pharmaceuticals and the lists of National Contract Pharmaceuticals and any associated DV Pharmaceuticals, of Discretionary Community Supply Pharmaceuticals and Assessed Pharmaceuticals included in Section H of the Schedule.

"Section H Part I" of this Pharmaceutical Schedule means the general rules for Hospital Pharmaceuticals.

"Section H Part II" of this Pharmaceutical Schedule means the list of National Contract Pharmaceuticals, the relevant Price, an indication of whether the Pharmaceutical has HSS and any associated DV Pharmaceuticals and DV Limit.

"Section H Part III" of this Pharmaceutical Schedule means the list of Assessed Pharmaceuticals.

"Section H Part IV" of this Pharmaceutical Schedule means the list of Discretionary Community Supply Pharmaceuticals. "Special Authority" means that the Community Pharmaceutical or Pharmaceutical Cancer Treatment is only eligible for Subsidy or additional Subsidy for a particular person if an application meeting the criteria specified in the Schedule has been approved, and the valid Special Authority number is present on the prescription.

"Specialist", in relation to a Prescription, a doctor who holds a current annual practising certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) or (d) below:

- a)
- i) the doctor is vocationally registered in accordance with the criteria set out by the Medical Council of New Zealand and the HPCA Act 2003 and who has written the Prescription in the course of practising in that area of medicine; and
- ii) the doctor's vocational scope of practice is one of those listed below: anaesthetics, cardiothoracic surgery, dermatology, diagnostic radiology, emergency medicine, general surgery, internal medicine, neurosurgery, obstetrics and gynaecology, occupational medicine, ophthalmology, oral and maxillofacial surgery, otolaryngology head and neck surgery, orthopaedic surgery, paediatric surgery, paediatrics, pathology, plastic and reconstructive surgery, psychological medicine or psychiatry, public health medicine, radiation oncology, rehabilitation medicine, urology and venereology;
- b) the doctor is recognised by the Ministry of Health as a specialist for the purposes of this Schedule and receives remuneration from a DHB at a level which that DHB considers appropriate for specialists and who has written that Prescription in the course of practising in that area of medicine;
- c) the doctor is recognised by the Ministry of Health as a specialist in relation to a particular area of medicine for the purpose of writing Prescriptions and who has written the Prescription in the course of practising in that area of medicine;
- d) the doctor writes the Prescription on DHB stationery and is appropriately authorised by the relevant DHB to do so.

"Subsidy" means the maximum amount that the Government will pay Contractors for a Community Pharmaceutical dispensed to a person eligible for Pharmaceutical Benefits and is different from the cost to Government of subsidising that Community Pharmaceutical. For the purposes of a DHB hospital pharmacy claiming for Pharmaceutical Cancer Treatments, Subsidy refers to any payment made to the DHB hospital pharmacy or service provider to which that pharmacy serves, and does not relate to a specific payment that might be made on submission of a claim.

"Supply Order" means a Bulk Supply Order, a Practitioner's Supply Order or a Wholesale Supply Order.

"Unapproved Indication" means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981. Practitioners prescribing Pharmaceuticals for Unapproved Indications should be aware of, and comply with, their obligations under Section 25 and/or Section 29 of the Medicines Act 1981 and as set out in Section A: General Rules, Part IV (Miscellaneous Provisions) rule 4.6.

"Wholesale Supply Order" means a written order by a Practitioner, on a form supplied by the Ministry of Health for the supply of certain Community Pharmaceuticals as listed in Section B and Section E Part I of the Schedule.

1.2 In addition to the above interpretations and definitions, unless the content requires otherwise, a reference in the Schedule to:

- a) the singular includes the plural; and
- b) any legislation includes a modification and re-enactment of, legislation enacted in substitution for, and a regulation, Order in Council, and other instrument from time to time issued or made under that legislation, where that legislation, regulation, Order in Council or other instrument has an effect on the prescribing, dispensing or subsidising of Community Pharmaceuticals.

PART II

COMMUNITY PHARMACEUTICALS SUBSIDY

- 2.1 Community Pharmaceuticals eligible for Subsidy include every medicine, therapeutic medical device or related product, or related thing listed in Sections B to G of the Schedule, and every preparation (having an inert base) of any of them, is hereby declared to be a Community Pharmaceutical for the purposes of the Schedule, subject to:
 - 2.1.1 clauses 2.2 and 2.3 of the Schedule; and
 - 2.1.2 clauses 3.1 to 4.4 of the Schedule; and
 - 2.1.3 the conditions (if any) specified in Sections B to G of the Schedule;
- 2.2 The following medicines, therapeutic medical devices, or related products or related things are not eligible for Subsidy:
 - 2.2.1 substances, or combinations of substances, ordered for any purpose other than:
 - a) treatment of a patient's medical or dental condition; or
 - b) pregnancy tests; or
 - c) the prevention of sexually transmitted disease; or
 - d) contraception.
 - 2.2.2 substances and combinations of substances packed under pressure in aerosol cans or other similar devices, unless it is specified in Sections B to G of the Schedule that they may be so packed;
 - 2.2.3 electrode jellies;
 - 2.2.4 eye drops packed in single-dose units, unless it is specified in Sections B to G of the Schedule that they may be so packed;
 - 2.2.5 insect repellents and similar preparations;
 - 2.2.6 oral preparations in long-acting form, unless it is specified in Sections B to G of the Schedule that they may be in such a form;
 - 2.2.7 substances or combinations of substances in lozenge or similar form, unless it is specified in Sections B to G of the Schedule that they may be in such a form;
 - 2.2.8 machine-spread plasters;
 - 2.2.9 preparations prescribed as foods, unless they are specified in Section D of the Schedule;
 - 2.2.10 substances, combinations of substances, or articles, in the form of proprietary medicines or proprietary articles, unless they are deemed or declared to be Pharmaceuticals elsewhere in the Schedule;
 - 2.2.11 shampoos, other than extemporaneously prepared medicated shampoos, or shampoos specified in Sections B to G of the Schedule intended for the treatment of a patient's medical condition;
 - 2.2.12 toilet preparations;
 - 2.2.13 tooth pastes and powders;
 - 2.2.14 lubricating jellies and catheter lubricants;
 - 2.2.15 sterile diluents for nebulising solutions;
 - 2.2.16 substances in a form intended to enable delivery by transdermal diffusion or osmosis or by the insertion of any solid object or substance into the eye cavity, unless it is specified in Sections B to G of the Schedule that they may be in such a form;
 - 2.2.17 substances in a form intended for intravenous delivery (other than by injection), unless it is specified in Sections B to G of the Schedule that they may be in such a form;
 - 2.2.18 substances packed in pre-loaded syringes known as Min-I-Jets, unless it is specified in Sections B to G of the Schedule that they may be so packed;
 - 2.2.19 Community Pharmaceuticals prescribed as cough mixtures, unless they are specified in Sections B to G of the Schedule otherwise than in combination with other ingredients;
 - 2.2.20 vitamin preparations in capsule form, unless they are specified in Sections B to G of the Schedule;
 - 2.2.21 substances prescribed for use as irrigating solutions, unless it is specified in Sections B to G of the Schedule that they may be prescribed for such use.
- 2.3 No claim by a Contractor for payment in respect of the supply of Community Pharmaceuticals will be allowed unless

the Community Pharmaceuticals so supplied:

- 2.3.1 comply with the appropriate standards prescribed by regulations for the time being in force under the Medicines Act 1981; or
- 2.3.2 in the absence of any such standards, comply with the appropriate standards for the time being prescribed by the British Pharmacopoeia; or
- 2.3.3 in the absence of the standards prescribed in clauses 2.3.1 and 2.3.2, comply with the appropriate standards for the time being prescribed by the British Pharmaceutical Codex; or
- 2.3.4 in the absence of the standards prescribed in clauses 2.3.1, 2.3.2 and 2.3.3, are of a grade and quality not lower than those usually applicable to Community Pharmaceuticals intended to be used for medical purposes.

PART III

PERIOD AND QUANTITY OF SUPPLY

- 3.1 Doctors', Midwives', Nurse Prescribers' and Optometrists' Prescriptions (other than oral contraceptives) The following provisions apply to all Prescriptions, other than those for an oral contraceptive, written by a Doctor, Midwife, Nurse Prescriber or Optometrist:
 - 3.1.1 For a Community Pharmaceutical other than a Class B Controlled Drug, only a quantity suffcient to provide treatment for a period not exceeding three Months will be subsidised.
 - 3.1.2 For methylphenidate hydrochloride and dexamphetamine sulphate, only a quantity sufficient to provide treatment for a period not exceeding one Month will be subsidised.
 - 3.1.3 For a Class B Controlled Drug other than methylphenidate hydrochloride and dexamphetamine sulphate, only a quantity:
 - a) sufficient to provide treatment for a period not exceeding 10 days; and
 - b) which has been dispensed pursuant to a Prescription sufficient to provide treatment for a period not exceeding one Month, will be subsidised.
 - 3.1.4 Subject to clauses 3.1.3 and 3.1.7, for a Doctor, Midwife or Nurse Prescriber and 3.1.7 for an Optometrist, where a practitioner has prescribed a quantity of a Community Pharmaceutical sufficient to provide treatment for:
 - a) one Month or less than one Month, but dispensed by the Contractor in quantities smaller than the quantity prescribed, the Community Pharmaceutical will only be subsidised as if that Community Pharmaceutical had been dispensed in a Monthly Lot;
 - b) more than one Month, the Community Pharmaceutical will be subsidised only if it is dispensed:
 - i) in a 90 Day Lot, where the Community Pharmaceutical is a Pharmaceutical covered by Section F Part I of the Pharmaceutical Schedule; or
 - ii) if the Community Pharmaceutical is not a Pharmaceutical referred to in Section F Part I of the Pharmaceutical Schedule, in Monthly Lots, unless:
 - A) the eligible person or his/her nominated representative endorses the back of the Prescription form with a statement identifying which Access Exemption Criterion (Criteria) applies and signs that statement to this effect; or
 - B) both:
 - the Practitioner endorses the Community Pharmaceutical on the Prescription with the words "certified exemption" written in the Practitioner's own handwriting, or signed or initialled by the Practitioner; and
 - every Community Pharmaceutical endorsed as "certified exemption" is covered by Section F Part II of the Pharmaceutical Schedule.
 - 3.1.5 A Community Pharmaceutical is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor:
 - a) for a Class B Controlled Drug, within eight days of the date on which the Prescription was written; or
 - b) for any other Community Pharmaceutical, within three Months of the date on which the Prescription was written.
 - 3.1.6 No subsidy will be paid for any Prescription, or part thereof, that is not fulfilled within:
 - a) in the case of a Prescription for a total supply of from one to three Months, three Months from the date the Community Pharmaceutical was first dispensed; or
 - b) in any other case, one Month from the date the Community Pharmaceutical was first dispensed. Only

that part of any Prescription that is dispensed within the time frames specified above is eligible for Subsidy.

- 3.1.7 If a Community Pharmaceutical:
 - a) is stable for a limited period only, and the Doctor, Midwife, Nurse Prescriber or Optometrist has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that may be dispensed at any one time; or
 - b) is stable for a limited period only, and the Contractor has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that should be dispensed at any one time in all the circumstances of the particular case; or
 - c) is Close Control,

The actual quantity dispensed will be subsidised in accordance with any such specification.

3.2 Oral Contraceptives

The following provisions apply to all Prescriptions written by a Doctor, Midwife or Nurse Prescriber for an oral contraceptive:

- 3.2.1 The prescribing Doctor, Midwife or Nurse Prescriber must specify on the Prescription the period of treatment for which the Community Pharmaceutical is to be supplied. This period must not exceed:
 - a) three Months if prescribed by a Midwife; or
 - b) six Months if prescribed by a Doctor or Nurse Practitioner.
- 3.2.2 Where the period of treatment specified in the Prescription does not exceed six Months, the Community Pharmaceutical is to be dispensed:
 - a) in Lots as specified in the Prescription if the Community Pharmaceutical is Close Control; or
 - b) where no Lots are specified, in one Lot sufficient to provide treatment for the period prescribed.
- 3.2.3 An oral contraceptive is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor within three Months of the date on which it was written.
- 3.2.4 An oral contraceptive prescribed by a Midwife is only eligible for Subsidy if the Prescription under which it has been dispensed has been written within the period of post natal care of the eligible person.
- 3.2.5 Where a Community Pharmaceutical in a Prescription is Close Control and a repeat on the Prescription remains unfulfilled after six Months from the date the Community Pharmaceutical was first dispensed only the actual quantity supplied by the Contractor within this time limit will be eligible for Subsidy.

3.3 Dentists' Prescriptions

- The following provisions apply to every Prescription written by a Dentist:
- 3.3.1 The maximum quantity of a Community Pharmaceutical that will be subsidised is as follows:
 - a) where the Community Pharmaceutical is a Controlled Drug, only such quantity as is necessary to provide treatment for a period not exceeding five days; and
 - b) in any other case, only such quantity as is necessary to provide treatment for a period not exceeding five days and, where the Prescription specifies a repeat, one further period not exceeding five days.
- 3.3.2 Notwithstanding clause 3.3.1, if, in the opinion of the Dentist, an eligible person needs extended treatment with sodium fluoride for up to three Months, the Community Pharmaceutical will be subsidised for that extended period. A Prescription for any such extended supply of sodium fluoride will be subsidised only if it is dispensed in Monthly Lots, unless the eligible person or his/her nominated representative endorses the back of the Prescription form with a statement identifying which Access Exemption Criterion (Criteria) applies and signs that statement to this effect.
- 3.3.3 A Community Pharmaceutical is only eligible for Subsidy if the Prescription under which it has been dispensed has been presented to the Contractor:
 - a) for a Class B Controlled Drug, within eight days of the date on which the Prescription was written; or
 - b) for any other Community Pharmaceutical, within three Months of the date on which the Prescription was written.
- 3.3.4 No Subsidy will be paid for any Prescription, or part thereof, that is not fulfilled within:
 - a) one Month from the date the Community Pharmaceutical was first dispensed; or
 - b) in the case of sodium fluoride, three Months from the date the Community Pharmaceutical was first dispensed.
 - Only that part of any Prescription that is dispensed within the time frames specified above is eligible for Subsidy.

3.4 Original Packs, and Certain Antibiotics

3.4.1 Notwithstanding clauses 3.1 and 3.3 of the Schedule, if a Practitioner prescribes or orders a Community

Pharmaceutical that is identified as an Original Pack (OP) on the Pharmaceutical Schedule and is packed in a container from which it is not practicable to dispense lesser amounts, every reference in those clauses to an amount or quantity eligible for Subsidy, is deemed to be a reference:

- a) where an amount by weight or volume of the Community Pharmaceutical is specified in the Prescription, to the smallest container of the Community Pharmaceutical, or the smallest number of containers of the Community Pharmaceutical, sufficient to provide that amount; and
- b) in every other case, to the amount contained in the smallest container of the Community Pharmaceutical that is manufactured in, or imported into, New Zealand.
- 3.4.2 If a Community Pharmaceutical is the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will be paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the balance of any pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where:
 - a) the difference the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100ml pack would be dispensed); and
 - b) in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner.

Note: For the purposes of audit and compliance it is an act of fraud to claim wastage and then use the wastage amount for any subsequent prescription.

PART IV MISCELLANEOUS PROVISIONS

- 4.1 Bulk Supply Orders
 - The following provisions apply to the supply of Community Pharmaceuticals under Bulk Supply Orders:
 - 4.1.1 No Community Pharmaceutical supplied under a Bulk Supply Order will be subsidised unless all the requirements in Section B, C or D of the Schedule applicable to that pharmaceutical are met.
 - 4.1.2 The person who placed the Bulk Supply Order may be called upon by the Ministry of Health to justify the amount ordered.
 - 4.1.3 Class B Controlled Drugs will be subsidised only if supplied under Bulk Supply Orders placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001.
 - 4.1.4 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Bulk Supply Order Controlled Drug Form supplied by the Ministry of Health.
 - 4.1.5 Community Pharmaceuticals listed in Part I of the First Schedule to the Medicines Regulations 1984 will be subsidised only if supplied under a Bulk Supply Order placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 and:
 - a) that institution employs a registered general nurse, registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003; and
 - b) the Bulk Supply Order is supported by a written requisition signed by a Hospital Care Operator.
 - 4.1.6 No Subsidy will be paid for any quantity of a Community Pharmaceutical supplied under a Bulk Supply Order in excess of what is a reasonable monthly allocation for the particular institution, after taking into account stock on hand.
 - 4.1.7 The Ministry of Health may, at any time, by public notification, declare that any approved institution within its particular region, is not entitled to obtain supplies of Community Pharmaceuticals under Bulk Supply Orders with effect from the date specified in that declaration. Any such notice may in like manner be revoked by the Ministry of Health at any time.

4.2 Practitioner's Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals to Practitioners under a Practitioner's Supply Order:

4.2.1 Subject to clause 4.2.3, a Practitioner may only order under a Practitioner's Supply Order those Community Pharmaceuticals listed in Section E Part I and only in such quantities as set out in Section E Part I that the

SECTION A: GENERAL RULES

Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.

- 4.2.2 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Practitioner's Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 4.2.3 A Practitioner may order such Community Pharmaceuticals as he or she expects to be required for personal administration to patients under the Practitioner's care if:
 - a) the Practitioner's normal practice is in the specified areas listed in Section E Part II of the Schedule, or if the Practitioner is a locum for a Practitioner whose normal practice is in such an area.
 - b) the quantities ordered are reasonable for up to one Month's supply under the conditions normally existing in the practice. (The Practitioner may be called on by the Ministry of Health to justify the amounts of Community Pharmaceuticals ordered.)
- 4.2.4 No Community Pharmaceutical ordered under a Practitioner's Supply order will be eligible for Subsidy unless:
 - a) the Practitioner's Supply Order is made on a form supplied for that purpose by the Ministry of Health, or approved by the Ministry of Health and which:
 - i) is personally signed and dated by the Practitioner; and
 - ii) sets out the Practitioner's address; and
 - iii) sets out the Community Pharmaceuticals and quantities, and;
 - b) all the requirements of Sections B and C of the Schedule applicable to that pharmaceutical are met.
- 4.2.5 The Ministry of Health may, at any time, on the recommendation of an Advisory Committee appointed by the Ministry of Health for that purpose, by public notification, declare that a Practitioner specified in such a notice is not entitled to obtain supplies of Community Pharmaceuticals under Practitioner's Supply Orders until such time as the Ministry of Health notifies otherwise.

4.3 Wholesale Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals to Practitioners under Wholesale Supply Orders:

- 4.3.1 Notwithstanding anything contained in the Schedule, but subject nevertheless to subclause 4.3.3 of this clause, a Practitioner may obtain from a wholesaler or distributor, pursuant to a Wholesale Supply Order made on a form supplied by the Ministry of Health, any Community Pharmaceutical specified in Section B and Section E Part I of the Schedule as being available on a Wholesale Supply Order.
- 4.3.2 Subject to clause 4.3.3, Community Pharmaceuticals supplied to Practitioners under Wholesale Supply Orders will be subsidised at a rate not exceeding the Manufacturer's Price for each such Community Pharmaceutical as set out in Section B and Section E Part I of the Schedule.
- 4.3.3 No subsidy will be paid for any quantity of a Community Pharmaceutical supplied to a Practitioner under a Wholesale Supply Order in excess of what is a reasonable monthly allocation for that particular Practitioner, after taking into account stock on hand.
- 4.3.4 The Ministry of Health may, at any time, on the recommendation of an Advisory Committee appointed by the Ministry of Health for that purpose, by public notification, declare that a Practitioner specified in such a notice is not entitled to obtain supplies of Community Pharmaceuticals under Wholesale Supply Orders until such time as the Ministry of Health notifies otherwise.

4.4 Retail Pharmacy and Hospital Pharmacy-Specialist Restriction

The following provisions apply to Prescriptions for Community Pharmaceuticals eligible to be subsidised as "Retail Pharmacy-Specialist" and "Hospital Pharmacy-Specialist":

4.4.1 Record Keeping

It is expected that a record will be kept by both the General Practitioner and the Specialist of the fact of consultation and enough of the clinical details to justify the recommendation. This means referral by telephone will need to be followed up by written consultation.

4.4.2 Expiry

The recommendation expires at the end of two years and can be renewed by a further consultation.

- 4.4.3 The circulation by Specialists of the circumstances under which they are prepared to recommend a particular Community Pharmaceutical is acceptable as a guide. It must however be followed up by the procedure in subclauses 4.4.1 and 4.4.2, for the individual Patient.
- 4.4.4 The use of preprinted forms and named lists of Specialists (as circulated by some pharmaceutical companies) is regarded as inappropriate.
- 4.4.5 The Rules for Retail Pharmacy-Specialist and Hospital Pharmacy-Specialist will be audited as part of the

Ministry of Health's routine auditing procedures.

4.5 Pharmaceutical Cancer Treatments

- 4.5.1 DHBs must provide access to Pharmaceutical Cancer Treatments by funding their use in the treatment of cancers in their DHB hospitals, and/or in association with Outpatient services provided in their DHB hospitals.
- 4.5.2 DHBs must only provide access to Pharmaceuticals for the treatment of cancer that are listed as Pharmaceutical Cancer Treatments in Sections A to G of the Schedule, provided that DHBs may provide access to an unlisted pharmaceutical for the treatment of cancer where that unlisted pharmaceutical:
 - a) has Cancer Exceptional Circumstances approval;
 - b) has Community Exceptional Circumstances or Hospital Exceptional Circumstances approval;
 - c) is being used as part of a bona fide clinical trial which has Ethics Committee approval;
 - d) is being used and funded as part of a paediatric oncology service; or
 - e) was being used to treat the patient in question prior to 1 July 2005.
- 4.5.3 A DHB hospital pharmacy that holds a claiming agreement for Pharmaceutical Cancer Treatements with the Funder may claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" or "PCT only" in Sections A to G of this Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with:
 - a) Part 1;
 - b) clauses 2.1 to 2.3;
 - c) clauses 3.1 to 3.4; and
 - d) clause 4.5,
 - of Section A of the Schedule
- 4.5.4 A Contractor (other than a DHB hospital pharmacy) may only claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" in Sections A to G of the Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with the rules applying to Sections A to G of the Schedule.
- 4.5.5 Some indications for Pharmaceutical Cancer Treatments listed in the Schedule are Unapproved Indications. Some of these formed part of the October 2001 direction from the Minister of Health as to pharmaceuticals and indications for which DHBs must provide funding. As far as reasonably practicable, these Unapproved Indications are marked in the Schedule. However, PHARMAC makes no representation and gives no guarantee as to the accuracy of this information. Practitioners prescribing Pharmaceutical Cancer Treatments for such Unapproved Indications should:
 - a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under the Medicines Act and the Medicines Regulations 1984;
 - b) be aware of and comply with their obligations under the Health and Disability Comissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
 - c) exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical Cancer Treatment or a Pharmaceutical Cancer Treatment for an Unapproved Indication.

4.6 Practitioners prescribing unapproved Pharmaceuticals

Practitioners should, where possible, prescribe Pharmaceuticals that are approved under the Medicines Act 1981. However, the access criteria under which a Pharmaceutical is listed on the Pharmaceutical Schedule may:

- a) in some case, explicitly permit Government funded access to a Pharmaceutical that is not approved under the Medicines Act 1981 or for an Unapproved Indication; or
- b) not explicitly preclude Government funded access to a Pharmaceutical when it is used for an Unapproved Indication;

Accordingly, if Practitioners are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, Practitioners should:

- a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984;
- b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
- c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication.

Practitioners should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as defined in the Medicines Act or otherwise.

4.7 Substitution

Where a Practitioner has prescribed a brand of a Community Pharmaceutical that has no Subsidy or has a Manufacturer's Price that is greater than the Subsidy and there is an alternative fully subsidised Community Pharmaceutical available, a Contractor may dispense the fully subsidised Community Pharmaceutical, subject to:

- a) the Contractor having received a general Authority to Substitute from the Practitioner in relation to the particular medicine or medicines in general; or
- b) the Practitioner having indicated their Authority to Substitute on the prescription; or
- c) the Practitioner having given their Authority to Substitute in relation to the particular prescription.

Such an Authority to Substitute is valid whether or not there is a financial implication for the Pharmaceutical Budget. When dispensing a subsidised alternative brand, the Contractor must annotate and initial the prescription.

4.8 Alteration to Presentation of Pharmaceutical Dispensed

A Contractor, when dispensing a Community Pharmaceutical, may alter the presentation of a Pharmaceutical dispensed but may not alter the total daily dose. If the change will result in additional cost to the DHBs, then:

- a) the Practitioner must authorise and initial the alteration; or
- b) in cases where PHARMAC has approved and notified in writing such a change in dispensing of a named Pharmaceutical due to an out of stock event or short supply, the Contractor must annotate and initial the alteration.

4.9 Amendment of Schedule

PHARMAC may amend the terms of the Schedule from time to time by notice in writing given in such manner as PHARMAC thinks fit, and in accordance with such protocols as agreed with the Pharmacy Guild of New Zealand (Inc) from time to time.

4.10 Conflict in Provisions

If any rules in Sections B-G of this Schedule conflict with the rules in Section A, the rules in Sections B-G apply.

SECTION B: ALIMENTARY TRACT AND METABOLISM

	Subsidy		Fully Brand or
	(Manufacturer's P		sidised Generic
	\$	Per	 Manufacturer
Antacids and Antiflatulants			
Antacids and Reflux Barrier Agents			
ALGINIC ACID			
Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet		30	 Gaviscon Infant
CALCIUM CARBONATE WITH AMINOACETIC ACID			
* Tab 420 mg with aminoacetic acid 180 mg – Higher subsidy	0.00	100	
of \$6.30 per 100 with Endorsement	3.00 (6.30)	100	Titralac
Additional subsidy by endorsement is available for pregnar	()	rescription mu	
SIMETHICONE			······································
* Oral liq aluminium hydroxide 200 mg with magnesium hydrox-			
ide 200 mg and activated simethicone 20 mg per 5 ml	1.50	500 ml	
	(4.26)		Mylanta P
SODIUM ALGINATE			
* Tab 500 mg with sodium bicarbonate 267 mg and calcium	4.00		
carbonate 160 mg - peppermint flavour		60	Gaviscon Double
	(8.60)		Strength
* Oral lig 500 mg with sodium bicarbonate 267 mg and calcium			ollongin
carbonate 160 mg per 10 ml		500 ml	
	(4.95)		Acidex
* Oral liq 500 mg with sodium bicarbonate 267 mg per 10 ml		500 ml	
(aniseed)	1.50 (8.64)	500 ml	Gaviscon
Phase shake D'adian Assata	(0.04)		Gaviscon
Phosphate Binding Agents			
ALUMINIUM HYDROXIDE			
Tab 600 mg	12.56	100	🖌 Alu-Tab
Antidiarrhoeals			
Agents Which Reduce Motility			
DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPH	ATE		
* Tab 2.5 mg with atropine sulphate 25 μg	3.90	100	 Diastop
LOPERAMIDE HYDROCHLORIDE – Up to 30 tab available on a	PSO		
* Tab 2 mg	11.50	400	✓ Nodia
Rectal and Colonic Anti-inflammatories			
BUDESONIDE			
Cap 3 mg - Special Authority see SA0913 on the next page			
- Retail pharmacy	166.50	90	 Entocort CIR

	Subsidy (Manufacturer's Price \$	e) Sub Per	Fully sidised	Brand or Generic Manufacturer
➡SA0913 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid	for 3 months for app	olications m	eeting	the following criteria:
Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disea	se and			
2 Any of the following:				
2.1 Diabetes; or				
2.2 Cushingoid habitus; or				
2.3 Osteoporosis where there is significant risk of fractu		.,		
2.4 Severe acne following treatment with conventional c Renewal from any relevant practitioner. Approvals valid for 3 mo			ins an	propriate and the patient is
benefiting from treatment.			uno up	propriate and the patient is
The patient may not have had more than 1 prior approval in the la	st year.			
Note: Clinical trials for Entocort CIR use beyond three months de	monstrated no impre	ovement in	relapse	e rate.
HYDROCORTISONE ACETATE				
Rectal foam 10 %, CFC-Free (14 applications)		1.1 g OP	v (Colifoam
MESALAZINE				
Tab 400 mg		100		Asacol
Tab long-acting 500 mg Enema 1 g per 100 ml		100 7		Pentasa Pentasa
Suppos 500 mg		20		Asacol
Suppos 1 g		28		Pentasa
OLSALAZINE				
Tab 500 mg	59.86	100	v [Dipentum
Cap 250 mg	31.51	100	v [Dipentum
SODIUM CROMOGLYCATE				
Cap 100 mg		100	~ N	lalcrom
SULPHASALAZINE				
* Tab 500 mg		100		Salazopyrin
* Tab EC 500 mg	9.44	100		Salazopyrin EN
Antihaemorrhoidals				
Corticosteroids				
FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVA		OCAINE		
Oint 950 µg, with fluocortolone pivalate 920 µg, and cin-		~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~		
chocaine hydrochloride 5 mg per g		30 g OP	<u>v</u> [JItraproct
Suppos 630 µg, with fluocortolone pivalate 610 µg, and cin- chocaine hydrochloride 1 mg		12	~1	JItraproct
	2.00	12	• •	
Soothing Agents				
ZINC OXIDE				
Oint zinc oxide with balsam peru		50 g OP		
Current fine evide with holes mere	(6.67)	10	A	Anusol
Suppos zinc oxide with balsam peru	4.47 (6.49)	12	4	Anusol
	(0.43)		F	

26

	Subsidy (Manufacturer's Price) Sub	Fully Brand or bsidised Generic
	\$	Per	 Manufacturer
Antispasmodics and Other Agents Altering Gut	Motility		
ATROPINE SULPHATE * Inj 600 μg, 1 ml – Up to 5 inj available on a PSO * Inj 1200 μg, 1 ml – Up to 5 inj available on a PSO		50 50	✓ AstraZeneca✓ AstraZeneca
HYOSCINE N-BUTYLBROMIDE * Tab 10 mg * Inj 20 mg, 1 ml – Up to 5 inj available on a PSO MEBEVERINE HYDROCHLORIDE		20 5	 ✓ <u>Gastrosoothe</u> ✓ <u>Buscopan</u>
* Tab 135 mg		90	✓ <u>Colofac</u>
Antiulcerants			
Antisecretory and Cytoprotective			
MISOPROSTOL * Tab 200 µg	52.70	120	✔ Cytotec
Helicobacter Pylori Eradication			
OMEPRAZOLE, AMOXYCILLIN AND CLARITHROMYCIN Omeprazole cap 20 mg × 14, amoxycillin cap 500 mg × 28 and clarithromycin tab 500 mg × 14		1 OP	✔ Losec Hp7 OAC
H2 Antagonists			
CIMETIDINE – Only on a prescription * Tab 200 mg * Tab 400 mg	(7.50)	100 100	Apo-Cimetidine Apo-Cimetidine
FAMOTIDINE – Only on a prescription * Tab 20 mg * Tab 40 mg	8.10	250 250	 ✓ Famox ✓ Famox
RANITIDINE HYDROCHLORIDE Only on a prescription * Tab 150 mg * Tab 300 mg * Oral liq 150 mg per 10 ml * Inj 25 mg per ml, 2 ml	10.94 7.95	250 250 300 ml 5	 Arrow-Ranitidine Arrow-Ranitidine Peptisoothe Zantac
Proton Pump Inhibitors			
LANSOPRAZOLE * Cap 15 mg * Cap 30 mg		28 28	✓ Solox ✓ Solox

	Subsidy (Manufacturer's Pric \$	e) S Per	Fully Subsidised	Brand or Generic Manufacturer
OMEPRAZOLE				
For omeprazole suspension refer, page 163 * Cap 10 mg	2 14	30		r Reddy's
* Cap 20 mg		30		<u>Omeprazole</u> r Reddy's
* Cap 40 mg		30		Omeprazole r Reddy's
* Inj 40 mg		5		Omeprazole r Reddy's
, .				Omeprazole
PANTOPRAZOLE * Tab 20 mg	2.24	28		r Reddy's
* Tab 40 mg	3.36	28	🗸 <u>Di</u>	Pantoprazole r Reddy's Pantoprazolo
* Inj 40 mg	8.75	1		Pantoprazole antocid IV
Site Protective Agents				
SUCRALFATE				
Tab 1 g	35.50 (48.28)	120	Ca	arafate
Diabetes				
Hyperglycaemic Agents				
GLUCAGON HYDROCHLORIDE Inj 1 mg syringe kit – Up to 5 kit available on a PSO	27.00	1	🖌 GI	lucagen Hypokit
Insulin - Short-acting Preparations				
INSULIN NEUTRAL				
▲ Inj human 100 u per ml	25.26	10 ml OP		ctrapid umulin R
▲ Inj human 100 u per ml, 3 ml	42.66	5	🖌 A0	ctrapid Penfill umulin R
Insulin - Intermediate-acting Preparations				
INSULIN ISOPHANE				
▲ Inj human 100 u per ml		10 ml OP		umulin NPH
▲ Inj human 100 u per ml, 3 ml		5	🖌 Hu	rotaphane umulin NPH rotaphane Penfill
INSULIN ISOPHANE WITH INSULIN NEUTRAL			₹ FI	otaphane i chini
Inj human with neutral insulin 100 u per ml	25.26	10 ml OP		umulin 30/70 ixtard 30
Inj human with neutral insulin 100 u per ml, 3 ml	42.66	5	✓ Hu ✓ Pe ✓ Pe	umulin 30/70 enMix 30 enMix 40 enMix 50

28

	Subsidy (Manufacturer's Price) \$	Su Per	Fully bsidised	Brand or Generic Manufacturer
INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE				
Inj lispro 25% with insulin lispro protamine 75% 100 u per ml, 3 ml		5	🗸 Н	umalog Mix 25
▲ Inj lispro 50% with insulin lispro protamine 50% 100 u per ml,3 ml		5	🗸 Н	umalog Mix 50
Insulin - Long-acting Preparations				
INSULIN GLARGINE - Special Authority see SA0834 below - Re	etail pharmacy			
▲ Inj 100 u per ml, 10 ml		1	🖌 La	antus
▲ Inj 100 u per ml, 3 ml		5	🖌 🖌 La	antus
▲ Inj 100 u per ml, 3 ml disposable pen	94.50	5	🖌 La	antus SoloStar

SA0834 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either:

- 1 Both:
 - 1.1 Patient has type 1 diabetes and has received an intensive regimen (injections at least three times a day) of an intermediate acting insulin in combination with a rapid acting insulin analogue for at least three months; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced more than one unexplained severe hypoglycaemic episode in the previous 12 months (severe defined as requiring the assistance of another person); or
 - 1.2.2 Patient has experienced unexplained symptomatic nocturnal hypoglycaemia, biochemically documented at <3.0 mmol/L, more than once a month despite optimal management; or
- 2 Patient has documented severe, or continuing, systemic or local allergic reaction to existing insulins. Note this does not include hypoglycaemic episodes.

Renewal only from a relevant specialist or general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Patient is continuing to derive benefit due to reduced hypoglycaemic events whilst maintaining similar or better glycaemic control; or
- 2 Patient's allergic reaction has significantly decreased, or resolved, following the change to long-acting insulin and patient is continuing to benefit from treatment.

Insulin - Rapid Acting Preparations

INSULIN ASPART ▲ Inj 100 u per ml, 3 ml ▲ Inj 100 u per ml, 10 ml String ▲ Inj 100 u per ml, 10 ml 30.03 INSULIN LISPRO ▲ Inj 100 u per ml, 10 ml ▲ Inj 100 u per ml, 30 ml 59.52	5 1 10 ml OP 5	 ✓ NovoRapid Penfill ✓ NovoRapid ✓ Humalog ✓ Humalog
Alpha Glucosidase Inhibitors		
ACARBOSE – Special Authority see SA0925 on the next page – Retail pharmacy * Tab 50 mg	90 90	✓ <u>Glucobay</u> ✓ <u>Glucobay</u>

	Subsidy (Manufacturer's Pric \$	ce) Su Per	Fully Brand or ubsidised Generic ✓ Manufacturer
 SA0925 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid the following criteria: Both: The patient has type 2 diabetes; and Either: Metformin is not tolerated, or is contraindicated; or The patient has not responded to the maximum app 			ess notified for applications me
Oral Hypoglycaemic Agents			
GLIBENCLAMIDE * Tab 2.5 mg * Tab 5 mg (Gliben Tab 2.5 mg to be delisted 1 February 2010) (Gliben Tab 5 mg to be delisted 1 February 2010)		100 100	✔ Gliben✔ Gliben✔ Daonil
GLICLAZIDE * Tab 80 mg	22.24	500	✓ Apo-Gliclazide
GLIPIZIDE * Tab 5 mg	3.50	100	✓ Minidiab
METFORMIN HYDROCHLORIDE * Tab 500 mg * Tab 850 mg		500 250	 ✓ Arrow-Metformin ✓ Arrow-Metformin
PIOGLITAZONE – Special Authority see SA0959 below – Retail p Tab 15 mg	harmacy	28	✓ Pizaccord
Tab 30 mg	45.78	28	 ✓ Actos ✓ Pizaccord ✓ Actos
Tab 45 mg		28	✓ Pizaccord ✓ Actos
(Actos Tab 15 mg to be delisted 1 December 2009) (Actos Tab 30 mg to be delisted 1 December 2009) (Actos Tab 45 mg to be delisted 1 December 2009)			
 SA0959 Special Authority for Subsidy Initial application — (Patients with type 2 diabetes) from ar unless notified for applications meeting the following criteria: Either: Patient has not achieved glycaemic control on maximum do are contraindicated or not tolerated; or Patient is on insulin. 			
Diabetes Management			
Glucose/Urine Testing			

COPPER

30

*	Tab, diagnostic – Not on a BSO	5.02	36 OP	
	-	(31.80)		Clinitest

	Qubaidu		Fully Drand ar
	Subsidy (Manufacturer's		Fully Brand or sidised Generic
	\$	Per	 Manufacturer
GLUCOSE OXIDASE			
Urine diagnostic test – Not on a BSO	4.11 (7.00)	50 strip OP	Diabur 5000
Urine diagnostic test with peroxidase - Not on a BSO	()	50 strip OP	Diabul 5000
5	(6.26)	1	Diastix
	4.13 (8.65)		Clinistix
Katana Taating	(0.03)		Cimisux
Ketone Testing			
GLUCOSE OXIDASE			
Urine diagnostic test with peroxidase, sodium nitroprusside	4.50	50 at at 00	
and aminoacetic acid – Not on a BSO	4.53 (8.00)	50 stick OP	Keto-Diabur 5000
Urine diagnostic test with peroxidase, potassium iodide,	(0.00)		Reio-Diabui 5000
sodium nitroprusside and aminoacetic acid – Not on			
a BSO	4.53	50 strip OP	
	(14.87)		Keto-Diastix
(Keto-Diabur 5000 Urine diagnostic test with peroxidase, sodium 2009)	nitroprusside	and aminoacetic	c acid to be delisted 1 December
(Keto-Diastix Urine diagnostic test with peroxidase, potassium ioc December 2009)	lide, sodium ni	troprusside and	aminoacetic acid to be delisted 1
KETONE BLOOD BETA-KETONE ELECTRODES - Subsidy by en	ndorsement		
Patient has type 1 diabetes and has had one or more episodes			
of 2 packs per annum. No further prescriptions will be subsidi			0,7
Test strip – Not on a BSO	8.50	10 strip OP	 Optium Blood Ketone Test Strips
SODIUM NITROPRUSSIDE			
* Test strip – Not on a BSO	14.14	20 strip OP	✓ Ketostix
* Urine diagnostic strips, buffered - Not on a BSO		50 strip OP	
	(6.00)		Ketur-Test
	3.40 (10.94)		Ketostix
(Ketur-Test Urine diagnostic strips, buffered to be delisted 1 Decer	· · · ·		Relosit
(Ketostix Urine diagnostic strips, buffered to be delisted 1 Decemb			
Blood Glucose Testing			
BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by en	dorsement		
a) Maximum of 1 meter per prescription	doroemont		
b)			
 A diagnostic blood glucose test meter is subsidised March 2005 or is prescribed for a pregnant woman y 		ho begin insulin	or sulphonylurea therapy after 1
2) Only one meter per patient. No further prescriptions		ised. The presc	ription must be endorsed accord-
ingly.			
Meter	9.00	1	✓ FreeStyle Lite
	19.00		 Optium Xceed Accu-Chek
	13.00		Performa

	Subsidy (Manufacturer's Price \$	e) Sub Per	Fully sidised	Brand or Generic Manufacturer
 BLOOD GLUCOSE DIAGNOSTIC TEST STRIP The number of test strips available on a prescription is restrianted in the same prescription as insulin or a sulphonylurea but are on a difference or Prescribed on the same prescription as insulin or a sulphonor Prescribed for a pregnant woman with diabetes and endo SensoCard blood glucose test strips are subsidised only if prescriptions and the same prescription as the same prescription as the same prescription as the same prescription as insulin or a sulphonor or Prescribed for a pregnant woman with diabetes and endo SensoCard blood glucose test strips are subsidised only if prescriptions are subsidised only if prescriptions and the same prescription as the same prescription as	erent prescription an onylurea in which cas rsed accordingly.	e the presc	ription i	s deemed to be endorsed;
Blood glucose test strips	21.65 50	0 test OP	v 0	reeStyle Lite ptium 5 second test
	22.00		• •	ccu-Chek Performa
	26.20		🗸 S	ensoCard
Insulin Syringes and Needles				

Subsidy is available for disposable insulin syringes, needles, and pen needles if prescribed on the same form as the one used for the supply of insulin or when prescribed for an insulin patient and the prescription is endorsed accordingly.

INSULIN PEN NEEDLES – Maximum of 100 dev per prescriptio	n		
★ 29 g × 12.7 mm		100	🖌 ABM
C C			B-D Micro-Fine
	11.75		SC Profi-Fine
✤ 31 g × 5 mm	11.75	100	B-D Micro-Fine
Ĵ			SC Profi-Fine
✤ 31 g × 6 mm		100	🖌 ABM
Ĵ	(26.00)		NovoFine
✤ 31 g × 8 mm		100	🖌 ABM
			B-D Micro-Fine
	11.75		SC Profi-Fine
INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE	- Maximum of 100) dev per pr	escription
* Syringe 0.3 ml with 29 g × 12.7 mm needle		100	✓ ABM
			B-D Ultra Fine
			M Ject
* Syringe 0.3 ml with 31 g × 8 mm needle	13.00	100	✓ ABM
			B-D Ultra Fine II
			M Ject
* Syringe 0.5 ml with 29 g × 12.7 mm needle	13.00	100	✓ ABM
			B-D Ultra Fine
			M Ject
* Syringe 0.5 ml with 31 g × 8 mm needle	13.00	100	ABM
			B-D Ultra Fine II
			M Ject
* Syringe 1 ml with 29 g × 12.7 mm needle	13.00	100	✓ ABM
		100	B-D Ultra Fine
			M Ject
* Syringe 1 ml with 31 g × 8 mm needle		100	✓ ABM
,			B-D Ultra Fine II
			✓ DM Ject

32

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
Digestives Including Enzymes					
PANCREATIC ENZYME					
Tab EC 1,900 BP u lipase, 1,700 BP u amylase, 110 BP u protease		300	🗸 Pa	ancrex V	
Tab EC 5,600 BP u lipase, 5,000 BP u amylase, 330 BP u protease	58.44	300	🖌 Pa	ancrex V Forte	
Cap 8,000 BP u lipase, 9,000 BP u amylase, 430 BP u pro- tease	67.26	300	🖌 Pa	ancrex V	
Cap 8,000 USP u lipase, 30,000 USP u amylase, 30,000 USP u protease – Retail pharmacy-Specialist	85.00	250	✔ C	otazym ECS	
Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease – Retail pharmacy-Specialist		100	🗸 Ci	reon 10000	
Cap EC 25,000 BP u lipase, 18,000 BP u amylase, 1,000 BP u protease – Retail pharmacy-Specialist	94.38	100	🗸 C	reon Forte	
Cap EC 25,000 BP u lipase, 22,500 BP u amylase, 1,250 BP u protease – Retail pharmacy-Specialist	94.40	100	🖌 Pa	anzytrat	
URSODEOXYCHOLIC ACID – Special Authority see SA0914 belo Cap 300 mg		y 100	✓ <u>A</u>	ctigall	

➡SA0914 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis).
- Note: Liver biopsy is not usually required for diagnosis but is helpful to stage the disease.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Actigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure – doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation.

Laxatives

Bulk-forming Agents

MUCILAGINOUS LAXATIVES - Only on a prescription 325 g OP KonsvI-D 380 g OP Mucilax 6.69 7.92 450 a OP (12.71)Isogel 8.80 500 g OP (16.49)Normacol 336 g OP (12.38) Metamucil 275 g OP Mucilax (10.60)

** Tab 50 mg 489 100 ✓ Coloxyl ** Tab 120 mg 6.73 100 ✓ Coloxyl ** Tab 120 mg 6.73 100 IO ✓ Coloxyl ** Enema conc 18% 5.40 100 ml OP ✓ Coloxyl DOCUSATE SODIUM WITH SENNOSIDES 5.40 100 ml OP ✓ Coloxyl ** Tab 50 mg with total sennosides 8 mg 7.98 200 ✓ Laxsol POLOXAMER – Only on a prescription 3.78 30 ml OP ✓ Coloxyl Osmotic Laxatives SUPCEROL * Suppose 3.6 g - Only on a prescription 5.00 20 ✓ PSM LACTULOSE – Only on a prescription .5.00 20 ✓ PSM LACTULOSE – Only on a prescription .6.65 1,000 ml ✓ Duphalac MACROGOL 3350 – Special Authority see SA0891 below – Retail pharmacy Powder 13.125 g, sachets – Maximum of 60 sach per prescription 18.14 30 ✓ Movicol **SA0891 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 12 months where the patient has problematic constipatic requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactudes barefit from treatment. SODIUM ACID PHOSPHATE – Only on a prescription	—	Subsidy		Fully Brand or
MUCLAGINOUS LAXATIVES WITH STIMULANTS 3.52 200 g OP ** Dry (7.69) Normacol Plus 8.80 500 g OP (16.49) Normacol Plus Faecal Softeners DOCUSATE SODIUM - Only on a prescription ** Tab 50 mg		· ·		
** Dry .3.52 200 g OP (7.69) Normacol Plus B.8.0 500 g OP (16.49) Normacol Plus Faecal Softeners DOCUSATE SODIUM On a prescription ** Tab 50 mg .489 100 ✓ Coloxyl ** Tab 50 mg .6.73 100 ✓ Coloxyl ** Tab 50 mg with total sennosides 8 mg .7.98 200 ✓ Laxsol POLOXAMER – Only on a prescription .3.78 30 ml OP ✓ Coloxyl ** Tab 50 mg with total sennosides 8 mg .7.98 200 ✓ Laxsol POLOXAMER – Only on a prescription .3.78 30 ml OP ✓ Coloxyl ** Oral drops 10% .3.78 30 ml OP ✓ Coloxyl OSmotic Laxatives		Ŷ	1.01	
(7.69) 8.80 500 g OP (16.49) Normacol Plus Faecal Softeners DOCUSATE SODIUM – Only on a prescription * Tab 50 mg 4.89 100 ✓ Coloxyl * Tab 20 mg 6.73 100 ✓ Coloxyl * Tab 50 mg with total sennosides 8 mg 5.40 100 ml OP ✓ Coloxyl DOCUSATE SODIUM WITH SENNOSIDES 5.40 100 ml OP ✓ Coloxyl * Tab 50 mg with total sennosides 8 mg 7.98 200 ✓ Laxsol POLOXARE - Only on a prescription 3.78 30 ml OP ✓ Coloxyl * Tab 50 mg over total sennosides 8 mg 5.00 20 ✓ PSM ACTULOSE - Only on a prescription 5.00 20 ✓ PSM ACTULUSE - Only on a prescription 6.65 1,000 ml ✓ Duphalac MACROGOL 3350 - Special Authority see SA0891 below - Retail pharmacy Powder 13.125 g, sachets - Maximum of 60 sach per prescription * Movicol *SA0891 Special Authority for Subsidy 11181 application from any relevant practitioner. Approvals valid for 6 months where the patient has problematic constipatic where laculose is not contraindicated. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient has including laculoa where laculose is not contraindicated. </td <td></td> <td>3 52</td> <td>200 a OP</td> <td></td>		3 52	200 a OP	
8.80 500 g OP (16.49) Normacol Plus Faecal Softeners DOCUSATE SODIUM - Only on a prescription * Tab 50 mg 4.89 100 ✓ Coloxyl * Tab 50 mg 6.73 100 ✓ Coloxyl * Tab 50 mg with total sennosides 8 mg 7.98 200 ✓ Laxsol POLOXAMEN - Only on a prescription 3.78 30 ml OP ✓ Coloxyl * Tab 50 mg with total sennosides 8 mg 7.98 200 ✓ Laxsol POLOXAMEN - Only on a prescription 8.79 200 ✓ Laxsol SUPCERAL Suppos 3.6 g - Only on a prescription 6.65 1,000 ml ✓ Duphalac MACROGOL 3350 - Special Authority see SA0891 below - Retail pharmacy Powedro 13.25 g, sachets - Maximum of 60 sach per pre- scription 18.14 30 ✓ Movicol >>>SA02931 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 12 months where the patient has problematic constipation requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactulos where lactulose is not contraindicated. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to ga senefit from treatment. SODIUM CITRATE WITH SODIUM LAUFYL SULPHOACETATE – On			200 9 01	Normacol Plus
Faecal Softeners DOCUSATE SODIUM – Only on a prescription * Tab 50 mg		(/	500 g OP	
DOCUSATE SODIUM - Only on a prescription ** Tab 50 mg		(16.49)		Normacol Plus
** Tab 50 mg 4.89 100 Coloxyl ** Tab 120 mg 6.73 100 Coloxyl ** Enema conc 18% 5.40 100 ml OP Coloxyl DOCUSATE SODIUM WITH SENNOSIDES 5.40 100 ml OP Coloxyl ** Tab 50 mg with total sennosides 8 mg 7.98 200 Laxsol POLOXAMER - Only on a prescription 3.78 30 ml OP Coloxyl * Oral drops 10% 3.78 30 ml OP Coloxyl Osmotic Laxatives SUPCEROL Suppos 3.6 g - Only on a prescription 5.00 20 PSM LACTULOSE - Only on a prescription 6.65 1,000 ml Duphalac MACROGOL 3350 - Special Authority see SA0891 below - Retail pharmacy Power 13.125 g, sachets - Maximum of 60 sach per pre- scription 18.14 30 Movicol >*SA0891 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 months where the patient has problematic constipatic requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including laculos where laculose is not contraindicated. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to ga confit from tramement. SODIUM ACID PHOSPHATE - Only on a prescr	Faecal Softeners			
** Tab 120 mg 6.73 100 ✓ Coloxyl ** Enema conc 18%	DOCUSATE SODIUM - Only on a prescription			
** Enema conc 18%				'
DOCUSATE SODIUM WITH SENNOSIDES ** Tab 50 mg with total sennosides 8 mg 7.98 200 ✓ Laxsol POLOXAMER – Only on a prescription	5			•
** Tab 50 mg with total sennosides 8 mg		5.40	100 ml OP	Coloxyl
POLOXAMER - Only on a prescription 3.78 30 ml OP ✓ Coloxyl Osmotic Laxatives GLYCEROL * Suppos 3.6 g - Only on a prescription 5.00 20 ✓ PSM LACTULOSE - Only on a prescription 6.65 1,000 ml ✓ Duphalac WACROGOL 3350 - Special Authority see SA0891 below - Retail pharmacy Powder 13.125 g, sachets - Maximum of 60 sach per presscription 18.14 30 ✓ Movicol >>SA0891 Special Authority for Subsidy 118.14 30 ✓ Movicol >>SA0891 Special Authority for Subsidy 118.14 30 ✓ Movicol >>SA0891 Special Authority for Subsidy 118.14 30 ✓ Movicol >>SA0891 Special Authority for Subsidy 118.14 30 ✓ Movicol >>SA0891 Special Authority for Subsidy 118.14 30 ✓ Movicol >>SA00891 Special Authority for Subsidy 118.14 30 ✓ Movicol >>SA0891 Special Authority for Subsidy 118.14 30 ✓ Movicol >>BA0001 Prevention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactulos where lactulose is not contriandicated. 2.50				
** Oral drops 10% 3.78 30 ml OP ✓ Coloxyl Osmotic Laxatives GLYCEROL * Suppos 3.6 g - Only on a prescription 5.00 20 ✓ PSM LACTULOSE - Only on a prescription * 6.65 1,000 ml ✓ Duphalac MACROGOL 3350 - Special Authority see SA0891 below - Retail pharmacy Powder 13.125 g, sachets - Maximum of 60 sach per prescription 18.14 30 ✓ Movicol SeS0891] Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 months where the patient has problematic constipation requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactulos where lactulose is not contraindicated. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to gabenefit from treatment. SODIUM ACID PHOSPHATE - Only on a prescription Enema Enema 16% with sodium phosphate 8% 2.50 1 ✓ Fleet Phosphate Enema SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE - Only on a prescription Enema 5.09 200 ✓ Lax-Tabs Sistemulant Laxatives (3.00) 2.35 6 Dulcolax ✓ Fleet SUPPos 5 mg (3.00) 2.35 6 2.35	* Tab 50 mg with total sennosides 8 mg	7.98	200	Laxsol
Osmotic Laxatives GLYCEROL * Suppos 3.6 g - Only on a prescription * Suppos 3.6 g - Only on a prescription * CTULOSE - Only on a prescription * Oral liq 10 g per 15 ml MACROGOL 3350 - Special Authority see SA0891 below - Retail pharmacy Powder 13.125 g, sachets - Maximum of 60 sach per prescription scription SA0891 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 months where the patient has problematic constipatic requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactulos where lactulose is not contraindicated. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to ga senefit from treatment. SODIUM ACID PHOSPHATE - Only on a prescription Enema 16% with sodium phosphate 8% SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE - Only on a prescription Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml 5 ml 7.30 Stimulant Laxatives BISACODYL - Only on a prescription * Tab 5 mg 2.35 * Suppos 10 mg 3.396 * Suppos 10 mg 3.396 SENN	POLOXAMER – Only on a prescription			
GLYCEROL # Suppos 3.6 g − Only on a prescription	* Oral drops 10%	3.78	30 ml OP	✓ <u>Coloxyl</u>
 ★ Suppos 3.6 g - Only on a prescription	Osmotic Laxatives			
ACTULOSE - Only on a prescription * Oral liq 10 g per 15 ml	GLYCEROL			
 ★ Oral liq 10 g per 15 ml MACROGOL 3350 – Special Authority see SA0891 below – Retail pharmacy Powder 13.125 g, sachets – Maximum of 60 sach per pre- scription ★SA0891 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 months where the patient has problematic constipation requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactulos where lactulose is not contraindicated. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to ga benefit from treatment. SODIUM ACID PHOSPHATE – Only on a prescription Enema 16% with sodium phosphate 8% SODIUM ACID PHOSPHATE – Only on a prescription Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml 7.30 12 ✓ Microlax Stimulant Laxatives BISACODYL – Only on a prescription * Tab 5 mg Suppos 5 mg (3.00) Dulcolax * Suppos 10 mg 3.96 12 ✓ Fleet SENNA – Only on a prescription * Tab, standardised 	* Suppos 3.6 g – Only on a prescription	5.00	20	V PSM
MACROGOL 3350 – Special Authority see SA0891 below – Retail pharmacy Powder 13.125 g, sachets – Maximum of 60 sach per pre- scription	LACTULOSE – Only on a prescription			
Powder 13.125 g, sachets - Maximum of 60 sach per pre- scription 18.14 30 ✓ Movicol ⇒SA0891 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 months where the patient has problematic constipation requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactulos where lactulose is not contraindicated. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to ga onenfit from treatment. SODIUM ACID PHOSPHATE - Only on a prescription Enema 16% with sodium phosphate 8% 2.50 1 ✓ Fleet Phosphate Enema SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE - Only on a prescription Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml 7.30 12 ✓ Microlax Stimulant Laxatives 8 2.35 6 0 0 0 BISACODYL - Only on a prescription * Tab 5 mg 2.39 1 ✓ Lax-Tabs * Suppos 10 mg 3.96 12 ✓ Fleet SENNA - Only on a prescription * Tab, standardised 2.17 100	* Oral liq 10 g per 15 ml	6.65	1,000 ml	Duphalac
scription 18.14 30 ✓ Movicol ▶SA0891 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 months where the patient has problematic constipation requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactulos where lactulose is not contraindicated. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to gate benefit from treatment. SODIUM ACID PHOSPHATE – Only on a prescription Enema 16% with sodium phosphate 8% SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE – Only on a prescription Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml 5 ml 7.30 12 ✓ Microlax Stimulant Laxatives BISACODYL – Only on a prescription * Tab 5 mg 2.35 * Suppos 5 mg 5.09 200 * Suppos 10 mg 3.96 12 * Senson 10 mg 3.96 12 ✓ Fleet SENNA – Only on a prescription 2.17 100	MACROGOL 3350 - Special Authority see SA0891 below - Re	tail pharmacy		
▶SA0891 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 months where the patient has problematic constipation requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactules where lactulose is not contraindicated. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to gate the patient from treatment. SODIUM ACID PHOSPHATE – Only on a prescription Enema 16% with sodium phosphate 8% SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE – Only on a prescription Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml 5 ml 5 mg 8 SUBSACODYL – Only on a prescription * Tab 5 mg * Suppos 5 mg * Suppos 10 mg * Suppos 10 mg * Suppos 10 mg * Tab, standardised	Powder 13.125 g, sachets – Maximum of 60 sach per pre	9-		
Initial application from any relevant practitioner. Approvals valid for 6 months where the patient has problematic constipution requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactulos where lactulose is not contraindicated. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to gate benefit from treatment. SODIUM ACID PHOSPHATE – Only on a prescription Enema 16% with sodium phosphate 8% SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE – Only on a prescription Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml 5 ml 5 ml 8 Tab 5 mg 8 Suppos 10 mg * Suppos 10 mg * Suppos 10 mg * Tab, standardised * Tab, standardised	scription		30	Movicol
requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactulos where lactulose is not contraindicated. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to gate benefit from treatment. SODIUM ACID PHOSPHATE – Only on a prescription Enema 16% with sodium phosphate 8%	SA0891 Special Authority for Subsidy			
where lactulose is not contraindicated. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to ga benefit from treatment. SODIUM ACID PHOSPHATE – Only on a prescription Enema 16% with sodium phosphate 8%				
Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to gate benefit from treatment. SODIUM ACID PHOSPHATE – Only on a prescription Enema 16% with sodium phosphate 8% SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE – Only on a prescription Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml 5 ml 7.30 12 V Microlax Stimulant Laxatives BISACODYL – Only on a prescription * Tab 5 mg Suppos 5 mg 2.35 6 (3.00) Dulcolax * Suppos 10 mg * Suppos 10 mg * Tab, standardised * Tab, standardised		adequate trial of o	other oral pharr	nacotherapies including lactulos
benefit from treatment. SODIUM ACID PHOSPHATE – Only on a prescription Enema 16% with sodium phosphate 8%				
SODIUM ACID PHOSPHATE - Only on a prescription 2.50 1 ✓ Fleet Phosphate Enema 16% with sodium phosphate 8% 2.50 1 ✓ Fleet Phosphate SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE - Only on a prescription Enema 5 Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 microlax Stimulant Laxatives 7.30 12 ✓ Microlax BISACODYL - Only on a prescription 5.09 200 ✓ Lax-Tabs * Suppos 5 mg 2.35 6 Dulcolax * Suppos 10 mg 3.96 12 ✓ Fleet SENNA - Only on a prescription 2.17 100 100		months where the	ne patient is co	ompliant and is continuing to gai
Enema 16% with sodium phosphate 8%				
Enema SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE – Only on a prescription Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml		2 50	1	Fleet Phosphate
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml			I	•
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml	SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE	- Only on a pres	scription	
5 ml		• •		
BISACODYL – Only on a prescription * Tab 5 mg	o i i		12	Microlax
* Tab 5 mg 5.09 200 ✓ Lax-Tabs * Suppos 5 mg 2.35 6 (3.00) Dulcolax * Suppos 10 mg 3.96 12 ✓ Fleet SENNA – Only on a prescription 2.17 100	Stimulant Laxatives			
* Tab 5 mg 5.09 200 ✓ Lax-Tabs * Suppos 5 mg 2.35 6 (3.00) Dulcolax * Suppos 10 mg 3.96 12 ✓ Fleet SENNA – Only on a prescription 2.17 100	BISACODYL – Only on a prescription			
** Suppos 5 mg 2.35 6 (3.00) Dulcolax ** Suppos 10 mg 3.96 12 ✓ Fleet SENNA – Only on a prescription 2.17 100			200	Lax-Tabs
(3.00) Dulcolax ★ Suppos 10 mg				·
SENNA – Only on a prescription * Tab, standardised				Dulcolax
* Tab, standardised	* Suppos 10 mg	3.96	12	✓ Fleet
* Tab, standardised	SENNA – Only on a prescription			
(6.16) Senokot		2.17	100	
		(6.16)		Senokot

34

	Subsidy		Fully Brand or
	(Manufacturer's \$	Price) Sub Per	sidised Generic Manufacturer
Metabolic Disorder Agents	Ψ	rei	Wanuacturer
Gaucher's Disease			
MIGLUCERASE – Special Authority see SA0473	below – Hospital pharmacy [H	P1]	
Inj 40 iu per ml, 200 iu vial		1	 Cerezyme
SA0473 Special Authority for Subsidy	went Denel		
Special Authority approved by the Gaucher's Treat lotes: Subject to a budgetary cap. Applications w	ill be considered and approved		ling availability.
pplication details may be obtained from PHARM			о ,
The Co-ordinator, Gaucher's Treatment Panel	Phone: (04) 460 4990		
PHARMAC, PO Box 10 254 Wellington	Facsimile: (04) 916 7571 Email: gaucherpanel@pharr	nac.govt.nz	
5	_mail: gauonorpanorephan	1140.901.112	
Mouth and Throat			
Agents Used in Mouth Ulceration			
BENZYDAMINE HYDROCHLORIDE			
Soln 0.15%		500 ml	Difflam
CHLORHEXIDINE GLUCONATE	(15.36)		Dillian
Mouthwash 0.2%		200 ml OP	✔ Orion
CHOLINE SALICYLATE WITH CETALKONIUM CI	HLORIDE		
Adhesive gel 8.7% with cetalkonium chloride		15 g OP	
	(5.25)		Bonjela
SODIUM CARBOXYMETHYLCELLULOSE	17.00		✓ Stomahesive
With pectin and gelatin paste	17.20 1.52	56 g OP 5 g OP	✓ Stomanesive
	(3.60)	0 9 01	Orabase
	4.55	15 g OP	
With pectin and gelatin powder	(7.90) 8.48	28 g OP	Orabase
with pectili and gelatili powder	(10.95)	20 y OP	Stomahesive
RIAMCINOLONE ACETONIDE			
0.1% in Dental Paste USP	4.38	5 g OP	✓ <u>Oracort</u>
Oropharyngeal Anti-infectives			
MPHOTERICIN B			
Lozenges 10 mg	5.86	20	🖌 Fungilin
/ICONAZOLE			
Oral gel 20 mg per g	8.70	40 g OP	 Daktarin
IYSTATIN Oral liq 100,000 u per ml	010	24 ml OP	A Niletat
Oral 114 100,000 u per 111		24 IIII UP	✓ <u>Nilstat</u>

	Subsidy (Manufacturer's P \$	rice) Sub Per	Fully Brand or sidised Generic Manufacturer
Other Oral Agents			
For folinic mouthwash, pilocarpine oral liquid or saliva substitute for	ormula refer, pag	e 163	
HYDROGEN PEROXIDE * Soln 10 vol – Maximum of 200 ml per prescription	1.28	100 ml	✔ PSM
THYMOL GLYCERIN * Compound, BPC	9.15	500 ml	✔ PSM
Vitamins			
Vitamin A			
VITAMIN A WITH VITAMINS D AND C Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops	4.38 (5.51)	10 ml OP	Vitadol C
Vitamin B Group			
HYDROXOCOBALAMIN * Inj 1 mg per ml, 1 ml – Up to 6 inj available on a PSO	9.21	3	 ✓ ABM Hydroxocobalamin ✓ Neo-B12
PYRIDOXINE HYDROCHLORIDE a) No more than 100 mg per dose b) Only on a prescription * Tab 25 mg – No patient co-payment payable		90	✔ Healtheries
* Tab 50 mg THIAMINE HYDROCHLORIDE – Only on a prescription		500	✓ Apo-Pyridoxine
* Tab 50 mg VITAMIN B COMPLEX		100	✓ Apo-Thiamine
* Tab, strong, BPC	12.10	500	✓ Apo-B-Complex
ASCORBIC ACID a) No more than 100 mg per dose b) Only on a prescription * Tab 100 mg		500	✓ Apo-Ascorbic Acid
Vitamin D			
ALFACALCIDOL Cap 0.25 µg Cap 1 µg Oral drops 2 µg per ml CALCITRIOL	87.98	100 100 20 ml OP	 ✓ One-Alpha ✓ One-Alpha ✓ One-Alpha
* Cap 0.25 μg * Cap 0.5 μg * Cap 0.5 μg * Oral liq 1 μg per ml CHOLECALCIFEROL	24.95	100 100 10 ml OP	 ✓ Calcitriol-AFT ✓ Calcitriol-AFT ✓ Rocaltrol solution
* Tab 1.25 mg (50,000 iu) – Maximum of 12 tab per prescription	n10.35	12	✓ Cal-d-Forte

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Pri \$	ce) Sub Per	Fully sidised	Brand or Generic Manufacturer		
Vitamin E						
ALPHA TOCOPHERYL ACETATE – Special Authority see SA05 Water solubilised soln 156 iu/ml, with calibrated dropper		l pharmacy [50 ml OP		icelle E		
 SA0915 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid Either: Cystic fibrosis patient; or Both: Infant or child with liver disease or short gut syndre Requires vitamin supplementation. 		lications mee	eting the	following criteria:		
Renewal from any relevant practitioner. Approvals valid for 2 y benefiting from treatment.	years where the treat	atment rema	ins app	ropriate and the patient is		
Multivitamin Preparations						
MULTIVITAMINS – Special Authority see SA0963 below – Reta Tab Powder Oral liq SA0963 Special Authority for Subsidy		100 100 g OP 150 ml OP	V Pa	etovite aediatric Seravit etovite Liquid		
Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 The patient has inborn errors of metabolism; or 2 For use as a supplement to a ketogenic diet in patients diagnosed with epilepsy. Note: Use of Paediatric Seravit is not recommended as a supplement to a ketogenic diet.						
* Tab (BPC cap strength)	14.80	1,000		ealtheries Multi-vitamin tablets		
Minerals						
Calcium						
CALCIUM * Tab eff 1 g (elemental) CALCIUM CARBONATE	6.54	30	✓ <u>C</u>	alsource		
* Tab 1.25 g * Tab 1.5 g CALCIUM GLUCONATE * Inj 10%, 10 ml	10.33	250 250 10		alci-Tab 500 alci-Tab 600 avne		
Fluoride						
SODIUM FLUORIDE Tab 1.1 mg	4.00	100	✔ P:	SM		

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
Iron				
FERROUS FUMARATE Tab 200 mg	4.35	100	🖌 F	erro-tab
FERROUS FUMARATE WITH FOLIC ACID Tab 310 mg with folic acid 350 µg	4.75	60	✔ F	erro-F-Tabs
FERROUS GLUCONATE WITH ASCORBIC ACID * Tab 170 mg with ascorbic acid 40 mg	12.04	500	✔ Н	ealtheries Iron with Vitamin C
FERROUS SULPHATE * Tab long-acting 325 mg	5.06 (15.58)	150	E	erro-Gradumet
*‡ Oral liq 150 mg per 5 ml FERROUS SULPHATE WITH FOLIC ACID	(/	500 ml	-	erodan
 * Tab long-acting 325 mg with folic acid 350 µg 	1.80 (3.73)	30	F	errograd-Folic
IRON POLYMALTOSE Inj 50 mg per ml, 2 ml		5	✓ <u>F</u>	errum H
Magnesium				
For magnesium hydroxide mixture refer, page 163 MAGNESIUM SULPHATE Inj 49.3%		10	🗸 M	layne
Zinc				
ZINC SULPHATE * Cap 220 mg		100	✓ <u>z</u>	incaps_

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

Antianaemics

Hypoplastic and Haemolytic

SA0922 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 Both:
 - 1.1 patient in chronic renal failure; and
 - 1.2 Haemoglobin \leq 100g/L; and
- 2 Any of the following:
 - 2.1 Both:
 - 2.1.1 patient is not diabetic; and
 - 2.1.2 glomerular filtration rate \leq 30ml/min; or
 - 2.2 Both:
 - 2.2.1 patient is diabetic; and
 - 2.2.2 glomerular filtration rate \leq 45ml/min; or
 - 2.3 patient is on haemodialysis or peritoneal dialysis.

Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Notes: Erythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

The Cockroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over:

GFR (ml/min) (male) = (140 - age) × Ideal Body Weight (kg) / 814 × serum creatinine (mmol/l)

GFR (ml/min) (female) = Estimated GFR (male) \times 0.85

	ERYTHROPOIETIN ALPHA	 Special Authority 	/ see SA0922 above – Hos	spital pharmacy [H	P3]
--	----------------------	---------------------------------------	--------------------------	--------------------	-----

	Inj human recombinant 1,000 iu prefilled syringe	6	Eprex
	Inj human recombinant 2,000 iu, prefilled syringe	6	Eprex
	Inj human recombinant 3,000 iu, prefilled syringe166.87	6	Eprex
	Inj human recombinant 4,000 iu, prefilled syringe	6	Eprex
	Inj human recombinant 5,000 iu, prefilled syringe	6	Eprex
	Inj human recombinant 6,000 iu, prefilled syringe	6	 Eprex
	Inj human recombinant 10,000 iu, prefilled syringe	6	Eprex
EF	YTHROPOIETIN BETA - Special Authority see SA0922 above - Hospital pharm	macy [HP3]	
	Inj 2,000 iu, prefilled syringe120.18	6	NeoRecormon
	Inj 3,000 iu, prefilled syringe166.87	6	NeoRecormon
	Inj 4,000 iu, prefilled syringe193.13	6	NeoRecormon
	Inj 5,000 iu, prefilled syringe243.26	6	NeoRecormon
	Inj 6,000 iu, prefilled syringe	6	NeoRecormon
	Inj 10,000 iu, prefilled syringe	6	NeoRecormon
N	legaloblastic		
FC	LIC ACID		
*	Tab 0.8 mg16.50	1,000	Apo-Folic Acid
*	Tab 5 mg6.59	500	Apo-Folic Acid
	Oral liq 50 µg per ml21.05	25 ml OP	Biomed

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Antifibrinolytics, Haemostatics and Local Sclero	osants			
SODIUM TETRADECYL SULPHATE				
* Inj 0.5% 2 ml		5	_	
	(45.52)	_	F	ibro-vein
* Inj 1% 2 ml		5	-	ïbro-vein
* Inj 3% 2 ml	(48.98) 28.50	5	Г	IDIO-VEIT
	(55.91)	5	F	ibro-vein
TRANEXAMIC ACID	(0000)			
Tab 500 mg	49.14	100		yklokapron
Vitamin K				<i>,</i> ,
PHYTOMENADIONE				
Tab 10 mg		10	🖌 K	Conakion
Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO		5		Conakion MM
Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO	9.21	5	V K	Conakion MM
Antithrombotic Agents				
Antiplatelet Agents				
ASPIRIN				
* Tab 100 mg		990	✓ <u>E</u>	thics Aspirin EC
CLOPIDOGREL - Special Authority see SA0867 below - Retail g	oharmacy			
Tab 75 mg	,	28		po-Clopidogrel
	(73.38)			Plavix

➡SA0867 Special Authority for Subsidy

Initial application — (aspirin allergic patients) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

- Both:
 - 1 The patient is allergic to aspirin (see definition below); and
 - 2 Any of the following:

The patient has:

- 2.1 suffered from a stroke, or transient ischaemic attack; or
- 2.2 experienced an acute myocardial infarction; or
- 2.3 experienced an episode of pain at rest of greater than 20 minutes duration due to coronary disease that required admission to hospital for at least 24 hours; or
- 2.4 had a troponin T or troponin I test result greater than the upper limit of the reference range; or
- 2.5 had a revascularisation procedure; or
- 2.6 experienced symptomatic peripheral vascular disease of a severity that has required specialist consultation.

Note: Aspirin allergy is defined as a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates or NSAIDs.

Initial application — (aspirin tolerant patients and aspirin naive patients) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Any of the following:

40

The patient has:

1 experienced an acute myocardial infarction; or

continued...

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 2 had an episode of pain at rest of greater than 20 minutes duration due to coronary disease that required admission to hospital for at least 24 hours; or
- 3 had a troponin T or troponin I test result greater than the upper limit of the reference range; or
- 4 had a revascularisation procedure.

Initial application — (patients awaiting revascularisation) from any relevant practitioner. Approvals valid for 6 months where the patient is on a waiting list or active review list for stenting, coronary artery bypass grafting, or percutaneous coronary angioplasty following acute coronary syndrome.

Initial application — (post stenting) from any relevant practitioner. Approvals valid for 6 months where the patient has had a stent inserted in the previous 4 weeks.

Initial application — (documented stent thrombosis) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has, while on treatment with aspirin or clopidogrel, experienced documented stent thrombosis.

Renewal — (aspirin tolerant patients) from any relevant practitioner. Approvals valid without further renewal unless notified where while on treatment with aspirin the patient has experienced an additional vascular event following the recent cessation of clopidogrel.

Renewal — (acute coronary syndrome - aspirin tolerant patients and aspirin naive patients) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Any of the following:

- The patient has:
- 1 experienced an acute myocardial infarction; or
- 2 had an episode of pain at rest of greater than 20 minutes duration due to coronary disease that required admission to hospital for at least 24 hours; or
- 3 had a troponin T or troponin I test result greater than the upper limit of the reference range; or
- 4 had a revascularisation procedure.

Renewal — (patients awaiting revascularisation) from any relevant practitioner. Approvals valid for 6 months where the patient is on a waiting list or active review list for stenting, coronary artery bypass grafting or percutaneous coronary angioplasty following acute coronary syndrome.

Renewal — (post stenting) from any relevant practitioner. Approvals valid for 6 months where the patient has had a stent inserted in the previous 4 weeks.

Renewal — (documented stent thrombosis) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has, while on treatment with aspirin or clopidogrel, experienced documented stent thrombosis.

DIPYRIDAMOLE

*	Tab 25 mg	8.36	84	Persantin
	Tab long-acting 150 mg		60	Pytazen SR

Heparin and Antagonist Preparations

ENOXAPARIN SODIUM - Special Authority see SA0975 on the next page - Retail pharmacy

Inj 20 mg	 10	Clexane
Inj 40 mg	 10	Clexane
Inj 60 mg	10	Clexane
Inj 80 mg	10	Clexane
Inj 100 mg	10	Clexane
Inj 120 mg	 10	Clexane
Inj 150 mg	10	✓ Clexane

Subsidy	F	ully Brand or	
(Manufacturer's Price)	Subsidi	ised Generic	
\$	Per	 Manufacturer 	

SA0975 Special Authority for Subsidy

Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patients pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.
- **Initial application** (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing warfarin treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

HEPARIN SODIUM

Inj 1,000 iu per ml, 5 ml		50	Mayne
Inj 1,000 iu per ml, 35 ml		1	Mayne
Inj 5,000 iu per ml, 1 ml	14.00	5	Mayne
Inj 5,000 iu per ml, 5 ml	43.67	10	Multiparin
Inj 25,000 iu per ml, 0.2 ml	9.50	5	Mayne
HEPARINISED SALINE			
* Inj 10 iu per ml, 5 ml		50	AstraZeneca
PROTAMINE SULPHATE			
* Inj 10 mg per ml, 5 ml	22.40	10	
	(86.54)		Artex

Oral Anticoagulants

WARFARIN SODIUM

	Note: Marevan and Coumadin are not interchangeable.			
*	Tab 1 mg	3.46	50	Coumadin
		5.69	100	Marevan
*	Tab 2 mg	4.31	50	Coumadin
*	Tab 3 mg	8.00	100	Marevan
	Tab 5 mg		50	Coumadin
	•	9.64	100	Marevan

	Subsidy (Manufacturer's Pri	aa) Suk	Fully Brand or bidised Generic
	(Manulacturers File \$	Per Suc	Manufacturer
Fluids and Electrolytes			
Intravenous Administration			
DEXTROSE		_	
 Inj 50%, 10 ml – Up to 5 inj available on a PSO Inj 50%, 90 ml – Up to 5 inj available on a PSO 		5 1	 ✓ <u>Biomed</u> ✓ Biomed
POTASSIUM CHLORIDE			4
 ✤ Inj 75 mg per ml, 10 ml ♣ Inj 150 mg per ml, 10 ml 		50 50	 AstraZeneca AstraZeneca
SODIUM BICARBONATE		50	♥ ASIId∠eneta
Inj 8.4%, 50ml a) Up to 5 inj available on a PSO b) Not in combination		1	✓ Biomed
Inj 8.4%, 100 ml a) Up to 5 inj available on a PSO b) Not in combination	20.50	1	 Biomed
SODIUM CHLORIDE Inf 0.9% – Up to 2000 ml available on a PSO	2.06	500 ml	✓ Baxter
Ini 0.3% – Op to 2000 mi available on a PSO	4.06	1,000 ml	Baxter
Only if prescribed on a prescription for renal dialysis, mater for emergency use. (500 ml and 1,000 ml packs)	rnity or post-nata	,	
Inj 23.4%, 20 ml		5	✓ Biomed
Inj 0.9%, 5 ml – Up to 5 inj available on a PSO		50	 AstraZeneca AstraZeneca
Inj 0.9%, 10 ml – Up to 5 inj available on a PSO Inj 0.9%, 20 ml		50 20	✓ Astrazeneca ✓ Multichem
	11.79	30	 Pharmacia
TOTAL PARENTERAL NUTRITION (TPN) - Hospital pharmacy [H	P1]-Specialist		
Infusion		1 OP	🖌 TPN
 On a prescription or Practitioner's Supply Order only when Schedule requiring a solvent or diluent; or On a bulk supply order; or When used in the extemporaneous compounding of eye dro 		m as an inje	ction listed in the Pharmaceuti
Purified for inj 5 ml – Up to 5 inj available on a PSO		50	 ✓ Multichem ✓ AstraZeneca
Purified for inj 10 ml - Up to 5 inj available on a PSO		50	 Multichem AstraZeneca
Purified for inj 20 ml – Up to 5 inj available on a PSO		20	✓ Multichem
Oral Administration			
CALCIUM POLYSTYRENE SULPHONATE Powder	169.85	300 g OP	Calcium Resonium
COMPOUND ELECTROLYTES		-	
Powder for soln for oral use 5 g - Up to 10 sach available on			
i official control of all cool of g op to no caon available off			

	Subsidy (Manufacturer's \$		Fully Brand or sidised Generic Manufacturer
	à	Fei	Manufacturer
DEXTROSE WITH ELECTROLYTES Soln with electrolytes	6.66	1,000 ml OP	✓ <u>Pedialyte -</u> Bubblegum
	6.78		 Pedialyte - Fruit Pedialyte - Plain
POTASSIUM BICARBONATE			
Tab eff 315 mg with sodium acid phosphate 1.937 g at sodium bicarbonate 350 mg For phosphate supplementation		100	Phosphate-Sandoz
POTASSIUM CHLORIDE			
* Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)	5.26 (11.85)	60	Chlorvescent
* Tab long-acting 600 mg	(/	200	✓ Span-K
SODIUM POLYSTYRENE SULPHONATE			
Powder		450 g OP	Resonium-A
Lipid Modifying Agents			
Fibrates			
BEZAFIBRATE			4 ·
* Tab 200 mg * Tab long-acting 400 mg		90 30	 ✓ <u>Fibalip</u> ✓ Bezalip Retard
Other Lipid Modifying Agents		00	• Bezanp Hetara
ACIPIMOX * Cap 250 mg		30	 Olbetam
NICOTINIC ACID			
* Tab 50 mg * Tab 500 mg		100 100	 Apo-Nicotinic Acid Apo-Nicotinic Acid
Resins		100	
CHOLESTYRAMINE WITH ASPARTAME Sachets 4 g with aspartame	19.25 (28.88)	50	Questran-Lite
COLESTIPOL HYDROCHLORIDE Sachets 5 g		30	✓ <u>Colestid</u>
HMG CoA Reductase Inhibitors (Statins)			
Droseriking Cuidelines			

Prescribing Guidelines

44

Treatment with HMG CoA Reductase Inhibitors (statins) is recommended for patients with dyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater.

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Brand or Generic Manufacturer
ATORVASTATIN - Additional subsidy by Special Authority see	SA0788 below – Retail	pharmacy	
See prescribing guideline on the preceding page			
* Tab 10 mg	4.03	30	
-	(18.32)	L	ipitor
* Tab 20 mg		30	
0	(26.70)	L	ipitor
* Tab 40 mg	()	30	
4. Tab to the second	(37.02)		ipitor
* Tob 90 mg	(/		ipitoi
* Tab 80 mg		30	
	(110.50)	L	lipitor

SA0788 Special Authority for Manufacturers Price

Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Either:
 - 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or
 - 2.2 Both:
 - 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either:
 - 2.2.2.1 All of the following:
 - 2.2.2.1.1 Patient has venous CABG; and
 - 2.2.2.1.2 LDL cholesterol test $1 \ge 2.0$ mmol/litre; and
 - 2.2.2.1.3 LDL cholesterol test $2 \ge 2.0$ mmol/litre (at least 1 week after test 1); or
 - 2.2.2.2 All of the following:
 - 2.2.2.2.1 Patient does not have venous CABG; and
 - 2.2.2.2.2 LDL cholesterol test 1 \geq 2.5 mmol/litre; and
 - 2.2.2.2.3 LDL cholesterol test $2 \ge 2.5$ mmol/litre (at least 1 week after test 1).

Notes: To confirm that cholesterol levels are not still improving, two lipid tests must be carried out during treatment with simvastatin 80 mg, and have results for LDL cholesterol that have reduced by <10% in the second test. The tests must be carried out while the patient is in a fasted state (with the exception of patients with IDDM).

The following indications of intolerance to simvastatin, are known as class effects for all statins, and hence are likely to mean that the patient may also be intolerant of atorvastatin:

- Constipation, flatulence (may occur in >1% of patients)
- Asthenia, abdominal pain, headache (may occur in >1% of patients)
- Myopathy, rhabdomyolysis (may occur in <3% of patients)
- Elevated serum transaminase levels (may occur in <1% of patients)

Statins have been shown to be generally well tolerated in clinical studies, with the rate of discontinuation due to adverse reactions being less than 5%, and similar to the discontinuation rate for patients taking a placebo.

PRAVASTATIN - Special Authority see SA0932 on the next page - Retail pharmacy

See prescribing guideline on the preceding page

Tab 10 mg	30	Pravachol
Tab 20 mg	30	Pravachol
Tab 40 mg65.31	30	Pravachol

	Subsidy		Fully Brand or	
	(Manufacturer's Pri	ce) Su Per	Ibsidised Generic Manufacturer	
SEC 40022 Crassial Authority for Subsidy	ψ	1.61		
SA0932 Special Authority for Subsidy nitial application — (Confirmed HIV/AIDS) from any releva	nt practitioner. Approv	als valid wit	hout further renewal unl	ess notifie
or applications meeting the following criteria:				
All of the following:				
1 Patient has dyslipidaemia and an absolute 5 year cardi	iovascular risk of 15%	or greater;	and	
2 Confirmed HIV infection; and				
3 Patient is being treated with an HIV protease inhibitor.				
SIMVASTATIN – See prescribing guideline on page 44				
* Tab 10 mg		90	Arrow-Simva 10	
* Tab 20 mg		90	✓ <u>Arrow-Simva 20</u>	
卷 Tab 40 mg 卷 Tab 80 mg		90 90	✓ <u>Arrow-Simva 40</u> ✓ Arrow-Simva 80	
		90	Arrow-Siniva 60	<u>ilig</u>
Selective Cholesterol Absorption Inhibitors				
EZETIMIBE – Special Authority see SA0796 below – Retail p Tab 10 mg		30	Ezetrol	
		30		
►SA0796 Special Authority for Subsidy	ulid for O years for any	liaationa m	acting the following crite	
nitial application only from a relevant specialist. Approvals v Both:	and for 2 years for app	incations m	eeting the following chie	ina.
1 Either:				
1.1 ezetimibe is to be used in combination with sime	vastatin: or			
1.2 ezetimibe is to be used without a statin; and				
2 Either:				
2.1 All of the following:				
2.1.1 Patient has a calculated absolute risk of 0 2.1.2 Patient cannot tolerate statin therapy at a			f 5 years; and	
2.1.3 Either: 2.1.3.1 All of the following:				
2.1.3.1 All of the following. 2.1.3.1.1 Patient has venous CABG;	and			
2.1.3.1.2 LDL cholesterol \geq 2.0 mmc				
2.1.3.1.3 LDL cholesterol \geq 2.0 mm		after test 1	- see note): or	
2.1.3.2 All of the following:			,	
2.1.3.2.1 Patient does not have veno	ous CABG; and			
2.1.3.2.2 LDL cholesterol \geq 2.5 mmc				
2.1.3.2.3 LDL cholesterol \geq 2.5 mmc	ol/litre (at least 1 week	after test 1	 see note); or 	
2.2 All of the following:		,		
 2.2.1 Patient has homozygous familial hyperch 2.2.2 Patient has been compliant for at least tw 2.2.3 LDL cholesterol ≥ 5 mmol/litre (see note) 	o months with maximu			mia; and
2.2.4 LDL cholesterol \geq 5 mmol/litre (at least 1		e note).		
Note: Two lipid tests are required to assess LDL cholesterol le			e week apart, and be ca	arried out
a fasted state (other than for patients with IDDM). The results f				
Renewal only from a relevant specialist. Approvals valid for 2				
Both:				
1 The treatment remains appropriate and the patient is b	enefiting from treatme	nt; and		
2 Either:				
2.1 ezetimibe is to be used in combination with simu	/astatin; or			
2.2 ezetimibe is to be used without a statin.				

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
EZETIMIBE WITH SIMVASTATIN – Special Authority see SA0826	5 below – Retail phar	macy			
Tab 10 mg with simvastatin 10 mg		30	V	/ytorin	
Tab 10 mg with simvastatin 20 mg		30	🖌 V	/ytorin	
Tab 10 mg with simvastatin 40 mg		30	🖌 V	/ytorin	
Tab 10 mg with simvastatin 80 mg		30	🗸 V	/ytorin	

SA0826 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and
 - 1.2 Patient cannot tolerate statin therapy at a dose of \geq 40 mg per day; and
 - 1.3 Either:
 - 1.3.1 All of the following:
 - 1.3.1.1 Patient has venous CABG; and
 - 1.3.1.2 LDL cholesterol \geq 2.0 mmol/litre (see note); and
 - 1.3.1.3 LDL cholesterol \geq 2.0 mmol/litre (at least 1 week after test 1 see note); or
 - 1.3.2 All of the following:
 - 1.3.2.1 Patient does not have venous CABG; and
 - 1.3.2.2 LDL cholesterol \geq 2.5 mmol/litre (see note); and
 - 1.3.2.3 LDL cholesterol \geq 2.5 mmol/litre (at least 1 week after test 1 see note); or
- 2 All of the following:
 - 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholesterolemia; and
 - 2.2 Patient has been compliant for at least two months with maximum dose statin therapy; and
 - 2.3 LDL cholesterol \geq 5 mmol/litre (see note); and
 - 2.4 LDL cholesterol \geq 5 mmol/litre (at least 1 week after test 1 see note).

Note: Two lipid tests are required to assess LDL cholesterol levels, the tests must be at least one week apart, and be carried out in a fasted state (other than for patients with IDDM). The results for LDL cholesterol levels in both tests must be above those specified. **Renewal** only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy (Manufacturer's P \$	rice) Su Per	Fully ubsidised	Brand or Generic Manufacturer
Alpha Adrenoceptor Blockers				
OOXAZOSIN MESYLATE				
₭ Tab 2 mg		500	🖌 🖌	oo-Doxazosin
₭ Tab 4 mg		500	V A	po-Doxazosin
PHENOXYBENZAMINE HYDROCHLORIDE				
Cap 10 mg	7 82	30	🖌 Di	benyline S29
			•	
HENTOLAMINE MESYLATE	17.07	F		
 Inj 10 mg per ml, 1 ml 		5	П	aitina
	(31.65)		H.	egitine
RAZOSIN HYDROCHLORIDE				
€ Tab 1 mg		100		oo-Prazo
* Tab 2 mg		100		oo-Prazo
 Tab 5 mg 	11.70	100	✓ <u>A</u>	oo-Prazo
ERAZOSIN HYDROCHLORIDE				
⊱ Tab 1 mg	2.50	28	🖌 Al	oo-Terazosin
First Tab 7 \times 1 mg and 7 \times 2 mg		14 OP		/trin Starter Pack
Tab 2 mg		28	V H	
0	23.30	500		oo-Terazosin
 Tab 5 mg 	1.62	28	V H	
č	29.00	500		oo-Terazosin
Hytrin Tab 2 mg to be delisted 1 October 2009)				

(Hytrin Tab 5 mg to be delisted 1 October 2009)

Agents Affecting the Renin-Angiotensin System

Perindopril and trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". **Definition of Congestive Heart Failure** At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include patients post myocardial infarction with an ejection fraction of less than 40%."

ACE Inhibitors

CAPTOPRIL

 * Tab 12.5 mg * Tab 25 mg * Tab 50 mg * Tab 50 mg * Oral liq 5 mg per ml Oral liquid restricted to children under 12 years of age. 	13.40 19.00	500 500 500 95 ml OP	 ✓ <u>Apo-Captopril</u> ✓ <u>Apo-Captopril</u> ✓ <u>Apo-Captopril</u> ✓ <u>Apo-Captopril</u> ✓ Capoten
CILAZAPRIL * Tab 0.5 mg * Tab 2.5 mg * Tab 5 mg	4.10	30 28 28	✓ Inhibace✓ Inhibace✓ Inhibace

	Subsidv		Fully Brand or
	(Manufacturer's Price) \$	Per	Subsidised Generic
	φ	rei	
	0.10	00	a m Englandil
Tab 5 mg		90	m-Enalapril
Tab 10 mg Tab 20 mg		90 90	 m-Enalapril m-Enalapril
°		90	
SINOPRIL			4 .
Tab 5 mg		30	Arrow-Lisinopril
Tab 10 mg		30	Arrow-Lisinopril
Tab 20 mg	2.87	30	Arrow-Lisinopril
ERINDOPRIL			
Tab 2 mg - Higher subsidy of \$18.50 per 30 with Endorsem	ent3.00	30	
	(18.50)		Coversyl
Tab 4 mg – Higher subsidy of \$25.00 per 30 with Endorsem	ent4.05	30	
	(25.00)		Coversyl
UINAPRIL			
Tab 5 mg	1.60	30	Accupril
Tab 10 mg	1.75	30	✓ Accupril
Tab 20 mg	2.35	30	Accupril
BANDOLAPRIL			
Cap 1 mg – Higher subsidy of \$18.67 per 28 with Endorsem	ent3.06	28	
	(18.67)		Gopten
Cap 2 mg - Higher subsidy of \$27.00 per 28 with Endorsem	()	28	
	(27.00)		Gopten
ACE Inhibitors with Diuretics			
LAZAPRIL WITH HYDROCHLOROTHIAZIDE			
Tab 5 mg with hydrochlorothiazide 12.5 mg	6.30	28	Inhibace Plus
VALAPRIL WITH HYDROCHLOROTHIAZIDE			
Tab 20 mg with hydrochlorothiazide 12.5 mg	3 30	30	
	(8.70)	50	Co-Renitec
	(0.70)		
UINAPRIL WITH HYDROCHLOROTHIAZIDE	0.07	~~	
Tab 10 mg with hydrochlorothiazide 12.5 mg		30	Accuretic 10
Tab 20 mg with hydrochlorothiazide 12.5 mg	4.57	30	Accuretic 20
Angiotension II Antagonists			
ANDESARTAN – Special Authority see SA0933 below – Retai	Inharmacy		
Tab 4 mg – No more than 1.5 tab per day		30	✓ Atacand
Tab 8 mg $-$ No more than 1.5 tab per day		30	✓ Atacand
		00	
Tab 16 mg - No more than 1 tab per day	23.54	30	Atacand

SA0933 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

1 Both:

- 1.1 Patient with congestive heart failure; and
- 1.2 Either:

continued...

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or
- 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or
- 2 All of the following:
 - 2.1 Patient with raised blood pressure; and
 - 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and
 - 2.3 Either:
 - 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or
 - 2.3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years.
- LOSARTAN Special Authority see SA0911 below Retail pharmacy

*	Tab 12.5 mg17.40	30	Cozaar
*	Tab 25 mg	30	Cozaar
	Tab 50 mg	30	Cozaar
	Tab 50 mg with hydrochlorothiazide 12.5 mg	30	🖌 Hyzaar
*	Tab 100 mg	30	Cozaar

➡SA0911 Special Authority for Subsidy

Initial application — (ACE inhibitor intolerance) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor); or
- 2 Patient has a history of angioedema.

Initial application — (Unsatisfactory response to ACE inhibitor) from any relevant practitioner. Approvals valid without further renewal unless notified where patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor.

Initial application — (Patient had an approval for Losartan with hydrochlorothiazide prior to 1 May 2008) from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Antiarrhythmics

For lignocaine hydrochloride refer to NERVOUS SYSTEM, Anaesthetics, Local, page 108

AMIODARONE HYDROCHLORIDE

	▲ Tab 100 mg - Retail pharmacy-Specialist	30	 ✓ Aratac ✓ Cordarone-X
	▲ Tab 200 mg - Retail pharmacy-Specialist	30	 ✓ Cordarone-X ✓ Aratac ✓ Cordarone-X
	Inj 50 mg per ml, 3 ml – Up to 5 inj available on a PSO60.84	10	✓ Cordarone-X
I	DIGOXIN		
÷	* Tab 62.5 µg – Up to 30 tab available on a PSO6.94	250	Lanoxin PG
÷	* Tab 250 µg – Up to 30 tab available on a PSO	250	Lanoxin
	*‡ Oral liq 50 μg per ml16.60	60 ml	Lanoxin
	DISOPYRAMIDE PHOSPHATE		
	▲ Cap 100 mg	100	
	(23.87)		Rythmodan
	▲ Cap 150 mg	100	 Rythmodan

	Subsidy (Manufacturer's Price) \$	Per	Full Subsidise	
FLECAINIDE ACETATE – Retail pharmacy-Specialist				
▲ Tab 50 mg		60		Tambocor
▲ Tab 100 mg		60		Tambocor
Cap long-acting 100 mg		30		Tambocor CR
▲ Cap long-acting 200 mg		30 5		Tambocor CR Tambocor
Inj 10 mg per ml, 15 ml		5		Tambocoi
	00 50	100		Mexitil
▲ Cap 50 mg ▲ Cap 200 mg		100		Mexitil
		100	•	MCAILII
PROPAFENONE HYDROCHLORIDE – Retail pharmacy-Speciali		50		Rytmonorm
▲ Tab 150 mg		50	•	nyunononn
Antihypotensives				
MIDODRINE - Special Authority see SA0934 below - Hospital ph	narmacy [HP3]			
Tab 2.5 mg		100	~	Gutron
Tab 5 mg	79.00	100	~	Gutron
►SA0934 Special Authority for Subsidy				
 Disabling orthostatic hypotension not due to drugs; and Patient has tried fludrocortisone (unless contra-indicated) v Patient has tried non pharmacological treatments such as head and trunk at night. Notes: Treatment should be started with small doses and titrated of Hypertension should be avoided, and the usual target is a standin Renewal from any relevant practitioner. Approvals valid for 2 ye benefiting from treatment. 	support hose, incre upwards as necessar g systolic blood pres	eased ry. sure c	salt intak f 90 mm	Hg.
Beta Adrenoceptor Blockers				
ACEBUTOLOL				
* Cap 100 mg		100	•	ACB
* Cap 200 mg	15.94	100	~	ACB
(ACB Cap 100 mg to be delisted 1 February 2010)				
ATENOLOL				
* Tab 50 mg		30		Noten S29
	6.18	500		Pacific Atenolol
* Tab 100 mg	10./3	500	~	Pacific Atenolol
CARVEDILOL		• -		
Tab 6.25 mg		30		Dilatrend
Tab 12.5 mg		30		Dilatrend
Tab 25 mg	33./5	30	V	Dilatrend
CELIPROLOL	10.45			• • •
* Tab 200 mg	19.00	180	~	Celol

		Subsidy (Manufacturer's Price)	Den	Full Subsidise	d Generic
		\$	Per		Manufacturer
	BETALOL				
*	Tab 50 mg		100		Hybloc
*	Tab 100 mg		100		Hybloc
ŧ	Tab 200 mg		100		Hybloc
ŧ	Tab 400 mg		100	V	Hybloc
ŧ	Inj 5 mg per ml, 20 ml		5		
		(88.60)			Trandate
ſΕ	TOPROLOL SUCCINATE				
ŧ	Tab long-acting 23.75 mg	2.73	30	~	Metoprolol - AFT CR
		3.61		~	Betaloc CR
÷	Tab long-acting 47.5 mg	3.41	30	~	Metoprolol - AFT CR
		4.50		~	Betaloc CR
÷	Tab long-acting 95 mg	5.88	30	~	Metoprolol - AFT CR
		7.40			Betaloc CR
ŧ	Tab long-acting 190 mg		30	V	Metoprolol - AFT CR
		12.50			Betaloc CR
IF	TOPROLOL TARTRATE				
÷	Tab 50 mg	16 50	100	~	Lopresor
÷	Tab 100 mg		60		Lopressor
÷	Tab long-acting 200 mg		28		Slow-Lopressor
-	Inj 1 mg per ml 5 ml		5	•	CION EOPICSSOI
•		(34.00)	0		Betaloc
		(01.00)			Dotaloo
	DOLOL	44.07	400		Asson Mandadad
ŧ	Tab 40 mg		100		Apo-Nadolol
÷	Tab 80 mg		100	V	Apo-Nadolol
IN	DOLOL				
÷	Tab 5 mg	4.50	100	~	Pindol
÷	Tab 10 mg	8.35	100	~	Pindol
÷	Tab 15 mg	12.00	100	~	Pindol
R	OPRANOLOL				
	Tab 10 mg	3 55	100	~	Cardinol
÷	Tab 40 mg		100		Cardinol
÷	Cap long-acting 160 mg		100		Cardinol LA
				•	
	TALOL	07 50			Malan
	Tab 80 mg		500		Mylan
ŧ	Tab 160 mg		100		Mylan
÷	Inj 10 mg per ml, 4 ml		5	V	Sotacor
	IOLOL MALEATE				
÷	Tab 10 mg		100	~	Apo-Timol
C	alcium Channel Blockers				
ש	hydropyridine Calcium Channel Blockers (Dh	IP CCBS)			
M	LODIPINE				
ŧ	Tab 5 mg		100	V	Apo-Amlodipine
ŧ	Tab 10 mg		100		Apo-Amlodipine
	·~~ · • ···y			•	

(Manufacturer's Price) \$ Pe	Subsidised Generic er 🖌 Manufacturer
ψ it	
FELODIPINE	
* Tab long-acting 2.5 mg – No more than 1 tab per day	✓ Plendil ER
* Tab long-acting 5 mg	Felo 5 ER
* Tab long-acting 10 mg 15.60 90	Felo 10 ER
ISRADIPINE	
Cap long-acting 2.5 mg	Dynacirc-SRO
Cap long-acting 5 mg7.85 30	Dynacirc-SRO
NIFEDIPINE	
* Tab long-acting 10 mg	
* Tab long-acting 20 mg	
* Tab long-acting 30 mg	 Adenni AL Arrow-Nifedipine XR
5.50	
(19.90)	Adalat Oros
* Tab long-acting 60 mg	Adefin XL
	Arrow-Nifedipine XR
8.00	
(29.50)	Adalat Oros
Other Calcium Channel Blockers	
DILTIAZEM HYDROCHLORIDE	
* Tab 30 mg4.60 100	· · · · · · · · · · · · · · · · · · ·
* Tab 60 mg	
* Cap long-acting 120 mg (once per day) 4.34 30 * Cap long-acting 180 mg	 ✓ <u>Cardizem CD</u> ✓ Cardizem CD
* Cap long-acting 240 mg	Cardizem CD
PERHEXILINE MALEATE – Special Authority see SA0256 below – Hospital pharmacy [HF * Tab 100 mg	
Č	V Pexsig
► SA0256 Special Authority for Subsidy	re for applications meeting the following
Initial application only from a cardiologist or general physician. Approvals valid for 2 year criteria:	is for applications meeting the following
Both:	
1 Refractory angina; and	
2 Patient is already on maximal anti-anginal therapy.	
Renewal only from a cardiologist or general physician. Approvals valid for 2 years where	the treatment remains appropriate and
the patient is benefiting from treatment.	
VERAPAMIL HYDROCHLORIDE	
* Tab 40 mg7.01 100	
* Tab 80 mg11.74 100	
* Tab long-acting 120 mg	•
* Tab long-acting 240 mg	
* Inj 2.5 mg per ml, 2 ml – Up to 5 inj available on a PSO7.54 5	 Isoptin
Centrally Acting Agents	
CLONIDINE	
* TDDS 2.5 mg, 100 μg per day – Only on a prescription	✓ Catapres-TTS-1
 TDDS 2.5 flig, 100 µg per day – Only on a prescription	Catapres-TTS-2
* TDDS 7.5 mg, 300 µg per day – Only on a prescription	✓ Catapres-TTS-3
	·

	Subsidy		Fully Brand or
	(Manufacturer's I		osidised Generic
	\$	Per	 Manufacturer
CLONIDINE HYDROCHLORIDE			
ж Таb 150 µg	30.33	100	Catapres
* Inj 150 μg per ml, 1 ml		5	✓ Catapres
		5	• Oddapies
METHYLDOPA			
* Tab 125 mg		100	Prodopa
* Tab 250 mg	13.10	100	Prodopa
* Tab 500 mg	20.85	100	Prodopa
Diuretics			
Loop Diuretics			
•			
BUMETANIDE			
* Tab 1 mg		100	Burinex
* Inj 500 μg per ml, 4 ml	7.95	5	Burinex
FUROSEMIDE			
* Tab 40 mg – Up to 30 tab available on a PSO	10 75	1,000	Diurin 40
		100	✓ <u>Diurin 40</u> ✓ Diurin 500
* Tab 500 mg			
*‡ Oral liq 10 mg per ml		30 ml OP	✓ Lasix
* Infusion 10 mg per ml, 25 ml		5	✓ Lasix
* Inj 10 mg per ml, 2 ml – Up to 5 inj available on a PSO		50	Mayne
Potassium Sparing Diuretics			
AMILORIDE			
	06.00	25 ml OP	Biomed
Oral liq 1 mg per ml	20.20	25 III OF	♥ Biolilea
SPIRONOLACTONE			
* Tab 25 mg	8.50	100	 Spirotone
* Tab 100 mg	21.70	100	Spirotone
Oral liq 5 mg per ml		25 ml OP	 Biomed
Potassium Sparing Combination Diuretics			
AMILORIDE WITH FRUSEMIDE			
* Tab 5 mg with frusemide 40 mg	4.67	28	
	(8.63)		Frumil
AMILORIDE WITH HYDROCHLOROTHIAZIDE			
 * Tab 5 mg with hydrochlorothiazide 50 mg 	13.00	500	Amizide
		500	Allizide
TRIAMTERENE WITH HYDROCHLOROTHIAZIDE			
* Tab 50 mg with hydrochlorothiazide 25 mg		100	Triamizide
(Triamizide Tab 50 mg with hydrochlorothiazide 25 mg to be deli	sted 1 February 2	2010)	
Thiazide and Related Diuretics			
BENDROFLUAZIDE			
* Tab 2.5 mg – Up to 150 tab available on a PSO		500	Neo-Naclex
May be supplied on a PSO for reasons other than emerg			
* Tab 5 mg		500	Neo-Naclex
•			
CHLOROTHIAZIDE			
Oral liq 50 mg per ml	22.60	25 ml OP	Biomed
CHLORTHALIDONE			
* Tab 25 mg		50	 Hygroton
		20	

	Subsidy		Fully Brand or
	(Manufacturer's \$	Price) Sub: Per	sidised Generic Manufacturer
	Ψ	1.61	 Manulacturer
INDAPAMIDE			4 1 1 1
* Tab 2.5 mg	4.00	100	Napamide
Nitrates			
GLYCERYL TRINITRATE			
* Tab 600 µg – Up to 100 tab available on a PSO	8.00	100 OP	Lycinate
* Oral pump spray 400 μg per dose – Up to 250 dose available	5.40		
on a PSO	5.16	250 dose OP	<u>Nitrolingual</u> <u>Pumpspray</u>
* TDDS 5 mg	16.56	30	✓ Nitroderm TTS
* TDDS 10 mg		30	✓ Nitroderm TTS
SOSORBIDE MONONITRATE			
* Tab 20 mg		100	🖌 Ismo 20
K Tab long-acting 40 mg		30	Corangin
k Tab long-acting 60 mg	4.15	90	V Duride
Smoking Cessation			
Nicotine Gum			
VICOTINE			
a) Maximum of 768 piece per prescription			
b) Maximum of 384 piece per dispensing			
c) For the avoidance of doubt Nicotine will not be funded Close	e Control in an	nounts less than	4 weeks.
Gum 2 mg (Fruit)		96 OP	✓ Habitrol
	23.41		✓ Nicotinell
Gum 2 mg (Mint)	14.97	96 OP	Habitrol
	23.41		 Nicotinell
Gum 4 mg (Fruit)		96 OP	✓ <u>Habitrol</u>
Gum 4 mg (Mint)	23.41	96 OP	 Nicotinell Habitrol
Guin 4 mg (Mint)	20.02 23.41	90 OF	✓ <u>Nicotinell</u>
Niastina Lanana	20.41		
Nicotine Lozenge			
NICOTINE			
a) Maximum of 432 loz per prescription			
b) Maximum of 216 loz per dispensing			
c) For the avoidance of doubt Nicotine will not be funded Close			
Lozenge 1 mg		36 OP 36 OP	✓ <u>Habitrol</u>
		30 UP	✓ <u>Habitrol</u>
Nicotine Patch			
IICOTINE			
a) Maximum of 56 patch per prescription			
b) Maximum of 28 patch per dispensing	A		
c) For the avoidance of doubt Nicotine will not be funded Close Poteb 7 mg			
Patch 7 mg Patch 14 mg		7 OP 7 OP	✓ <u>Habitrol</u> ✓ Habitrol
Patch 21 mg		7 OP 7 OP	✓ <u>Habitrol</u>
1 alon 21 mg	12.02	/ UF	

	Subsidy (Manufacturer's Price) \$	Per	Fully Brand or Subsidised Generic ✓ Manufacturer
Other Agents			
3UPROPION HYDROCHLORIDE Tab modified-release 150 mg		30	✔ Zyban
Sympathomimetics			·
ADRENALINE Inj 1 in 1,000, 1 ml – Up to 5 inj available on a PSO	4.98 5.25	5	 ✓ Aspen Adrenaline ✓ Mayne
Inj 1 in 10,000, 10 ml – Up to 5 inj available on a PSO SOPRENALINE HYDROCHLORIDE		5	 Mayne
к Inj 200 µg per ml, 1 ml	36.80 (135.00)	25	Isuprel
Vasodilators			
AMYL NITRITE * Ampoule, 0.3 ml crushable		12	Baxter
HYDRALAZINE ₭ Inj 20 mg per ml, 1 ml	25.90	5	✔ Apresoline
XYPENTIFYLLINE – Hospital pharmacy [HP3] Tab 400 mg		50	Trental 400
PAPAVERINE HYDROCHLORIDE ₭ Inj 12 mg per ml, 10 ml		5	✓ Mayne
Endothelin Receptor Antagonists			
SA0967 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hyperten Notes: Application details may be obtained from PHARMAC's w The Coordinator, PAH Panel PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac	vebsite <u>http://www.phari</u> govt.nz	nac.g	ovt.nz or:
3OSENTAN – Special Authority see SA0967 above – Hospital Tab 62.5 mg Tab 125 mg		60 60	✓ Tracleer✓ Tracleer
Phosphodiesterase Type 5 Inhibitors			
►SA0968 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hyperten Votes: Application details may be obtained from PHARMAC's w The Coordinator, PAH Panel PHARMAC, PO Box 10-254, WELLINGTON Fel: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac	vebsite http://www.phar	nac.g	ovt.nz_or:
SILDENAFIL – Special Authority see SA0968 above – Hospita Tab 25 mg Tab 50 mg Tab 100 mg	l pharmacy [HP1] 47.00 59.50	4 4 4	✔ Viagra ✔ Viagra ✔ Viagra
1 fully subsidized			no supplied under Section 20

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Generic
Prostacyclin Analogues			
► SA0969 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hypertensic Notes: Application details may be obtained from PHARMAC's wel The Coordinator, PAH Panel PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac.g	bsite http://www.pharr	mac.govt.nz or:	
ILOPROST – Special Authority see SA0969 above – Hospital ph Nebuliser soln 10 µg per ml, 2 ml		30	Ventavis

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Antiacne Preparations				
For systemic antibacterials, refer to INFECTIONS, Antibacterials, p.	age 83			
ISOTRETINOIN - Special Authority see SA0955 below - Retail ph	armacy			
Cap 10 mg		100	🖌 İs	otane 10
	48.48	180	V 0	ratane
Cap 20 mg	47.50	100	🖌 İs	otane 20
· -	69.70	180	V 0	ratane
BACA0055 Chastel Authority for Subsidy				

SA0955 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Patient has had an adequate trial on other available treatments and has failed these treatments or these are contraindicated; and
- 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 4 Either:
 - 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
 - 4.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Patient has had an adequate trial on other available treatments and has failed these treatments or these are contraindicated; and
- 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 4 Either:

58

- 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
- 4.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

	Subsidy		Fully Brand or
	(Manufacturer's		osidised Generic
	\$	Per	 Manufacturer
Antibacterials Topical			
For systemic antibacterials, refer to INFECTIONS, Antibact	erials, page 83		
FUSIDIC ACID			
Crm 2 %	3.95	15 g OP	Foban
 a) Maximum of 15 g per prescription b) Only on a prescription 			
c) Not in combination			
Oint 2 %	3.95	15 g OP	Foban
a) Maximum of 15 g per prescription			
b) Only on a prescription			
c) Not in combination HYDROGEN PEROXIDE			
* Crm 1%	8 56	10 g OP	Crystacide
MUPIROCIN		10 9 01	• orystablac
Oint 2%		15 g OP	
/ -	(9.26)		Bactroban
a) Only on a prescription			
b) Not in combination			
SILVER SULPHADIAZINE	15.04	100 - 00	
Crm 1% with chlorhexidine digluconate 0.2%a) Up to 500 g available on a PSO	15.04	100 g OP	 Silvazine
b) Not in combination			
Antifungals Topical			
For systemic antifungals, refer to INFECTIONS, Antifungals	s, page 87		
AMOROLFINE a) Only on a prescription			
b) Not in combination			
		5 ml OP	
	(61.87)		Loceryl
CICLOPIROXOLAMINE			
a) Only on a prescription			
b) Not in combination Crm 1%	1.00	20 g OP	
Unit 1/0	(12.82)	20 9 01	Batrafen
Nail soln 8%		3.5 ml OP	✓ Batrafen
Soln 1%		20 ml OP	
	(11.54)		Batrafen
	0.50	00 = 00	(Clemencl
 Crm 1%a) Only on a prescription 	0.50	20 g OP	✓ <u>Clomazol</u>
b) Not in combination			
* Soln 1%	4.36	20 ml OP	
	(7.55)		Canesten
a) Only on a prescription			
b) Not in combination			

	(Manufacturer's \$	Price) Sul Per	osidised Generic Manufacturer
CONAZOLE NITRATE			
Crm 1%	1.00	20 g OP	
	(7.48)	Ū	Pevaryl
a) Only on a prescription			
b) Not in combination			
Foaming soln 1%, 10 ml sachets		3	
	(17.23)		Pevaryl
a) Only on a prescription			
b) Not in combination			
ETOCONAZOLE			
Crm 2%		15 g OP	NP
	(9.50)		Nizoral
a) Only on a prescription			
b) Not in combination			
IICONAZOLE NITRATE			4 •• •• •
 € Crm 2% 	0.42	15 g OP	Multichem
a) Only on a prescription			
b) Not in combination	4.00		
€ Lotn 2%		30 ml OP	Delsterin
a) Only on a pressription	(10.03)		Daktarin
a) Only on a prescription b) Not in combination			
← Tinct 2%	1 36	30 ml OP	
F TINGE 2 /0	(12.10)	30 III OF	Daktarin
a) Only on a prescription	(12.10)		Dakiaiiii
b) Not in combination			
IYSTATIN			
Crm 100,000 u per g	1.00	15 g OP	
	(5.10)	15 9 01	Mycostatin
a) Only on a prescription	(0.10)		Wyoootaan
b) Not in combination			
,			
Antipruritic Preparations			
ALAMINE			
a) Only on a prescription			
b) Not in combination			
Crm, aqueous, BP	2.78	100 g	healthE
	3.02	-	🖌 ABM
Lotn, BP	16.70	2,000 ml	🖌 API
	19.44		🖌 ABM
ROTAMITON			
a) Only on a prescription			
b) Not in combination			
Ćrm 10%	4.26	20 g OP	
	(4.45)	-	Eurax
IENTHOL – Only in combination			
Only in combination with aqueous cream, 10% urea cream,	wool fat with mine	eral oil lotion. 19	% hydrocortisone with wool fa
mineral oil lotion, and glycerol, paraffin and cetyl alcohol loti			
		25 g	🖌 PSM
Crystals		20 u	F OW
Crystals	7.40 29.60	25 g 100 g	✓ MidWest

	Subsidy (Manufacturer's I \$	Price) Sul Per	Fully Brand or bsidised Generic Manufacturer
Corticosteroids Topical			
or systemic corticosteroids, refer to CORTICOSTERO	IDS AND RELATED AGEN	ITS, page 75	
Corticosteroids - Plain			
TAMETHASONE DIPROPIONATE			
Crm 0.05%	2.96	15 g OP	
	(6.91)		Diprosone
	8.97	50 g OP	
	(18.36)	0	Diprosone
Crm 0.05% in propylene glycol base	4.33	30 g OP	
	(13.83)	·	Diprosone OV
Oint 0.05%	2.96	15 g OP	·
	(6.51)	·	Diprosone
	8.97	50 g OP	
	(17.11)	·	Diprosone
Oint 0.05% in propylene glycol base	4.33	30 g OP	
	(13.83)	•	Diprosone OV
ETAMETHASONE VALERATE			
Crm 0.1%	2.00	50 g OP	🖌 Beta Cream
Oint 0.1%		50 g OP	 Beta Ointment
Lotn 0.1%		50 ml OP	✓ Betnovate
			• Bolliovalo
OBETASOL PROPIONATE	0.05	00 00	
Crm 0.05%		30 g OP	✓ Dermol
Oint 0.05%	1.60	30 g OP	 Dermol
OBETASONE BUTYRATE			
Crm 0.05%	5.38	30 g OP	
	(7.09)		Eumovate
	16.13	100 g OP	
	(22.00)		Eumovate
FLUCORTOLONE VALERATE			
Crm 0.1%	8.97	50 g OP	
	(15.86)	3 •.	Nerisone
Fatty oint 0.1%		50 g OP	
,	(15.86)		Nerisone
(DROCORTISONE	()		
	0.44	100 a	1 I ampie Eatty Cream
Crm 1% – Only on a prescription		100 g	 Lemnis Fatty Cream HC
	10.00	E00 -	
Dourdor Only in combination	12.20	500 g	✓ <u>PSM</u>
Powder – Only in combination		25 g	✓ ABM
Up to 5% in a dermatological base (not propri	(37.64)		m-Hydrocortisone

galenicals. Refer, page 160 (m-Hydrocortisone Powder to be delisted 1 November 2009)

	Subsidy	Drice) Out	Fully Brand or
	(Manufacturer's \$	Price) Sub Per	sidised Generic Manufacturer
YDROCORTISONE BUTYRATE			
Lipocream 0.1%	5.00	30 g OP	Locoid Lipocream
•	15.00	100 g OP	Locoid Lipocream
Oint 0.1%		100 g OP	✓ Locoid
Milky emul 0.1%		30 ml OP	Locoid Crelo
	15.00	100 ml OP	Locoid Crelo
YDROCORTISONE WITH WOOL FAT AND MINERAL OIL			
Lotn 1% with wool fat hydrous 3% and mineral oil - Only on			
a prescription	9.95	250 ml	DP Lotn HC
ETHYLPREDNISOLONE ACEPONATE			
Crm 0.1%	4 95	15 g OP	Advantan
Oint 0.1%		15 g OP	✓ Advantan
		10 9 01	
OMETASONE FUROATE		15 00	
Crm 0.1%		15 g OP	✓ Elocon
	10.82	45 g OP	Elocon
Oint 0.1%		15 g OP	Elocon
	10.82	45 g OP	Elocon
Lotn 0.1%	4.80	30 ml OP	Elocon
RIAMCINOLONE ACETONIDE			
Crm 0.02%	6.63	100 g OP	Aristocort
Oint 0.02%		100 g OP	✓ Aristocort
Corticosteroids - Combination			
ETAMETHASONE VALERATE WITH CLIOQUINOL - Only on a	prescription		
Crm 0.1% with clioquinol 3%	3.49	15 g OP	
	(4.90)		Betnovate-C
Oint 0.1% with clioquinol 3%		15 g OP	
	(4.90)	-	Betnovate-C
ETAMETHASONE VALERATE WITH FUSIDIC ACID			
Crm 0.1% with fusidic acid 2%	3 49	15 g OP	
	(9.61)		Fucicort
 a) Maximum of 15 g per prescription b) Only on a prescription 	(0.01)		
	D	de the se	
YDROCORTISONE BUTYRATE WITH CHLORQUINALDOL - (<i>4</i> .
Crm 0.1% with chlorquinaldol 3%	3.49	15 g OP	Locoid C
YDROCORTISONE WITH MICONAZOLE - Only on a prescript	ion		
Crm 1% with miconazole nitrate 2%		15 g OP	Micreme H
		0	
YDROCORTISONE WITH NATAMYCIN AND NEOMYCIN – On	, , ,		Pimafucort
Crm 1% with natamycin 1% and neomycin sulphate 0.5%		15 g OP	
Oint 1% with natamycin 1% and neomycin sulphate 0.5%	4.40	15 g OP	Pimafucort
RIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN	AND NYSTAT	IN	
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg			
and gramicidin 250 µg per g – Only on a prescription		15 g OP	
3 ···· ··· ··· ··· ··· ·······	(6.60)	3	Viaderm KC
	(0.00)		

(Manulacture*SPrice) Subsidied Generic S Per ✓ Manufacture* Disinfecting and Cleansing Agents Momenta DHLORHEXIDINE GLUCONATE – Subsidy by endorsement a) No more than 500 ml per month 5.40 500 ml ✓ Orion s Soln 4%		Subsidy		Fully Brand or
Disinfecting and Cleansing Agents CHLORHEXIDINE GLUCONATE – Subsidy by endorsement a) No more than 500 ml per month b) Ohy if prescribed for a dialysis patient and the prescription is endorsed accordingly. * Handru 170% * Soln 4% Only if prescribed for a dialysis patient and the prescription is endorsed accordingly. Prescription endorsed accordingly. Powder 2% Constrate Creams and Emollients Barrier Creams Soln 4 QINC AND CASTOR OL Ci		(Manufacturer's F		osidised Generic
HUORHEXIDINE GLUCONATE - Subsidy by endorsement a) No more than 500 ml per month b) Only if prescribed for a dialysis patient and the prescription is endorsed accordingly. * Handrub 1% with ethanol 70% SODUM HYPOCHLORITE - Subsidy by endorsement Only if prescribed for a dialysis patient and the prescription is endorsed accordingly. * Soin 2.71 2.500 ml ✓ Orion SODUM HYPOCHLORITE - Subsidy by endorsement Only if prescribed for a namputee with an artificial limb, or for a paraplegic patient and the prescription endorsed accordingly. * Soin 2.71 2.500 ml ✓ Janola Dusting Powders (13.54) Prantal Barrier Creams and Emollients Barrier Creams (13.54) Prantal Barrier Creams (9.79) PSM ZINC (9.79) PSM Crm BP 5.11 500 g ✓ PEM Emollients 3.69 500 g ✓ PSM AQUEOUS CREAM 2.28 500 g ✓ AFI StrOCEROGOL 3.69 500 g ✓ AFI StrOCENC 3.69 500 g ✓ AFI StrOCENC 6.10 QV QV <t< td=""><td></td><td>\$</td><td>Per</td><td> Manufacturer </td></t<>		\$	Per	 Manufacturer
a) No more than 500 ml per month b) Only if prescribed for a dialysis patient and the prescription is endorsed accordingly. ★ Handrub 1% with ethanal 70%	Disinfecting and Cleansing Agents			
b) Only if prescribed for a dialysis patient and the prescription is endorsed accordingly. ★ Handrub 1% with ethanol 70%	CHLORHEXIDINE GLUCONATE – Subsidy by endorsement			
** Handrub 1% with ethanol 70%				
** Soln 4%				1 Orion
SODIUM HYPOCHLORITE – Subsidy by endorsement Only if prescribed for a dialysis patient and the prescription is endorsed accordingly. ★ Soln				
Only if prescribed for a dialysis patient and the prescription is endorsed accordingly. ★ Soln 2.71 2,500 ml ✓ Janola Dusting Powders 0 2.71 2,500 ml ✓ Janola Diverservent of the prescription of a paraplegic patient and the prescription endorsed accordingly. Powder 2% 6.81 50 g OP Only if prescribed for an amputee with an artificial limb, or for a paraplegic patient and the prescription endorsed accordingly. Powder 2% 6.81 50 g OP Powder 2% (13.54) Prantal Paratal Barrier Creams and Emollients 9.79 PSM ZINC 6.55 500 g PSM Crm BP .5.11 500 g ✓ PSM Emollients 2.28 500 g ✓ AFT AQUEOUS CREAM 2.28 500 g ✓ AFT CETOMACROGOL 3.50 500 g ✓ AFT SUYCEROL WITH PARAFFIN AND CETYL ALCOHOL - Only on a prescription 8. (al.10) QV W Crm 2.80 500 g ✓ AFT SUYCEROL WITH PARAFFIN AND CETYL ALCOHOL - Only on a prescription * Loth 5% with paraffin lig 5% and cetyl alcohol 2% 1.4.0 250 ml Cut Si Si Si				· <u></u>
Dusting Powders DIPHEMANIL METHYLSULPHATE - Subsidy by endorsement Only if prescribed for an ampulee with an artificial limb, or for a paraplegic patient and the prescription endorsed accordingly. Powder 2%	, ,	is endorsed accor	dingly.	
DIPHEMANIL METHYLSULPHATE – Subsidy by endorsement Only if prescribed for an amputee with an artificial limb, or for a paraplegic patient and the prescription endorsed accordingly. Powder 2%	* Soln	2.71	2,500 ml	 Janola
Only if prescribed for an amputee with an artificial limb, or for a paraplegic patient and the prescription endorsed accordingly. Powder 2% 6.81 50 g OP (13.54) Prantal Barrier Creams and Emollients Barrier Creams and Emollients Barrier Creams ZINC Crm BP 6.55 500 g (9.79) PSM ZINC AND CASTOR OIL Oint BP 5.11 500 g ✓ PSM Emollients AQUEOUS CREAM * Crm BP 3.50 500 g ✓ PSM EMULSIFYING OINTMENT * Oint BP 3.69 500 g ✓ AFT SUCCETONACROGOL * Oint BP 3.69 500 g ✓ AFT GUYCEROL WITH PARAFFIN AND CETYL ALCOHOL – Only on a prescription * Oint BP 1.40 250 ml QV OIL IN WATER EMULSION 2.80 500 g ✓ Lemnis Fatty Cream * Crm BP 2.80 500 g ✓ Lemnis Fatty Cream Lemnis Fatty Cream Crm to be delisted 1 December 2009) DUIV CREAM	Dusting Powders			
Powder 2% 6.81 (13.54) 50 g OP (13.54) Prantal Barrier Creams and Emollients Prantal Barrier Creams Prantal ZINC Orm BP 6.55 (9.79) 500 g PSM ZINC AND CASTOR OIL Oint BP 6.55 (9.79) 500 g ✓ PSM Emollients AQUEOUS CREAM 2.28 CETOMACROGOL 500 g ✓ AFT CETOMACROGOL 3.50 500 g ✓ AFT SULSIFYING OINTMENT 3.69 500 g ✓ AFT SUCCEROL WITH PARAFFIN AND CETYL ALCOHOL – Only on a prescription * Lotn 5% with paraffin lig 5% and cetyl alcohol 2% 2.80 500 g ✓ Lemnis Fatty Cream Charmis Fatty Cream Crm to be delisted 1 December 2009) OU Our Graig PSM David Craig PSM JREA * Crm 10% Crm 10% 2.52 100 g OP	DIPHEMANIL METHYLSULPHATE – Subsidy by endorsement			
(13.54) Prantal Barrier Creams Prantal Barrier Creams Prantal ZINC Orm BP 6.55 500 g Orm BP (9.79) PSM ZINC AND CASTOR OIL (9.79) PSM Oint BP 5.11 500 g ✓ PSM Emollients AQUEOUS CREAM 2.28 500 g ✓ AFT CETOMACROGOL 2.28 500 g ✓ PSM MQUEOUS CREAM 2.28 500 g ✓ AFT CETOMACROGOL 3.50 500 g ✓ PSM MOULSIFYING OINTMENT 3.69 500 g ✓ AFT SUYCEROL WITH PARAFFIN AND CETYL ALCOHOL – Only on a prescription * Lotn 5% with paraffin lig 5% and cetyl alcohol 2% 1.40 250 ml % OINT BP 2.80 500 g ✓ Lemnis Fatty Cream ✓ healthE Fatty Cream * Crm SP 2.80 500 g ✓ Lemnis Fatty Cream ✓ healthE Fatty Cream * Crm BP 2.80 500 g David Craig PSM // Lemnis Fatty Cream Crm to be delisted 1 December 2009) David Craig PSM // Lemnis Fatty Cream Crm to be delisted 1 Decemb	Only if prescribed for an amputee with an artificial limb, or fo			rescription endorsed accordingly.
Barrier Creams and Emollients Barrier Creams ZINC Crm BP	Powder 2%		50 g OP	Drantal
Barrier Creams ZINC Crm BP 6.55 500 g PSM ZINC AND CASTOR OIL (9.79) PSM Oint BP .5.11 500 g ✓ PSM Emollients AQUEOUS CREAM * Crm .2.28 500 g ✓ AFT CETOMACROGOL * Crm BP .3.50 500 g ✓ PSM EMULSIFYING OINTMENT * Oint BP .3.69 500 g ✓ AFT GLYCEROL WITH PARAFFIN AND CETYL ALCOHOL – Only on a prescription * Lotn 5% with paraffin lig 5% and cetyl alcohol 2% .1.40 250 ml (8.10) QV QV UI IN WATER EMULSION 2.80 500 g ✓ Lemnis Fatty Cream * Crm BP .2.80 500 g (13.60) David Craig PSM OIL IN WATER EMULSION .2.80 500 g David Craig PSM % Crm BP .2.80 500 g David Craig PSM U/L CREAM .2.80 500 g David Craig PSM % Crm BP .2.80 500 g David Craig <td></td> <td>(13.54)</td> <td></td> <td>Fidilla</td>		(13.54)		Fidilla
ZINC Crm BP	Barrier Creams and Emollients			
ZINC Crm BP	Barrier Creams			
Crm BP				
(9.79) PSM ZINC AND CASTOR OIL Oint BP 5.11 500 g ✓ PSM Emollients AQUEOUS CREAM * Crm 2.28 500 g ✓ AFT CETOMACROGOL ** Crm BP 3.50 500 g ✓ PSM EMULSIFYING OINTMENT ** Oint BP 3.69 500 g ✓ AFT GLYCEROL WITH PARAFFIN AND CETYL ALCOHOL – Only on a prescription ** Lotn 5% with paraffin liq 5% and cetyl alcohol 2% 1.40 250 ml (8.10) QV DIL IN WATER EMULSION ** Crm 2.80 500 g ✓ Lemnis Fatty Cream ✓ healthE Fatty Cream Mutanis Fatty Cream Crm to be delisted 1 December 2009) DILY CREAM ** Crm BP 500 g Javid Craig PSM JREA ** Crm 10% 2.52 100 g OP David Craig		6 55	500 a	
ZINC AND CASTOR OIL Dint BP .5.11 500 g ✓ PSM Emollients AQUEOUS CREAM * Crm 2.28 500 g ✓ AFT CETOMACROGOL * Crm BP 3.50 500 g ✓ PSM EMULSIFYING OINTMENT * Oint BP 3.69 500 g ✓ AFT GLYCEROL WITH PARAFFIN AND CETYL ALCOHOL – Only on a prescription * Lotn 5% with paraffin liq 5% and cetyl alcohol 2% 1.40 250 ml & Lotn 5% with paraffin liq 5% and cetyl alcohol 2% .1.40 250 ml QV DIL IN WATER EMULSION 2.80 500 g ✓ Lemnis Fatty Cream * Crm BP 2.80 500 g ✓ Lemnis Fatty Cream /Lemnis Fatty Cream Crm to be delisted 1 December 2009) DILY CREAM 500 g David Craig Store BP 2.80 500 g David Craig PSM JREA * Crm 10% 2.52 100 g OP Devid Craig			500 g	PSM
Emollients AQUEOUS CREAM * Crm 2.28 500 g ✓ AFT CETOMACROGOL * Crm BP 3.50 500 g ✓ PSM EMULSIFYING OINTMENT * Oint BP 3.69 500 g ✓ AFT GLYCEROL WITH PARAFFIN AND CETYL ALCOHOL – Only on a prescription * Lotn 5% with paraffin lig 5% and cetyl alcohol 2% 1.40 250 ml (8.10) QV DIL IN WATER EMULSION 2.80 500 g ✓ Lemnis Fatty Cream * Crm 2.80 500 g ✓ leanthe Fatty Cream //Lemnis Fatty Cream Crm to be delisted 1 December 2009) DULY CREAM 2.80 500 g * Crm BP 2.80 500 g David Craig (13.60) David Craig PSM JREA * Crm 10% 2.52 100 g OP	ZINC AND CASTOR OIL	()		
AQUEOUS CREAM * Crm Crm * Crm 2.28 500 g ✓ AFT CETOMACROGOL * Crm BP 3.50 500 g ✓ PSM EMULSIFYING OINTMENT * Oint BP 3.69 500 g ✓ AFT GLYCEROL WITH PARAFFIN AND CETYL ALCOHOL – Only on a prescription * Lotn 5% with paraffin lig 5% and cetyl alcohol 2% 1.40 250 ml (8.10) QV DIL IN WATER EMULSION 2.80 500 g ✓ Lemnis Fatty Cream * Crm 2.80 500 g (13.60) David Cream /Lemnis Fatty Cream Crm to be delisted 1 December 2009) DILY CREAM 2.80 500 g Mainthe Fatty Cream * Crm BP 2.80 500 g David Craig PSM JREA * Crm 10% 2.52 100 g OP PM	Oint BP	5.11	500 g	✓ <u>PSM</u>
** Crm 2.28 500 g ✓ AFT CETOMACROGOL 3.50 500 g ✓ PSM EMULSIFYING OINTMENT 3.69 500 g ✓ AFT GLYCEROL WITH PARAFFIN AND CETYL ALCOHOL – Only on a prescription * AFT SLYCEROL WITH PARAFFIN AND CETYL ALCOHOL – Only on a prescription * Lotn 5% with paraffin liq 5% and cetyl alcohol 2% 1.40 250 ml (8.10) QV 01 NATER EMULSION 250 ml QV String Fatty Cream Crm to be delisted 1 December 2009) 500 g ✓ Lemnis Fatty Cream DILY CREAM 2.80 500 g 13.60 David Craig * Crm BP 2.52 100 g OP PSM	Emollients			
CETOMACROGOL ★ Crm BP EMULSIFYING OINTMENT ★ Oint BP ★ Oint BP SILYCEROL WITH PARAFFIN AND CETYL ALCOHOL – Only on a prescription ★ Lotn 5% with paraffin liq 5% and cetyl alcohol 2% BL (8.10) QV Oll IN WATER EMULSION ★ Crm 2.80 500 g (Lemnis Fatty Cream Crm to be delisted 1 December 2009) DILY CREAM ★ Crm BP 2.80 500 g (13.60) (13.60) PSM JREA ★ Crm 10%	AQUEOUS CREAM			
** Crm BP	* Crm	2.28	500 g	✓ <u>AFT</u>
EMULSIFYING OINTMENT ★ Oint BP	CETOMACROGOL			
 ★ Oint BP		3.50	500 g	✓ <u>PSM</u>
GLYCEROL WITH PARAFFIN AND CETYL ALCOHOL – Only on a prescription 1.40 250 ml ** Lotn 5% with paraffin liq 5% and cetyl alcohol 2% 1.40 250 ml (8.10) QV DIL IN WATER EMULSION 2.80 500 g * Crm 2.80 500 g /Lemnis Fatty Cream Crm to be delisted 1 December 2009) 2.80 500 g DILY CREAM 2.80 500 g 13.60) * Crm BP 2.80 500 g 104 Craig JREA 2.52 100 g OP 100 g OP		0.00	500	4
★ Lotn 5% with paraffin liq 5% and cetyl alcohol 2%			500 g	✓ <u>AFI</u>
(8.10) QV DIL IN WATER EMULSION ★ Crm			250 ml	
DIL IN WATER EMULSION * Crm		(250 111	QV
★ Crm	OIL IN WATER EMULSION	()		
(Lemnis Fatty Cream Crm to be delisted 1 December 2009) DILY CREAM ★ Crm BP2.80 500 g (13.60) David Craig (15.40) PSM JREA ★ Crm 10%2.52 100 g OP		2.80	500 g	
DILY CREAM * Crm BP			-	healthE Fatty Cream
* Crm BP2.80 500 g (13.60) David Craig (15.40) PSM JREA * Crm 10%2.52 100 g OP				
(13.60) David Craig (15.40) PSM # Crm 10%2.52 100 g OP		0.00	500 a	
(15.40) PSM JREA * Crm 10%2.52 100 g OP	★ VIII DF		500 y	David Craig
* Crm 10%2.52 100 g OP		` '		0
	UREA	. ,		
(3.07) Nutraplus	* Crm 10%		100 g OP	
		(3.07)		Nutraplus

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

	Subsidy	D: \	Fully Brand or
	(Manufacturer's \$	Price) Sub Per	sidised Generic Manufacturer
WOOL FAT WITH MINERAL OIL – Only on a prescription * Lotn hydrous 3% with mineral oil	1 40	250 ml OP	
	(2.92)	200 111 01	Hydroderm Lotion
	5.60	1,000 ml	
	(9.54)	1,000 111	Hydroderm Lotion
	1.40	250 ml OP	
	(3.50)	200 111 01	DP Lotion
	5.60	1,000 ml	DI LOUOII
	(10.90)	1,000 111	DP Lotion
	1.12	200 ml OP	DI LOUOTI
	(5.00)	200 111 01	Alpha Kari Lation
	(/	275 ml OD	Alpha-Keri Lotion
	2.10	375 ml OP	Alpha Kari Lation
	(9.38)	1 000 m	Alpha-Keri Lotion
	5.60	1,000 ml	Alaba Kost Latter
	(18.43)		Alpha-Keri Lotion
	1.40	250 ml OP	
	(7.73)		BK Lotion
	5.60	1,000 ml	
	(23.91)		BK Lotion
Other Dermatological Bases			
•			
PARAFFIN	~~~~	0.500	
White soft – Only in combination		2,500 g	V IPW
	3.58	500 g	2014
Only in combination with a demonstrate sized and with the	(8.69)		PSM
Only in combination with a dermatological galenical or as	a diluent for a pi	roprietary Topica	al Corticosteroid – Plain.
Minor Skin Infections	a diluent for a pi	roprietary Topica	al Corticosteroid – Plain.
Minor Skin Infections	a diluent for a pi	roprietary Topica	Il Corticosteroid – Plain.
Minor Skin Infections POVIDONE IODINE			Il Corticosteroid – Plain.
Minor Skin Infections	2.88	roprietary Topica 25 g OP	
Minor Skin Infections POVIDONE IODINE Oint 10%			Il Corticosteroid – Plain. Betadine
Minor Skin Infections POVIDONE IODINE Oint 10% a) Maximum of 100 g per prescription	2.88		
Minor Skin Infections POVIDONE IODINE Oint 10% a) Maximum of 100 g per prescription b) Only on a prescription	2.88 (3.27)	25 g OP	Betadine
Minor Skin Infections POVIDONE IODINE Oint 10% a) Maximum of 100 g per prescription	2.88 (3.27)		Betadine
Minor Skin Infections POVIDONE IODINE Oint 10% a) Maximum of 100 g per prescription b) Only on a prescription Antiseptic soln 10%		25 g OP 500 ml	Betadine Betadine Riodine
Minor Skin Infections POVIDONE IODINE Oint 10% a) Maximum of 100 g per prescription b) Only on a prescription Antiseptic soln 10% Skin preparation, povidone iodine 10% with 30% alcohol		25 g OP 500 ml 500 ml	Betadine
Minor Skin Infections POVIDONE IODINE Oint 10% a) Maximum of 100 g per prescription b) Only on a prescription Antiseptic soln 10%		25 g OP 500 ml	Betadine ✓ Betadine ✓ Riodine ✓ Betadine Skin Prep
Minor Skin Infections POVIDONE IODINE Oint 10% a) Maximum of 100 g per prescription b) Only on a prescription Antiseptic soln 10% Skin preparation, povidone iodine 10% with 30% alcohol		25 g OP 500 ml 500 ml	Betadine Betadine Riodine
Minor Skin Infections POVIDONE IODINE Oint 10% a) Maximum of 100 g per prescription b) Only on a prescription Antiseptic soln 10% Skin preparation, povidone iodine 10% with 30% alcohol		25 g OP 500 ml 500 ml	Betadine ✓ Betadine ✓ Riodine ✓ Betadine Skin Prep
Minor Skin Infections POVIDONE IODINE Oint 10% a) Maximum of 100 g per prescription b) Only on a prescription Antiseptic soln 10% Skin preparation, povidone iodine 10% with 30% alcohol Skin preparation, povidone iodine 10% with 70% alcohol Parasiticidal Preparations		25 g OP 500 ml 500 ml	Betadine ✓ Betadine ✓ Riodine ✓ Betadine Skin Prep
Minor Skin Infections POVIDONE IODINE Oint 10% a) Maximum of 100 g per prescription b) Only on a prescription Antiseptic soln 10% Skin preparation, povidone iodine 10% with 30% alcohol Skin preparation, povidone iodine 10% with 70% alcohol Parasiticidal Preparations GAMMA BENZENE HEXACHLORIDE		25 g OP 500 ml 500 ml 500 ml	Betadine Betadine Riodine Betadine Skin Prep Orion
Minor Skin Infections POVIDONE IODINE Oint 10% a) Maximum of 100 g per prescription b) Only on a prescription Antiseptic soln 10% Skin preparation, povidone iodine 10% with 30% alcohol Skin preparation, povidone iodine 10% with 70% alcohol Parasiticidal Preparations GAMMA BENZENE HEXACHLORIDE Crm 1%		25 g OP 500 ml 500 ml	Betadine ✓ Betadine ✓ Riodine ✓ Betadine Skin Prep
Minor Skin Infections POVIDONE IODINE Oint 10% a) Maximum of 100 g per prescription b) Only on a prescription Antiseptic soln 10% Skin preparation, povidone iodine 10% with 30% alcohol Skin preparation, povidone iodine 10% with 70% alcohol Parasiticidal Preparations GAMMA BENZENE HEXACHLORIDE Crm 1% MALATHION		25 g OP 500 ml 500 ml 500 ml	Betadine Betadine Betadine Riodine Betadine Skin Prep Orion V Benhex
Minor Skin Infections POVIDONE IODINE Oint 10% a) Maximum of 100 g per prescription b) Only on a prescription Antiseptic soln 10% Skin preparation, povidone iodine 10% with 30% alcohol Skin preparation, povidone iodine 10% with 70% alcohol Parasiticidal Preparations GAMMA BENZENE HEXACHLORIDE Crm 1%		25 g OP 500 ml 500 ml 500 ml	Betadine Betadine Riodine Betadine Skin Prep Orion

Subsidy (Manufacturer's Price)	,		Brand or Generic	
\$	Per	~	Manufacturer	

PERMETHRIN

- 1) Should be strictly reserved for use as second line therapy in:
 - 1) patients unable to tolerate the other medications, such as infants, young children and patients with allergies or eczema;

30 g OP

Lyderm

- 2) cases of scabies which are resistent to gamma benzene hexachloride and resistant to malathion.
- 2) Verification of drug resistance is dependent on the persistence of the condition after treatment. In order to establish whether there is drug resistance, the following criteria should be fulfilled:
 - 1) a definite diagnosis of scabies should be made;
 - 2) it should be ascertained that the medication was administered properly;
 - 3) the possibility of reinfestation should have been excluded.

Psoriasis and Eczema Preparations

ACITRETIN - Special Authority see SA0954 below - Retail pharmacy

Cap 10 mg	75.80	100	Neotigason
Cap 25 mg		100	 Neotigason

➡SA0954 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin; and
- 3 Either:
 - 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if actiretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
 - 3.2 Patient is male.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- All of the following:
 - 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
 - 2 Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin; and
 - 3 Either:
 - 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
 - 3.2 Patient is male.

CALCIPOTRIOL

Crm 50 µg per g20.76	30 g OP	Daivonex
57.89	100 g OP	Daivonex
Oint 50 µg per g20.76	30 g OP	Daivonex
57.89	100 g OP	Daivonex
Soln 50 µg per ml	30 ml OP	Daivonex
34.72	60 ml OP	Daivonex

	Subsidy		Fully Brand or
	(Manufacturer's \$	Price) Sub Per	osidised Generic Manufacturer
COAL TAR			
Soln BP – Only in combination		500 ml	✔ PSM
	12.98	200 ml	
	(16.20)		David Craig
Up to 10 % Only in combination with a dermatological b With or without other dermatological galenicals.	base or proprietai	ry Topical Corti	icosteriod – Plain, refer, page 16
0 0	סווווס		
COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SUL			
Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% an allantoin crm 2.5%		30 g OP	
	(4.35)	00 9 01	Egopsoryl TA
	6.59	75 g OP	_gopool j1
	(8.00)	0	Egopsoryl TA
COAL TAR WITH SALICYLIC ACID AND SULPHUR			
Soln 12% with salicylic acid 2% and sulphur 4% oint	7.95	40 g OP	Coco-Scalp
DITHRANOL			
Crm 1%		50 g OP	Micanol
SALICYLIC ACID		•	
Powder – Only in combination		500 g	🖌 ABM
	18.88	250 g	🖌 PSM
1) Only in combination with a dermatological base or	proprietary Topica	al Corticosteroi	d – Plain or collodion flexible, ref
page 160			
 With or without other dermatological galenicals. Maximum 20 a series of all new properties when area 			r selledien flevilele
3) Maximum 20 g or 20 ml per prescription when pres		e son paranin o	r collogion liexible.
SULPHUR Precipitated – Only in combination	6 50	100 g	🖌 ABM
Precipitated - Only in combination	(9.25)	100 g	PSM
1) Only in combination with a dermatological base or		al Corticostero	
2) With or without other dermatological galenicals.	r - r		, ,
AR WITH CADE OIL			
Bath emul 7.5% coal tar, 2.5% cade oil, 7.5% compound	9.70	350 ml	
	(29.60)		Polytar Emollient
AR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLU	JORESCEIN - C	only on a presci	ription
Soln 2.3% with triethanolamine lauryl sulphate and fluores	3-		
cein sodium	2.90	500 ml	Pinetarsol
Scalp Preparations			
BETAMETHASONE VALERATE			
₭ Scalp app 0.1%	5.25	100 ml OP	Beta Scalp
CLOBETASOL PROPIONATE			
₭ Scalp app 0.05%	3.20	30 ml OP	Dermol
IYDROCORTISONE BUTYRATE			
Scalp lotn 0.1%	7.52	100 ml OP	✓ Locoid
ETOCONAZOLE			
Shampoo 2%	3.48	100 ml OP	✓ Sebizole
a) Maximum of 100 ml per prescription			
 b) Only on a prescription 			

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully osidised	Brand or Generic Manufacturer
Sunscreens				
SUNSCREENS, PROPRIETARY – Subsidy by endorsement Only if prescribed for a patient with severe photosensitivity endorsed accordingly.	secondary to a	defined clinica	l conditic	on and the prescription is
Crm	2.55	100 g OP		
	(5.89)		Ha	milton Sunscreen
	1.28	50 g OP		
	(5.84)			uasun Oil Free Faces SPF30+
Lotn	2.55	100 ml OP		arine Blue Lotion SPF 30+
	5.10	200 ml OP		arine Blue Lotion SPF 30+
	3.19	125 ml OP		
	(8.82)			uasun Sensitive SPF 30+
	(9.38)		Aq	uasun 30+
Wart Preparations				
For salicylic acid preparations refer to PSORIASIS AND ECZEM	A PREPARATION	VS, page 65		
IMIQUIMOD - Special Authority see SA0923 below - Retail pha	armacy			
Crm 5% sachet	•	12	🖌 Al	dara
►SA0923 Special Authority for Subsidy				
Production Special Authority for Subsidy	l far 1 mantha far	onnligations m	acting th	a fallandaa adtada.

Initial application from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria: Any of the following:

- 1 The patient has external anogenital warts and podophyllotoxin has been tried and failed (or is contraindicated); or
- 2 The patient has external anogenital warts and podophyllotoxin is unable to be applied accurately to the site; or
- 3 The patient has confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate.

Notes: Superficial basal cell carcinoma

- Surgical excision remains first-line treatment for superficial basal cell carcinoma as it has a higher cure rate than imiquimod and allows histological assessment of tumour clearance.
- Imiquimod has not been evaluated for the treatment of superficial basal cell carcinoma within 1 cm of the hairline, eyes, nose, mouth or ears.
- Imiquimod is not indicated for recurrent, invasive, infiltrating, or nodular basal cell carcinoma.
- External anogenital warts
 - Imiquimod is only indicated for external genital and perianal warts (condyloma acuminata).

Renewal from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria: Any of the following:

- 1 Inadequate response to initial treatment for anogenital warts; or
- 2 New confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate; or
- 3 Inadequate response to initial treatment for superficial basal cell carcinoma.

Note: Confirmation that the lesion is a superficial basal cell carcinoma should be obtained using a biopsy

PODOPHYLLOTOXIN

Soln 0.5%	3.5 ml OP	 Condyline
a) Maximum of 3.5 ml per prescription		-
h) Only on a propagintion		

b) Only on a prescription

	Subsidy (Manufacturer's Prio \$	ce) Sub Per	Fully osidised	Brand or Generic Manufacturer
Other Skin Preparations				
Antineoplastics				
FLUOROURACIL SODIUM Crm 5%		20 g OP	🗸 Ei	fudix
Topical Analgesia				
For aspirin & chloroform application refer, page 163 CAPSAICIN – Subsidy by endorsement Subsidised only if prescribed for post-herpetic neuralgia or accordingly. Crm 0.075%		neuropathy 45 g OP		e prescription is endorsed
Wound Management Products				
HYDROGEN PEROXIDE * Soln 20 vol – Maximum of 500 ml per prescription	3.13 (7.00)	500 ml	P	SM
MAGNESIUM SULPHATE Paste	2.98 (4.90)	80 g	P	SM

GENITO-URINARY SYSTEM

	Subsidy (Manufacturer's Pr \$	rice) S Per	Fully ubsidised	Brand or Generic Manufacturer
Contraceptives - Non-hormonal				
Condoms				
CONDOMS				
# 49 mm – Up to 144 dev available on a P	5013.36	144	🖌 Ma	old Knight arquisTantiliza nield 49
✤ 52 mm – Up to 144 dev available on a Particular to the second seco	5013.36	144	🖌 Ma	arquis Selecta arquis Sensolite
* 52 mm extra strength – Up to 144 dev av	ailable on a PSO 13.36	144		arquis Supalite arquis Protecta
★ 53 mm – Up to 144 dev available on a P		144	✔ Go ✔ Ma ✔ Ma	old Knight arquis Black arquis Titillata nield Blue
* 53 mm (chocolate) – Up to 144 dev avail	able on a PSO13.36	144		old Knight
* 53 mm (strawberry) - Up to 144 dev ava	lable on a PSO13.36	144	🖌 Go	old Knight
 53 mm extra strength – Up to 144 dev availabl 54 mm, shaped – Up to 144 dev availabl 	e on a PSO13.36	144 144		old Knight
* 55 mm - Up to 144 dev available on a P	(14.84) SO13.36	144	🖌 Go	festyles Flared old Knight arguis Conforma
* 56 mm – Up to 144 dev available on a Pa	5013.36	144	🖌 Di	urex Select Flavours
 56 mm extra strength - Up to 144 dev availabl 56 mm, shaped - Up to 144 dev availabl 60 mm - Up to 144 dev available on a Page 	e on a PSO13.36	144 144 144	🖌 Di	urex Extra Safe urex Confidence nield XL
Spermicidal Agents				
APPLICATOR When ordered with a spermicide.				
 Applicator – Up to 1 dev available on a P NONOXYNOL-9 	SO4.34	1	🖌 01	rtho
Jelly 2% – Up to 108 g available on a PS	O10.95	108 g OP	🖌 G	ynol II
Contraceptive Devices				
DIAPHRAGM * Diaphragm – Up to 1 dev available on a	PSO42.90	1		rtho All-flex rtho Coil
One of each size is permitted on a PS	Э.			
INTRA-UTERINE DEVICE – Only on a WSO * IUD		1		ultiload Cu 375
Distributed by Pharmaco NZ Ltd, PO E	ox 4079, Auckland Ph 09 377 3336		✓ M	ultiload Cu 375 SL

	Subsidy (Manufacturer's Price \$	Fully) Subsidised Per 🖌	
Contraceptives - Hormonal			
Combined Oral Contraceptives			
 SA0500 Special Authority for Alternate Subsidy nitial application from any medical practitioner. Approvals v 3oth: Either: Patient is on a Social Welfare benefit; or	fit; and as been unable to tolerai	e it.	,
2 Patient has an income no greater than the benefit. lotes: The approval numbers of Special Authorities approv larvelon, Minuelt and Fernodene.			
The additional subsidy will fund Mercilon, Marvelon, Minulet ar as identified on the Schedule at 1 November 1999.	na Fernodene up to the m	anutacturers pric	e for each of these products
Special Authorities approved before 1 November 1999 remain are still either: • on a Social Welfare benefit; or • back an income percenter than the bacefit	a valid until the expiry dat	e and can be rer	ewed providing that women
 have an income no greater than the benefit. The approval numbers of Special Authorities approved before prined oral contraceptives and progestogen-only contraceptive ETHINYLOESTRADIOL WITH DESOGESTREL 		0	
★ Tab 20 µg with desogestrel 150 µg	6.62 (16.50)	63	Mercilon 21

	(16.50)		Mercilon 21
	a) Higher subsidy of \$13.80 per 63 with Special Authority see SA0500 above		
	b) Up to 63 tab available on a PSO		
*	Tab 20 µg with desogestrel 150 µg and 7 inert tab	84	
	(16.50)		Mercilon 28
	a) Higher subsidy of \$13.80 per 84 with Special Authority see SA0500 above b) Up to 84 tab available on a PSO		
*	Tab 30 µg with desogestrel 150 µg6.62	63	
	(16.50)		Marvelon 21
	 a) Higher subsidy of \$13.80 per 63 with Special Authority see SA0500 above b) Up to 63 tab available on a PSO 		
*		84	
	(16.50)	01	Marvelon 28
	a) Higher subsidy of \$13.80 per 84 with Special Authority see SA0500 above		
	b) Up to 84 tab available on a PSO		
ET	HINYLOESTRADIOL WITH GESTODENE		
*	Tab 30 μg with gestodene 75 μg and 7 inert tab	84	Femodene 28
	a) Higher subsidy of \$14.49 per 84 with Special Authority see SA0500 above b) Up to 84 tab available on a PSO		

GENITO-URINARY SYSTEM

	Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic
	\$	Per	~	Manufacturer
ETHINYLOESTRADIOL WITH LEVONORGESTREL				
* Tab ethinyloestradiol 30 μg with levonorgestrel 50 μg (6) and tab ethinyloestradiol 40 μg with levonorgestrel 75 μg (5)	9			
and tab ethinyloestradiol 30 µg with levonorgestrel 125 µg	·	~ 1		
(10) and 7 inert tab		84		r ifeme riguilar ED
a) Higher subsidy of up to \$9.45 per 84 with Special Authors) Up to 84 tab available on a PSO	(9.45) prity see SA0500 on th	ne pre		1
* Tab 50 μ g with levonorgestrel 125 μ g and 7 inert tab – Up to	1			
84 tab available on a PSO		84	V N	licrogynon 50 ED
* Tab 30 μg with levonorgestrel 150 μg		63	•	
· · · · · · · · · · · · · · · · · · ·	(16.50)		Ν	licrogynon 30
a) Higher subsidy of \$15.00 per 63 with Special Authority	see SA0500 on the pr	ecedi		07
b) Up to 63 tab available on a PSO			01 0	
* Tab 30 µg with levonorgestrel 150 µg and 7 inert tab	6.62	84		evlen ED Ionofeme
	(14.49)		N	ordette 28
	(16.50)		N	licrogynon 30 ED
and tab ethinyloestradiol 30 µg with levonorgestrel 125 µg (10) a ETHINYLOESTRADIOL WITH NORETHISTERONE * Tab 35 µg with norethisterone 1 mg – Up to 63 tab available		liotou	1 20001120	. 2000)
on a PSO * Tab 35 µg with norethisterone 1 mg and 7 inert tab - Up to	6.62	63	✓ <u>B</u>	revinor 1/21
84 tab available on a PSO	6.62	84	✓ <u>B</u>	revinor 1/28
* Tab 35 μg with norethisterone 500 μg – Up to 63 tab available on a PSO		63	V B	revinor 21
* Tab 35 μg with norethisterone 500 μg and 7 inert tab – Up to		00	• •	
84 tab available on a PSO		84	🖌 N	orimin
NORETHISTERONE WITH MESTRANOL				
* Tab 1 mg with mestranol 50 μg and 7 inert tab	6.62 (13.80)	84	N	orinyl-1/28
a) Higher subsidy of \$13.80 per 84 with Special Authority b) Up to 84 tab available on a PSO	()	ecedi		onnyi-nzo
Combined Oral Contraceptives - Other				
ETHINYLOESTRADIOL WITH LEVONORGESTREL				
* Tab 20 μg with levonorgestrel 100 μg and 7 inert tab – Up to				
84 tab available on a PSO		84		
	(16.50)			oette
	(16.50)		N	licrogynon 20 ED

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

Progestogen-only Contraceptives

➡SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Either:

- 1.1 Patient is on a Social Welfare benefit; or
- 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon, Marvelon, Minulet and Femodene.

The additional subsidy will fund Mercilon, Marvelon, Minulet and Femodene up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- . have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

LEVONORGESTREL

* Tab 30 μg6.62 (16.50)	84	Microlut
a) Higher subsidy of \$13.80 per 84 with Special Authority see SA0500 above b) Up to 84 tab available on a PSO		
MEDROXYPROGESTERONE ACETATE		
Inj 150 mg per ml, 1 ml – Up to 5 inj available on a PSO	1	Depo-Provera
Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a PSO8.05	1	Depo-Provera
NORETHISTERONE		
* Tab 350 μg – Up to 84 tab available on a PSO7.15	84	Noriday 28
Emergency Contraceptives		
LEVONORGESTREL		
 * Tab 1.5 mg12.50 a) Maximum of 2 tab per prescription 	1	 Postinor-1

b) Up to 5 tab available on a PSO

Antiandrogen Oral Contraceptives

Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows:

- \$3.00 prescription charge (patient co-payment) will apply.
- prescription may be written for up to six months supply.

Prescriptions coded in any other way are subject to the non contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply.

CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL

*	Tab 2 mg with ethinyloestradic	I 35 μg and 7 inert tabs	6.30	84	 Estelle 35-ED
---	--------------------------------	-------------------------------	------	----	-----------------------------------

GENITO-URINARY SYSTEM

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully Brand or sidised Generic ✓ Manufacturer
Gynaecological Anti-infectives			
ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC A Jelly with glacial acetic acid 0.94%, hydroxyquinoline sul- phate 0.025%, glycerol 5% and ricinoleic acid 0.75% with	CID		
applicator	8.43 (11.32)	100 g OP	Aci-Jel
CLOTRIMAZOLE			
* Vaginal crm 1% with applicator(s)		35 g OP	✓ <u>Clomazol</u>
* Vaginal crm 2% with applicators	2.75	20 g OP	Clomazol
MICONAZOLE NITRATE * Vaginal crm 2% with applicator	2.75 (3.70)	40 g OP	Micreme
NYSTATIN			
Vaginal crm 100,000 u per 5 g with applicator(s)	4.71	75 g OP	✓ Nilstat
Myometrial and Vaginal Hormone Preparations			
ERGOMETRINE MALEATE			
Inj 500 μg per ml, 1 ml $$ – Up to 5 inj available on a PSO	11.60	5	🖌 Mayne
METHYLERGOMETRINE Inj 200 µg per ml, 1 ml – Up to 10 inj available on a PSO	9.28	10	✔ Hospira S29
OESTRIOL			
* Crm 1 mg per g with applicator		15 g OP	✓ Ovestin
* Pessaries 500 μg		15	 Ovestin
OXYTOCIN – Up to 5 inj available on a PSO Inj 5 iu per ml, 1 ml	E 40	5	Syntocinon
Inj 10 iu per mi, 1 mi		5	Syntocinon
Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml		5	 ✓ Syntometrine
Pregnancy Tests - HCG Urine			-
PREGNANCY TESTS - HCG URINE – Only on a WSO			
Cassette		25 test	MDS Quick Card
Distributed by MDS Diagnostics, PO Box 24-162, Royal Oa	ak, Auckland. Ph	n 09 570 5761	
Urinary Agents			
For urinary tract Infections refer to INFECTIONS, Antibacterials, p.	age 94		
5-Alpha Reductase Inhibitors			
FINASTERIDE – Special Authority see SA0928 on the next page Tab 5 mg		acy 30	✓ <u>Fintral</u>

(Manufacturer's Price) Subsidised Generic \$ Per ✔ Manufacturer		Subsidy (Manufacturer's Price) \$		Fully Subsidised		
--	--	---	--	---------------------	--	--

SA0928 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 Either:
 - 2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or
 - 2.2 Symptoms are not adequately controlled with non-selective alpha blockers.

Note: Patients with enlarged prostates are the appropriate candidates for therapy with finasteride.

Other Urinary Agents

OXYBUTYNIN		
* Tab 5 mg	500	Apo-Oxybutynin
* Oral liq 5 mg per 5 ml	473 ml OP	✓ Apo-Oxybutynin
SODIUM CITRO-TARTRATE		
* Grans eff 4 g sachets2.75	28	✓ <u>Ural</u>

	Subsidy		Fully Brand or
	(Manufacturer's Pric		osidised Generic
	\$	Per	 Manufacturer
nabolic Agents			
NDROLONE DECANOATE – Retail pharmacy-Specialist			
Inj 50 mg per ml, 1 ml	21.15	1	 Deca-Durabolin Orgaject
orticosteroids and Related Agents for Systemic	c Use		
TAMETHASONE SODIUM PHOSPHATE WITH BETAMETHAS	ONE ACETATE		
Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1ml		5	
	(33.60)		Celestone Chronodose
XAMETHASONE	10.00	100	
Tab 1 mg – Retail pharmacy-Specialist Up to 30 tab available on a PSO		100	Douglas
Tab 4 mg – Retail pharmacy-Specialist	61.89	100	V Douglas
Up to 30 tab available on a PSO			· ·
Oral liq 1 mg per ml – Retail pharmacy-Specialist		25 ml OP	 Biomed
Oral liq prescriptions: 1) Must be written by a Paediatrician or Paediatric Card	diologist: or		
2) On the recommendation of a Paediatrician or Paedia	U .		
XAMETHASONE SODIUM PHOSPHATE	0		
Inj 4 mg per ml, 1 ml – Up to 5 inj available on a PSO		5	Mayne
Inj 4 mg per ml, 2 ml – Up to 5 inj available on a PSO	31.00	5	Mayne
UDROCORTISONE ACETATE			
Tab 100 µg	7.62	100	 Florinef
DROCORTISONE	7.05	100	
Tab 5 mg Tab 20 mg		100 100	 Douglas Douglas
Inj 50 mg per ml, 2 ml		1	Solu-Cortef
a) Up to 5 inj available on a PSO			
b) Only on a PSO			
THYLPREDNISOLONE – Retail pharmacy-Specialist			
Tab 4 mg		100	Medrol
Tab 100 mg		20	Medrol
	6.02	1	A Dono Modrol
Inj 40 mg per ml, 1 ml	0.03	I	Depo-Medrol
THYLPREDNISOLONE ACETATE WITH LIGNOCAINE Inj 40 mg per ml with lignocaine 1 ml	6.02	1	Depo-Medrol with
nij +o nig per nir with lighodanië 1 mil	0.03	I	lidocaine
THYLPREDNISOLONE SODIUM SUCCINATE - Retail pharm			
Inj 40 mg per ml, 1 ml		25	Solu-Medrol
Inj 62.5 mg per ml, 2 ml		25 1	 Solu-Medrol Solu-Medrol
Inj 500 mg Inj 1 g		1	Solu-Medrol
REDNISOLONE SODIUM PHOSPHATE			
Oral lig 5 mg per ml – Up to 30 ml available on a PSO		30 ml OP	Redipred

(1	Subsidy Manufacturer's Price) \$	S Per	Fully Subsidised	Brand or Generic Manufacturer
PREDNISONE				
* Tab 1 mg	10.68	500	✓ <u>A</u>	po-Prednisone
* Tab 2.5 mg		500	✓ <u>A</u>	po-Prednisone
* Tab 5 mg – Up to 30 tab available on a PSO		500	. —	po-Prednisone
* Tab 20 mg	29.03	500	✓ <u>A</u>	po-Prednisone
TETRACOSACTRIN				
* Inj 250 μg	177.18	10	✓ S	ynacthen
* Inj 1 mg per ml, 1 ml	26.88	1	✓ S	ynacthen Depot
TRIAMCINOLONE ACETONIDE				
Inj 10 mg per ml, 1 ml		5	V K	enacort-A
Inj 40 mg per ml, 1 ml		5	K	enacort-A40
Sex Hormones Non Contraceptive Androgen Agonists and Antagonists				
Androgon Agomoto and Andgomoto				
CYPROTERONE ACETATE – Hospital pharmacy [HP3]-Specialist Tab 50 mg	21.10	50	✔ S	iterone
Tab 100 mg	41.50	50	🖌 S	iterone
TESTOSTERONE				
Transdermal patch 2.5 mg per day	80.00	60	🗸 🗛	ndroderm
		00	• //	
TESTOSTERONE CYPIONATE – Retail pharmacy-Specialist	61.41	1		ana Taataatarana
Inj long-acting 100 mg per ml, 10 ml	01.41	I	<u>v</u> <u>b</u>	epo-Testosterone
TESTOSTERONE ESTERS – Retail pharmacy-Specialist				
Inj 250 mg per ml, 1 ml	12.98	1	V S	ustanon Ampoules
TESTOSTERONE UNDECANOATE – Retail pharmacy-Specialist				
Cap 40 mg	60.71	60		ndriol Testocaps anteston

Hormone Replacement Therapy - Systemic

SA0312 Special Authority for Alternate Subsidy

Initial application only from an obstetrician, gynaecologist, general practitioner or general physician. Approvals valid for 5 years for applications meeting the following criteria:

Any of the following:

- 1 acute or significant liver disease where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record; or
- 2 oestrogen induced hypertension requiring antihypertensive therapy documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens; or
- 3 hypertriglyceridaemia documented evidence must be kept on file that triglyceride levels increased to at least $2 \times$ normal triglyceride levels post oral oestrogens.

Note: Prescriptions with a valid Special Authority (CHEM) number will be reimbursed at the level of the lowest priced TDDS product within the specified dose group.

Renewal only from an obstetrician, gynaecologist, general practitioner or general physician. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.

Prescribing Guideline

76

HRT should be taken at the lowest dose for the shortest period of time necessary to control symptoms. Patients should be reviewed 6 monthly in line with the updated NZGG "Evidence-based Best Practice Guideline on Hormone Replacement Therapy March 2004".

	Subsidy (Manufacturer) \$		Fully Brand or Subsidised Generic Manufacturer
Oestrogens			
OESTRADIOL – See prescribing guideline on th	ne preceding page		
* Tab 1 mg		28 OP	
	(10.55)		Estrofem
* Tab 2 mg		28 OP	Fatrofom
* TDDS 25 µg per day	(10.55)	8	Estrofem
* 1003 25 µg per day	(10.86)	0	Estraderm TTS 25
 a) Higher subsidy of \$10.86 per 8 with Sp b) No more than 2 patch per week c) Only on a prescription 	(/	the preceding	
* TDDS 3.9 mg (releases 50 µg of oestradio)	per day)4.12	4	
	(14.50)		Climara 50
	(32.50)		Femtran 50
 a) Higher subsidy of \$13.18 per 4 with Sp b) No more than 1 patch per week c) Only on a prescription 	pecial Authority see SA0312 on	the preceding	page
 TDDS 50 µg per day 	4.12	8	
	(13.18)		Estraderm TTS 50
 a) Higher subsidy of \$13.18 per 8 with Sp b) No more than 2 patch per week c) Only on a prescription 	pecial Authority see SA0312 on	the preceding	page
* TDDS 7.8 mg (releases 100 μg of oestradio	l per day)7.05 (17.75) (35.00)	4	Climara 100 Femtran 100
a) Higher subsidy of \$16.14 per 4 with Sp	()	the preceding	page
 b) No more than 1 patch per week c) Only on a prescription 			
 C) Only on a prescription TDDS 100 μg per day 	7 05	8	
	(16.14)	0	Estraderm TTS 100
a) Higher subsidy of \$16.14 per 8 with Sp b) No more than 2 patch per week c) Only on a prescription	pecial Authority see SA0312 on	the preceding	
OESTRADIOL VALERATE – See prescribing gu	1 01 0		4-
* Tab 1 mg		56	Progynova
* Tab 2 mg		56	Progynova
OESTROGENS - See prescribing guideline on			
* Conjugated, equine tab 300 μg		28	Duranda
K Conjugated equipe to COF	(11.48)	00	Premarin
* Conjugated, equine tab 625 µg		28	Premarin
Progestogens	(11.40)		Temann
MEDROXYPROGESTERONE ACETATE – See	prescribing guideline on the pre	eceding page	
* Tab 2.5 mg	1 00 1	30	✓ Provera
* Tab 5 mg		100	✓ Provera
* Tab 10 mg		30	✓ Provera

	Subsidy (Manufacturer's Pri	ce) Sul	Fully Brand or bsidised Generic
	\$	Per	 Manufacturer
Progestogen and Oestrogen Combined Preparat	tions		
OESTRADIOL WITH LEVONORGESTREL – See prescribing gui	ideline on page 76	i	
* Tab 2 mg with 75 μg levonorgestrel (36) and tab 2 mg oestra-			4 • • • •
diol (48) (Nuvelle Tab 2 mg with 75 μg levonorgestrel (36) and tab 2 mg oe.		84 delisted 1 D	Nuvelle
OESTRADIOL WITH NORETHISTERONE – See prescribing quit		ucilisicu i D	
* Tab 1 mg with 0.5 mg norethisterone acetate		28 OP	
	(14.52)		Kliovance
* Tab 2 mg with 1 mg norethisterone acetate	5.40 (14.52)	28 OP	Kliogest
* Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg	()		Riogest
oestradiol tab (12) and 1 mg oestradiol tab (6)		28 OP	
	(14.52)		Trisequens
OESTROGENS WITH MEDROXYPROGESTERONE - See pres	cribing guideline c	on page 76	
* Tab 625 µg conjugated equine with 2.5 mg medroxyproges- terone acetate tab (28)	5.40	28 OP	
	(22.96)	20 01	Premia 2.5
			Continuous
* Tab 625 μg conjugated equine with 5 mg medroxyproges- terone acetate tab (28)	E 40		
terone acetate tab (28)		28 OP	Premia 5 Continuous
Other Oestrogen Preparations	()		
ETHINYLOESTRADIOL * Tab 10 µg	17.60	100	NZ Medical and
* Tab 10 μg	17.00	100	Scientific
OESTRIOL			
* Tab 2 mg	7.00	30	✓ Ovestin
Other Progestogen Preparations			
DYDROGESTERONE			
Tab 10 mg		50	
	(29.90)		Duphaston
LEVONORGESTREL			
* Levonorgestrel - releasing intrauterine system 20μg/24 hr – Special Authority see SA0782 below – Retail pharmacy.		1	🖌 Mirena
SA0782 Special Authority for Subsidy			
Initial application — (No previous use) only from a relevant sp	pecialist or genera	I practitione	r. Approvals valid for 6 months fo
applications meeting the following criteria:			
All of the following: 1 The patient has a clinical diagnosis of heavy menstrual ble	eding: and		
2 The patient has failed to respond to or is unable to toleral		te pharmace	eutical therapies as per the Heav
Menstrual Bleeding Guidelines; and			
 Either: 3.1 serum ferritin level < 16 μg/l (within the last 12 mont 	ths): or		
3.2 haemoglobin level $<$ 120 g/l.			
			continued

	Subsidy (Manufacturer's Price) \$	Su Per	Fully bsidised	Brand or Generic Manufacturer
ontinued lote: Applications are not to be made for use in patients as contr nitial application — (Previous use before 1 October 2002) alid for 6 months for applications meeting the following criteria: Il of the following:				
 The patient had a clinical diagnosis of heavy menstrual ble Patient demonstrated clinical improvement of heavy mens Applicant to state date of the previous insertion. 	0			
Jote: Applications are not to be made for use in patients as contractional only from a relevant specialist or general practitioner. A riteria: Both:				
 Either: Patient demonstrated clinical improvement of heavy Previous insertion was removed or expelled within Applicant to state date of the previous insertion. 	, U.			
IEDROXYPROGESTERONE ACETATE		100 30	_	rovera rovera
IORETHISTERONE ₭ Tab 5 mg – Up to 30 tab available on a PSO		100	✓ <u>Pi</u>	rimolut N
Thyroid and Antithyroid Agents				
CARBIMAZOLE ≰ Tab 5 mg		100	🗸 N	eo-Mercazole
EVOTHYROXINE ≰ Tab 50 µg	45.00	28 1,000	V S	oldshield ynthroid
‡ Safety cap for extemporaneously compounded oral liqui ★ Tab 100 µg		28		ltroxin oldshield
+ Safety cap for extemporaneously compounded oral liqui	66.78	1,000		ynthroid Itroxin
 Safety cap for extemporaneously compounded oral liqui Tab 25 µg ‡ Safety cap for extemporaneously compounded oral liqui 		1,000	✓ S	ynthroid
Trophic Hormones				

➡SA0755 Special Authority for Subsidy

 Special Authority approved by the Growth Hormone Committee

 Notes: Subject to budgetary cap. Applications will be considered and approved subject to funding availability.

 Application details may be obtained from PHARMAC's website
 http://www.pharmac.govt.nz

 NZGHC Coordinator

 PHARMAC, PO Box 10-254, WELLINGTON

 Tel: 0800 808 476, Fax: (09) 929 3221, Email:
 growthhormone@pharmac.govt.nz

	Subsidy (Manufacturer's Price) \$	Per	Ful Subsidise	,
GROWTH HORMONE BIOSYNTHETIC HUMAN - Special Author	ority see SA0755 on t	he pre	ceding p	age
* Cartridge 16 iu per vial		5		Genotropin
* Cartridge 36 iu per vial	3,600.00	5	~	Genotropin
RECOMBINANT HUMAN GROWTH HORMONE - Special Author	ority see SA0755 on t	he pre	ceding p	age
* Inj 5 mg		1	~	Norditropin SimpleXx 5mg
* Inj 10 mg	600.00	1	~	Norditropin SimpleXx 10mg
* Inj 15 mg	900.00	1	~	Norditropin SimpleXx 15mg
GnRH Analogues				
BUSERELIN ACETATE – Special Authority see SA0835 below – Inj 1 mg per ml, 5.5 ml		IP3] 2		

(272.53) Suprefact

➡SA0835 Special Authority for Subsidy

Initial application — (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer.

Initial application — (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where the patient has advanced prostatic cancer.

Note: Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiated.

Initial application — (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Endometriosis; and
- 2 Either:
 - 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or

2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months.

Note: The maximum treatment period for a GnRH analogue is:

- 3 months to assess whether surgery is appropriate
- 3 months for infertile patients after surgery
- 6 months for patients with symptoms of endometriosis After the first 3 months patients should be assessed to determine whether there has been a satisfactory response to the first 3 months treatment.

Initial application — (Precocious puberty) only from a paediatrician or endocrinologist. Approvals valid for 1 year where the patient is affected by gonadotropin dependent precocious puberty.

Renewal — (Breast or prostate cancer) from any medical practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If a patient had an approval for any GnRH analogue prior to 1 July 2006 the applicant is required to submit a fresh initial application, not a renewal application.

Renewal — (Endometriosis) from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 There has been a satisfactory response to the first 3 months treatment; and
- 1.2 Surgery is inappropriate; or
- 2 The first three months of therapy did not follow surgery for infertility.

continued...

	Subsidy (Manufacturer's Pi	rice) Su	Fully osidised	Brand or Generic
	\$	Per	~	Manufacturer
ontinued				
ote: If a patient had an approval for any GnRH analogue prior	to 1 July 2006 th	he applicant i	s require	ed to submit a fresh ini
pplication, not a renewal application.		A	الما المربر ال	
enewal — (Precocious puberty) only from a paediatrician or mains appropriate and the patient is benefiting from treatment.	endocrinologist.	Approvais va	and for t	year where the treath
ote: If a patient had an approval for any GnRH analogue prior	to 1 July 2006 th	he applicant i	s require	ed to submit a fresh ini
plication, not a renewal application.	,			
OSERELIN ACETATE – Hospital pharmacy [HP3]				
Inj 3.6 mg		1		oladex
Inj 10.8 mg	554.70	1	V Zo	oladex
UPRORELIN – Hospital pharmacy [HP3]				
Inj 3.75 mg prefilled syringe		1		ucrin Depot PDS
Inj 3.75 mg		1		ucrin Depot
Inj 7.5 mg		1		ligard
Inj 11.25 mg prefilled syringe Inj 11.25 mg		1		ucrin Depot PDS ucrin Depot
Inj 22.5 mg		1		ligard
Inj 30 mg		1		ligard
Inj 30 mg prefilled syringe		1	🖌 Li	ucrin Depot PDS
Inj 45 mg	1,109.40	1	🖌 El	ligard
/asopressin Agonists				
ESMOPRESSIN				
Nasal drops 100 µg per ml – Retail pharmacy-Specialist		2.5 ml OP	🗸 M	inirin
Nasal spray 10 µg per dose - Retail pharmacy-Specialist		6 ml OP	✓ <u>D</u>	esmopressin-
				PH&T
Inj 4 µg per ml, 1 ml – Special Authority see SA0090 below –		40		la lata
Hospital pharmacy [HP3]		10	V M	inirin
SA0090 Special Authority for Subsidy Hist application only from a valuate application. Approvale well	id for 0 years wh	are the notion	+	tuna danmankanain na
itial application only from a relevant specialist. Approvals val ray or nasal drops.	to for 2 years whi	ere the patier	nt canno	t use desmopressin na
enewal only from a relevant specialist. Approvals valid for 2 ye	ears where the tr	eatment rema	ains app	ropriate and the patien
nefiting from treatment.				rophato and the pation
Other Endocrine Agents				
ABERGOLINE				
Tab 0.5 mg – Maximum of 2 tab per prescription; can be				
waived by Special Authority see SA0175 below		2		rrow-Cabergoline
	105.03	8		rrow-Cabergoline
			V D	ostinex
SA0175 Special Authority for Waiver of Rule				
itial application only from an obstetrician, endocrinologist or g	gynaecologist. Ap	oprovals valid	for 2 ye	ars where the patient h
thological hyperprolactinemia.				
enewal only from an obstetrician, endocrinologist or gynaecol	ogist. Approvals	valid for 2 ye	ears whe	ere the treatment rema
propriate and the patient is benefiting from treatment.				
LOMIPHENE CITRATE – Retail pharmacy-Specialist				
Only a prescription for a female patient.				
Tab 50 mg	0 50	5		henate

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	d Generic
DANAZOL – Retail pharmacy-Specialist				
Cap 100 mg		30	~	D-Zol
	68.33	100	~	Azol
Cap 200 mg (D-Zol Cap 100 mg to be delisted 1 October 2009)		30	~	D-Zol
GESTRINONE – Retail pharmacy-Specialist	101.07	0 00	~	Dimetriose
Cap 2.5 mg	101.87	8 OP	v	Dimetriose
METYRAPONE Cap 250 mg – Hospital pharmacy [HP3]-Specialist	238.00	50	~	Metopirone

	Subsidy		Fully Brand or
	(Manufacturer's P \$	rice) Su Per	bsidised Generic Manufacturer
Anthelmintics			
MEBENDAZOLE – Only on a prescription			
Tab 100 mg		24	✓ <u>De-Worm</u>
Oral liq 100 mg per 5 ml	2.18 (7.17)	15 ml	Vermox
Antibacterials			
a) For topical antibacterials, refer to DERMATOLOGICALS, page 9)) For anti-infective eye preparations, refer to SENSORY ORGAN			
Cephalosporins and Cephamycins			
CEFACLOR MONOHYDRATE			
Cap 250 mg		100 100 ml	Ranbaxy-Cefaclor
Grans for oral liq 125 mg per 5 ml		100 mi	Ranbaxy-Cefaclor
CEFAZOLIN SODIUM – Hospital pharmacy [HP3] – Subsidy by e Only if prescribed for dialysis or cystic fibrosis patient and the		ndorsed acco	rdinaly
Inj 500 mg		5	V Hospira
Inj 1 g	8.00	5	✓ Hospira
EFOXITIN SODIUM – Hospital pharmacy [HP3]-Specialist – Su	bsidy by endorse	ement	
Only if prescribed for dialysis or cystic fibrosis patient and the	prescription is e		
Inj 1 g		5	Mayne
CEFTRIAXONE SODIUM – Hospital pharmacy [HP3] – Subsidy I	by endorsement		
 a) Up to 5 inj available on a PSO b) Subsidised only if prescribed for a dialysis or cystic fibro 	sis nationt or th	a traatmant (of confirmed ciproflovacin-resi
gonorrhoea, or the treatment of suspected meningitis in patier			
PSO is endorsed accordingly.			
Inj 500 mg		1	✓ AFT
Inj 1 g	5.40	1	🖌 AFT
CEFUROXIME AXETIL – Subsidy by endorsement	aviation is analow		
Only if prescribed for prophylaxis of endocarditis and the pres Tab 250 mg	•	sed according 50	^{µy.} ✓ Zinnat
EFUROXIME SODIUM – Hospital pharmacy [HP3]		00	
Inj 250 mg – Maximum of 3 inj per prescription; can be waived			
by endorsement		10	Mayne
Inj 750 mg - Maximum of 1 inj per prescription; can be waived			
		5	✓ Zinacef
by endorsement	10.71	•	
by endorsement Inj 1.5 g – Hospital pharmacy [HP3]-Specialist – Subsidy by endorsement.		,	✓ Zinacef

	Subsidy (Manufacturer's Pi \$	ice) S Per	Fully ubsidised	Brand or Generic Manufacturer
Macrolides				
AZITHROMYCIN – Subsidy by endorsement a) Maximum of 2 tab per prescription; can be waived by Spub) b) Up to 4 tab available on a PSO c) Subsidised only if prescribed for patients with uncomplicat trachomatis and their sexual contacts and prescription or PS SA0964. Tab 500 mg	ed urethritis or cerv O is endorsed acco	icitis proven	or presun be waive	
 SA0964 Special Authority for Waiver of Rule Initial application only from a respiratory specialist or paediat applications meeting the following criteria: All of the following: The applicant is part of multidisciplinary team experience The patient has been definitively diagnosed with cystic fill The patient has chronic infection with Pseudomonas a defined by two positive respiratory tract cultures at least t The patient has negative cultures for non-tuberculous my Notes: Caution is advised if using azithromycin as an antibiotic i Testing for non-tuberculosis mycobacteria should occur annually Indications marked with * are Unapproved Indications (refer to S Part IV (Miscellaneous Provisions) rule 4.6). 	d in the manageme prosis*; and eruginosa or Pseu hree months apart cobacteria. n the treatment of o	ent of cystic domonas re ;; and cystic fibrosi	fibrosis; a elated gra s patients	nd m negative organisms as with pneumonia.
CLARITHROMYCIN – Maximum of 500 mg per prescription; ca Tab 250 mg Grans for oral liquid 125 mg per 5 ml	7.75	ecial Authori 14 70 ml		lamycin
SA0657 Special Authority for Waiver of Rule Initial application — (Helicobacter pylori infections) only fro months for applications meeting the following criteria: Both: 1 Eradication of Helicobacter pylori in patient with proven ir 2 Peptic ulcer disease proven by endoscopy.	m a general practiti			
Alle Andrews and the second and the second				
nitial application — (Mycobacterial infections) only from a Approvals valid for 2 years for applications meeting the following Any of the following: 1 Mycobacterium Avium Intracellulare Complex infections i	criteria:		disease	specialist or paediatrician.
nitial application — (Mycobacterial infections) only from a Approvals valid for 2 years for applications meeting the following: 1 Mycobacterium Avium Intracellulare Complex infections i 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium 3.2 HIV infection; and 3.3 CD4 count ≤ 50 cells/mm ³ .	criteria: n patient with AIDS Avium Intracellular	; or e Complex i	nfection; a	and
nitial application — (Mycobacterial infections) only from a lapprovals valid for 2 years for applications meeting the following: 1 Mycobacterium Avium Intracellulare Complex infections i 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium 3.2 HIV infection; and 3.3 CD4 count ≤ 50 cells/mm ³ . Renewal — (Mycobacterial infections) only from a respiratory ralid for 2 years where the treatment remains appropriate and th	criteria: n patient with AIDS Avium Intracellular specialist, infectiou	; or e Complex i is disease s	nfection; a	and
 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium 3.2 HIV infection; and 3.3 CD4 count ≤ 50 cells/mm³. Renewal — (Mycobacterial infections) only from a respiratory valid for 2 years where the treatment remains appropriate and the teryTHROMYCIN ETHYL SUCCINATE Tab 400 mg – Up to 30 tab available on a PSO. 	criteria: n patient with AIDS Avium Intracellular specialist, infectiou ne patient is benefit 	; or e Complex i is disease s	nfection; a pecialist c atment.	and
nitial application — (Mycobacterial infections) only from a lapprovals valid for 2 years for applications meeting the following: 1 Mycobacterium Avium Intracellulare Complex infections i 2 Atypical and drug-resistant mycobacterial infection; or 3 All of the following: 3.1 Prophylaxis against disseminated Mycobacterium 3.2 HIV infection; and 3.3 CD4 count ≤ 50 cells/mm ³ . Renewal — (Mycobacterial infections) only from a respiratory valid for 2 years where the treatment remains appropriate and th ERYTHROMYCIN ETHYL SUCCINATE	criteria: n patient with AIDS Avium Intracellular specialist, infectiou ne patient is benefit 	; or e Complex i us disease s ing from trea	nfection; a pecialist c atment.	and or paediatrician. Approvals

			Fully Brand or
	(Manufacturer's Pric \$	e) Subs Per	sidised Generic Manufacturer
	Ŷ	1.01	
ERYTHROMYCIN LACTOBIONATE Inj 1 g	10.02	1	Erythrocin IV
	10.95	I	
ERYTHROMYCIN STEARATE	11.05	100	
Tab 250 mg – Up to 30 tab available on a PSO		100	
T 500	(22.29)	100	ERA
Tab 500 mg		100	
	(44.58)		ERA
ROXITHROMYCIN			
Tab 150 mg	8.98	50	Arrow-
			Roxithromycin
Tab 300 mg	16.48	50	Arrow-
			Roxithromycin
Penicillins			
MOXYCILLIN			
Cap 250 mg - Up to 30 cap available on a PSO		500	Apo-Amoxi
Cap 500 mg		500	Apo-Amoxi
Grans for oral lig 125 mg per 5 ml - Up to 200 ml available			
on a PSO		100 ml	Ranbaxy Amoxicillin
Grans for oral lig 250 mg per 5 ml - Up to 200 ml available			•
on a PSO		100 ml	Ranbaxy Amoxicillin
Drops 125 mg per 1.25 ml	4.00	30 ml OP	Ospamox Paediatric
			Drops
Inj 250 mg	12.42	10	Ibiamox
Inj 500 mg		10	Ibiamox
Inj 1 g – Up to 5 inj available on a PSO	21.62	10	Ibiamox
MOXYCILLIN CLAVULANATE			
Tab amoxycillin 500 mg with potassium clavulanate 125 mg			
- Up to 30 tab available on a PSO		100	Synermox
Grans for oral liq amoxycillin 125 mg with potassium clavu-			
lanate 31.25 mg per 5 ml - Up to 200 ml available on a			
PSO	2.75	100 ml	Augmentin
Grans for oral liq amoxycillin 250 mg with potassium clavu-			-
lanate 62.5 mg per 5 ml - Up to 200 ml available on a			
PSO	4.75	100 ml	Augmentin
BENZATHINE BENZYLPENICILLIN			-
Inj 1.2 mega u per 2.3 ml – Up to 5 inj available on a PSO		10	Bicillin LA
, , ,			
BENZYLPENICILLIN SODIUM (PENICILLIN G) Inj 1 mega u – Up to 5 inj available on a PSO	10.40	10	✓ Sandoz
nij i meya u – op to o nij avaliable on a Foo	10.49	10	✓ <u>Januuz</u>

	Subsidy		Fully Brand or
	(Manufacturer's F		bsidised Generic
	\$	Per	 Manufacturer
FLUCLOXACILLIN SODIUM			
Cap 250 mg – Up to 30 cap available on a PSO		250	 Staphlex
Cap 500 mg		500	Staphlex
Grans for oral liq 125 mg per 5 ml – Up to 200 ml available		100	
on a PSO		100 ml	🖌 AFT
Grans for oral liq 250 mg per 5 ml – Up to 200 ml available on a PSO		100 ml	🖌 AFT
lnj 250 mg		100 111	✓ Flucloxin
Inj 500 mg		10	✓ Flucloxin
Inj 1 g – Up to 5 inj available on a PSO		10	✓ Flucloxin
			<u> </u>
PHENOXYMETHYLPENICILLIN (PENICILLIN V) Cap potassium salt 250 mg – Up to 30 cap available on a PS	0 4 20	50	Cilicaine VK
Cap potassium salt 500 mg		50	✓ <u>Cilicaine VK</u>
Grans for oral lig 125 mg per 5 ml – Up to 200 ml available		00	· ····································
on a PSO		100 ml	✓ AFT
Grans for oral lig 250 mg per 5 ml - Up to 200 ml available			
on a PSO		100 ml	🖌 AFT
PROCAINE PENICILLIN			·
Inj 1.5 mega u – Up to 5 inj available on a PSO	50.86	5	Cilicaine
, , ,		Ŭ	v <u>enioanio</u>
Tetracyclines			
DOXYCYCLINE HYDROCHLORIDE			
* Tab 50 mg – Up to 30 tab available on a PSO	2.90	30	
	(6.00)		Doxy-50
* Tab 100 mg – Up to 30 tab available on a PSO	8.10	250	 Doxine
MINOCYCLINE HYDROCHLORIDE			
* Tab 50 mg	5.79	60	
-	(12.05)		Mino-tabs
* Cap 100 mg	19.32	100	
	(52.04)		Minomycin
Other Antibiotics			
For topical antibiotics, refer to DERMATOLOGICALS, page 59			
CIPROFLOXACIN			
Tab 250 mg – Up to 5 tab available on a PSO	3 35	30	Rex Medical
Tab 500 mg – Up to 5 tab available on a PSO		30	✓ Rex Medical
Tab 750 mg – Retail pharmacy-Specialist		30	✓ Rex Medical
CLINDAMYCIN			
Cap hydrochloride 150 mg – Maximum of 4 cap per prescrip-			
tion; can be waived by endorsement - Retail pharmacy -			
Specialist		16	Dalacin C
Inj phosphate 150 mg per ml, 4 ml - Retail pharmacy-			
Specialist		1	Dalacin C
-r		•	

	Subsidy		Fully Brand or
	(Manufacturer's P		bsidised Generic
	\$	Per	 Manufacturer
CO-TRIMOXAZOLE			
* Tab trimethoprim 80 mg and sulphamethoxazole 400 mg Up to 30 tab available on a PSO		500	✔ Trisul
 Oral liq sugar-free trimethoprim 40 mg and sulphamethox zole 200 mg per 5 ml - Up to 200 ml available on PSO 	а	500 ml	✔ Trisul
 Oral liq trimethoprim 40 mg and sulphamethoxazole 200 n per 5 ml – Up to 200 ml available on a PSO 	ng	100 ml	Deprim
(Trisul Oral liq sugar-free trimethoprim 40 mg and sulphametho.			
COLISTIN SULPHOMETHATE – Hospital pharmacy [HP3]-Spe Only if prescribed for dialysis or cystic fibrosis patient and t			
Inj 150 mg FUSIDIC ACID	65.00	1	✓ <u>Colistin-Link</u>
Tab 250 mg – Hospital pharmacy [HP3]-Specialist Inj 500 mg sodium fusidate per 10 ml – Hospital pharma		12	✓ Fucidin
[HP3]-Specialist – Subsidy by endorsement		1	Fucidin
Only if prescribed for a dialysis or cystic fibrosis patient a	and the prescription	n is endorsed	accordingly.
GENTAMICIN SULPHATE	-1 -		
Inj 10 mg per ml, 1 ml – Hospital pharmacy [HP3] – Subsi by endorsement		5	Mayne
Only if prescribed for a dialysis or cystic fibrosis patient accordingly. Inj 40 mg per ml, 2 ml – Hospital pharmacy [HP3] – Subsi	or for prophylaxis		
by endorsement.		10	✓ Pfizer
Only if prescribed for a dialysis or cystic fibrosis patient accordingly.	or for prophylaxis	of endocarditi	s and the prescription is endorse
TOBRAMYCIN			
Inj 40 mg per ml, 2 ml – Hospital pharmacy [HP3] – Subsi by endorsement		5	🖌 Mayne
Only if prescribed for dialysis or cystic fibrosis patient an	id the prescription is	s endorsed a	ccordingly.
TRIMETHOPRIM Tab 300 mg – Up to 30 tab available on a PSO 	8.69	50	✓ <u>TMP</u>
VANCOMYCIN HYDROCHLORIDE – Hospital pharmacy [HP3 Only if prescribed for a dialysis or cystic fibrosis patient or endocarditis and the prescription is endorsed accordingly.			pranous colitis or for prophylaxis
Inj 50 mg per ml, 10 ml	5.04	1	✓ Pacific
Antifungals			
 a) For topical antifungals refer to DERMATOLOGICALS, page 5 b) For topical antifungals refer to GENITO URINARY, page 73 	59		
FLUCONAZOLE – Hospital pharmacy [HP3]-Specialist			
Cap 50 mg		28 1	 ✓ <u>Pacific</u> ✓ Pacific
Cap 150 mg Cap 200 mg		28	✓ Pacific
ITRACONAZOLE – Hospital pharmacy [HP3]-Specialist		20	
Cap 100 mg	23.70	15	✓ Sporanox
· · · · · ·			

	0.1.11		
	Subsidy (Manufacturer's F	Price) Su	Fully Brand or bsidised Generic
	\$	Per	 Manufacturer
KETOCONAZOLE			
Tab 200 mg – Retail pharmacy-Specialist		30	Nizoral
			• • • • • • • • • • • • • • • • • • • •
NYSTATIN	0.60	50	
Tab 500,000 u Cap 500,000 u		50 50	✓ <u>Nilstat</u> S29 ✓ Nilstat
		50	Mistat
TERBINAFINE	05 50	100	4 A B B B B B B B B B B
Tab 250 mg	25.50	100	Apo-Terbinafine
Antimalarials			
HYDROXYCHLOROQUINE SULPHATE			
* Tab 200 mg		100	Plaguenil
Antitrichomonal Agents			
-			
METRONIDAZOLE	0.50	100	1 Tricherola
Tab 200 mg – Up to 30 tab available on a PSO		100	 Trichozole Trichozole
Tab 400 mg		100 100 ml	 Trichozole Elegnd S
Oral liq benzoate 200 mg per 5 ml		100 mi	Flagyl-S
Suppos 500 mg	24.40	10	Flagyl
ORNIDAZOLE	10.00	10	
Tab 500 mg		10	 Tiberal
Antituberculotics and Antileprotics			
	lists of in the Austitud		
Note: There is no co-payment charge for all pharmaceuticals	listed in the Antitut	perculotics and	a Antileprotics group regardless of
immigration status.			
DAPSONE – No patient co-payment payable			
Tab 25 mg	05.00	100	
Tab 100 mg		100	✓ Dapsone
		100 100	DapsoneDapsone
ETHAMBUTOL HYDROCHLORIDE – No patient co-payment	110.00 payable	100	 Dapsone
•	110.00 payable		
ETHAMBUTOL HYDROCHLORIDE – No patient co-payment Tab 400 mg	110.00 payable	100	 Dapsone
ETHAMBUTOL HYDROCHLORIDE – No patient co-payment Tab 400 mg	110.00 payable	100	 Dapsone
ETHAMBUTOL HYDROCHLORIDE – No patient co-payment Tab 400 mg ISONIAZID – Retail pharmacy-Specialist No patient co-payment payable	110.00 payable 56.84	100	 Dapsone Myambutol s29 PSM
ETHAMBUTOL HYDROCHLORIDE – No patient co-payment Tab 400 mg ISONIAZID – Retail pharmacy-Specialist No patient co-payment payable * Tab 100 mg	110.00 payable 56.84 20.50	100 56	 Dapsone Myambutol s29 PSM Rifinah
ETHAMBUTOL HYDROCHLORIDE – No patient co-payment Tab 400 mg ISONIAZID – Retail pharmacy-Specialist No patient co-payment payable * Tab 100 mg * Tab 100 mg with rifampicin 150 mg	110.00 payable 56.84 20.50 90.04	100 56 100	 Dapsone Myambutol s29 PSM
ETHAMBUTOL HYDROCHLORIDE – No patient co-payment Tab 400 mg ISONIAZID – Retail pharmacy-Specialist No patient co-payment payable * Tab 100 mg * Tab 100 mg with rifampicin 150 mg * Tab 150 mg with rifampicin 300 mg	110.00 payable 56.84 20.50 90.04	100 56 100 100	 Dapsone Myambutol s29 PSM Rifinah
 ETHAMBUTOL HYDROCHLORIDE – No patient co-payment Tab 400 mg ISONIAZID – Retail pharmacy-Specialist No patient co-payment payable * Tab 100 mg * Tab 100 mg with rifampicin 150 mg * Tab 150 mg with rifampicin 300 mg 	110.00 payable 56.84 20.50 90.04	100 56 100 100	 Dapsone Myambutol s29 PSM Rifinah
 ETHAMBUTOL HYDROCHLORIDE – No patient co-payment Tab 400 mg ISONIAZID – Retail pharmacy-Specialist No patient co-payment payable * Tab 100 mg * Tab 100 mg with rifampicin 150 mg * Tab 150 mg with rifampicin 300 mg * PYRAZINAMIDE – Retail pharmacy-Specialist No patient co-payment payable 		100 56 100 100	 Dapsone Myambutol s29 PSM Rifinah
ETHAMBUTOL HYDROCHLORIDE – No patient co-payment Tab 400 mg ISONIAZID – Retail pharmacy-Specialist No patient co-payment payable * Tab 100 mg * Tab 100 mg with rifampicin 150 mg * Tab 150 mg with rifampicin 300 mg PYRAZINAMIDE – Retail pharmacy-Specialist No patient co-payment payable * Tab 500 mg		100 56 100 100 100	 Dapsone Myambutol \$29 PSM Rifinah Rifinah
ETHAMBUTOL HYDROCHLORIDE – No patient co-payment Tab 400 mg ISONIAZID – Retail pharmacy-Specialist No patient co-payment payable * Tab 100 mg * Tab 100 mg with rifampicin 150 mg * Tab 150 mg with rifampicin 300 mg PYRAZINAMIDE – Retail pharmacy-Specialist No patient co-payment payable * Tab 500 mg RIFABUTIN – Hospital pharmacy [HP3]-Specialist		100 56 100 100 100	 Dapsone Myambutol \$29 PSM Rifinah Rifinah
 ETHAMBUTOL HYDROCHLORIDE – No patient co-payment Tab 400 mg ISONIAZID – Retail pharmacy-Specialist No patient co-payment payable * Tab 100 mg * Tab 100 mg with rifampicin 150 mg * Tab 150 mg with rifampicin 300 mg PYRAZINAMIDE – Retail pharmacy-Specialist No patient co-payment payable * Tab 500 mg * Tab 500 mg * RIFABUTIN – Hospital pharmacy [HP3]-Specialist No patient co-payment payable 		100 56 100 100 100	 Dapsone Myambutol \$29 PSM Rifinah Rifinah
ETHAMBUTOL HYDROCHLORIDE – No patient co-payment Tab 400 mg ISONIAZID – Retail pharmacy-Specialist No patient co-payment payable * Tab 100 mg * Tab 100 mg with rifampicin 150 mg * Tab 150 mg with rifampicin 300 mg PYRAZINAMIDE – Retail pharmacy-Specialist No patient co-payment payable * Tab 500 mg RIFABUTIN – Hospital pharmacy [HP3]-Specialist No patient co-payment payable * Cap 150 mg		100 56 100 100 100	 Dapsone Myambutol \$29 PSM Rifinah Rifinah AFT-Pyrazinamide
ETHAMBUTOL HYDROCHLORIDE – No patient co-payment Tab 400 mg ISONIAZID – Retail pharmacy-Specialist No patient co-payment payable * Tab 100 mg * Tab 100 mg with rifampicin 150 mg * Tab 150 mg with rifampicin 300 mg PYRAZINAMIDE – Retail pharmacy-Specialist No patient co-payment payable * Tab 500 mg RIFABUTIN – Hospital pharmacy [HP3]-Specialist No patient co-payment payable * Cap 150 mg RIFAMPICIN – Retail pharmacy-Specialist		100 56 100 100 100	 Dapsone Myambutol \$29 PSM Rifinah Rifinah AFT-Pyrazinamide
ETHAMBUTOL HYDROCHLORIDE – No patient co-payment Tab 400 mg ISONIAZID – Retail pharmacy-Specialist No patient co-payment payable * Tab 100 mg * Tab 100 mg with rifampicin 150 mg * Tab 150 mg with rifampicin 300 mg PYRAZINAMIDE – Retail pharmacy-Specialist No patient co-payment payable * Tab 500 mg RIFABUTIN – Hospital pharmacy [HP3]-Specialist No patient co-payment payable * Cap 150 mg RIFAMPICIN – Retail pharmacy-Specialist No patient co-payment payable		100 56 100 100 100	 Dapsone Myambutol \$29 PSM Rifinah Rifinah AFT-Pyrazinamide
ETHAMBUTOL HYDROCHLORIDE – No patient co-payment Tab 400 mg ISONIAZID – Retail pharmacy-Specialist No patient co-payment payable * Tab 100 mg * Tab 100 mg with rifampicin 150 mg * Tab 150 mg with rifampicin 300 mg PYRAZINAMIDE – Retail pharmacy-Specialist No patient co-payment payable * Tab 500 mg RIFABUTIN – Hospital pharmacy [HP3]-Specialist No patient co-payment payable * Cap 150 mg RIFAMPICIN – Retail pharmacy-Specialist No patient co-payment payable * Cap 150 mg		100 56 100 100 100 100 30	 Dapsone Myambutol \$29 PSM Rifinah Rifinah AFT-Pyrazinamide Mycobutin
 ETHAMBUTOL HYDROCHLORIDE – No patient co-payment Tab 400 mg ISONIAZID – Retail pharmacy-Specialist No patient co-payment payable * Tab 100 mg * Tab 100 mg with rifampicin 150 mg * Tab 150 mg with rifampicin 300 mg PYRAZINAMIDE – Retail pharmacy-Specialist No patient co-payment payable * Tab 500 mg RIFABUTIN – Hospital pharmacy [HP3]-Specialist No patient co-payment payable * Cap 150 mg RIFAMPICIN – Retail pharmacy-Specialist RIFAMPICIN – Retail pharmacy-Specialist 		100 56 100 100 100 100 30 30	 Dapsone Myambutol \$29 PSM Rifinah Rifinah AFT-Pyrazinamide <u>Mycobutin</u> Rifadin

(Manufacturer's Price) Subsidised Generic S Per ✓ Manufacturer Antivirals For eye preparations refer to Eye Preparations, Anti-Infective Preparations, page 154 Hepatitis B Treatment ADEFOVIR DIPIVOXIL – Special Authority see SA0829 below – Retail pharmacy Tab 10 mg For eye preparations, and the pharmacy Tab 10 mg Special Authority for Subsidy For eye preparation only from a gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Patient has confirmed Hepatitis B infection (HBsAg+); and Documented resistance to lamivudine, defined as: 2 Patient has raised serum ALT (> 1 × ULN); and 3 Patient has raised serum ALT (> 1 × ULN); and 3 Patient is cirrhotic; and 5.1.1 Patient is cirrhotic; and 5.2.2 adefovir dipivoxil to be used as monotherapy. Section of M2041 or 1/2 years where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatment. Notes: Ladefovir dipivoxil to be used as monotherapy. Renewal only from a gaster than 100,000 copies per mL, or viral load ≥ 10 fold over nadir; and ii) Detection of N236T or A181T/V mutation. Adefovir dipivoxil to be used as monotherapy. Renewal only from a gaster than 100,000 copies per mL, or viral load ≥ 10 fold over nadir; and iii) Detection of N236T or A181T/V mutation. </th <th></th> <th></th> <th></th> <th></th>				
For eye preparations refer to Eye Preparations, Anti-Infective Preparations, page 154 Hepatitis B Treatment ADEFOVIR DIPIVOXIL – Special Authority see SA0829 below – Retail pharmacy Tab 10 mg				
Hepatitis B Treatment ADEFOVIR DIPIVOXIL – Special Authority see SA0629 below – Retail pharmacy Tab 10 mg Special Authority for Subsidy Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following: 1 Patient has confirmed Hepatitis B infection (HBsAg+); and Documented resistance to lamivudine, defined as: 2 Patient has raised serum ALT (>1 × ULN); and 3 Patient has raised serum ALT (>1 × ULN); and 4 Detection of M2041 or M204V mutation; and 5 Etither: 5.1 Patient has raised serum ALT (>1 × ULN); and 5 Both: 5.1.1 Patient is not cirrholic; and 5.2.2 addroivr dipivoxil to be used in combination with lamivudine; or 5.2 Both: 5.2.1 Patient is not cirrholic; and 5.2.2 addroivr dipivoxil to be used as monotherapy. Renewal only form a gastroenterologist or infectious disease specialist. Approvals valid for 2 years where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatment. Notes: Lamivudine should be added to adeforir dipivoxil if a patient develops documented resistance to adeforir dipivoxil, defined as: i) resised serum ALT (> 1 × ULN); and ii) HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10 fold over nadir; and ii) HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10 fold over nadir; and iii) HBV DNA greater than 100	Antivirals			
ADEFOVIR DIPIVOXIL – Special Authority see SA0829 below – Retail pharmacy Tab 10 mg	For eye preparations refer to Eye Preparations, Anti-Infective Pre	parations, page 154		
Tab 10 mg	Hepatitis B Treatment			
Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following: 1 Patient has confirmed Hepatitis B infection (HBsAg+); and Documented resistance to lamivudine, defined as: 2 Patient has raised server MAIT (> 1 × ULN); and 3 Patient has raised server MAIT (> 1 × ULN); and 5 Ether: 5.1 Both: 5.1.1 Patient is cirrhotic; and 5.2.2 adeforvir dipivoxil to be used in combination with lamivudine; or 5.2.2 adeforvir dipivoxil to be used as monotherapy. Renewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatment. Notes: Lamivudine should be added to adefovir dipivoxil if a patient develops documented resistance to adefovir dipivoxil, defined as: i) raised serum ALT (> 1 × ULN); and i) HEV DNA greater than 100,000 copies per mL, or viral load ≥ 10 fold over nadir; and ii) Detection of N236T or A181TV mutation. Adefovir dipivoxil to be avoided in pregnant women and children. RAterowite with real insufficiency adefovir dipivoxil is no more than 10mg daily. In patients with real insufficiency adefovir dipivoxil dose should be reduced in accordance with the datasheet guidelines. Adefovir dipivoxil, should be avoided in pregnant women and children. ENTECAVIR - Special Authority see SA0977 below - Retail pharmac			30 🖌 H	lepsera
Renewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatment. Notes: Lamivudine should be added to adefovir dipivoxil if a patient develops documented resistance to adefovir dipivoxil, defined as: i) raised serum ALT (> 1 × ULN); and ii) HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10 fold over nadir; and iii) Detection of N236T or A181T/V mutation. Adefovir dipivoxil should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg+ prior to commencing adefovir dipivoxil. The recommended dose of adefovir dipivoxil is no more than 10mg daily. In patients with renal insufficiency adefovir dipivoxil dose should be reduced in accordance with the datasheet guidelines. Adefovir dipivoxil should be avoided in pregnant women and children. ENTECAVIR – Special Authority see SA0977 below – Retail pharmacy Tab 0.5 mg	Initial application only from a gastroenterologist or infectious dis the following criteria: All of the following: 1 Patient has confirmed Hepatitis B infection (HBsAg+); and Documented resistance to lamivudine, defined as: 2 Patient has raised serum ALT (> 1 × ULN); and 3 Patient has HBV DNA greater than 100,000 copies per mL 4 Detection of M204I or M204V mutation; and 5 Either: 5.1 Both: 5.1.1 Patient is cirrhotic; and 5.1.2 adefovir dipivoxil to be used in combination w 5.2 Both: 5.2.1 Patient is not cirrhotic; and	., or viral load ≥ 10 fo vith lamivudine; or		
 i) raised serum ALT (> 1 × ULN); and ii) HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10 fold over nadir; and iii) Detection of N236T or A181T/V mutation. Adefovir dipivoxil should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg+ prior to commencing adefovir dipivoxil. The recommended dose of adefovir dipivoxil is no more than 10mg daily. In patients with renal insufficiency adefovir dipivoxil dose should be reduced in accordance with the datasheet guidelines. Adefovir dipivoxil should be avoided in pregnant women and children. ENTECAVIR – Special Authority see SA0977 below – Retail pharmacy Tab 0.5 mg Special Authority for Subsidy Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and Patient is Hepatitis B nucleoside analogue treatment-naive; and Enttecavir dose 0.5 mg/day; and Either: ALT greater than upper limit of normal; or Bridging fibrosis or cirrhosis (Metavir stage 3 or greater) on liver histology; and 	Renewal only from a gastroenterologist or infectious disease s treating physician, treatment remains appropriate and patient is b Notes: Lamivudine should be added to adefovir dipivoxil if a pati-	pecialist. Approvals va enefiting from treatme	ent.	
In patients with renal insufficiency adefovir dipivoxil dose should be reduced in accordance with the datasheet guidelines. Adefovir dipivoxil should be avoided in pregnant women and children. ENTECAVIR – Special Authority see SA0977 below – Retail pharmacy Tab 0.5 mg	 i) raised serum ALT (> 1 × ULN); and ii) HBV DNA greater than 100,000 copies per mL, or viral loa iii) Detection of N236T or A181T/V mutation. Adefovir dipivoxil should be stopped 6 months following HBeAg seadefovir dipivoxil. 	eroconversion for patie		eAg+ prior to commencing
Tab 0.5 mg	In patients with renal insufficiency adefovir dipivoxil dose should a Adefovir dipivoxil should be avoided in pregnant women and child	be reduced in accorda Iren.	nce with the data	sheet guidelines.
Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and 2 Patient is Hepatitis B nucleoside analogue treatment-naive; and 3 Entecavir dose 0.5 mg/day; and 4 Either: 4.1 ALT greater than upper limit of normal; or 4.2 Bridging fibrosis or cirrhosis (Metavir stage 3 or greater) on liver histology; and 5 Either:	Tab 0.5 mg	•	30 🖌 B	araclude
continued	Initial application only from a gastroenterologist or infectious d notified for applications meeting the following criteria: All of the following: 1 Patient has confirmed Hepatitis B infection (HBsAg positiv 2 Patient is Hepatitis B nucleoside analogue treatment-naive 3 Entecavir dose 0.5 mg/day; and 4 Either: 4.1 ALT greater than upper limit of normal; or 4.2 9 or greater than upper limit of normal; or g	e for more than 6 mor ; and	ths); and	
t safatu can				

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	

continued...

- 5.1 HBeAg positive; or
- 5.2 patient has ≥ 2,000 IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and
- 6 No continuing alcohol abuse or intravenous drug use; and
- 7 Not co-infected with HCV, HIV or HDV; and
- 8 Neither ALT nor AST greater than 10 times upper limit of normal; and
- 9 No history of hypersensitivity to entecavir; and
- 10 No previous documented lamivudine resistance (either clinical or genotypic).

Notes:

 Entecavir should be continued for 6 months following documentation of complete HBeAg seroconversion (defined as loss of HBeAg plus appearance of anti-HBe plus loss of serum HBV DNA) for patients who were HBeAg positive prior to commencing this agent. This period of consolidation therapy should be extended to 12 months in patients with advanced fibrosis (Metavir Stage F3 or F4).

• Entecavir should be taken on an empty stomach to improve absorption.

LAMIVUDINE - Special Authority see SA0832 below - Retail pharmacy

Tab 100mg	 28	Zeffix
Oral liq 5 mg per ml	 240 ml	🖌 Zeffix

➡SA0832 Special Authority for Subsidy

Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 All of the following:
 - 1.1.1 HBsAg positive for more than 6 months; and
 - 1.1.2 HBeAg positive or HBV DNA positive defined as > 100,000 copies per ml by quantitative PCR at a reference laboratory; and
 - 1.1.3 ALT greater than twice upper limit of normal or bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent) on liver histology clinical/radiological evidence of cirrhosis; or
 - 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or
 - 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or
 - 1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and
- 2 All of the following:
 - 2.1 No continuing alcohol abuse or intravenous drug use; and
 - 2.2 Not coinfected with HCV or HDV; and
 - 2.3 Neither ALT nor AST greater than 10 times upper limit of normal; and
 - 2.4 No history of hypersensitivity to lamivudine; and
 - 2.5 No previous lamivudine therapy with genotypically proven lamivudine resistance.

Renewal only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

Renewal for patients who have maintained continuous treatment and response to lamivudine

- 1 All of the following:
 - 1.1 Have maintained continuous treatment with lamivudine; and
 - 1.2 Most recent test result shows continuing biochemical response (normal ALT); and
 - 1.3 HBV DNA <100,00 copies per ml by quantitative PCR at a reference laboratory; or

Renewal when given in combination with adefovir dipivoxil for patients with cirrhosis and resistance to lamivudine

- 2 All of the following:
 - 2.1 Lamivudine to be used in combination with adefovir dipivoxil; and

Subsidy (Manufacturer's Price)	Su	Fully Ibsidised	Brand or Generic	
 \$	Per	~	Manufacturer	

continued...

2.2 Patient is cirrhotic; and

Documented resistance to lamivudine, defined as:

- 2.3 Patient has raised serum ALT (> 1 $\times\,$ ULN); and
- 2.4 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and 2.5 Detection of M204I or M204V mutation; or
- Renewal when given in combination with adefovir dipivoxil for patients with resistance to adefovir dipivoxil

3 All of the following:

- 3.1 Lamivudine to be used in combination with adefovir dipivoxil; and Documented resistance to adefovir, defined as:
- 3.2 Patient has raised serum ALT (> $1 \times ULN$); and
- 3.3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and
- 3.4 Detection of N236T or A181T/V mutation.

Herpesvirus Treatments

ACICLOVIR

* Tab dispersible 200 mg1.98	25	Lovir
* Tab dispersible 400 mg6.64	56	Lovir
* Tab dispersible 800 mg7.38	35	 Lovir
VALACICLOVIR - Special Authority see SA0957 below - Retail pharmacy		
Tab 500 mg102.72	30	 Valtrex

SA0957 Special Authority for Subsidy

Initial application — (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily.

Renewal — (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (ophthalmic zoster) from any medical practitioner. Approvals valid without further renewal unless notified where the patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment.

Initial application — (CMV prophylaxis) from any medical practitioner. Approvals valid for 3 months where the patient has undergone organ transplantation.

Antiretrovirals

➡SA0779 Special Authority for Subsidy

Initial application — (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 \times total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
 - 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and
 - 2.4.2 CD4 counts < 350 cells/mm³.

Subsidy (Manufacturer's Price)	F Subsid	ully ised	Brand or Generic	
\$	Per	V	Manufacturer	

continued...

Note: Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including ritonavir plus indinavir or saquinavir or atazanavir will be counted as one protease inhibitor for the purpose of accessing funding to anti-retrovirals.

Initial application — (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Note: Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including ritonavir plus indinavir or saquinavir or atazanavir will be counted as one protease inhibitor for the purpose of accessing funding to anti-retrovirals.

Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

1 Prevention of maternal foetal transmission; or

2 Treatment of the newborn for up to eight weeks.

Notes: Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including ritonavir plus indinavir or saquinavir or atazanavir will be counted as one protease inhibitor for the purpose of accessing funding to anti-retrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

Renewal — (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Non-nucleosides Reverse Transcriptase Inhibitors

EFAVIRENZ - Special Authority see SA0779 on the precedir	a nage – Hospital nh	armacy (HP	11
Tab 50 mg	01011	30	Stocrin
Tab 200 mg		90	✓ Stocrin
Tab 600 mg		30	✓ Stocrin
Cap 50 mg		30	 Stocrin
Cap 200 mg		90	 Stocrin
(Stocrin Cap 50 mg to be delisted 1 December 2009)			

(Stocrin Cap 200 mg to be delisted 1 December 2009)

NEVIRAPINE - Special Authority see SA0779 on the	preceding page - Hospital ph	armacy [HP	1]
Tab 200 mg		60	 Viramune
Oral suspension 10 mg per ml		240 ml	 Viramune
			Suspension

Nucleosides Reverse Transcriptase Inhibitors

ABACAVIR SULPHATE – Special Authority see SA0779 on the p Tab 300 mg Oral liq 20 mg per ml		- Hospital pharr 60 240 ml OP	nacy [HP1] ✓ Ziagen ✓ Ziagen
ABACAVIR SULPHATE WITH LAMIVUDINE – Special Authority Note: Kivexa counts as two anti-retroviral medications for the Tab 600 mg with lamivudine 300 mg	purposes of the		
DIDANOSINE [DDI] - Special Authority see SA0779 on the prece			y [HP1]
Cap 125 mg		30	Videx EC
Cap 200 mg		30	Videx EC
Cap 250 mg		30	Videx EC
Cap 400 mg		30	Videx EC

	Subsidy (Manufacturer's Price \$) Subs	Fully Brand or sidised Generic Manufacturer
EMTRICITABINE – Special Authority see SA0779 on page 91 –	Hospital pharmacy [I	HP1]	
Cap 200 mg		30	 Emtriva
LAMIVUDINE – Special Authority see SA0779 on page 91 – Ho Tab 150 mg		60	✓ 3TC
Oral liq 10 mg per ml		40 ml OP	✓ 3TC
STAVUDINE [D4T] - Special Authority see SA0779 on page 91	- Hospital pharmacy	[HP1]	
Cap 20 mg		60	✓ Zerit
Cap 30 mg		60	✓ Zerit
Cap 40 mg		60	✓ Zerit
Powder for oral soln 1 mg per ml		00 ml OP	Zerit
TENOFOVIR DISOPROXIL FUMARATE – Special Authority see Tab 300 mg	1.0	- Hospital p 30	vharmacy [HP1]
ZIDOVUDINE [AZT] - Special Authority see SA0779 on page 9			
Cap 100 mg		100	✓ Retrovir
Oral liq 10 mg per ml		00 ml OP	 Retrovir
ZIDOVUDINE [AZT] WITH LAMIVUDINE - Special Authority see	e SA0779 on page 91	I – Hospital	pharmacy [HP1]
Combivir counts as two anti-retroviral medications for the pu Tab 300 mg with lamivudine 150 mg		roviral Spec 60	Ial Authority.
.	007.20	00	Compivit
Protease Inhibitors			
ATAZANAVIR SULPHATE - Special Authority see SA0779 on pa	age 91 – Hospital pha	armacy [HP [.]	1]
Cap 150 mg		60	✓ Reyataz
Cap 200 mg	757.79	60	✓ Reyataz
INDINAVIR - Special Authority see SA0779 on page 91 - Hosp			
Cap 200 mg		360	Crixivan
Cap 400 mg		180	 Crixivan
LOPINAVIR WITH RITONAVIR – Special Authority see SA0779			
Tab 200 mg with ritonavir 50 mg Oral lig 80 mg with ritonavir 20 mg per ml		120 00 ml OP	 ✓ Kaletra ✓ Kaletra
			• Raleua
RITONAVIR – Special Authority see SA0779 on page 91 – Hosp Cap 100 mg		84	V Norvir
Oral lig 80 mg per ml		0 ml OP	✓ Norvir
SAQUINAVIR – Special Authority see SA0779 on page 91 – Ho			
Tab 500 mg		120	Invirase
(Invirase Tab 500 mg to be delisted 1 February 2010)			
Antiretrovirals - Additional Therapies			
HIV Fusion Inhibitors			
ENFUVIRTIDE - Special Authority see SA0845 on the next pag	e – Hospital pharmad	y [HP1]	
Powder for inj 90 mg per ml \times 60		1	✓ Fuzeon

Subsidy (Manufacturer's Price)	:	Fully Subsidised	Brand or Generic
 \$	Per	~	Manufacturer

SA0845 Special Authority for Subsidy

Initial application only from a named specialist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 Confirmed HIV infection; and
- 2 Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that
- the patient has never previously been exposed to) for treatment failure; and
- 3 Either:
 - 3.1 Patient has evidence of HIV replication, despite ongoing therapy; or
 - 3.2 Patient has treatment-limiting toxicity to previous antiretroviral agents; and
- 4 Previous treatment with 3 different antiretroviral regimens has failed; and
- 5 All of the following:
 - 5.1 Previous treatment with a non-nucleoside reverse transcriptase inhibitor has failed: and
 - 5.2 Previous treatment with a nucleoside reverse transcriptase inhibitor has failed; and
 - 5.3 Previous treatment with a protease inhibitor has failed.

Renewal only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria: Both:

- - 1 Evidence of at least a 10 fold reduction in viral load at 12: and
 - 2 The treatment remains appropriate and the patient is benefiting from treatment.

Immune Modulators

Guidelines for the use of interferon in the treatment of hepatitis C:

Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or an infectious disease physician. All subjects undergoing treatment require careful monitoring for side effects.

Patients should be otherwise fit.

Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level.

Criteria for Treatment

1) Diagnosis

- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or
- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or
- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following.
- 2) Establishing Active Chronic Liver Disease
 - Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six months averaging > $1.5 \times$ upper limit of normal. (ALT is the preferable enzyme); or
 - Liver biopsy showing significant inflammatory activity (active hepatitis) with or without cirrhosis. This is not a necessary requirement for those patients with coagulopathy. (Some patients have active disease on histology with normal transaminase enzymes).

Exclusion Criteria

- 1) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as well as other autoimmune diseases such as thyroid disease).
- 2) Pregnancy.
- 3) Neutropenia (<2.0 \times 10⁹) and/or thrombocytopenia.
- 4) Continuing alcohol abuse and/or continuing intravenous drug users.

Dosage

The current recommended dosage is 3 million units of interferon alpha-2a or interferon apha-2b administered subcutaneously 3 times a week for 52 weeks (twelve months)

Exit Criteria

The patient's response to interferon treatment should be reviewed at either three or four months. Interferon treatment should be discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment ALT level at this stage.

	Subsidy (Manufacturer's P	rico) C	Fully ubsidised	Brand or Generic
	(Manulacturers F	Per		Manufacturer
NTERFERON ALPHA-2A – PCT – Hospital pharmacy [HP3]-	Specialist			
a) See prescribing guideline on the preceding page				
b) Only one multidose cartridge starter pack to be prescrib				
Inj 3 m iu prefilled syringe		1		oferon-A
Inj 4.5 m iu prefilled syringe		1		oferon-A
Inj 6 m iu prefilled syringe		1	· · ·	oferon-A
Inj 9 m iu prefilled syringe		1	· · ·	oferon-A
Inj 18 m iu multidose cartridge		1		oferon-A
Inj 18 m iu multidose cartridge \times 2 starter pack				oferon-A
NTERFERON ALPHA-2A WITH RIBAVIRIN – Special Authori	ty see SA0784 belo	w – Hospita	l pharmac	y [HP3]
See prescribing guideline on the preceding page				
Inj 18 m iu multidose cartridge \times 2 with ribavirin tab 200 r	0			
× 168	1,375.84	1 OP		oferon RBV
				Combination Pack
Inj 18 m iu multidose cartridge \times 2 with with pen and need				
with ribavirin tab 200 mg $ imes$ 168	1,375.84	1 OP		oferon RBV Combination Pack Starter Kit
SA0784 Special Authority for Subsidy				
- SAUTON Special Authority for Subsidy				
itial application from any specialist. Approvals valid for 12 m	nonths where patien	it has chroni	c hepatitis	C (all genotypes).
itial application from any specialist. Approvals valid for 12 m		it has chroni	c hepatitis	C (all genotypes).
itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]-		it has chroni	c hepatitis	C (all genotypes).
itial application from any specialist. Approvals valid for 12 m	Specialist	it has chroni 1		C (all genotypes).
itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]- See prescribing guideline on the preceding page	Specialist		✓ In	,
itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]- See prescribing guideline on the preceding page Inj 18 m iu, 1.2 ml multidose pen	Specialist 	1	✓ In ✓ In	itron-A
itial application from any specialist. Approvals valid for 12 rr ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]- See prescribing guideline on the preceding page Inj 18 m iu, 1.2 ml multidose pen Inj 30 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen	Specialist 	1 1 1	✓ in ✓ in ✓ in	tron-A tron-A tron-A
itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]- See prescribing guideline on the preceding page Inj 18 m iu, 1.2 ml multidose pen Inj 30 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen EGYLATED INTERFERON ALPHA-2A – Special Authority se	Specialist 	1 1 1	✓ in ✓ in ✓ in	tron-A tron-A tron-A
itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]- See prescribing guideline on the preceding page Inj 18 m iu, 1.2 ml multidose pen Inj 30 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen EGYLATED INTERFERON ALPHA-2A – Special Authority se See prescribing guideline on the preceding page	Specialist 	1 1 1 Hospital pha	✓ In ✓ In ✓ In armacy [H	tron-A tron-A tron-A P3]
itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]- See prescribing guideline on the preceding page Inj 18 m iu, 1.2 ml multidose pen Inj 30 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen EGYLATED INTERFERON ALPHA-2A – Special Authority se See prescribing guideline on the preceding page Inj 10 m iu, 1.2 ml multidose pen Inj 50 m iu, 1.2 ml multidose pen EGYLATED INTERFERON ALPHA-2A – Special Authority se See prescribing guideline on the preceding page Inj 135 µg prefilled syringe	Specialist 	1 1 1 Hospital pha	✓ In ✓ In ✓ In armacy [H	ttron-A ttron-A ttron-A P3] egasys
itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B PCT – Hospital pharmacy [HP3]- See prescribing guideline on the preceding page Inj 18 m iu, 1.2 ml multidose pen Inj 30 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen EGYLATED INTERFERON ALPHA-2A – Special Authority se See prescribing guideline on the preceding page Inj 135 µg prefilled syringe Inj 130 µg prefilled syringe	Specialist 	1 1 1 Hospital pha	✓ In ✓ In ✓ In armacy [H	tron-A tron-A tron-A P3]
itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]- See prescribing guideline on the preceding page Inj 18 m iu, 1.2 ml multidose pen Inj 30 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen EGYLATED INTERFERON ALPHA-2A – Special Authority se See prescribing guideline on the preceding page Inj 135 µg prefilled syringe Inj 135 µg prefilled syringe Inj 135 µg prefilled syringe Inj 135 µg prefilled syringe × 4 with ribavirin tab 200 mg	Specialist 	1 1 Hospital pha 1 1	✓ In ✓ In ✓ In ✓ In armacy [H ✓ Pe	ttron-A ttron-A ttron-A P3] egasys egasys
itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]- See prescribing guideline on the preceding page Inj 18 m iu, 1.2 ml multidose pen Inj 30 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen EGYLATED INTERFERON ALPHA-2A – Special Authority se See prescribing guideline on the preceding page Inj 135 µg prefilled syringe Inj 180 µg prefilled syringe	Specialist 	1 1 1 Hospital pha	✓ In ✓ In ✓ In armacy [H ✓ Pe ✓ Pe	tron-A tron-A P3] egasys egasys egasys RBV
itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]-See prescribing guideline on the preceding page Inj 18 m iu, 1.2 ml multidose pen	Specialist 	1 1 Hospital pha 1 1	✓ In ✓ In ✓ In armacy [H ✓ Pe ✓ Pe	ttron-A ttron-A ttron-A P3] egasys egasys
itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]-See prescribing guideline on the preceding page Inj 18 m iu, 1.2 ml multidose pen Inj 30 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen EGYLATED INTERFERON ALPHA-2A – Special Authority se See prescribing guideline on the preceding page Inj 135 μg prefilled syringe Inj 135 μg prefilled syringe × 4 with ribavirin tab 200 mg 112 Inj 135 μg prefilled syringe × 4 with ribavirin tab 200 mg	Specialist 	1 1 Hospital pha 1 1 1 OP	✓ In ✓ In ✓ In ✓ In ✓ Pr ✓ Pr ✓ Pr	ttron-A ttron-A P3] egasys egasys egasys RBV Combination Pack
itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]-See prescribing guideline on the preceding page Inj 18 m iu, 1.2 ml multidose pen	Specialist 	1 1 Hospital pha 1 1	✓ In ✓ In ✓ In ✓ Pr ✓ Pr ✓ Pr ✓ Pr	ttron-A ttron-A P3] egasys egasys egasys RBV Combination Pack egasys RBV
itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]-See prescribing guideline on the preceding page Inj 18 m iu, 1.2 ml multidose pen Inj 30 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen Inj 135 µg prefilled syringe Inj 135 µg prefilled syringe Inj 135 µg prefilled syringe Inj 135 µg prefilled syringe × 4 with ribavirin tab 200 mg 112 Inj 135 µg prefilled syringe × 4 with ribavirin tab 200 mg	Specialist 	1 1 Hospital pha 1 1 1 OP	✓ In ✓ In ✓ In ✓ Pr ✓ Pr ✓ Pr ✓ Pr	ttron-A ttron-A P3] egasys egasys egasys RBV Combination Pack
itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]-See prescribing guideline on the preceding page Inj 18 m iu, 1.2 ml multidose pen Inj 30 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen EGYLATED INTERFERON ALPHA-2A – Special Authority set See prescribing guideline on the preceding page Inj 135 µg prefilled syringe Inj 135 µg prefilled syringe × 4 with ribavirin tab 200 mg 112 Inj 135 µg prefilled syringe × 4 with ribavirin tab 200 mg 112 Inj 136 µg prefilled syringe × 4 with ribavirin tab 200 mg 103 104 105 105 106 107 108 108 109 101 101 102 103 104 105 105 106 107 108 108 109 109 101 102 103 <	Specialist 	1 1 Hospital pha 1 1 OP 1 OP	In In In In Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr	ttron-A ttron-A P3] egasys egasys RBV Combination Pack egasys RBV Combination Pack
itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]-See prescribing guideline on the preceding page Inj 18 m iu, 1.2 ml multidose pen Inj 30 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen Inj 60 m ju, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen Inj 135 μg prefilled syringe Inj 135 μg prefilled syringe Inj 135 μg prefilled syringe Inj 135 μg prefilled syringe × 4 with ribavirin tab 200 mg 112 Inj 135 μg prefilled syringe × 4 with ribavirin tab 200 mg	Specialist 	1 1 Hospital pha 1 1 1 OP	In In In In Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr	ttron-A ttron-A P3] egasys egasys RBV Combination Pack egasys RBV Combination Pack egasys RBV
 itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]- See prescribing guideline on the preceding page Inj 18 m iu, 1.2 ml multidose pen	Specialist 	1 1 Hospital pha 1 1 OP 1 OP	In In In In Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr	ttron-A ttron-A P3] egasys egasys RBV Combination Pack egasys RBV Combination Pack
 itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]- See prescribing guideline on the preceding page Inj 18 m iu, 1.2 ml multidose pen	Specialist 	1 1 Hospital pha 1 1 OP 1 OP 1 OP	In In In In Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr	ttron-A ttron-A P3] egasys egasys egasys RBV Combination Pack egasys RBV Combination Pack egasys RBV Combination Pack
 itial application from any specialist. Approvals valid for 12 m ITERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]- See prescribing guideline on the preceding page Inj 18 m iu, 1.2 ml multidose pen	Specialist 	1 1 Hospital pha 1 1 OP 1 OP	In In In In Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr	ttron-A ttron-A P3] egasys egasys RBV Combination Pack egasys RBV Combination Pack egasys RBV

SA0952 Special Authority for Subsidy Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist. Approvals valid for 48 weeks for applications meeting the following criteria: Either:

1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or

2 Patient has chronic hepatitis C and is co-infected with HIV.

Notes:

Subsidy Fully Brand or (Manufacturer's Price) Subsidised Generic \$ Per 🖌 Manufacturer
--

continued...

- Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
- Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml

Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 6 months where patient has chronic hepatitis C, genotype 2 or 3 infection.

Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 48 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naive; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log10 IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 serum HBV DNA \geq 2,000 units/ml and significant fibrosis (\geq Metavir Stage F2); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon.

Notes:

- Approved dose is 180 µg once weekly.
- The recommended dose of Pegylated Interferon-alpha 2a is 180 µg once weekly.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon-alpha 2a dose should be reduced to 135 µg once weekly.
- In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.
- Pegylated Interferon-alpha 2a is not approved for use in children.

	Subsidy		Fully	Brand or
	(Manufacturer's Price) \$	Per	Subsidised	
PEGYLATED INTERFERON ALPHA-2B WITH RIBAVIRIN – Sp				
[HP3]	ecial Authonity see 3A	10955 (i page – nospilai phannacj
See prescribing guideline on page 94				
Inj 50 μ g \times 4 with ribavirin cap 200 mg \times 112	1,080.40	1 OP	V	Pegatron Combination Therapy
Inj 50 $\mu g \times 4$ with ribavirin cap 200 mg \times 84 $\hfill \hfill	976.80	1 OP	V F	Pegatron Combination Therapy
Inj 80 $\mu g \times 4$ with ribavirin cap 200 mg \times 140 $$	1,583.60	1 OP	V F	Pegatron Combination Therapy
Inj 80 $\mu g \times 4$ with ribavirin cap 200 mg \times 168 $\hfill \ldots$	1,687.20	1 OP	V F	Pegatron Combination Therapy
Inj 80 $\mu g \times 4$ with ribavirin cap 200 mg \times 84 $\hfill \hfill	1,376.40	1 OP	✔ F	Pegatron Combination Therapy
Inj 100 $\mu g \times 4$ with ribavirin cap 200 mg \times 112 $\hfill 100$	1,746.40	1 OP	🖌 F	Pegatron Combination Therapy
Inj 100 $\mu g \times 4$ with ribavirin cap 200 mg $\times 84$	1,642.80	1 OP	✔ F	Pegatron Combination Therapy
Inj 120 $\mu g \times 4$ with ribavirin cap 200 mg \times 140 $$	2,116.40	1 OP	✔ F	Pegatron Combination Therapy
Inj 120 $\mu g \times 4$ with ribavirin cap 200 mg \times 84 $\hfill \hfill	1,909.20	1 OP	✔ F	Pegatron Combination Therapy
Inj 150 $\mu g \times 4$ with ribavirin cap 200 mg \times 140 $\hfill \ldots $	2,516.00	1 OP	✔ F	Pegatron Combination Therapy
Inj 150 $\mu g \times 4$ with ribavirin cap 200 mg \times 168 $\hfill \ldots $	2,619.60	1 OP	✔ F	Pegatron Combination Therapy
Inj 150 $\mu g \times 4$ with ribavirin cap 200 mg \times 84 $$	2,308.80	1 OP	✔ F	Pegatron Combination Therapy
(Pegatron Combination Therapy Inj 50 μ g × 4 with ribavirin cap 2 (Pegatron Combination Therapy Inj 50 μ g × 4 with ribavirin cap 2 (Pegatron Combination Therapy Inj 80 μ g × 4 with ribavirin cap 2 (Pegatron Combination Therapy Inj 80 μ g × 4 with ribavirin cap 2 (Pegatron Combination Therapy Inj 80 μ g × 4 with ribavirin cap 2 (Pegatron Combination Therapy Inj 100 μ g × 4 with ribavirin cap 2 (Pegatron Combination Therapy Inj 100 μ g × 4 with ribavirin cap (Pegatron Combination Therapy Inj 100 μ g × 4 with ribavirin cap (Pegatron Combination Therapy Inj 100 μ g × 4 with ribavirin cap (Pegatron Combination Therapy Inj 120 μ g × 4 with ribavirin cap (Pegatron Combination Therapy Inj 150 μ g × 4 with ribavirin cap (Pegatron Combination Therapy Inj 150 μ g × 4 with ribavirin cap (Pegatron Combination Therapy Inj 150 μ g × 4 with ribavirin cap (Pegatron Combination Therapy Inj 150 μ g × 4 with ribavirin cap (Pegatron Combination Therapy Inj 150 μ g × 4 with ribavirin cap (Pegatron Combination Therapy Inj 150 μ g × 4 with ribavirin cap	$\begin{array}{l} 200 \mbox{ mg} \times 84 \mbox{ to be del} \\ 200 \mbox{ mg} \times 140 \mbox{ to be del} \\ 200 \mbox{ mg} \times 168 \mbox{ to be del} \\ 200 \mbox{ mg} \times 84 \mbox{ to be del} \\ 200 \mbox{ mg} \times 84 \mbox{ to be del} \\ 200 \mbox{ mg} \times 140 \mbox{ to be del} \\ 200 \mbox{ mg} \times 140 \mbox{ to be del} \\ 200 \mbox{ mg} \times 140 \mbox{ to be del} \\ 200 \mbox{ mg} \times 140 \mbox{ to be del} \\ 200 \mbox{ mg} \times 140 \mbox{ to be del} \\ 200 \mbox{ mg} \times 140 \mbox{ to be del} \\ 200 \mbox{ mg} \times 140 \mbox{ to be del} \\ 200 \mbox{ mg} \times 140 \mbox{ to be del} \\ 200 \mbox{ mg} \times 168 \mbox{ to be del} \\ 200 \mbox{ mg} \times 168 \mbox{ to be del} \\ 200 \mbox{ mg} \times 168 \mbox{ to be del} \\ 200 \mbox{ mg} \times 168 \mbox{ to be del} \\ 200 \mbox{ mg} \times 168 \mbox{ to be del} \\ 200 \mbox{ mg} \times 168 \mbox{ to be del} \\ 200 \mbox{ mg} \times 168 \mbox{ to be del} \\ 200 \mbox{ mg} \times 168 \mbox{ to be del} \\ 200 \mbox{ mg} \times 168 \mbox{ to be del} \\ 200 \mbox{ mg} \times 168 \mbox{ to be del} \\ 200 \mbox{ mg} \times 168 \mbox{ to be del} \\ 200 \mbox{ mg} \times 168 \mbox{ to be} \\ 200 \mbox{ mg} \times 168 \mbox{ to be del} \\ 200 \mbox{ mg} \times 168 \mbox{ to bel} \\ 200 \mbox{ mg} \times 168 \mbox{ to bel} \\ 20$	listed 1 elisted elisted 1 delisted elisted delisted delisted delisted delisted	March 20 1 March 2 1 March 20 1 March 20 1 March 2 1 March 2 1 March 2 1 March 2 1 March 2 1 March 2 1 March 2	010) 10) 010) 010) 2010) 2010) 2010) 2010) 2010) 2010) 2010)

	Subsidy (Manufacturer's Price) \$	Subsi Per	Fully dised	Brand or Generic Manufacturer
►SA0953 Special Authority for Subsidy Initial application — (chronic hepatitis C - genotype 1, 4, 5 of Approvals valid for 11 months where patient has an existing Specia Note: Existing current approvals are still valid but no new application	al Authority.		with H	HV) from any specialist
Urinary Tract Infections				
HEXAMINE HIPPURATE * Tab 1 g		100	Hij	orex
NITROFURANTOIN * Tab 50 mg * Tab 100 mg		100 100	✔ Ni ✔ Ni	i an an i
NORFLOXACIN Tab 400 mg – Maximum of 6 tab per prescription; can be waived by endorsement - Retail pharmacy - Specialist		100	🖌 Ar	row-Norfloxacin
Vaccines				
Influenza vaccine				
INFLUENZA VACCINE – Hospital pharmacy [Xpharm] 1) Subsidy is available between 1 March and 30 September of	each vear			

1) Subsidy is available between 1 March and 30 September of each year.

2) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under (1) above for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.

3) Influenza Vaccine does not fall within the definition Community Pharmaceutical as it is not funded directly from the Pharmaceutical Budget. Pharmacists are unable to claim for the dispensing of influenza vaccine from the Funder.

Inj9.00	1	Fluvax
		Fluarix
90.00	10	Fluarix
		Vaxigrip

	Subsidy		Fully Brand or
	(Manufacturer's Prio \$	ce) Su Per	ubsidised Generic Manufacturer
Anticholinesterases	Y		
EOSTIGMINE			
Inj 2.5 mg per ml, 1 ml	20.30	50	✓ AstraZeneca
	20.00	50	▼ <u>Astrazeneea</u>
	40.00	100	Mestinon
Tab 60 mg		100	Mesunon
Anti-inflammatory Non Steroidal Drugs (NSAI	DS)		
SA0291 Special Authority for Manufacturers Price	11 d f = 0		and a state of the state of the state
itial application from any medical practitioner. Approvals va oth:	and for 2 years for appl	ications me	eeting the following criteria:
 Inflammatory arthritis (including osteoarthritis with an ir 	flammatory compone	nt): and	
2 Stabilised and are well controlled on the particular NSA		ny, and	
enewal from any medical practitioner. Approvals valid for 2		atment rem	ains appropriate and the patier
nefiting from treatment.			
CLOFENAC SODIUM			
Tab EC 25 mg	3.51	100	Apo-Diclo
Tab 50 mg dispersible - Additional subsidy by Special	Au-		
thority see SA0291 above - Retail pharmacy		20	
	(8.00)		Voltaren D
Tab EC 50 mg		500	Apo-Diclo
Tab long-acting 75 mg		500	Apo-Diclo SR
Tab long-acting 100 mg		500	Apo-Diclo SR
Inj 25 mg per ml, 3 ml	12.00	5	Voltaren
Up to 5 inj available on a PSO			
Suppos 12.5 mg	1.85	10	Voltaren
Suppos 25 mg	2.22	10	Voltaren
Suppos 50 mg	3.84	10	Voltaren
Up to 10 supp available on a PSO			
Suppos 100 mg	6.36	10	Voltaren
JPROFEN – Additional subsidy by Special Authority see SA	A0291 above - Retail	pharmacy	
Tab 200 mg		1,000	Ethics Ibuprofen
Tab 400 mg	1.07	30	
	(4.56)		Brufen
Tab 600 mg	1.60	30	
	(6.84)		Brufen
Tab long-acting 800 mg	1.50	30	
	(9.12)		Brufen Retard
‡ Oral liq 100 mg per 5 ml	3.49	200 ml	Fenpaed
TOPROFEN - Additional subsidy by Special Authority see	SA0291 above - Reta	ail pharmac	v
Cap long-acting 100 mg		100	
	(21.56)		Oruvail 100
Cap long-acting 200 mg		100	
	(43.12)		Oruvail 200
EFENAMIC ACID – Additional subsidy by Special Authority	see SA0291 above -	Retail nhar	macy
Cap 250 mg		100	
	(18.33)		Ponstan
	(10.00)		ronotari

	Subsidy (Manufacturer's Prio	ce) S	Fully ubsidised	Brand or Generic
	(Wandacturer ST Ho \$	Per	••••••••••••••••••••••••••••••••••••••	Manufacturer
IAPROXEN				
₭ Tab 250 mg		500	V N	loflam 250
₭ Tab 500 mg		250		loflam 500
K Tab long-acting 750 mg		90		laprosyn SR 750
K Tab long-acting 1,000 mg		90		laprosyn SR 1000
IAPROXEN SODIUM				
₭ Tab 275 mg	6.00	120	V S	onaflam
 K Tab 550 mg 		100		Synflex
ULINDAC – Additional subsidy by Special Authority see SA0				•
 Tab 100 mg 	1 0	100 page – Re	all pliall	пасу
iau iou iiig		100		Daclin
← Tab 200 mg	(12.00)	100	L	auill
F Tab 200 mg		100		Daclin
	(20.00)	50	L	aulli
	3.36	50	~	Ninoril
	(15.87)		C	Clinoril
ENOXICAM				
Fab 20 mg	23.75	100	🗸 T	ilcotil
APROFENIC ACID - Additional subsidy by Special Authority	see SA0291 on the	preceding	page – R	etail pharmacy
Tab 300 mg		60	0	, ,
-	(19.26)		S	Surgam
NSAIDs Other	. /			-
IDOMETHACIN				
Cap 25 mg		100		lheumacin
Cap 50 mg		100		lheumacin
Cap long-acting 75 mg	13.30	100		heumacin SR
· Suppos 100 mg	14.50	30	🗸 A	rthrexin
Rheumacin Cap 25 mg to be delisted 1 December 2009)				
Rheumacin Cap 50 mg to be delisted 1 October 2009)				
ROXICAM				
F Tab dispersible 10 mg		50	🖌 P	Piram-D
Tab dispersible 20 mg		100	🖌 P	Piram-D
Antirheumatoid Agents				
-				
URANOFIN				
Tab 3 mg	68.99	60	V R	lidaura
EFLUNOMIDE				
Tab 10 mg	55.00	30	🗸 A	FT-Leflunomide
	79.27		🗸 A	rava
Tab 20 mg	76.00	30	🗸 A	FT-Leflunomide
	108.60		🗸 A	rava
Tab 100 mg		3	🗸 A	rava
	61 93	100	🖌 🖊 🗅)-Penamine
ENICILLAMINE Tab 125 mg Tab 250 mg		100 100)-Penamine)-Penamine

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
SODIUM AUROTHIOMALATE Inj 10 mg per 0.5 ml Inj 20 mg per 0.5 ml Inj 50 mg per 0.5 ml	113.17	10 10 10	🖌 N	Nyocrisin Nyocrisin Nyocrisin
Tumour Necrosis Factor (TNF) Inhibitors				
ADALIMUMAB – Special Authority see SA0974 below – Retail ph Inj 40 mg per 0.8 ml prefilled pen Inj 40 mg per 0.8 ml prefilled syringe	1,799.92	2 2	• •	łumiraPen łumira

SA0974 Special Authority for Subsidy

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with at least two of the following (triple therapy): sulphasalazine, prednisone at a dose of at least 7.5 mg per day, azathioprine, intramuscular gold, or hydroxychloroquine sulphate (at maximum tolerated doses); and
- 5 Either:
 - 5.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of cyclosporin alone or in combination with another agent; or
 - 5.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
- 6 Either:
 - 6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
 - 6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following:
 - wrist, elbow, knee, ankle, and either shoulder or hip; and
- 7 Either:
 - 7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (Crohn's disease) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Subsidy (Manufacturer's Price) \$	Su Per	Fully bsidised	Brand or Generic Manufacturer	
Ŧ		-		

continued...

All of the following:

- 1 Either:
 - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
- 3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
- 2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
- 3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
- 4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regimen supervised by a physiotherapist; and
- 5 Either:
 - 5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or
 - 5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
- 6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale; and

7 Either:

- 7.1 An elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
- 7.2 A C-reactive protein (CRP) level greater than 15 mg per litre.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI, ESR and CRP measures must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

- 18-24 years Male: 7.0 cm; Female: 5.5 cm
- 25-34 years Male: 7.5 cm; Female: 5.5 cm
- 35-44 years Male: 6.5 cm; Female: 4.5 cm
- 45-54 years Male: 6.0 cm; Female: 5.0 cm
- 55-64 years Male: 5.5 cm; Female: 4.0 cm
- 65-74 years Male: 4.0 cm; Female: 4.0 cm
- 75+ years Male: 3.0 cm; Female: 2.5 cm

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic
\$	Per	~	Manufacturer

continued...

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
- 2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and

4 Either:

- 4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
- 4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 5 Any of the following:
 - 5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
 - 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 3 Either:
 - 3.1 Following 4 months initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Renewal — (Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Applicant is a gastroenterologist; or
 - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Both:

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	bsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 2.1.1 Patient has "whole body" severe chronic plaque psoriasis; and
- 2.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or

2.2 Both:

2.2.1 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and

2.2.2 Either:

- 2.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
- 2.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value.

Note: An adalimumab treatment course is defined as a minimum of 12 weeks adalimumab treatment.

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from pre-adalimumab baseline on a 10 point scale, or by 50%, whichever is less; and
- 3 ESR or CRP is within the normal range; and
- 4 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 Either:

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment: and
- 2 Either:
 - 2.1 Following 4 months initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the treating physician; or
 - 2.2 The patient demonstrates at least a continuing 50% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician.

ETANERCEPT - Retail pharmacy-Specialist prescription - Special Authority see SA0868 below

	949.96	4	 Enbrel
--	--------	---	----------------------------

➡SA0868 Special Authority for Subsidy

Initial application only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
- 3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20mg/m² weekly or at the maximum tolerated dose) in combination with oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose); and
- 5 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-15mg/m² weekly or at the maximum tolerated dose) in combination with one other disease-modifying agent; and
- 6 Both:
 - 6.1 Either:
 - 6.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 active, swollen, tender joints; or
 - 6.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 6.2 Physician's global assessment indicating severe disease; and
- 7 The patient or their legal guardian consents to details of their treatment being held on a central registry and has signed a consent form outlining conditions of ongoing treatment.

Note: A patient declaration form http://www.pharmac.govt.nz/special_authority_forms/SA0667-declaration.pdf must be signed by the legal guardian of the patient and the prescriber in the presence of a witness (over 18 years of age)

Renewal only from a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 4 months initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Calcium Homeostasis

Alendronate for Osteoporosis

SA0948 Special Authority for Subsidy

Initial application — (Underlying cause – Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score \leq -3.0.

Initial application — (Underlying cause – glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
 - 1 The patient is receiving systemic glucocorticosteriod therapy (\geq 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
 - 2 Either:
 - 2.1 The patient has documented BMD $\geq~$ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score $\leq~$ -1.5); or

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Brand or Generic Manufacturer	

continued...

2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents).

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

- Any of the following:
 - 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5); or
 - 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 4 Documented T-Score \leq -3.0.

Notes:

- a) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5, and therefore do not require BMD measurement for treatment with bisphosphonates.
- b) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- c) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

ALENDRONATE SODIUM - Special Authority see SA094	8 on the preceding page - R	etail pharmacy	/
Tab 70 mg		4 🗸	' Fosamax
ALENDRONATE SODIUM WITH CHOLECALCIFEROL -	Special Authority see SA094	8 on the prece	eding page – Retail pharmacy
Tab 70 mg with cholecalciferol 2800 iu		4 🖌	Fosamax Plus

Alendronate for Paget's Disease

➡SA0949 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or
 - 2.5 Preparation for orthopaedic surgery.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

ALENDRONATE SODIUM - Special Authority see SA0949 above - Retail pharmacy

Tab 40 mg	
-----------	--

Fosamax

	Subsidy (Manufacturer's Price)	ç	Fully Brand or Subsidised Generic
	(Manulaciulei Sirrice) \$	Per	Manufacturer
Other Treatments			
CALCITONIN	440.00	_	
* Inj 100 iu per ml, 1 ml	110.00	5	Miacalcic
ETIDRONATE DISODIUM	00.00	60	V Didronel
* Tab 200 mg	22.80 38.00	60 100	✓ Etidrate
Prescribing Guidelines	00.00	100	
Etidronate for osteoporosis should be prescribed for 14 days (400			
not be taken at the same time of the day as any calcium suppleme	`		00 mg per day of elemental calcium
Etidronate should be taken at least 2 hours before or after any foo	d or fluid, except wat	er.	
PAMIDRONATE DISODIUM – Hospital pharmacy [HP3] Inj 3 mg per ml, 5 ml	18 75	1	Pamisol
Inj 3 mg per ml, 10 ml		1	✓ Pamisol
Inj 6 mg per ml, 10 ml	75.00	1	✓ Pamisol
Inj 9 mg per ml, 10 ml	112.50	1	Pamisol
Enzymes			
HYALURONIDASE			
Inj 1,500 iu per ml		10	
	(243.24)		Hyalase
Hyperuricaemia and Antigout			
ALLOPURINOL			
* Tab 100 mg		250	Apo-Allopurinol
* Tab 300 mg	4.03	100	Apo-Allopurinol
COLCHICINE			
* Tab 500 μg	9.60	100	✓ <u>Colgout</u>
PROBENECID	55.00	400	
* Tab 500 mg	55.00	100	🖌 AFT
Muscle Relaxants			
BACLOFEN			
* Tab 10 mg	3.75	100	Pacifen
DANTROLENE SODIUM			
* Cap 25 mg		100	✓ Dantrium
* Cap 50 mg	51./0	100	 Dantrium
ORPHENADRINE CITRATE	10 5 4	100	A Norfloy
Tab 100 mg	18.54	100	✓ Norflex
QUININE SULPHATE	15.05	250	✓ O 200
* Tab 200 mg ‡ Safety cap for extemporaneously compounded oral liquid		250	✔ Q 200
* Tab 300 mg		500	🖌 Q 300
‡ Safety cap for extemporaneously compounded oral liquid			

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully sidised	Brand or Generic Manufacturer
Anaesthetics				
Local				
BUPIVACAINE HYDROCHLORIDE – Hospital pharmacy [HP3] Inj 0.5%, 4 ml Inj 0.5%, 8% glucose, 4 ml		5 5		arcain Isobaric arcain Heavy
LIGNOCAINE HYDROCHLORIDE Inj 0.5%, 5 ml – Up to 5 inj available on a PSO Only if prescribed on prescription for a dialysis patient or of Inj 1%, 5 ml – Up to 5 inj available on a PSO Only if prescribed on prescription for a dialysis patient or of Data if prescription and prescription for a dialysis patient or of New If prescription on the prescription for a dialysis patient or of New If prescription on the prescription for a dialysis patient or of New If prescription on the prescription for a dialysis patient or of New If prescription on the prescription for a dialysis patient or of New If prescription of the prescription for a dialysis patient or of New If prescription of the prescription of th	hild with rheumatic fe	50	n PSO f ✔ <u>X</u>	ylocaine
Only if prescribed on prescription for a dialysis patient or or Inj 1%, 20 ml – Up to 5 inj available on a PSO Only if prescribed on prescription for a dialysis patient or o	23.50	5	✓ X	vlocaine
LIGNOCAINE WITH CHLORHEXIDINE Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes	43.26	10	🗸 Pi	fizer
LIGNOCAINE WITH PRILOCAINE – Special Authority see SA09 Crm 2.5% with prilocaine 2.5% Crm 2.5% with prilocaine 2.5% (5 g tubes)		pharmacy [0 g OP 5	HP3] <u>E</u>	
► SA0906 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals vali	d for 2 years where	the patient	is a ch	ild with a chronic medica

Initial application from any relevant practitioner. Approvals valid for 2 years where the patient is a child with a chronic medical condition requiring frequent injections or venepuncture.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Analgesics

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 99

Non-Opioid Analgesics

ASPIRIN			
* Tab EC 300 mg	2.15	100	
-	(8.10)		Aspec 300
* Tab dispersible 300 mg - Up to 30 tab available on a PSO	2.15	100	Ethics Aspirin
NEFOPAM HYDROCHLORIDE			
Tab 30 mg	23.40	90	Acupan
PARACETAMOL			
* Tab 500 mg – Up to 30 tab available on a PSO	9.60	1,000	Pharmacare
*‡ Oral liq 120 mg per 5 ml	6.80	1,000 ml	Paracare Junior
a) Up to 200 ml available on a PSO			
b) Not in combination			
* + Oral liq 250 mg per 5 ml	7.00	1,000 ml	Paracare Double
			Strength
a) Up to 100 ml available on a PSO			
b) Not in combination			
* Suppos 125 mg		20	Panadol
* Suppos 250 mg		20	Panadol
* Suppos 500 mg	20.50	50	Paracare

	Subsidy		Fully	Brand or
	(Manufacturer's Price) \$	Per	Subsidised	
Opioid Analgesics				
BUPRENORPHINE HYDROCHLORIDE - Only on a controlled	drug form			
Inj 0.3 mg per ml, 1 ml		5		
	(9.38)		٦	Temgesic
CODEINE PHOSPHATE				
Tab 15 mg		100		
Tab 30 mg		100	-	<u>PSM</u>
Tab 60 mg		100	✓ <u>I</u>	<u>25M</u>
DEXTROPROPOXYPHENE WITH PARACETAMOL				
Tab napsylate 50 mg with paracetamol 325 mg	()	500	_	
	(22.50)		F	Paradex
Cap hydrochloride 32.5 mg with paracetamol 325 mg	(500	,	Demostary.
	(33.14)		(Capadex
DIHYDROCODEINE TARTRATE				
Tab long-acting 60 mg		60	v [OHC Continus
FENTANYL – Special Authority see SA0935 below – Retail phar	macy			
 a) Only on a controlled drug form 				
b) No patient co-payment payable				
Transdermal patch, matrix 25 µg per hour		5		Durogesic
Transdermal patch, matrix 50 μg per hour		5		Durogesic
Transdermal patch, matrix 75 µg per hour		5		Durogesic
Transdermal patch, matrix 100 µg per hour		5	V	Durogesic
► SA0935 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid	I for 3 months for appl	ication	is meeting	the following criteria:
Both:				
1 Patient is terminally ill and is opioid-responsive; and 2 Fither:				
2 Either:				
2 Either: 2.1 is unable to take oral medication; or	rated			
 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindic 		ment r	emains ap	propriate and the patient
 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindic Renewal from any relevant practitioner. Approvals valid for 3 mediate 		ment r	emains ap	propriate and the patient
 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindic Renewal from any relevant practitioner. Approvals valid for 3 more penefiting from treatment. 		ment r	emains ap	propriate and the patient
 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindic Renewal from any relevant practitioner. Approvals valid for 3 morenefiting from treatment. FENTANYL CITRATE 		ment r	emains ap	propriate and the patient
 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindic Renewal from any relevant practitioner. Approvals valid for 3 monopenefiting from treatment. TENTANYL CITRATE a) Only on a controlled drug form 		ment r	emains ap	propriate and the patient
 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindic Renewal from any relevant practitioner. Approvals valid for 3 monopenefiting from treatment. TENTANYL CITRATE a) Only on a controlled drug form b) No patient co-payment payable 	onths where the treatr	ment r 5		propriate and the patient i
 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindic Renewal from any relevant practitioner. Approvals valid for 3 monopenefiting from treatment. TENTANYL CITRATE a) Only on a controlled drug form 	onths where the treatr			
 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindic Renewal from any relevant practitioner. Approvals valid for 3 morenefiting from treatment. FENTANYL CITRATE a) Only on a controlled drug form b) No patient co-payment payable Inj 50 µg per ml, 2 ml 	onths where the treatr	5		lospira
 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindic Renewal from any relevant practitioner. Approvals valid for 3 menefiting from treatment. TENTANYL CITRATE a) Only on a controlled drug form b) No patient co-payment payable Inj 50 µg per ml, 2 ml Inj 50 µg per ml, 10 ml METHADONE HYDROCHLORIDE 	onths where the treatr	5		lospira
 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindic Renewal from any relevant practitioner. Approvals valid for 3 menefiting from treatment. ENTANYL CITRATE a) Only on a controlled drug form b) No patient co-payment payable Inj 50 µg per ml, 2 ml Inj 50 µg per ml, 10 ml INETHADONE HYDROCHLORIDE a) Only on a controlled drug form 	onths where the treatr	5		lospira
 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindic Renewal from any relevant practitioner. Approvals valid for 3 morenefiting from treatment. ENTANYL CITRATE a) Only on a controlled drug form b) No patient co-payment payable Inj 50 µg per ml, 2 ml Inj 50 µg per ml, 10 ml INETHADONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable 	onths where the treatr	5 5		lospira lospira
 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindic Renewal from any relevant practitioner. Approvals valid for 3 more predicting from treatment. FENTANYL CITRATE a) Only on a controlled drug form b) No patient co-payment payable Inj 50 µg per ml, 2 ml Inj 50 µg per ml, 10 ml METHADONE HYDROCHLORIDE a) Only on a controlled drug form 	onths where the treatr	5 5		lospira lospira
 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindic Renewal from any relevant practitioner. Approvals valid for 3 more penefiting from treatment. TENTANYL CITRATE a) Only on a controlled drug form b) No patient co-payment payable Inj 50 µg per ml, 2 ml Inj 50 µg per ml, 10 ml METHADONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable Inj 50 µg per ml, 2 ml METHADONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Extemporaneously compounded methadone will only be a 	onths where the treatr	5 5		lospira lospira
 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindic Renewal from any relevant practitioner. Approvals valid for 3 more penefiting from treatment. FENTANYL CITRATE a) Only on a controlled drug form b) No patient co-payment payable Inj 50 µg per ml, 2 ml METHADONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable Inj 50 µg per ml, 10 ml METHADONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Extemporaneously compounded methadone will only be a powder, not methadone tablets). 	onths where the treatr 6.10 15.65 reimbursed at the rate	5 5	cheapest	lospira lospira
 2 Either: 2.1 is unable to take oral medication; or 2.2 is intolerant to morphine, or morphine is contraindic Renewal from any relevant practitioner. Approvals valid for 3 more penefiting from treatment. FENTANYL CITRATE a) Only on a controlled drug form b) No patient co-payment payable Inj 50 µg per ml, 2 ml Inj 50 µg per ml, 10 ml METHADONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable Inj 50 µg per ml, 10 ml METHADONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Extemporaneously compounded methadone will only be a powder, not methadone tablets). d) For methadone hydrochloride oral liquid refer, page 163 Tab 5 mg 	onths where the treatr 	5 5 e of the	<pre></pre>	Iospira Iospira form available (methadon <u>Methatabs</u> Biodone
 2 Either: is unable to take oral medication; or is intolerant to morphine, or morphine is contraindic Renewal from any relevant practitioner. Approvals valid for 3 morenefiting from treatment. FENTANYL CITRATE Only on a controlled drug form No patient co-payment payable fo g per ml, 2 ml WETHADONE HYDROCHLORIDE Only on a controlled drug form No patient co-payment payable fo g per ml, 10 ml WETHADONE HYDROCHLORIDE Only on a controlled drug form No patient co-payment payable Extemporaneously compounded methadone will only be powder, not methadone tablets). For methadone hydrochloride oral liquid refer, page 163 Tab 5 mg Oral liq 2 mg per ml 		5 5 • of the 10	<pre></pre>	Hospira Hospira form available (methadon <u>Methatabs</u> Biodone Biodone Forte
 2 Either: is unable to take oral medication; or is intolerant to morphine, or morphine is contraindic Renewal from any relevant practitioner. Approvals valid for 3 mobenefiting from treatment. FENTANYL CITRATE Only on a controlled drug form No patient co-payment payable Jo 50 µg per ml, 2 ml METHADONE HYDROCHLORIDE Only on a controlled drug form No patient co-payment payable Extemporaneously compounded methadone will only be a powder, not methadone tablets). For methadone hydrochloride oral liquid refer, page 163 Tab 5 mg 		5 5 • of the 10 200 ml	<pre></pre>	Hospira Hospira form available (methadon <u>Methatabs</u> Biodone Biodone Forte Biodone Extra Forte

	Subsidy		Fully Brand or
	(Manufacturer's P		ubsidised Generic
	\$	Per	 Manufacturer
MORPHINE HYDROCHLORIDE			
a) Only on a controlled drug form			
b) No patient co-payment payable			
Oral lig 1 mg per ml		200 ml	RA-Morph
t Oral lig 2 mg per ml		200 ml	✓ RA-Morph
Cral liq 5 mg per ml		200 ml	RA-Morph
Oral liq 10 mg per ml		200 ml	RA-Morph
MORPHINE SULPHATE			
a) Only on a controlled drug form			
b) No patient co-payment payable			
Tab immediate-release 10 mg	2 64	10	Sevredol
Tab long-acting 10 mg		10	✓ LA-Morph
Tab immediate-release 20 mg		10	✓ Sevredol
Tab long-acting 30 mg		10	✓ LA-Morph
Tab long-acting 60 mg		10	LA-Morph
Tab long-acting 100 mg		10	✓ LA-Morph
Cap long-acting 10 mg		10	✓ m-Eslon
Cap long-acting 30 mg		10	✓ m-Eslon
Cap long-acting 60 mg		10	✓ m-Eslon
Cap long-acting 100 mg		10	m-Eslon
Cap long-acting 200 mg	17.00	10	🖌 m-Eslon
Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO	5.17	5	Mayne
Inj 10 mg per ml, 1 ml - Up to 5 inj available on a PSO	4.50	5	Mayne
Inj 15 mg per ml, 1 ml - Up to 5 inj available on a PSO	4.70	5	Mayne
Inj 30 mg per ml, 1 ml – Up to 5 inj available on a PSO	4.98	5	Mayne
MORPHINE TARTRATE			
a) Only on a controlled drug form			
b) No patient co-payment payable			
Inj 80 mg per ml, 1.5 ml		5	Mayne
Inj 80 mg per ml, 5 ml		5	Mayne
OXYCODONE HYDROCHLORIDE			-
a) Only on a controlled drug form			
b) No patient co-payment payable			
Tab controlled-release 5 mg	7.51	20	OxyContin
Tab controlled-release 10 mg		20	✓ OxyContin
Tab controlled-release 20 mg		20	✓ OxyContin
Tab controlled-release 40 mg		20	✓ OxyContin
Tab controlled-release 80 mg		20	✓ OxyContin
Cap 5 mg		20	✓ OxyNorm
Cap 10 mg		20	V OxyNorm
Cap 20 mg		20	V OxyNorm
Cral liq 5 mg per 5 ml		250 ml	V OxyNorm
Inj 10 mg per ml, 1 ml		5	V OxyNorm
Inj 10 mg per ml, 2 ml		5	✓ OxyNorm
Prescribing Guideline			
Prescribers should note that oxycodone is significantly more	e expensive than lon	ig-acting mor	rphine sulphate and clinical ad
suggests that it is reasonable to consider this as a second-line	•		
PARACETAMOL WITH CODEINE	-		
 * Tab paracetamol 500 mg with codeine phosphate 8 mg . 		100	Codalgin
Proceeding the country from the proceeding the			

	Subsidy		Fully	Brand or
	(Manufacturer's Price)	Dev	Subsidised	Generic
	\$	Per	~	Manufacturer
PETHIDINE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable			4 -	
Tab 50 mg		10	PS	
Tab 100 mg		10	✓ P:	
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 50 mg per ml, 1.5 ml – Up to 5 inj available on a PSO		5 5	✓ M ✓ M	
Inj 50 mg per ml, 2 ml $-$ Up to 5 inj available on a PSO		5	✓ M	•
		5	U INI	ayne
Antidepressants				
Cyclic and Related Agents				
AMITRIPTYLINE				
Tab 10 mg		50	🖌 A	
Tab 25 mg		100		mitrip
Tab 50 mg	5.20	100	V A	mitrip
CLOMIPRAMINE HYDROCHLORIDE				
Tab 10 mg	10.00	100		opress
Tab 25 mg		500	V C	opress
DOTHIEPIN HYDROCHLORIDE				
Tab 75 mg	8.75	100		opress
Cap 25 mg	4.75	100	V D	opress
DOXEPIN HYDROCHLORIDE				
Cap 10 mg	5.24	100	🖌 A	
Cap 25 mg		100	V A	
Cap 50 mg	7.34	100	V A	nten
MIPRAMINE HYDROCHLORIDE				
Tab 10 mg		50		ofranil
Tab 25 mg	8.80	50	V To	ofranil
IAPROTILINE HYDROCHLORIDE				
Tab 25 mg	25.06	100		udiomil
Tab 75 mg	21.01	30	🖌 Li	udiomil
/IANSERIN HYDROCHLORIDE - Special Authority see SA08	64 below – Retail pharr	nacy		
Tab 30 mg		30	🖌 To	olvon
SA0864 Special Authority for Subsidy				
nitial application from any relevant practitioner. Approvals valid	d for 2 years for applica	tions	meeting the	following criteria:
Both:				
1 Depression; and				
2 Either:				
2.1 Co-existent bladder neck obstruction; or				
2.2 Cardiovascular disease.	lears where the treatm	ont r	amaine ann	ronriate and the nationt i
Zanawal trom any relevant practitionar. Approvale valid for () is			emains appi	opnate and the patient i
, , , ,, ,,				
penefiting from treatment.				
Renewal from any relevant practitioner. Approvals valid for 2 y benefiting from treatment. NORTRIPTYLINE HYDROCHLORIDE Tab 10 mg		100	V N	orpress

	Subsidy (Manufacturer's Pri		Fully Brand or Ibsidised Generic
	\$	Per	 Manufacturer
TRIMIPRAMINE MALEATE Cap 25 mg	6.20	100	✓ Tripress
Cap 50 mg		100	✓ Tripress
(Tripress Cap 25 mg to be delisted 1 March 2010)			
Monoamine-Oxidase Inhibitors (MAOIs) - Non	Selective		
PHENELZINE SULPHATE Tab 15 mg	95.00	100	✓ Nardil
TRANYLCYPROMINE SULPHATE Tab 10 mg	22.94	50	✓ Parnate
Monoamine-Oxidase Type A Inhibitors			
MOCLOBEMIDE Note: There is a significant cost differential between moclo expensive). For depressive syndromes it is therefore more ing prescribing moclobemide. Table 450 mm	cost-effective to star	t treatment	with fluoxetine first before conside
Tab 150 mg Tab 300 mg		500 100	 Apo-Moclobemide Apo-Moclobemide
Selective Serotonin Reuptake Inhibitors			
* Tab 20 mg FLUOXETINE HYDROCHLORIDE	3.78	84	Arrow-Citalopram
 Tab dispersible 20 mg, scored – Subsidy by endorsement Subsidised by endorsement 	5.50	30	✓ <u>Fluox</u>
 When prescribed for a patient who cannot swallow ingly; or 	w whole tablets or cap	osules and t	he prescription is endorsed accord
 When prescribed in a daily dose that is not a endorsed. Note: Tablets should be combined wit Cap 20 mg 	h capsules to facilitate		
PAROXETINE HYDROCHLORIDE	4.39	90	
Tab 20 mg	5.90	30	✓ Loxamine
Other Antidepressants			
/ENLAFAXINE - Special Authority see SA0789 below - Reta			
		28	 Efexor XR
Cap 37.5 mg Cap 75 mg		28	Efexor XR

Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1 The patient has 'treatment-resistant' depression; and

2 Either:

2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or

2.2 Both:

Subsidy	rice) S	Fully	Brand or
(Manufacturer's P		Subsidised	Generic
\$	Per	~	Manufacturer

continued...

2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and

2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time.

Renewal from any medical practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

Antiepilepsy Drugs

Agents for Control of Status Epilepticus

CLONAZEPAM Inj 1 mg per ml, 1 ml	5	✓ Rivotril
DIAZEPAM	Ũ	
Inj 5 mg per ml, 2 ml – Subsidy by endorsement9.24 a) Up to 5 inj available on a PSO b) Only on a PSO	5	🗸 Mayne
c) PSO must be endorsed "not for anaesthetic procedures".	F	✓ Stesolid
Rectal tubes 5 mg – Up to 5 tube available on a PSO	5 5	✓ Stesolid
PARALDEHYDE	0	• otcoolia
* Inj 5 ml	5	🖌 AFT
PHENYTOIN SODIUM	Ũ	• /
* Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO	5	Mayne
* Inj 50 mg per ml, 5 ml – Up to 5 inj available on a PSO	5	✓ Mayne
Control of Epilepsy		
CARBAMAZEPINE		
* Tab 200 mg14.53	100	 Tegretol
* Tab long-acting 200 mg	100	✓ Tegretol CR
* Tab 400 mg	100 100	 Tegretol Tegretol CR
 * Tab long-acting 400 mg	250 ml	✓ Tegretol
CLOBAZAM	200 111	• logiciói
Tab 10 mg9.12	50	✓ Frisium
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
CLONAZEPAM		
Tab 500 µg6.26	100	✓ Paxam
Tab 2 mg	100	✓ <u>Paxam</u>
Cral drops 2.5 mg per ml7.38	10 ml OP	Rivotril
ETHOSUXIMIDE	000	✓ Zarontin
* Cap 250 mg	200 200 ml	✓ Zarontin
GABAPENTIN – Special Authority see SA0936 on the next page – Retail pharmac		
▲ Cap 100 mg	-y 100	✓ Nupentin
▲ Cap 300 mg	100	✓ <u>Nupentin</u>
▲ Cap 400 mg	100	✓ <u>Nupentin</u>

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

SA0936 Special Authority for Subsidy

Initial application — (Epilepsy - new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Either:

- 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
- 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Initial application — (Epilepsy - patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life from gabapentin, topiramate, vigabatrin and/or lamotrigine.

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Initial application — (Neuropathic pain - new patients) from any relevant practitioner. Approvals valid for 3 months where the patient has tried and failed, or has been unable to tolerate, treatment with a tricyclic antidepressant.

Initial application — (Neuropathic pain - patient has had an approval for gabapentin for neuropathic pain prior to 1 August
 2007) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

- Either:
 - 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or
 - 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

Renewal — (Epilepsy) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application.

Renewal — (Neuropathic pain) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or
- 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

Note: If the patient had an approval for gabapentin for neuropathic pain prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application.

GABAPENTIN (NEURONTIN) - Special Authority see SA0973 below - Retail pharmacy

Tab 600 mg	79.79	100	Neurontin
Cap 100 mg	15.67	100	Neurontin
Cap 300 mg		100	Neurontin
Cap 400 mg		100	Neurontin

■SA0973 Special Authority for Subsidy

Notes: Subsidy for patients pre-approved by PHARMAC on 1 August 2009. Approvals valid without further renewal unless notified. No new approvals will be granted from 1 August 2009.

	Subsidy (Manufacturer's Price) \$	Per	Fully Brand or Subsidised Generic Manufacturer
AMOTRIGINE	Ŷ	T CI	• Manufacturer
Tab dispersible 2 mg	6 74	30	Lamictal
Tab dispersible 5 mg		30	✓ Lamictal
	15.00	56	✓ Arrow-Lamotrigine
Tab dispersible 25 mg		56	✓ Logem
	20.40	00	 Arrow-Lamotrigine
	20.40		✓ Mogine
	29.09		
Tab dispersible 50 mg		56	✓ Logem
	34.70	00	 Arrow-Lamotrigine
	01.70		✓ Mogine
	47.89		
Tab dispersible 100 mg		56	✓ Logem
	59.90	00	 Arrow-Lamotrigine
	00.00		✓ Mogine
	79.16		
Tab dispersible 200 mg		56	 Arrow-Lamotrigine
		00	✓ Mogine
Mogine Tab dispersible 200 mg to be delisted 1 March 203	10)		• mognie
EVETIRACETAM – Special Authority see SA0921 below	- Retail pharmacy		
Tab	· · · ·	60	Keppra
ubsidy by application to the Levetiracetam Special Access		rmaala	out pz. or:
otes: Application details may be obtained from PHARMAG The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254	C's website http://www.pha Phone: (04) 916-7553 Facsimile: (09) 929-3226		
otes: Application details may be obtained from PHARMAG The Coordinator, Levetiracetam Special Access Panel	C's website http://www.pha Phone: (04) 916-7553		
otes: Application details may be obtained from PHARMAG The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254	C's website http://www.pha Phone: (04) 916-7553 Facsimile: (09) 929-3226		
lotes: Application details may be obtained from PHARMA(The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254 Wellington	C's website http://www.pha Phone: (04) 916-7553 Facsimile: (09) 929-3226		
lotes: Application details may be obtained from PHARMAG The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254 Wellington HENOBARBITONE For phenobarbitone oral liquid refer, page 163 Tab 15 mg	C's website http://www.pha Phone: (04) 916-7553 Facsimile: (09) 929-3226 Email: Isacoordinator@pl		
lotes: Application details may be obtained from PHARMA(The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254 Wellington HENOBARBITONE For phenobarbitone oral liquid refer, page 163	C's website http://www.pha Phone: (04) 916-7553 Facsimile: (09) 929-3226 Email: Isacoordinator@pl	harmad	c.govt.nz
Iotes: Application details may be obtained from PHARMA0 The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254 Wellington HENOBARBITONE For phenobarbitone oral liquid refer, page 163 © Tab 15 mg © Tab 30 mg	C's website http://www.pha Phone: (04) 916-7553 Facsimile: (09) 929-3226 Email: Isacoordinator@pl	harmad 500	c.govt.nz ✔ PSM
Iotes: Application details may be obtained from PHARMA0 The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254 Wellington HENOBARBITONE For phenobarbitone oral liquid refer, page 163 Cab 15 mg © Tab 30 mg HENYTOIN SODIUM	C's website http://www.pha Phone: (04) 916-7553 Facsimile: (09) 929-3226 Email: Isacoordinator@pl 	500 500	c.govt.nz ✔ PSM ✔ PSM
Intersection details may be obtained from PHARMAC The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254 Wellington HENOBARBITONE For phenobarbitone oral liquid refer, page 163 © Tab 15 mg HENYTOIN SODIUM © Tab 50 mg	C's website http://www.pha Phone: (04) 916-7553 Facsimile: (09) 929-3226 Email: Isacoordinator@pl 	harmad 500	c.govt.nz ✓ PSM ✓ PSM ✓ Dilantin Infatab
Intersection details may be obtained from PHARMA(The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254 Wellington HENOBARBITONE For phenobarbitone oral liquid refer, page 163 © Tab 15 mg © Tab 30 mg HENYTOIN SODIUM © Tab 50 mg © Cap 30 mg	C's website http://www.pha Phone: (04) 916-7553 Facsimile: (09) 929-3226 Email: Isacoordinator@pl 	500 500 200	c.govt.nz ✔ PSM ✔ PSM
Iotes: Application details may be obtained from PHARMA(The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254 Wellington HENOBARBITONE For phenobarbitone oral liquid refer, page 163 © Tab 15 mg © Tab 30 mg HENYTOIN SODIUM © Tab 50 mg © Cap 30 mg	C's website http://www.phai Phone: (04) 916-7553 Facsimile: (09) 929-3226 Email: Isacoordinator@pl 	500 500 200 200	2.govt.nz ✓ PSM ✓ PSM ✓ Dilantin Infatab ✓ Dilantin
Intersection details may be obtained from PHARMAG The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254 Wellington HENOBARBITONE For phenobarbitone oral liquid refer, page 163 © Tab 15 mg © Tab 30 mg HENYTOIN SODIUM © Cap 30 mg © Cap 100 mg © Cap 100 mg © Cap 100 mg	C's website http://www.phai Phone: (04) 916-7553 Facsimile: (09) 929-3226 Email: Isacoordinator@pl 	500 500 200 200 200	2.govt.nz ✓ PSM ✓ PSM ✓ Dilantin Infatab ✓ Dilantin ✓ Dilantin
Intersection details may be obtained from PHARMA(The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254 Wellington HENOBARBITONE For phenobarbitone oral liquid refer, page 163 € Tab 15 mg € Tab 30 mg HENYTOIN SODIUM € Tab 50 mg € Cap 30 mg € Cap 100 mg € Oral liq 30 mg per 5 ml RIMIDONE	C's website http://www.pha Phone: (04) 916-7553 Facsimile: (09) 929-3226 Email: Isacoordinator@pl 	500 500 200 200 200 500 ml	s.govt.nz ✓ PSM ✓ PSM ✓ Dilantin Infatab ✓ Dilantin ✓ Dilantin ✓ Dilantin
Intersection details may be obtained from PHARMAG The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254 Wellington HENOBARBITONE For phenobarbitone oral liquid refer, page 163 Cap 10 mg Tab 15 mg Tab 30 mg HENYTOIN SODIUM Cap 30 mg Cap 100 mg Cap 100 mg For alliq 30 mg per 5 ml RIMIDONE Tab 250 mg	C's website http://www.pha Phone: (04) 916-7553 Facsimile: (09) 929-3226 Email: Isacoordinator@pl 	500 500 200 200 200	2.govt.nz ✓ PSM ✓ PSM ✓ Dilantin Infatab ✓ Dilantin ✓ Dilantin
Iotes: Application details may be obtained from PHARMA(The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254 Wellington HENOBARBITONE For phenobarbitone oral liquid refer, page 163 Tab 15 mg Tab 30 mg Tab 50 mg Cap 30 mg Cap 100 mg Cap 100 mg Tab 250 mg Tab 250 mg Ong Linux RIMIDONE Fab 250 mg ODIUM VALPROATE ON	C's website http://www.pha Phone: (04) 916-7553 Facsimile: (09) 929-3226 Email: Isacoordinator@pl 	500 500 200 200 200 500 ml	C.govt.nz ✓ PSM ✓ PSM ✓ Dilantin Infatab ✓ Dilantin ✓ Dilantin ✓ Dilantin ✓ Dilantin
Iotes: Application details may be obtained from PHARMAC The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254 Wellington HENOBARBITONE For phenobarbitone oral liquid refer, page 163 Tab 15 mg Tab 30 mg Tab 50 mg Cap 30 mg Cap 100 mg Cap 100 mg Tab 250 mg Tab 100 mg Tab 100 mg 	C's website http://www.pha Phone: (04) 916-7553 Facsimile: (09) 929-3226 Email: Isacoordinator@pl 	500 500 200 200 200 200 500 ml 100	2.govt.nz PSM PSM Dilantin Infatab Dilantin Dilantin Dilantin Apo-Primidone Epilim Crushable
Iotes: Application details may be obtained from PHARMAC The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254 Wellington HENOBARBITONE For phenobarbitone oral liquid refer, page 163 Tab 15 mg Tab 30 mg Tab 50 mg Cap 30 mg Cap 100 mg Cap 100 mg Tab 250 mg Tab 250 mg Tab 200 mg Tab 200 mg Tab 100 mg Tab 100 mg Tab 200 mg EC Tab 200 mg EC 	C's website http://www.pha Phone: (04) 916-7553 Facsimile: (09) 929-3226 Email: Isacoordinator@pl 	500 500 200 200 200 500 ml 100 100	2.govt.nz ✓ PSM ✓ PSM ✓ Dilantin Infatab ✓ Dilantin ✓ Dilantin ✓ Dilantin ✓ Dilantin ✓ Dilantin ✓ Epilim Crushable ✓ Epilim
Iotes: Application details may be obtained from PHARMAC The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254 Wellington HENOBARBITONE For phenobarbitone oral liquid refer, page 163 Tab 15 mg Tab 30 mg Tab 50 mg Cap 30 mg Cap 100 mg Cap 100 mg Tab 250 mg Tab 100 mg Tab 100 mg 	C's website http://www.pha Phone: (04) 916-7553 Facsimile: (09) 929-3226 Email: Isacoordinator@pl 	500 500 200 200 200 200 500 ml 100	 c.govt.nz PSM PSM Dilantin Infatab Dilantin Dilantin Dilantin Dilantin Apo-Primidone Epilim Crushable Epilim Epilim
Iotes: Application details may be obtained from PHARMAC The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254 Wellington HENOBARBITONE For phenobarbitone oral liquid refer, page 163 Tab 15 mg Tab 30 mg Tab 50 mg Cap 30 mg Cap 100 mg Cap 100 mg Tab 250 mg Tab 250 mg Tab 200 mg Tab 200 mg Tab 100 mg Tab 100 mg Tab 200 mg EC Tab 200 mg EC 	C's website http://www.phai Phone: (04) 916-7553 Facsimile: (09) 929-3226 Email: Isacoordinator@pl 	500 500 200 200 200 500 ml 100 100	 c.govt.nz PSM PSM Dilantin Infatab Dilantin Dilantin Dilantin Dilantin Epilim Crushable Epilim
Iotes: Application details may be obtained from PHARMAC The Coordinator, Levetiracetam Special Access Panel PHARMAC, PO Box 10 254 Wellington HENOBARBITONE For phenobarbitone oral liquid refer, page 163 © Tab 15 mg © Tab 30 mg © Cap 30 mg © Cap 100 mg © Tab 250 mg © Tab 250 mg © Tab 250 mg © DIUM VALPROATE © Tab 200 mg EC © Tab 500 mg EC	C's website http://www.phai Phone: (04) 916-7553 Facsimile: (09) 929-3226 Email: Isacoordinator@pl 	500 500 200 200 200 500 ml 100 100 100	 ∠ PSM ✓ PSM ✓ PSM ✓ Dilantin Infatab ✓ Dilantin ✓ Dilantin ✓ Dilantin ✓ Apo-Primidone ✓ Epilim Crushable ✓ Epilim ✓ Epilim

	Subsidy (Manufacturer's Price) \$	Su Per	Fully Ibsidised	Brand or Generic Manufacturer
TOPIRAMATE				
▲ Tab 25 mg		60	🖌 To	opamax
▲ Tab 50 mg		60	🖌 To	opamax
▲ Tab 100 mg	75.25	60	🖌 To	opamax
▲ Tab 200 mg	129.85	60	🖌 To	opamax
Sprinkle cap 15 mg	20.84	60	🖌 To	opamax
Sprinkle cap 25 mg		60	🖌 To	opamax
VIGABATRIN – Special Authority see SA0937 below – Retail phan Tab 500 mg	,	100	🖌 Si	abril

SA0937 Special Authority for Subsidy

Initial application — (new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Both:

1 Either:

- 1.1 Patient has infantile spasms; or
- 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:
 - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and

2 Either:

- 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
- 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Initial application — (patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life from gabapentin, topiramate, vigabatrin and or lamotrigine; and
- 2 Either:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for the duration of treatment with vigabatrin; or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and 2 Fither:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or

Subsidy (Manufacturer's Pric	e)	Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application.

Antimigraine Preparations

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 99

Acute Migraine Treatment

-			
ERGOTAMINE TARTRATE WITH CAFFEINE Tab 1 mg with caffeine 100 mg	31.00	100	✓ Cafergot
METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL			· · ····
Tab 5 mg with paracetamol 500 mg	6.77	60	Paramax
RIZATRIPTAN BENZOATE			1
Wafer 10 mg	25.32	3	Maxalt Melt
SUMATRIPTAN Tab 50 mg	12.00	4	 Arrow-Sumatriptan
Tab 50 mg	12.00	4	Sumagran
	22.00		🖌 Imigran
Tab 100 mg	12.00	2	 Arrow-Sumatriptan Sumagran
	22.00		✓ Sumagran ✓ Imigran
Inj 12 mg per ml, 0.5 ml – Hospital pharmacy [HP3]-Specialist . Maximum of 10 inj per prescription	80.00	2 OP	 Imigran
Prophylaxis of Migraine			
For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYST	EM, page 51		
CLONIDINE HYDROCHLORIDE			
* Таb 25 µg	17.53	100	 Dixarit
PIZOTIFEN		100	
* Tab 500 μg	21.10 (24.10)	100	Sandomigran
Antinausea and Vertigo Agents	(=		Canachighan
For Antispasmodics refer to ALIMENTARY TRACT, page 27			
BETAHISTINE DIHYDROCHLORIDE * Tab 16 mg	9.26	84	✔ Vergo 16
CYCLIZINE HYDROCHLORIDE		01	· ····
Tab 50 mg	1.59	10	Nausicalm
CYCLIZINE LACTATE			
Inj 50 mg per ml, 1 ml		5	Valoid (AFT)
DOMPERIDONE – Additional subsidy by Special Authority see SA			tail pharmacy
* Tab 10 mg	3.90 (7.99)	100	Motilium
	(

Subsidy (Manufacturers Price) Fully Subsidiated Generic Fully Subsidiated Generic Initial application from any relevant practitioner. Approvals valid for 6 months where the patient is terminally ill and requires control of nausea and vomiting. Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. HYOSCINE (SCOPCLANINE) – Special Authority see SA0939 below – Hospital pharmacy [HP3] Patches, 15 mg 11.95 2 ✓ Scopoderm TTS ■SA09333 Special Authority for Subsidy 11.95 2 ✓ Scopoderm TTS ■SA09333 Special Authority for Subsidy version to one on adequately respond to orial anti-nausea ganets; and 3 The applicant more any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease; and 2 Patient cannot tolerate or des not adequately respond to oral anti-nausea ganets; and 3 The applicant must specify the underlying malignancy or chronic disease. Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment. HYOSCINE HYDROBROMIDE * Inj 0 up ger ml, 1 ml 6.66 ✓ Mayne METCOLOPRAMIDE HYDROCHCONIDE * Inj 0 mg per ml, 2 ml – Up to 5 inj available on a PSO. 10 ✓ Pitzer ONDANSETTRON					
S Per ✓ Manufacturer Imitial application from any relevant practitioner. Approvals valid for 6 months where the patient is terminally ill and requires control of nausea and vomiting. Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. HYOSCINE (SCOPCLAMINE) – Special Authority see SA0939 below – Hospital pharmacy (IPP3) Patches, 15 mg. Scopoderm TTS Imitial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Control of infractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease; and 2 Patient cannot tolerate or does not adequately respond to oral anti-nausea agents; and 3 The application may relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment. HYOSCINE HYDROBROMIDE # Tab 10 mg			-o) C.		
Initial application from any relevant practitioner. Approvals valid for 6 months where the patient is terminally ill and requires control of nausea and vomiting. Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. HYOSCINE (COPOLAMINE) – Special Authority see SA0939 below – Hospital pharmacy [HP3] Patches, 1.5 mg					
Initial application from any relevant practitioner. Approvals valid for 6 months where the patient is terminally ill and requires control of nausea and vomiting. Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. HYOSCINE (COPOLAMINE) – Special Authority see SA0939 below – Hospital pharmacy [HP3] Patches, 1.5 mg	SA0028 Special Authority for Manufacturara Bridg				
of naises and voming. Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. HYOSCINE (SCOPCLAMINE) – Special Authority see SA0339 below – Hospital pharmacy [HP3] Patches, 1.5 mg		d for 6 months where	the nation	t is tormin	ally ill and requires control
Renewall from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. HVOSCINE (SCOPOLAMINE) – Special Authority see SA0939 below – Hospital pharmacy [HP3] Patches, 1.5 mg 12 Patches, 1.5 mg 11.95 2 ✓ Scopoderm TTS Poscone Corpol_Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease; and 2 Patient cannot tolerate or does not adequately respond to oral anti-nausea agents; and 3 The applicant must specify the underlying malignancy or chronic disease. Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment. HVOSCINE HVDROBROMIDE * Tab 10 mg 5.15 10 ✓ Metamide * Inj 400 up per ml, 2 ml – Up to 5 inj available on a PSO. 4.50 10 ✓ Pitzer ONDANSETRION – Retail pharmacy-Specialist a) Maximum of 12 tab per prescription, can be waived by Special Authority see SA0887 below 0) Maximum of 6 tab per dispensing; can be waived by Special Authority see SA0887 below. 0) The maximum of 6 tab per dispensing; can be waived by Special Authority see SA0887 below. 0) The maximum of 6 tab per dispensing; can be waived via Acces			ine patient		
benefiting from treatment. HYOSCINE (SCOPOLAMINE) – Special Authority see SA0939 below – Hospital pharmacy [HP3] Patches, 15 mg		onths where the tre	atment ren	nains apr	propriate and the patient is
Patches, 1.5 mg					
Patches, 1.5 mg	HYOSCINE (SCOPOLAMINE) - Special Authority see SA0939	below - Hospital pha	armacv [HF	23]	
PSA0939 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease; and 2 Patient cannot tolerate or does not adequately respond to oral anti-nausea agents; and 3 The applicant must specify the underlying malignancy or chronic disease. Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment. HYOSCINE HYDROBROMIDE * Inj 400 µg per ml, 1 ml * Tab 10 mg .5.15 * Inj 5m per ml, 2 ml – Up to 5 inj available on a PSO .4.50 10 Maximum of 12 tab per prescription; can be waived by Special Authority see SA0887 below • Pitzer ONDANSETRON - Retail pharmacy-Specialist			, ,		copoderm TTS
Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease; and 2 Patient cannot tolerate or does not adequately respond to oral anti-nausea agents; and 3 The applicant must specify the underlying malignancy or chronic disease. Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment. HYOSCINE HYDROBROMIDE * Inj 400 µg per ml, 1 ml .6.66 5 ✓ Mayne METOCLOPRAMIDE HYDROCHLORIDE * Tab 10 mg .5.15 100 ✓ Metamide * Inj 5 mg per ml, 2 ml – Up to 5 inj available on a PSO .4.50 10 ✓ Pitzer ONDANSETRON – Retail pharmacy-Specialist a) Maximum of 12 tab per prescription; can be waived by Special Authority see SA0887 below b) Maximum of 6 tab per dispensing cannot be waived by Special Authority see SA0887 below. C) Not more than one prescription per month; can be waived by Special Authority see SA0887 below. C) The maximum of 6 tab per dispensing cannot be waived by Special Authority see SA0887 below. C) The maximum of a tab per grescription per month; can be waived by Special Authority see SA0887 below. C) The maximum of a tab per secription per month; can be waived by Special Authority see SA0887 be	►SA0939 Special Authority for Subsidy				
All of the following: 1 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease; and 2 Patient cannot tolerate or does not adequately respond to oral anti-nausea agents; and 3 The applicant must specify the underlying malignancy or chronic disease. Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment. HYOSCINE HYDROBROMIDE ★ * Tab 10 mg		d for 1 year for applic	ations me	eting the	following criteria:
 2 Patient cannot tolerate or does not adequately respond to oral anti-nausea agents; and 3 The applicant must specify the underlying malignancy or chronic disease. Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment. HYOSCINE HYDROBROMIDE * Inj 400 µg per ml, 1 ml6.66 5 ✓ Mayne METOCLOPRAMIDE HYDROCHLORIDE * Tab 10 mg7.15 100 ✓ Metamide * Inj 5 mg per ml, 2 ml – Up to 5 inj available on a PSO4.50 10 ✓ Pfizer ONDANSETRON – Retail pharmacy-Specialist a) Maximum of 12 tab per prescription; can be waived by Special Authority see SA0887 below b) Maximum of 6 tab per dispensing: can be waived by Special Authority see SA0887 below. c) Not more than one prescription; can be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived via Access Exemption Criteria. Tab disp 4 mg17.18 10 ✓ Zofran Tad isp 8 mg33.89 20 ✓ Zofran Zydis Tab disp 8 mg33.89 20 ✓ Zofran Zydis Tab disp 8 mg35.9 20.43 10 ✓ Zofran Zydis Tab disp 8 mg35.9 20 ✓ Zofran Zydis Tab disp 8 mg35.9 20 ✓ Zofran Zydis Tab disp 8 mg36.9 20 ✓ Zofran Zydis Tab disp 8 mg36.9 20 ✓ Zofran Zydis Tab disp 8 mg	All of the following:			-	-
3 The applicant must specify the underlying malignancy or chronic disease. Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment. HYOSCINE HYDROBROMIDE * Inj 400 µg per ml, 1 ml				nalignanc	cy or chronic disease; and
Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment. HIYOSCINE HYDROBROMIDE ** Inj 400 µg per ml, 1 ml 6.66 5 ✓ Mayne METOCLOPRAMIDE HYDROCHLORIDE ** Inj 400 µg per ml, 2 ml – Up to 5 inj available on a PSO			ents; and		
benefiting from treatment. HYOSCINE HYDROBROMIDE * Inj 400 µg per ml, 1 ml				-:	ware winter and the metions in
HYOSCINE HYDROBROMIDE ** Inj 400 µg per ml, 1 ml .6.66 5 ✓ Mayne METOCLOPRAMIDE HYDROCHLORIDE ** Inj 5 mg per ml, 2 ml – Up to 5 inj available on a PSO. .4.50 10 ✓ Metamide ** Inj 5 mg per ml, 2 ml – Up to 5 inj available on a PSO. .4.50 10 ✓ Pfizer ONDANSETRON – Retail pharmacy-Specialist a) Maximum of 12 tab per prescription; can be waived by Special Authority see SA0887 below b) Maximum of 6 tab per dispensing; can be waived by Special Authority see SA0887 below. c) Not more than one prescription per month; can be waived by Special Authority see SA0887 below. c) Not more than one prescription grant be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived via Access Exemption Criteria. Tab 4 mg		year where the trea	ument rem	ains app	ropriate and the patient is
** Inj 400 µg per ml, 1 ml 6.66 5 ✓ Mayne METOCLOPRAMIDE HYDROCHLORIDE ** Tab 10 mg 5.15 100 ✓ Pfizer ONDANSETRON - Retail pharmacy-Specialist 4.50 10 ✓ Pfizer ONDANSETRON - Retail pharmacy-Specialist a) Maximum of 12 tab per prescription; can be waived by Special Authority see SA0887 below b) Maximum of 6 tab per dispensing; can be waived by Special Authority see SA0887 below. c) Not more than one prescription per month; can be waived by Special Authority see SA0887 below. c) Not more than one prescription; can be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived via Access Exemption Criteria. Tat 4 mg 17.18 10 ✓ Zofran Tab disp 4 mg					
METOCLOPRAMIDE HYDROCHLORIDE \$.15 10 ✓ Metamide ** Tab 10 mg		8 66	5	🖌 M	lavne
* Tab 10 mg 5.15 100 ✓ Metamide * Inj 5 mg per ml, 2 ml – Up to 5 inj available on a PSO 4.50 10 ✓ Pfizer ONDANSETRON – Retail pharmacy-Specialist a) Maximum of 12 tab per prescription; can be waived by Special Authority see SA0887 below b) Maximum of 6 tab per dispensing; can be waived by Special Authority see SA0887 below c) Not more than one prescription per month; can be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived via Access Exemption Criteria. Tab 4 mg 17.18 10 ✓ Zofran Tab disp 4 mg 17.18 10 ✓ Zofran Zydis Tab disp 8 mg 20.43 10 ✓ Zofran Zydis Tab disp 8 mg 20.43 10 ✓ Zofran Zydis PSA0887 Special Authority for Waiver of Rule Initial application from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy. PRecwal from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy. PROCHLORPERAZINE 5.97 50 * Tab 3 mg buccal 5.97 50 </td <td>, 101</td> <td>0.00</td> <td>5</td> <td>• 11</td> <td>layne</td>	, 101	0.00	5	• 11	layne
 * Inj 5 mg per ml, 2 ml – Up to 5 inj available on a PSO		E 1E	100		latamida
ONDANSETRON - Retail pharmacy-Specialist a) Maximum of 12 tab per prescription; can be waived by Special Authority see SA0887 below b) Maximum of 6 tab per dispensing; can be waived by Special Authority see SA0887 below. c) Not more than one prescription per month; can be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived via Access Exemption Criteria. Tab 4 mg					
a) Maximum of 12 tab per prescription; can be waived by Special Authority see SA0887 below b) Maximum of 6 tab per dispensing; can be waived by Special Authority see SA0887 below c) Not more than one prescription per month; can be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived by Special Authority see SA0887 below. d) Tab disp 4 mg			10	• -	
b) Maximum of 6 tab per dispensing; can be waived by Special Authority see SA0887 below c) Not more than one prescription per month; can be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived via Access Exemption Criteria. Tab 4 mg		pooial Authority coo	210997 ha	low	
 c) Not more than one prescription per month; can be waived by Special Authority see SA0887 below. d) The maximum of 6 tab per dispensing cannot be waived via Access Exemption Criteria. Tab 4 mg					
 d) The maximum of 6 tab per dispensing cannot be waived via Access Exemption Criteria. Tab 4 mg					V.
Tab 4 mg 17.18 10 ✓ Zofran Tab disp 4 mg 17.18 10 ✓ Zofran Zydis Tab 8 mg 33.89 20 ✓ Zofran Tab disp 8 mg 20.43 10 ✓ Zofran Zydis Tab disp 8 mg 20.43 10 ✓ Zofran Zydis Imitial application from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy. PROCHLORPERAZINE 5.97 50 * Tab 5 mg – Up to 30 tab available on a PSO 16.85 500 ✓ Antinaus * Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO 23.87 5 ✓ Stemetil * Suppos 25 mg 1.20 10 (6.24) Avomine TROPISETRON – Hospital pharmacy [HP3]-Specialist a) Maximum of 6 cap per prescription 4 Avomine					
Tab 8 mg	Tab 4 mg	17.18	10	✓ <u>∠</u>	ofran
Tab disp 8 mg 20.43 10 ✓ Zofran Zydis ▶SA0887 Special Authority for Waiver of Rule Initial application from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy. PROCHLORPERAZINE \$197 * Tab 3 mg buccal 5.97 (15.00) Buccastem * Tab 5 mg – Up to 30 tab available on a PSO 5.97 * Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO 25.81 10 ✓ Stemetil * Suppos 25 mg 23.87 5 ✓ Stemetil PROMETHAZINE THEOCLATE * 1.20 10 (6.24) Avomine TROPISETRON – Hospital pharmacy [HP3]-Specialist a) Maximum of 6 cap per prescription 1.20 10	1 5				
▶SA0887 Special Authority for Waiver of Rule Initial application from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy. PROCHLORPERAZINE \$197 50 * Tab 3 mg buccal 5.97 50 (15.00) Buccastem * Tab 5 mg – Up to 30 tab available on a PSO. 16.85 500 ✓ Antinaus * Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO. 25.81 10 ✓ Stemetil PROMETHAZINE THEOCLATE * 1.20 10 (6.24) Avomine TROPISETRON – Hospital pharmacy [HP3]-Specialist a) Maximum of 6 cap per prescription 1.20 10 10 10	5				
Initial application from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy. PROCHLORPERAZINE * Tab 3 mg buccal		20.43	10	<u>v</u> <u>z</u>	ofran Zydis
with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy. Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy. PROCHLORPERAZINE * Tab 3 mg buccal					
Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy. PROCHLORPERAZINE 5.97 50 * Tab 3 mg buccal 5.97 50 (15.00) Buccastem * Tab 5 mg - Up to 30 tab available on a PSO 16.85 500 ✓ Antinaus * Inj 12.5 mg per ml, 1 ml - Up to 5 inj available on a PSO 23.87 5 ✓ Stemetil PROMETHAZINE THEOCLATE 1.20 10 (6.24) Avomine TROPISETRON - Hospital pharmacy [HP3]-Specialist a) Maximum of 6 cap per prescription 1.20 10 1.20					
highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy. PROCHLORPERAZINE * Tab 3 mg buccal 5.97 50 (15.00) Buccastem * Tab 5 mg - Up to 30 tab available on a PSO					
PROCHLORPERAZINE 5.97 50 * Tab 3 mg buccal 5.97 50 (15.00) Buccastem * Tab 5 mg - Up to 30 tab available on a PSO					
* Tab 3 mg buccal 5.97 50 (15.00) Buccastem * Tab 5 mg - Up to 30 tab available on a PSO					
(15.00) Buccastem * Tab 5 mg - Up to 30 tab available on a PSO		5.97	50		
* Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO				В	uccastem
* Suppos 25 mg 23.87 5 ✓ Stemetil PROMETHAZINE THEOCLATE 10 10 10 * Tab 25 mg 10 10 (6.24) Avomine 10 TROPISETRON - Hospital pharmacy [HP3]-Specialist a) Maximum of 6 cap per prescription 10	* Tab 5 mg – Up to 30 tab available on a PSO		500	🖌 A	Intinaus
PROMETHAZINE THEOCLATE * Tab 25 mg1.20 10 (6.24) Avomine TROPISETRON – Hospital pharmacy [HP3]-Specialist a) Maximum of 6 cap per prescription	* Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO	25.81	10		
 Tab 25 mg	* Suppos 25 mg	23.87	5	🗸 S	temetil
(6.24) Avomine TROPISETRON – Hospital pharmacy [HP3]-Specialist a) Maximum of 6 cap per prescription					
TROPISETRON – Hospital pharmacy [HP3]-Specialist a) Maximum of 6 cap per prescription	* Tab 25 mg	1.20	10		
a) Maximum of 6 cap per prescription		(6.24)		A	vomine
	b) Maximum of 3 cap per dispensing				
c) Not more than one prescription per month. Cap 5 mg		77 /1	5	م <i>ا</i>	lavohan
	Cap 5 mg		5	₩ IV	

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Antiparkinson Agents				
Dopamine Agonists and Related Agents				
AMANTADINE HYDROCHLORIDE				
▲ Cap 100 mg	47.81	60	✓ <u>Sy</u>	<u>mmetrel</u>
APOMORPHINE HYDROCHLORIDE	50.40	-		
▲ Inj 10 mg per ml, 2 ml		5		PO-go S29 Domine
▲ Inj 10 mg per ml, 1 ml		5	✓ Ma	
(APO-go s29 Inj 10 mg per ml, 2 ml to be delisted 1 October 200 (Mayne Inj 10 mg per ml, 1 ml to be delisted 1 October 2009)	09)			-
BROMOCRIPTINE MESYLATE				
* Tab 2.5 mg		100	V Al	•
* Tab 10 mg	120.86	100	🖌 Al	Bromocriptine
		100		Bromocriptine
* Cap 5 mg	60.43	100	🖌 Ap	bo- Bromocriptine S29
(Alpha-Bromocriptine Tab 10 mg to be delisted 1 March 2010)				
ENTACAPONE				
▲ Tab 200 mg	116.00	100	✓ <u>Co</u>	omtan
LEVODOPA WITH BENSERAZIDE				
* Tab dispersible 50 mg with benserazide 12.5 mg		100		adopar Dispersible
* Cap 50 mg with benserazide 12.5 mg	8.00	100		adopar 62.5
* Cap 100 mg with benserazide 25 mg		100		adopar 125
* Cap long-acting 100 mg with benserazide 25 mg		100		adopar HBS
* Cap 200 mg with benserazide 50 mg	25.00	100	🖌 Ma	adopar 250
LEVODOPA WITH CARBIDOPA	40.00		4.01	
* Tab 100 mg with carbidopa 25 mg		50 100		ndopa nemet
* Tab long-acting 200 mg with carbidopa 50 mg - Retai		100	• 01	nemet
pharmacy-Specialist		100	🖌 Si	nemet CR
* Tab 250 mg with carbidopa 25 mg	57.50	100	🖌 Si	nemet
LISURIDE HYDROGEN MALEATE				
▲ Tab 200 μg	27.50	30	V Do	opergin
PERGOLIDE			4.5	
▲ Tab 0.25 mg ▲ Tab 1 mg		100 100	✓ <u>Pe</u> ✓ Pe	
ů		100	• <u>re</u>	
ROPINIROLE HYDROCHLORIDE Tab 0.25 mg	7.90	84	🖌 Ro	nin
▲ Tab 1 mg		84		
▲ Tab 2 mg		84	✓ Ro	
▲ Tab 5 mg	90.00	84	✓ <u>Ro</u>	<u>opin</u>
SELEGILINE HYDROCHLORIDE	10.55		4 -	o
* Tab 5 mg	16.06	100	🗸 Ap	oo-Selegiline

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

(Subsidy Manufacturer's Price) \$	Per	Fully Subsidised	
 TOLCAPONE – Retail pharmacy-Specialist prescription Specialist must be a neurologist, geriatrician or general physicia ▲ Tab 100 mg 		100	• 1	Fasmar
Anticholinergics				
BENZTROPINE MESYLATE Tab 2 mg Inj 1 mg per ml, 2 ml a) Up to 5 inj available on a PSO b) Only on a PSO		60 5		Benztrop Cogentin
ORPHENADRINE HYDROCHLORIDE Tab 50 mg	31.93	250	~ [Disipal
PROCYCLIDINE HYDROCHLORIDE Tab 5 mg	7.40	100	•	Kemadrin
Antipsychotics				

Guidelines for the use of atypical antipsychotic agents

Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical antipsychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional antipsychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.

General

AMISULPRIDE

Tab 100 mg Tab 200 mg Tab 400 mg Oral liq 100 mg per ml	97.03 185.44	30 60 60 60 ml	 ✓ Solian ✓ Solian ✓ Solian ✓ Solian
ARIPIPRAZOLE - Special Authority see SA0920 below	 Retail pharmacy 		
Tab 10 mg		30	🖌 Abilify
Tab 15 mg		30	Abilify
Tab 20 mg	213.42	30	Abilify
Tab 30 mg		30	🖌 Abilify

SA0920 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 Patient is suffering from schizophrenia or related psychoses; and
- 2 Either:
 - 2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or
 - 2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy (Manufacturer's Pric	e)	Fully Brand or Subsidised Generic
	\$	Per	 Manufacturer
CHLORPROMAZINE HYDROCHLORIDE			
Tab 10 mg – Up to 30 tab available on a PSO		100	Largactil
Tab 25 mg – Up to 30 tab available on a PSO		100	✓ Largactil
Tab 100 mg – Up to 30 tab available on a PSO		100	 Largactil
Inj 25 mg per ml, 2 ml - Up to 5 inj available on a PSO		10	 Largactil
CLOZAPINE – Hospital pharmacy [HP4]			
Tab 25 mg	13.37	50	Clozaril
	26.74	100	✓ Clozaril
	6.69	50	✓ Clopine
	13.37	100	✓ Clopine
Tab 50 mg		50	✓ Clopine
	17.33	100	✓ Clopine
Tab 100 mg		50	Clozaril
0	69.30	100	Clozaril
	17.33	50	Clopine
	34.65	100	✓ Clopine
Tab 200 mg		50	Clopine
Ŭ	69.30	100	✓ Clopine
Suspension 50 mg per ml		100 ml	✓ Clopine
HALOPERIDOL			
Tab 500 µg – Up to 30 tab available on a PSO	4 93	100	Serenace
Tab 1.5 mg – Up to 30 tab available on a PSO		100	✓ Serenace
Tab 5 mg – Up to 30 tab available on a PSO		100	✓ Serenace
Oral lig 2 mg per ml – Up to 200 ml available on a PSO		100 ml	✓ Serenace
Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO		10	✓ Serenace
LITHIUM CARBONATE			
Tab 250 mg	26.10	500	Lithicarb
Tab 400 mg		100	✓ Lithicarb
Tab long-acting 400 mg		100	
Cap 250 mg		100	✓ Douglas
		100	Douglas
METHOTRIMEPRAZINE			<i>.</i>
Tab 25 mg		100	✓ Nozinan
Tab 100 mg		100	Nozinan
Inj 25 mg per ml, 1 ml	73.68	10	Nozinan
OLANZAPINE - Special Authority see SA0741 below - Retail p	harmacy		
Tab 2.5 mg	51.07	28	 Zyprexa
Tab 5 mg		28	 Zyprexa
Tab 10 mg		28	Zyprexa

➡SA0741 Special Authority for Subsidy

Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following:

1 Patient presents with first episode schizophrenia or related psychoses; or

2 Both:

2.1 Patient suffering from schizophrenia and related psychoses or acute mania in bipolar disorder who is likely to benefit from antipsychotic treatment; and

2.2 Either:

2.2.1 An effective dose of risperidone had been trialled and has been discontinued because of unacceptable side effects; or

	Subsidy (Manufacturer's Pri \$	ice) Su Per	Fully Brand or ubsidised Generic ✓ Manufacturer
continued			
2.2.2 An effective dose of risperidone had been	n trialled and has bee	en discontin	ued because of inadequate clinica
response after 4 weeks; or 3 The patient has suffered from an acute episode of sch short-acting intra-muscular injection.	izophrenia or bipola	r mania and	has been treated with olanzapin
Renewal only from a psychiatrist. Approvals valid for 2 years w from treatment.	here the treatment re	emains appr	opriate and the patient is benefitin
Note: Initial prescriptions to be written by psychiatrists or psy General Practitioners.	chiatric registrars ar	nd subseque	ent prescriptions can be written b
PERICYAZINE			
Tab 2.5 mg		100	✓ Neulactil
Tab 10 mg		100	Neulactil
QUETIAPINE			
Tab 25 mg	20.62	90	Quetapel
	46.20	60	Seroquel
Tab 100 mg		90	V Quetapel
T 000	92.40	60	Seroquel
Tab 200 mg		90	Quetapel
T-h 000 mm	158.76	60	Seroquel
Tab 300 mg	119.25 267.12	90 60	 Quetapel Seroquel
	207.12	00	Seloquel
RISPERIDONE			
Tab 0.5 mg		20	✓ Ridal
	15.60	60	✓ Ridal
Tele 4 wear	5.20	20	✓ Risperdal
Tab 1 mg		60	✓ Ridal
Top 0 mg	61 50	60	 Risperdal Ridal
Tab 2 mg	01.55	60	✓ Risperdal
Tab 3 mg	00.30	60	✓ Ridal
		00	✓ Risperdal
Tab 4 mg	123.05	60	✓ Ridal
	120.00	00	✓ Risperdal
Oral liquid 1 mg per ml		30 ml	✓ Risperdal
TRIFLUOPERAZINE HYDROCHLORIDE			
Tab 1 mg	0.92	100	✓ Stelazine S29
Tab 2 mg		100	✓ Stelazine S29
Tab 5 mg		100	✓ Stelazine S29
ZIPRASIDONE – Subsidy by endorsement			
Ziprasidone is subsidised for patients suffering from schiz risperidone or quetiapine that has been discontinued, or is effects or inadequate response, and the prescription is end	in the process of bei		
Cap 20 mg		60	Zeldox
Cap 40 mg		60	✓ Zeldox ✓ Zeldox
Cap 40 mg		60	✓ Zeldox
Cap 80 mg		60	✓ Zeldox
	020100		
ZUCLOPENTHIXOL HYDROCHLORIDE Tab 10 mg		100	Clopixol
· / • · · · · ·			

	Subsidy (Manufacturer's Price) \$	Subsic Per	Fully lised	Brand or Generic Manufacturer
Depot Injections				
FLUPENTHIXOL DECANOATE Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	20.90	5	🖌 Fl	luanxol luanxol luanxol
FLUPHENAZINE DECANOATE Inj 12.5 mg per 0.5 ml, 0.5 ml – Up to 5 inj available on a PSO Inj 25 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	27.90	5	✔ M	lodecate lodecate lodecate
HALOPERIDOL DECANOATE Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO		-		aldol aldol Concentrate
PIPOTHIAZINE PALMITATE Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO				iportil iportil
RISPERIDONE – Special Authority see SA0926 below – Retail ph Microspheres for injection 25 mg Microspheres for injection 37.5 mg Microspheres for injection 50 mg	175.00 230.00	1	✔ R	isperdal Consta isperdal Consta isperdal Consta

SA0926 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 The patient has schizophrenia or other psychotic disorder; and
- 2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
- 3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had less than 12 months treatment with risperidone microspheres; and
- 1.2 There is no clinical reason to discontinue treatment; or
- 2 The initiation of risperidone microspheres has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone microspheres.

Note: Risperidone microspheres should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialing risperidone microspheres.

ZUCLOPENTHIXOL DECANOATE

Inj 200 mg per ml, 1 ml – Up to 5 inj available on a PSO19.8	30 5	Clopixol
Orodispersible Antipsychotics		
OLANZAPINE - Special Authority see SA0739 on the next page - Retail ph	narmacy	
Wafer 5 mg	19 28	Zyprexa Zydis
Wafer 10 mg204.3	37 28	Zyprexa Zydis

		Subsidy (Manufacturer's Price) \$	Subs Per	Fully idised	Brand or Generic Manufacturer
⇒SA0	739 Special Authority for Subsidy				
nitial a	pplication only from a psychiatrist. Approvals valid for 1 y	ear for applications m	eeting the	followi	ng criteria:
All of th	e following:		-		-
11	he patient meets the current criteria for standard olanzap	ine tablets; and			
21	The patient is unable to take standard olanzapine tablets, o	r once stabilized refus	es to take	olanza	pine tablets; or the patient
i	s non-adherent to oral therapy with standard olanzapine ta	blets; and			
3 1	The patient is under direct supervision for administration of	f medicine.			
Renewa	al only from a psychiatrist. Approvals valid for 1 year for ap	plications meeting the	e following	criteria	1:
Both:			-		
11	The patient is unable to take standard olanzapine tablets, o	or once stabilized refus	ses to take	olanza	apine tablets; and
2 1	The patient is under direct supervision for administration of	medicine.			
Note: Ir	nitial prescriptions to be written by psychiatrists and sub-	sequent prescriptions	can be w	ritten b	v psychiatric registrars o

Note: Initial prescriptions to be written by psychiatrists and subsequent prescriptions can be written by psychiatric registrars or General Practitioners.

RISPERIDONE - Special Authority see SA0927 below - Retail pharmacy

Orally-disintegrating tablets 0.5 mg	' '	Risperdal Quicklet
Orally-disintegrating tablets 1 mg		Risperdal Quicklet
Orally-disintegrating tablets 2 mg		 Risperdal Quicklet

SA0927 Special Authority for Subsidy

Initial application - (Acute situations) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

1 In А

R В

1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and

2 The patient is under direct supervision for administration of medicine.

Initial application — (Chronic situations) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.
- Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Note: Risperdal Quicklets cost significantly more than risperidone tablets and should only be used where necessary.

Anxiolytics

ALPRAZOLAM – Month Restriction		
Tab 250 μg3.25	50	Arrow-Alprazolam
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
Tab 500 μg4.30	50	Arrow-Alprazolam
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
Tab 1 mg7.85	50	Arrow-Alprazolam
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
BUSPIRONE HYDROCHLORIDE - Special Authority see SA0863 on the next page	- Retail pl	harmacy
Month Restriction		
Tab 5 mg28.00	100	Pacific Buspirone
Tab 10 mg17.00	100	Pacific Buspirone

	Subsidy (Manufacturer's Price) \$	Su Per	Fully bsidised	Brand or Generic Manufacturer
SA0863 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid both:	for 2 years for application	ations me	eting the	e following criteria:
1 For use only as an anxiolytic; and				
2 Other agents are contraindicated or have failed.				
Renewal from any relevant practitioner. Approvals valid for 2 ye benefiting from treatment.	ars where the treatn	nent rem	ains app	ropriate and the patient is
DIAZEPAM				
Tab 2 mg – Month Restriction	8.40	500		ro-Pam
	11.44		🗸 A	rrow-Diazepam
\$ Safety cap for extemporaneously compounded oral liquid			4 -	_
Tab 5 mg – Month Restriction	5.00 13.71	250		ro-Pam
\$ Safety cap for extemporaneously compounded oral liquid		500	V A	rrow-Diazepam
Tab 10 mg – Month Restriction		100	V P	ro-Pam
‡ Safety cap for extemporaneously compounded oral liquid		100	• •	
(Pro-Pam Tab 2 mg to be delisted 1 February 2010)				
(Pro-Pam Tab 5 mg to be delisted 1 March 2010)				
LORAZEPAM – Month Restriction				
Tab 1 mg		250	V A	tivan
‡ Safety cap for extemporaneously compounded oral liquid				
Tab 2.5 mg		100	V A	tivan
‡ Safety cap for extemporaneously compounded oral liquid	preparations.			
OXAZEPAM – Month Restriction	4.00	100		
Tab 10 mg		100	0	x-Pam
\$ Safety cap for extemporaneously compounded oral liquid	(5.50) preparations		0	x-Falli
Tab 15 mg		100		
	(7.60)		0	x-Pam
‡ Safety cap for extemporaneously compounded oral liquid				

Multiple Sclerosis Treatments

➡SA0855 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC).

Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

These agents will NOT be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their clinicians by courier.

Prescribers must send quarterly prescriptions for approved patients to the MSTAC coordinator.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, or 20 mg glatiramer acetate daily will be subsidised.

Appeals against MSTAC's decision and/or the processing of any application may be lodged with the MSTAC coordinator. Concerns that cannot be or have not been adequately addressed by MSTAC will be forwarded to a separate Appeal Committee if necessary. Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. The MSTAC coordinator should be notified of the change and a new prescription provided.

Entry Criteria

- Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis should as a rule include MRI confirmation. For patients diagnosed before MRI was widely utilised in New Zealand, confirmation of diagnosis via clinical assessment and laboratory/ancillary data must be provided; and
- 2) patients must have active relapsing MS (confirmed by MR scan where necessary) with or without underlying progression; and
- 3) patients must have either:
 - a) EDSS score 2.5 5.5 with 2+ relapses:
 - experienced at least 2 significant relapses of MS in the previous 12 months, and
 - an EDSS score of between 2.5 and 5.5 inclusive; or
 - b) EDSS score 2.0 with 3+ relapses:
 - experienced at least 3 significant relapses of MS in the previous 12 months, and
 - an EDSS score of 2.0; and
- 4) Each relapse must:
 - a) be confirmed by a neurologist or general physician (the patient may not necessarily have been seen during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) follow a period of stability of at least one month;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke functional systems scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T>37.5 $^{\circ}$ C); and
- 5) applications must be made at least four weeks after the date of the onset of the last known relapse; and
- 6) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate (see criteria for stopping).
- 7) applications must be submitted to the Multiple Sclerosis Treatment Assessment Committee (MSTAC) by the patient's neurologist or a general physician; and
- 8) patients must agree (via informed consent) to co-operate if as a result of their meeting the stopping criteria, funding is withdrawn. Patients must agree to the collection of clinical data relating to their MS and use of those data by PHARMAC; and
- 9) patients must agree to allow clinical data to be collected and reviewed by MSTAC annually for each year in which they receive funding for beta-interferon or glatiramer acetate.

Stopping Criteria

- Confirmed progression of disability that is sustained for three months after a minimum of one year of treatment. Progression
 of disability is defined as either an increase of 1 EDSS point from the starting EDSS or an increase in EDSS score to 6.0 or
 more; or
- 2) stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment); or
- 3) pregnancy and/or lactation; or
- 4) within the 12 month approval year, intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or
- 5) non-compliance with treatment, including refusal to undergo annual assessment or refusal to allow the results of the assessment to be submitted to MSTAC; or
- 6) patients may, subject to conclusions drawn from published evidence available at the time, be excluded if they develop a high titre of neutralising anti-bodies to beta-interferon or glatiramer acetate.

Subsidy (Manufacturer's Price \$) Per	Fully Brand or Subsidised Generic ✓ Manufacturer
GLATIRAMER ACETATE – Special Authority see SA0855 on page 125	-	
Inj 20 mg prefilled syringe	28	Copaxone
NTERFERON BETA-1-ALPHA – Special Authority see SA0855 on page 125		
Inj 6 million iu prefilled syringe	4	Avonex
Inj 6 million iu per vial1,329.65	4	✓ Avonex
NTERFERON BETA-1-BETA - Special Authority see SA0855 on page 125		
Inj 8 million iu per 1 ml	15	Betaferon
· ·		
Sedatives and Hypnotics		
ORMETAZEPAM – Month Restriction		
Tab 1 mg3.11	30	
(23.50)		Noctamid
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
/IDAZOLAM		
Tab 7.5 mg – Month Restriction10.38	100	
(25.00)		Hypnovel
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
Inj 1 mg per ml, 5 ml10.75	10	 Hypnovel
(14.73)	-	Pfizer
Inj 5 mg per ml, 3 ml	5	Hypnovel Pfizer
(19.64)		FIIZEI
ITRAZEPAM – Month Restriction	400	
Tab 5 mg	100	Nitrodoo
(4.65) ‡ Safety cap for extemporaneously compounded oral liquid preparations.		Nitrados
EMAZEPAM – Month Restriction Tab 10 mg0.83	25	Normison
‡ Safety cap for extemporaneously compounded oral liquid preparations.	20	
RIAZOLAM – Month Restriction		
Tab 125 µg	100	
(6.50)	100	Hypam
‡ Safety cap for extemporaneously compounded oral liquid preparations.		Typan
Таb 250 µg4.10	100	
(7.20)		Hypam
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
OPICLONE – Month Restriction		
Tab 7.5 mg21.02	500	Apo-Zopiclone
Other CNS Agents		
TOMOXETINE – Special Authority see SA0951 on the next page – Retail pharmacy		
Cap 10 mg 107.03	28	✓ Strattera
Cap 18 mg	28 28	 Strattera Strattera
Cap 25 mg107.03 Cap 40 mg107.03	28 28	Strattera
Cap 40 mg	28	✓ Strattera
Cap 80 mg	28	✓ Strattera
Cap 100 mg	28	✓ Strattera

	Subsidy (Manufacturer's Price) \$	Full Subsidise Per •	
►SA0951 Special Authority for Subsidy			
Initial application from any relevant practitioner. Approvals v	alid for 6 months for appli	cations meeting	g the following criteria:
All of the following:	D : 1 \ 1		
1 Patient has ADHD (Attention Deficit and Hyperactivity	Disorder) diagnosed acco	ording to DSM-I	V or ICD 10 criteria; and
2 Once-daily dosing; and3 Any of the following:			
 3.1 Treatment with a subsidised formulation of a adverse reactions or where the combination or unacceptable medical risk; or 3.2 Treatment with a subsidised formulation of a s 	f subsidised stimulant tre	eatment with ar	nother agent would pose an
there is a significant risk of diversion with subsi			-morbid substance abuse of
3.3 An effective dose of a subsidised formulation of	1.77		aan discontinued because of
inadequate clinical response; and			
4 The patient will not be receiving treatment with atom	oxetine in combination w	ith a subsidise	d formulation of a stimulant.
except for the purposes of transitioning from subsidise			
Renewal from any relevant practitioner. Approvals valid for	2 years where the treatm	nent remains ap	opropriate and the patient is
benefiting from treatment.			
Note: A "subsidised formulation of a stimulant" refers to cu	, , , , , , , , , , , , , , , , , , , ,		ochloride tablet formulations
(immediate-release, sustained-release and extended-release			
DEXAMPHETAMINE SULPHATE - Special Authority see SA	.0907 below – Retail phari	macy	
Only on a controlled drug form Tab 5 mg	17.00	100	PSM
Tab 5 Hig		100	<u>r Swi</u>
 SA0907 Special Authority for Subsidy Initial application — (ADHD in patients 5 or over – new patients on the recommendation of a relevant specialist. Approvals va All of the following: ADHD (Attention Deficit and Hyperactivity Disorder) patients 	lid for 24 months for applie	cations meeting	
2 Diagnosed according to DSM-IV or ICD 10 criteria; an	d		
3 Either:			
3.1 Applicant is a paediatrician or psychiatrist; or			
3.2 Both:3.2.1 Applicant is a medical practitioner and c	onfirms that a relevant so	ocialist has hos	an consulted within the last of
years and has recommended treatment		cualist has Det	
3.2.2 Provide name of the recommending spe			
Initial application — (ADHD in patients 5 or over - patient		or dexamphet	amine for ADHD prior to 1
April 2008) only from a paediatrician, psychiatrist or medical			
valid for 24 months for applications meeting the following crite	eria:		
Both:			
 The treatment remains appropriate and the patient is b Either: 	penetiting from treatment;	and	
2.1 Applicant is a paediatrician or psychiatrist; or			
2.2 Both:			
2.2.1 Applicant is a medical practitioner and c	onfirms that a relevant sp	ecialist has bee	en consulted within the last 2

- 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
- 2.2.2 Provide name of the recommending specialist.

Initial application — (ADHD in patients under 5 – new patients) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both:

1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (ADHD in patients under 5 - patient has had an approval for dexamphetamine for ADHD in patients under 5 prior to 1 April 2008) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Narcolepsy – new patients) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Initial application — (Narcolepsy - patient has had an approval for dexampletamine for narcolepsy prior to 1 April 2008) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both:

1 The treatment remains appropriate and the patient is benefiting from treatment; and

2 Either:

2.1 Applicant is a paediatrician or psychiatrist; or

2.2 Both:

- 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
- 2.2.2 Provide name of the recommending specialist.

Note: If the patient had an approval for dexampletamine for ADHD prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If the patient had an approval for dexamphetamine for ADHD in patients under 5 prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If the patient had an approval for dexampletamine for narcolepsy prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

DISULFIRAM

Tab 200 mg	24.30	100	 Antabuse
METHYLPHENIDATE HYDROCHLORIDE – Special Authority se Only on a controlled drug form	e SA0908 on the	next page –	Retail pharmacy
Tab immediate-release 5 mg	3.20	30	Rubifen
Tab immediate-release 10 mg		30	Ritalin
-			Rubifen
Tab immediate-release 20 mg	7.85	30	Rubifen
Tab sustained-release 20 mg		30	Rubifen SR
-	50.00	100	Ritalin SR

Subsidy		Fully	Brand or
(Manufacturer's Price)	9	Subsidised	Generic
\$	Per	~	Manufacturer

➡SA0908 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over – new patients) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Both:
 - 3.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
 - 3.2.2 Provide name of the recommending specialist.

Initial application — (ADHD in patients 5 or over - patient has had an approval for methylphenidate for ADHD prior to 1 April 2008) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both:

1 The treatment remains appropriate and the patient is benefiting from treatment; and

2 Either:

- 2.1 Applicant is a paediatrician or psychiatrist; or
- 2.2 Both:
 - 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
 - 2.2.2 Provide name of the recommending specialist.

Initial application — (ADHD in patients under 5 – new patients) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (ADHD in patients under 5 - patient has had an approval for methylphenidate for ADHD in patients under 5 prior to 1 April 2008) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Narcolepsy – new patients) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Initial application — (Narcolepsy - patient has had an approval for methylphenidate for narcolepsy prior to 1 April 2008) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Both:
 - 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
 - 2.2.2 Provide name of the recommending specialist.

Note: If the patient had an approval for methylphenidate for ADHD prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

Subsidy		Fully	Brand or	
(Manufacturer's Pric	e)	Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If the patient had an approval for methylphenidate for ADHD in patients under 5 prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If the patient had an approval for methylphenidate for narcolepsy prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

30

Concerta

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE - Special Authority see SA0924 below - Retail pharmacy

11	Only on a controlled drug for
	Tab extended-release 18 mg
6E 11	Tab autondod rologog 07 mg

Tab extended-release 27 mg65.44	30	Concerta
Tab extended-release 36 mg71.93	30	Concerta
Tab extended-release 54 mg86.24	30	Concerta
Cap modified-release 20 mg25.50	30	Ritalin LA
Cap modified-release 30 mg	30	Ritalin LA
Cap modified-release 40 mg	30	Ritalin LA

➡SA0924 Special Authority for Subsidy

Initial application only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder); and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Both:
 - 3.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
 - 3.2.2 Provide name of the recommending specialist; and
- 4 Either:
 - 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
 - 4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

Renewal only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Both:
 - 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
 - 2.2.2 Provide name of the recommending specialist.

NALTREXONE HYDROCHLORIDE - Special Authority see SA0909 on the next page - Retail pharmacy

Tab 50 mg						
	Tab 50 mg	 	 .180.00	30	V	' <u>ReVia</u>

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

SA0909 Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and
- 2 Applicant works in a community Alcohol and Drug Service contracted to one of the 21 District Health Boards or accredited

against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard. Renewal from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Compliance with the medication (prescriber determined); and
- 2 Any of the following:
 - 2.1 Patient is still unstable and requires further treatment; or
 - 2.2 Patient achieved significant improvement but requires further treatment; or
 - 2.3 Patient is well controlled but requires maintenance therapy.

The patient may not have had more than 1 prior approval in the last 12 months.

TETRABENAZINE

Tab 25 mg	Гаb 25 mg		112	Xenazine 25
-----------	-----------	--	-----	-------------

	Subsidy (Manufacturer's \$	Price) Sub	Fully sidised	Brand or Generic Manufacturer
Chemotherapeutic Agents	Ψ			
Alkylating Agents				
BUSULPHAN – PCT – Retail pharmacy-Specialist	17.00	100		
Tab 2 mg		100	V M	yleran
CARBOPLATIN – PCT only – Specialist	10.00			and a set of the File second
Inj 10 mg per ml, 5 ml		1		arboplatin Ebewe
Inj 10 mg per ml, 15 ml		1 1		arboplatin Ebewe
Inj 10 mg per ml, 45 ml Inj 10 mg per ml, 100 ml		1		arboplatin Ebewe arboplatin Ebewe
Inj 1 mg for ECP		1 mg	✓ B	
, .	0.13	i ng	V D	axter
CARMUSTINE – PCT only – Specialist			4 -	
Inj 100 mg		1	V B	
Inj 100 mg for ECP	204.13	100 mg OP	🗸 В	axter
CHLORAMBUCIL – PCT – Retail pharmacy-Specialist				
Tab 2 mg	22.35	25	🖌 Li	eukeran FC
CISPLATIN – PCT only – Specialist				
Inj 1 mg per ml, 50 ml	19.00	1	V C	isplatin Ebewe
			V M	
Inj 1 mg per ml, 100 ml		1		isplatin Ebewe
3 3 5 5 5 5			V M	•
Inj 1 mg for ECP	0.46	1 mg		axter
CYCLOPHOSPHAMIDE		-		
Tab 50 mg – PCT – Retail pharmacy-Specialist	25 71	50		vcloblastin
Inj 1 g – PCT – Retail pharmacy-Specialist		1		ndoxan
	127.80	6		ytoxan
Inj 2 g – PCT only – Specialist		1		ndoxan
Inj 1 mg for ECP – PCT only – Specialist		1 mg		axter
, , , ,				
FOSFAMIDE – PCT only – Specialist	06.00	1	1 L	oloxan
lnj 1 g lnj 2 g		1		oloxan
Inj 1 mg for ECP		1 mg		axter
	0.10	i ng	• 0	axter
LOMUSTINE – PCT only – Specialist				
Cap 10 mg		20		eeNU
Cap 40 mg		20	VC	eeNU
MELPHALAN				
Tab 2 mg – PCT – Retail pharmacy-Specialist		25	· · ·	lkeran
Inj 50 mg – PCT only – Specialist	52.15	1	🗸 A	lkeran
OXALIPLATIN - PCT only - Specialist - Special Authority se	e SA0900 on the	next page		
Inj 50 mg		1	🖌 E	loxatin
Inj 100 mg		1	🖌 E	loxatin
Inj 1 mg for ECP	4.36	1 mg	🖌 В	axter

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
---	-----	---------------------	-------------------------------------	--

SA0900 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Fither:

1 Both:

- 1.1 The patient has metastatic colorectal cancer; and
- 1.2 To be used for first or second line use as part of a combination chemotherapy regimen; or

2 Both:

- 2.1 The patient has stage III (Duke's C) colorectal* cancer; and
- 2.2 Adjuvant oxaliplatin to be given in combination with a fluoropyrimidine (fluorouracil or capecitabine).

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

1 The patient requires continued therapy; or

2 The tumour has relapsed and requires re-treatment.

Note: Indications marked with * are Unapproved Indications, oxaliplatin is indicated for adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of the primary tumour.

THIOTEPA – PCT only – Specialist

Inj 15 mgCBS	1	✓ Bedford S29
Antimetabolites		
CALCIUM FOLINATE Tab 15 mg – PCT – Hospital pharmacy [HP3]-Specialist63.89 Inj 3 mg per ml, 1 ml – PCT – Hospital pharmacy [HP1]-	10	🗸 Mayne
Specialist	5	Mayne
Inj 50 mg – PCT – Hospital pharmacy [HP1]-Specialist24.50	5	Calcium Folinate <u>Ebewe</u>
Inj 100 mg – PCT only – Specialist9.75	1	 Calcium Folinate Ebewe
Inj 300 mg – PCT only – Specialist	1	 Calcium Folinate Ebewe
Inj 1 g – PCT only – Specialist100.00	1	 Calcium Folinate Ebewe
Inj 1 mg for ECP – PCT only – Specialist0.10	1 mg	Baxter
CAPECITABINE - Hospital pharmacy [HP1]-Specialist - Special Authority see SA	A0869 below	
Tab 150 mg 115.00 Tab 500 mg	60 120	✔ Xeloda ✔ Xeloda

SA0869 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following:

- 1 The patient has advanced gastrointestinal malignancy; or
- 2 The patient has metastatic breast cancer*; or
- 3 The patient has stage III (Duke's stage C) colorectal*# cancer and undergone surgery; or
- 4 Both:
 - 4.1 The patient has poor venous access or needle phobia*; and
 - 4.2 The patient requires a substitute for single agent fluoropyrimidine*.

Renewal only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

A)	Subsidy /Ianufacturer's Pi \$	rice) Su Per	Fully bsidised	Brand or Generic Manufacturer
continued				
1 The patient requires continued therapy; or				
2 The tumour has relapsed and requires re-treatment.				
Note: Indications marked with * are Unapproved Indications, # capec	itabine is appr	oved for stage	e III (Duk	(e's stage C) colon cance
CLADRIBINE – PCT only – Specialist				
Inj 2 mg per ml, 5 ml	873.00	1	🖌 Li	itak S29
Inj 1 mg per ml, 10 ml	.5,249.72	7	🖌 Lo	eustatin
Inj 10 mg for ECP	749.96	10 mg OP	🖌 В	axter
CYTARABINE		•		
Inj 100 mg – PCT – Retail pharmacy-Specialist	80.00	5	🖌 M	layne
ng too ng tot notal phantaoy opeolalist		0		harmacia
Inj 100 mg per ml, 5 ml – PCT – Retail pharmacy-Specialist	95.36	5		lavne
Inj 100 mg per ml, 10 ml – PCT – Retail pharmacy-Specialist		1	V M	
Inj 100 mg per ml, 20 ml – PCT only – Specialist		1	V M	
Inj 1 mg for ECP – PCT only – Specialist		1 mg		axter
Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist		100 mg OP		axter
LUDARABINE PHOSPHATE – PCT only – Specialist				
Tab 10 mg	650.25	15		ludara
Tab TO THY	867.00	20		ludara Oral
Ini 50 mg		5		ludara
Inj 50 mg for ECP	,	50 mg OP		axter
	200.00	JU IIIg OI	• 0	antei
LUOROURACIL SODIUM				
Inj 50 mg per ml, 10 ml – PCT only – Specialist		1		luorouracil Ebewe
Inj 50 mg per ml, 20 ml – PCT only – Specialist		1		luorouracil Ebewe
Inj 25 mg per ml, 100 ml – PCT only – Specialist		1		ayne
Inj 50 mg per ml, 50 ml – PCT only – Specialist		1		luorouracil Ebewe
Inj 50 mg per ml, 100 ml – PCT only – Specialist		1		luorouracil Ebewe
Inj 1 mg for ECP – PCT only – Specialist		1 mg	🗸 В	axter
GEMCITABINE HYDROCHLORIDE – PCT only – Specialist – Spe	cial Authority s	see SA0877 b	below	
lnj 1 g		1		emcitabine Ebewe
	349.20			emzar
Inj 200 mg		1		emcitabine Ebewe
	78.00			emzar
Inj 1 mg for ECP	0.26	1 mg	🖌 В	axter

➡SA0877 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or
- 2 The patient has advanced malignant mesothelioma*; or
- 3 The patient has advanced pancreatic carcinoma; or
- 4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*; or
- 5 The patient has advanced transitional cell carcinoma of the urothelial tract (locally advanced or metastatic).

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

1 The patient requires continued therapy; or

2 The tumour has relapsed and requires re-treatment.

Note: Indications marked with a * are Unapproved Indications.

	Subsidy (Manufacturer's Price) \$		Fully Subsidised	Brand or Generic Manufacturer
IRINOTECAN – PCT only – Specialist – Special Authority see SA	0878 below			
Inj 20 mg per ml, 2 ml	124.00	1	V (Camptosar
Inj 20 mg per ml, 5 ml	310.00	1	V (Camptosar
Inj 1 mg for ECP	3.19	l mg	🖌 E	Baxter

SA0878 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

1 The patient has metastatic colorectal cancer; and

- 2 Either:
 - 2.1 To be used for first or second line use as part of a combination chemotherapy regimen; or
 - 2.2 As single agent chemotherapy in fluropyrimidine-relapsed disease.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient requires continued therapy; or
- 2 The tumour has relapsed and requires re-treatment.

MERCAPTOPURINE - PCT - Retail pharmacy-Specialist

Tab 50 mg	25	Purinethol
METHOTREXATE		
* Tab 2.5 mg – PCT – Hospital pharmacy [HP3]-Specialist	30	Methoblastin
* Tab 10 mg – PCT – Hospital pharmacy [HP3]-Specialist	50	 Methoblastin
* Inj 2.5 mg per ml, 2 ml – PCT – Hospital pharmacy [HP1]-		
Specialist	5	Mayne
* Inj 25 mg per ml, 2 ml – PCT – Hospital pharmacy [HP1]-		
Specialist	5	Mayne
* Inj 25 mg per ml, 20 ml – PCT – Hospital pharmacy [HP1]-		
Specialist	1	Mayne
* Inj 100 mg per ml, 10 ml – PCT – Hospital pharmacy [HP1]-		
Specialist27.50	1	Methotrexate Ebewe
* Inj 100 mg per ml, 50 ml – PCT – Hospital pharmacy [HP1]-		
Specialist135.00	1	Methotrexate Ebewe
* Inj 1 mg for ECP – PCT only – Specialist0.09	1 mg	✓ Baxter
* Inj 5 mg intrathecal syringe for ECP – PCT only – Specialist4.73	5 mg OP	Baxter
THIOGUANINE – PCT – Hospital pharmacy [HP3]-Specialist		
Tab 40 mg97.16	25	Lanvis
Other Cytotoxic Agents		
AMSACRINE – PCT only – Specialist		
Inj 75 mgCBS	6	Amsidyl S29
ANAGRELIDE HYDROCHLORIDE - PCT only - Specialist - Special Authority see	e SA0879 on	the next page
Cap 0.5 mgCBS	100	V Agrylin S29

	Subsidy (Manufacturer's Pric \$	ce) Subs Per	Fully idised	Brand or Generic Manufacturer
►>SA0879 Special Authority for Subsidy Initial application only from a relevant specialist or medical pract valid for 12 months for applications meeting the following criteria: Both: 1 The patient has primary thrombocythaemia; and	itioner on the recor	mmendation o	of a rel	levant specialist. Approvals
 2 Either: 2.1 is at high risk (previous thromboembolic disease, bl. 2.2 is intolerant or refractory to hydroxyurea or interfero Renewal only from a relevant specialist or medical practitioner or 	n.		,.	ecialist. Approvals valid for
12 months where the treatment remains appropriate and the patie Note: It is recommended that treatment with anagrelide be initiate ARSENIC TRIOXIDE – PCT only – Specialist	d only on the recor			0
Inj 10 mg BLEOMYCIN SULPHATE – PCT only – Specialist Inj 15,000 iu		10 10	V B	AFT \$29
Inj 1,000 iu for ECP COLASPASE (L-ASPARAGINASE) – PCT only – Specialist Inj 10,000 iu		1,000 iu 1	✔ L	Baxter Leunase
Inj 10,000 iu for ECP DACARBAZINE – PCT only – Specialist Inj 200 mg Inj 200 mg for ECP	43.86	0,000 iu OP 1 200 mg OP	✓ N	3axter Nayne Baxter
DACTINOMYCIN (ACTINOMYCIN D) – PCT only – Specialist Inj 0.5 mg Inj 0.5 mg for ECP		1 0.5 mg OP	~ 0	Cosmegen Baxter
DAUNORUBICIN – PCT only – Specialist Inj 2 mg per ml, 10 ml Inj 5 mg per ml, 4 ml		1 1	✔ P	Pfizer S29 Navne
Inj 20 mg for ECP DOCETAXEL – PCT only – Specialist – Special Authority see S Inj 20 mg	99.00 2 A0880 below	20 mg OP	V B	axter axotere
Inj 20 mg Inj 80 mg Inj 1 mg for ECP	1,650.00	1 1 mg	VT	axotere axotere Baxter

➡SA0880 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

- Any of the following:
 - 1 Both:
 - 1.1 The patient has ovarian*, fallopian* or primary peritoneal cancer*; and
 - 1.2 Either:
 - 1.2.1 Has not received prior chemotherapy; or
 - 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or
 - 2 The patient has metastatic breast cancer; or
 - 3 Both:
 - 3.1 The patient has early breast cancer; and
 - 3.2 Docetaxel is to be given concurrently with trastuzumab; or
 - 4 Both:

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
continued				
4.1 The patient has non small-cell lung cancer; and4.2 Either:				
4.2.1 Has advanced disease (stage Illa or above);4.2.2 Is receiving combined chemotherapy and race				
5 Both: 5.1 The patient has small-cell lung cancer*; and				
5.2 Docetaxel is to be used as second-line therapy.	the recommendation	n of o	rolevent on	acialist Approvale valid fo
Renewal only from a relevant specialist or medical practitioner or I2 months for applications meeting the following criteria: Both:	i the recommendation	on of a	relevant spe	ecialist. Approvais valid ic
1 The patient has metastatic breast cancer, non small-cell lu 2 Either:	ng cancer, or small-	cell lung	g cancer*; a	and
2.1 The patient requires continued therapy; or2.2 The tumour has relapsed and requires re-treatment				
Note: indications marked with * are Unapproved Indications.				
DOXORUBICIN – PCT only – Specialist Inj 10 mg	8.80	1	V D	oxorubicin Ebewe
Inj 50 mg		1		oxorubicin Ebewe
Inj 100 mg		1	V D	oxorubicin Ebewe
Inj 200 mg		1	🖌 D	oxorubicin Ebewe
Inj 1 mg for ECP	0.87	1 mg	🖌 В	axter
EPIRUBICIN – PCT only – Specialist				
Inj 2 mg per ml, 5 ml		1		pirubicin Ebewe
lnj 2 mg per ml, 25 ml		1		pirubicin Ebewe
Inj 2 mg per ml, 50 ml		1		pirubicin Ebewe
Inj 2 mg per ml, 100 ml		1		pirubicin Ebewe
Inj 1 mg for ECP	1.90	1 mg	V B	axter
ETOPOSIDE	240 72	20		epesid
Cap 50 mg – PCT – Hospital pharmacy [HP3]-Specialist Cap 100 mg – PCT – Hospital pharmacy [HP3]-Specialist		20 10		epesid
Inj 20 mg per ml, 5 ml – PCT – Hospital pharmacy [HP1]-		10	• •	epesia
Specialist		1	V M	lavne
	612.20	10		epesid
Inj 1 mg for ECP – PCT only – Specialist	• • = • = •	1 mg		axter
TOPOSIDE PHOSPHATE – PCT only – Specialist		5		
Inj 100 mg (of etoposide base)	40.00	1	V F	topophos
Inj 1 mg (of etoposide base) for ECP		1 mg		axter
		i ing	• 0	antei
HYDROXYUREA – PCT – Retail pharmacy-Specialist	21.76	100	1	vdroo
Cap 500 mg		100	ΨΠ	ydrea
DARUBICIN HYDROCHLORIDE – PCT only – Specialist			<i>.</i> –	
Cap 5 mg		1		avedos
Cap 10 mg		1		avedos
Inj 5 mg		1		avedos
Inj 10 mg		1		avedos
Inj 1 mg for ECP		1 mg	V B	axter

	Subsidy		Fully Brand or
	(Manufacturer's F \$	Price) Su Per	Ibsidised Generic ✓ Manufacturer
SNA – PCT only – Specialist			
Tab 400 mg	168.30	50	Uromitexan
Tab 600 mg		50	✓ Uromitexan
Inj 100 mg per ml, 4 ml		15	✓ Uromitexan
Inj 100 mg per ml, 10 ml		15	✓ Uromitexan
Inj 1 mg for ECP		1 mg	✓ Baxter
FOMYCIN C – PCT only – Specialist		Ū	
lnj 2 mg		10	Mitomycin-C S29
Inj 10 mg		5	✓ Mitomycin-C S29
Inj 1 mg for ECP		1 mg	✓ Baxter
TOZANTRONE – PCT only – Specialist		-	
Inj 2 mg per ml, 5 ml		1	Mitozantrone Ebewe
Inj 2 mg per ml, 10ml		1	Mitozantrone Ebewe
Inj 2 mg per ml, 12.5 ml		1	Onkotrone
Inj 1 mg for ECP		1 mg	✓ Baxter
CLITAXEL – PCT only – Specialist		•	
Inj 30 mg	189 75	5	Paclitaxel Ebewe
Inj 100 mg		1	Paclitaxel Ebewe
Inj 150 mg		1	Paclitaxel Ebewe
Inj 300 mg		1	Paclitaxel Ebewe
Inj 600 mg		1	Paclitaxel Ebewe
Inj 1 mg for ECP		1 mg	✓ Baxter
NTOSTATIN (DEOXYCOFORMYCIN) - PCT only - Specia	list	-	
Inj 10 mg		1	Vipent S29
OCARBAZINE HYDROCHLORIDE - PCT only - Specialis	t		
Cap 50 mg		50	V Natulan S29
MOZOLOMIDE - Special Authority see SA0831 below - Ho	spital pharmacy [H	IP31	
Cap 5 mg		5	Temodal
Cap 20 mg		5	Temodal
Cap 100 mg		5	Temodal
1 0		5	Temodal
Cap 250 mg			

- 1 Patient has newly diagnosed glioblastoma multiforme; and
- 2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
- 3 Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m².

Notes: Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Reapplications will not be approved. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.

	ml, 5 ml	845.11	10	🖌 Vumon
	ECP		50 mg OP	 Baxter
	 PCT only – Specialist – Special Authority see SA trolled drug form 	.0882 on the	next page	
Cap 50 mg		490.00	28	 Thalidomide Pharmion

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

➡SA0882 Special Authority for Subsidy

Initial application — (for new patients) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

1 The patient has refractory, progressive or relapsed multiple myeloma; and

2 The patient has received prior chemotherapy.

Initial application — (for patients receiving thalidomide prior to 1 January 2006) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient was receiving treatment with thalidomide for multiple myeloma on or before 31 December 2005.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient has obtained a response from treatment during the initial approval period. Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

TRETINOIN - PCT only - Specialist

Cap 10 mg	100	 Vesanoid
VINBLASTINE SULPHATE		
Inj 10 mg – PCT – Retail pharmacy-Specialist137.50	5	Mayne
Inj 1 mg for ECP – PCT only – Specialist	1 mg	Baxter
VINCRISTINE SULPHATE		
Inj 1 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist	5	Mayne
Inj 1 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist	5	Mayne
Inj 1 mg for ECP – PCT only – Specialist21.46	1 mg	 Baxter
VINORELBINE - PCT only - Specialist - Special Authority see SA0901 below		
Inj 10 mg per ml, 1 ml24.00	1	Navelbine
42.00		Vinorelbine Ebewe
Inj 10 mg per ml, 5 ml120.00	1	Navelbine
210.00		Vinorelbine Ebewe
Inj 1 mg for ECP2.71	1 mg	Baxter

➡SA0901 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has metastatic breast cancer; or
- 2 The patient has non-small cell lung cancer (stage IIIa, or above); or
- 3 All of the following:
 - 3.1 The patient has stage IB-IIIA non-small cell lung cancer; and
 - 3.2 Vinorelbine is to be given as adjuvant treatment in combination with cisplatin; and
 - 3.3 The patient has good performance status (WHO/ECOG grade 0-1).

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient requires continued therapy; or
- 2 The tumour has relapsed and requires re-treatment.

Protein-tyrosine Kinase Inhibitors

DASATINIB - Special Authority see SA0976 on the next page

Tab 20 mg		60	Sprycel
Tab 50 mg	6,214.20	60	Sprycel
Tab 70 mg	7,692.58	60	 Sprycel

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

SA0976 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website <u>http://www.pharmac.govt.nz</u>, and prescriptions should be sent to:

The CML/GIST Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: mary.chesterfield@pharmac.govt.nz

Wellington

Special Authority criteria for CML - access by application

- a) Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase.
- b) Maximum dose of 140 mg/day for accelerated or blast phase, and 100 mg/day for chronic phase CML.
- c) Subsidised for use as monotherapy only.
- d) Initial approvals valid seven months.
- e) Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Note: Dasatinib is indicated for the treatment of adults with chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.

Guideline on discontinuation of treatment for patients with CML

- a) Prescribers should consider discontinuation of treatment if, after 6 months from initiating therapy, a patient did not obtain a haematological response as defined as any one of the following three levels of response:
 - 1) complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5×10^9 /L, platelets > 100×10^9 /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - 2) no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0×10^9 /L, platelets > 20×10^9 /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver).
- b) Prescribers should consider discontinuation of treatment if, after 18 months from initiating therapy, a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.

IMATINIB MESYLATE - Special Authority see SA0643 below

Tab 100 mg2,400.00 60 🗸 Glivec

➡SA0643 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz, and prescriptions should be sent to:

The CML/GIST Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: mary.chesterfield@pharmac.govt.nz
Mollington	

Wellington

Special Authority criteria for CML – access by application

a) Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase.

b) Maximum dose of 600 mg/day for accelerated or blast phase, and 400 mg/day for chronic phase CML.

c) Subsidised for use as monotherapy only.

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

- d) Initial approvals valid seven months.
- e) Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Guideline on discontinuation of treatment for patients with CML

- a) Prescribers should consider discontinuation of treatment if after 6 months from initiating therapy a patient did not obtain a haematological response as defined as any one of the following three levels of response:
 - 1) complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5×10^{9} /L, platelets > 100×10^{9} /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - 2) no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0×10^9 /L, platelets > 20×10^9 /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver).
- b) Prescribers should consider discontinuation of treatment if after 18 months from initiating therapy a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.

Special Authority criteria for GIST – access by application

- a) Funded for patients:
 - 1) with a diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and
 - 2) who have immunohistochemical documentation of c-kit (CD117) expression by the tumour.
- b) Maximum dose of 400 mg/day.
- c) Applications to be made and subsequent prescriptions can be written by an oncologist.
- d) Initial and subsequent applications are valid for one year. The re-application criterion is an adequate clinical response to the treatment with imatinib (prescriber determined).

Endocrine Therapy

For GnRH ANALOGUES - refer to HORMONE PREPARATIONS, Trophic Hormones, page 79

ANASTROZOLE Tab 1 mg	146.46	30	✔ Arimidex
ANASTROZOLE-DP Tab 1 mg	29.50	30	DP-Anastrozole
BICALUTAMIDE – Special Authority see SA0941 below – Retail ph Tab 50 mg		30	✓ <u>Bicalox</u>
►>SA0941 Special Authority for Subsidy Initial application from any medical practitioner. Approvals valid advanced prostate cancer.	without further	r renewal unle	ess notified where the patient has
EXEMESTANE Tab 25 mg	175.00	30	✓ Aromasin
FLUTAMIDE – Hospital pharmacy [HP3]-Specialist Tab 250 mg	48.30	100	✓ Flutamin
LETROZOLE			
Tab 2.5 mg – Higher subsidy of \$200.00 per 30 with Special Authority see SA0943 on the next page	146.46 (200.00)	30	Femara

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

SA0943 Special Authority for Alternate Subsidy

Initial application — (New patients) only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria:

All of the following:

- 1 Patient is a postmenopausal woman; and
- 2 Patient has hormone receptor positive early breast cancer; and
- 3 Either:
 - 3.1 The patient has a very clear history of intolerance to tamoxifen; or
 - 3.2 The use of tamoxifen is contraindicated due to a history of thromboembolic disease.

Initial application — (Patient has had a Special Authority approval for letrozole prior to 1 December 2008) only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If the patient had an approval for letrozole prior to 1 December 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone Ministry of Health Sector Services on 0800 243 666 for clarification if needed.

MEGESTROL ACETATE - Retail pharmacy-Specialist

Tab 160 mg	74.25	30	✓ Megace
OCTREOTIDE (SOMATOSTATIN ANALOGUE) - Special Authorit	y see SA0563 below	– Hospital	pharmacy [HP3]
Inj 50 μg per ml, 1 ml		5	 Hospira
	43.50		 Sandostatin
Inj 100 µg per ml, 1 ml		5	Hospira
	81.00		 Sandostatin
Inj 500 µg per ml, 1 ml	175.00	5	Hospira
	399.00		 Sandostatin
LAR 10 mg prefilled syringe	1,772.50	1	 Sandostatin LAR
LAR 20 mg prefilled syringe	2,358.75	1	Sandostatin LAR
LAR 30 mg prefilled syringe	2,951.25	1	 Sandostatin LAR

➡SA0563 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following:

- 1 Both:
 - 1.1 Acromegaly; and
 - 1.2 Patient has failed surgery, radiotherapy, bromocriptine and other oral therapies; or
- 2 VIPomas and Glucagonomas for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 3 Both:
 - 3.1 Gastrinoma; and
 - 3.2 Either:
 - 3.2.1 Patient has failed surgery; or
 - 3.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
- 4 Both:
 - 4.1 Insulinomas; and
 - 4.2 Surgery is contraindicated or has failed; or
- 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or
- 6 Both:
 - 6.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
 - 6.2 Disabling symptoms not controlled by maximal medical therapy.

	Subsidy		Fully Brand or
	(Manufacturer's P \$	rice) Su Per	ıbsidised Generic ✔ Manufacturer
continued Note: The use of octreotide in patients with fistulae, oesophag funded as a Special Authority item Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment.			
TAMOXIFEN CITRATE * Tab 10 mg * Tab 20 mg		100 60 100	 ✔ Genox ✔ Tamoxifen Sandoz ✔ Genox
Immunosuppressants			
Cytotoxic Immunosuppressants			
AZATHIOPRINE – Retail pharmacy-Specialist * Tab 50 mg	25.00 (34.90)	100	 ✓ Azamun ✓ Thioprine Imuran
* Inj 50 mg	()	1	Imuran
 (Thioprine Tab 50 mg to be delisted 1 October 2009) MYCOPHENOLATE MOFETIL – Special Authority see SA0960 Tab 500 mg Cap 250 mg Powder for oral liq 1 g per 5 ml – Subsidy by endorsement . Mycophenolate powder for oral liquid is subsidised only prescription is endorsed accordingly. ⇒SA0960 Special Authority for Subsidy 		50 100 165 ml OP	 ✓ Cellcept ✓ Cellcept ✓ Cellcept
Initial application only from a relevant specialist. Approvals va the following criteria: Any of the following: 1 Renal transplant recipient; or 2 Heart transplant recipient; or 3 Liver transplant recipient; or 4 Patient has an organ transplant and has severe tophaced			
Immune Modulators			
ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Speci Inj 50 mg per ml, 5 ml		5	✔ ATGAM
RITUXIMAB – PCT only – Specialist – Special Authority see S Inj 100 mg per 10 ml vial Inj 500 mg per 50 ml vial Inj 1 mg for ECP	1,195.00 2,987.00	page 2 1 1 mg	 ✓ Mabthera ✓ Mabthera ✓ Baxter

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Out side		Euller	Duran di au	
Subsidy			Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	~	Manufacturer	

SA0961 Special Authority for Subsidy

Initial application — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.

Initial application — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: Fither:

1 Both:

- 1.1 The patient has indolent low grade NHL with relapsed disease following prior chemotherapy; and
- 1.2 To be used for a maximum of 4 treatment cycles; or
- 2 Both:
 - 2.1 The patient has indolent, low grade lymphoma requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. Rituximab is not funded for Chronic lymphocytic leukaemia/small lymphocytic lymphoma.

Initial application — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has treatment-naive aggressive CD20 positive NHL; and
- 2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 3 To be used for a maximum of 8 treatment cycles.
- Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Renewal — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 4 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. Rituximab is not funded for Chronic lymphocytic leukaemia/small lymphocytic lymphoma.

Renewal — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

TRASTUZUMAB - PCT only - Specialist - Special Authority see SA0885 on the next page

Inj 150 mg vial1,350.00	1	~
Inj 440 mg vial	1	~
Inj 1 mg for ECP9.36	1 mg	~

Herceptin Herceptin Baxter

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

SA0885 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months where the patient has metastatic breast cancer expressing HER-2 IHC 3+ or FISH+.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The patient has metastatic breast cancer; and
- 2 The cancer has not progressed.

Initial application — (early breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or FISH +; and
- 2 Maximum cumulative dose of 20mg/kg (9 weeks treatment)*; and
- 3 Trastuzumab is to be given concurrently with adjuvant taxane chemotherapy*; and
- 4 Trastuzumab is not to be given concurrently with anthracycline chemotherapy.

Notes: indications marked with * are Unapproved Indications.

It is recommended that for early breast cancer trastuzumab be administered concurrently with docetaxel prior to anthracyclines as per the FinHer regimen (Joensuu H, Kellokumpu-Lehtinen P, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20).

Other Immunosuppressants

CYCLOSPORIN A – Hospital pharmacy [HP3]

Cap 25 mg		50	Neoral
Cap 50 mg		50	Neoral
Cap 100 mg		50	Neoral
Oral liq 100 mg per ml		50 ml OP	Neoral
SIROLIMUS - Special Authority see SA0866 below - Hospi	tal pharmacy [HP3]		
Tab 1 mg		100	Rapamune
Tab 2 mg		100	Rapamune
Oral liq 1 mg per ml		60 ml OP	 Rapamune

SA0866 Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid without further renewal unless notified where the drug is to be used for rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR<30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencepthalopathy; or
- Significant malignant disease

TACROLIMUS - Special Authority see SA0669 below - Hospital pharmacy [HP3]

Cap 0.5 mg	 100	Prograf
Cap 1 mg	 100	Prograf
Cap 5 mg	 50	Prograf

SA0669 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid without further renewal unless notified where the patient is an organ transplant recipient.

Note: Subsidy applies for either primary or rescue therapy.

	Cubaidu		Fully Drand or
	Subsidy (Manufacturer's Pric	e) Sut	Fully Brand or osidised Generic
	\$	Per	 Manufacturer
Antiallergy Preparations			
BEE VENOM ALLERGY TREATMENT - Special Authority see \$	SA0053 below – Hos	spital pharm	acy [HP3]
Maintenance kit - 6 vials 120 µg freeze dried venom, 6 diluer	nt		
1.8 ml		1 OP	Albay
Treatment kit - 1 vial 550 µg freeze dried venom, 1 diluer 9 ml, 3 diluent 1.8 ml		1 OP	✓ Albay
SA0053 Special Authority for Subsidy		TOF	V Albay
Initial application only from a relevant specialist. Approvals vali	d for 2 years for app	lications me	eting the following criteria:
Both:	a lor 2 youro lor app		in the following officina.
1 RAST or skin test positive; and			
2 Patient has had severe generalised reaction to the sensiti			the second state and the second state is
Renewal only from a relevant specialist. Approvals valid for 2 y benefiting from treatment.	years where the trea	atment rema	ains appropriate and the patient is
WASP VENOM ALLERGY TREATMENT - Special Authority see	e SA0053 below – H	losnital nhai	macy [HP3]
Treatment kit (Paper wasp venom) - 1 vial 550 µg freeze drie			indoy [in o]
polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml		1 OP	Albay
Treatment kit (Yellow jacket venom) - 1 vial 550 µg freez			
dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml		1 OP	Albay
► SA0053 Special Authority for Subsidy			
Initial application only from a relevant specialist. Approvals vali Both:	d for 2 years for app	lications me	eeting the following criteria:
1 RAST or skin test positive; and			
2 Patient has had severe generalised reaction to the sensiti	sing agent.		
Renewal only from a relevant specialist. Approvals valid for 2 y	years where the trea	atment rema	ains appropriate and the patient is
benefiting from treatment.			
Antihistamines			
AZATADINE MALEATE			
* Tab 1 mg	6.94	50	
	(16.90)		Zadine
(Zadine Tab 1 mg to be delisted 1 February 2010)			
CETIRIZINE HYDROCHLORIDE			4
* Tab 10 mg		100 200 ml	 ✓ <u>Zetop</u> ✓ Cetirizine - AFT
*‡ Oral liq 1 mg per ml		200 111	
CHLORPHENIRAMINE MALEATE *‡ Oral liq 2 mg per 5 ml	8.08	500 ml	✓ Histafen
		500 111	
CYPROHEPTADINE HYDROCHLORIDE * Tab 4 mg	6 27	100	Periactin
		100	

	Subsidy		Fully Brand or
	(Manufacturer's) \$	Price) Su Per	Ibsidised Generic Manufacturer
EXTROCHLORPHENIRAMINE MALEATE			
 Tab 2 mg 	2.52	50	
1 au 2 mg	(9.99)	50	Polaramine
← Tab long-acting 6 mg	(/	40	Tolaramine
	(12.56)	40	Polaramine
	(12.00)		Colour-Free
			Repetab
	(12.56)		Polaramine Repetab
€‡ Oral lig 2 mg per 5 ml	(/	100 ml	i olarannio riopotab
· · · · · · · · · · · · · · · · · · ·	(10.29)		Polaramine
Polaramine Repetab Tab long-acting 6 mg to be delisted 1 Ja	nuary 2010)		
EXOFENADINE HYDROCHLORIDE	, ,		
Tab 60 mg	1 3/	20	
	(11.53)	20	Telfast
← Tab 120 mg		30	render
	(29.81)	00	Telfast
	(20.01)		Tondot
ORATADINE	0.50	100	
 Tab 10 mg 		100	✓ Loraclear Hayfever
• Oral lig 1 mg per ml	2.65	100 ml	Relief
		100 111	Lorapaed
ROMETHAZINE HYDROCHLORIDE			
 Tab 10 mg 		50	✓ <u>Allersoothe</u>
 Tab 25 mg 		50	Allersoothe
€‡ Oral liq 5 mg per 5 ml		100 ml	
(Jai 05 ma age al 0 ml - Un to 5 ini quailable on o BCO	(8.51)	-	Phenergan
Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO		5	Mayne
RIMEPRAZINE TARTRATE			
Oral liq 30 mg per 5 ml		100 ml OP	
	(8.06)		Vallergan Forte
Inhaled Corticosteroids			
ECLOMETHASONE DIPROPIONATE			
Aerosol inhaler, 100 µg per dose CFC-free		200 dose OF	
Aerosol inhaler, 250 µg per dose CFC-free		200 dose OF	
Aerosol inhaler, 50 µg per dose CFC-free		200 dose OF	
Aerosol inhaler, 50 µg per dose		200 dose OF	
Aerosol inhaler, 100 µg per dose		200 dose OF 200 dose OF	
Aerosol inhaler, 250 µg per dose Beclazone 50 Aerosol inhaler, 50 µg per dose to be delisted 1		200 005e OP	✓ Deciazone 200
Beclazone 100 Aerosol inhaler, 100 µg per dose to be delisted f	. ,		
Beclazone 250 Aerosol inhaler, 250 µg per dose to be delisted	. ,		
101	2 1 1 COldary 2010)		
UDESONIDE	17.00	000 4 00	
Powder for inhalation, 100 µg per dose	17.00	200 dose OF	
			Turbuhaler
Powder for inhalation, 200 µg per dose		200 dose OF	
			Turbuhaler
Powder for inhalation, 400 µg per dose		200 dose OF	
			Turbuhaler

	Subsidy (Manufacturer's \$		Fully Brand or sidised Generic Manufacturer
FLUTICASONE			
Aerosol inhaler, 50 µg per dose CFC-free	7.50	120 dose OP	 Flixotide
Powder for inhalation, 50 µg per dose	5.10	60 dose OP	
	(8.67)		Flixotide Accuhaler
Powder for inhalation, 100 µg per dose	7.50	60 dose OP	
	(13.87)		Flixotide Accuhaler
Aerosol inhaler, 125 µg per dose CFC-free		120 dose OP	 Flixotide
Aerosol inhaler, 250 µg per dose CFC-free		120 dose OP	 Flixotide
Powder for inhalation, 250 µg per dose		60 dose OP	
	(24.51)		Flixotide Accuhaler

Inhaled Long-acting Beta-adrenoceptor Agonists

Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor Agonists

The addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended:

- For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 µg beclomethasone or budesonide (or 100 µg fluticasone).
- For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 µg beclomethasone or budesonide (or 200 µg fluticasone).

Note:

Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).

EFORMOTEROL FUMARATE – See prescribing guideline above Powder for inhalation, 6 μg per dose, breath activated	60 dose OP 60 dose	✔ Oxis Turbuhaler✔ Foradil
SALMETEROL – See prescribing guideline above Aerosol inhaler CFC-free, 25 µg per dose	120 dose OP 60 dose OP	✔ Serevent✔ Serevent Accuhaler

Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

➡SA0958 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 Patient is a child under the age of 12; and
 - 1.2 All of the following:
 - Has, for 3 months of more, been treated with:
 - 1.2.1 An inhaled long-acting beta adrenoceptor agonist; and
 - 1.2.2 Inhaled corticosteroids at a dose of at least 400 µg per day beclomethasone or budesonide, or 200 µg per day fluticasone; and
 - 1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product; or
- 2 All of the following:
 - 2.1 Patient is over the age of 12; and
 - 2.2 All of the following:
 - Has, for 3 months of more, been treated with:
 - 2.2.1 An inhaled long-acting beta adrenoceptor agonist; and

continued...

	Subsidy (Manufacturer's \$		Fully bsidised	Brand or Generic Manufacturer
continued				
2.2.2 Inhaled corticosteroids at a dose of at least 8 fluticasone; and	00 µg per day l	peclomethason	e or bud	esonide, or 500 μg per day
2.3 The prescriber considers that the patient would rec product.	ceive additiona	I clinical benef	it from s	witching to a combination
Renewal from any relevant practitioner. Approvals valid for 2 ye benefiting from treatment.	ars where the	treatment remain	ains app	ropriate and the patient is
BUDESONIDE WITH EFORMOTEROL – Special Authority see S		010		
Aerosol inhaler 100 µg with eformoterol fumarate 6 µg Powder for inhalation 100 µg with eformoterol fumarate 6 µg		120 dose OP 120 dose OP		annair ymbicort Turbuhaler 100/6
Aerosol inhaler 200 µg with eformoterol fumarate 6 µg	60.00	120 dose OP	🖌 V	annair
Powder for inhalation 200 μg with eformoterol fumarate 6 μg		120 dose OP	✔ S	ymbicort Turbuhaler 200/6
Powder for inhalation 400 μg with eformoterol fumarate 12 μg – No more than 2 dose per day	60.00	60 dose OP	✔ S	ymbicort Turbuhaler 400/12
FLUTICASONE WITH SALMETEROL - Special Authority see SA		010		
Aerosol inhaler 50 µg with salmeterol 25 µg		120 dose OP		eretide
Aerosol inhaler 125 µg with salmeterol 25 µg Powder for inhalation 100 µg with salmeterol 50 µg – No more		120 dose OP	V 5	eretide
than 2 dose per day Powder for inhalation 250 µg with salmeterol 50 µg – No more		60 dose OP	🗸 S	eretide Accuhaler
than 2 dose per day		60 dose OP	🗸 S	eretide Accuhaler
Beta-Adrenoceptor Agonists				
SALBUTAMOL				
‡ Oral liq 2 mg per 5 ml Infusion 1 mg per ml, 5 ml	118.38	150 ml 10		alapin_
Inj 500 μg per ml, 1 ml $-$ Up to 5 inj available on a PSO	(130.21) 12.90	5		entolin entolin
Inhaled Beta-Adrenoceptor Agonists				
SALBUTAMOL				
Aerosol inhaler, 100 µg per dose CFC free – Up to 1000 dose available on a PSO		200 dose OP		espigen
	(6.00)			alamol entolin
Nebuliser soln, 1 mg per ml, 2.5 ml – Up to 30 neb available on a PSO	· · · ·	20		sthalin
Nebuliser soln, 2 mg per ml, 2.5 ml – Up to 30 neb available on a PSO		20	🗸 A	sthalin
TERBUTALINE SULPHATE				
Powder for inhalation, 250 μg per dose, breath activated		200 dose OP	🗸 В	ricanyl Turbuhaler

	Subsidy (Manufacturer's	Price) Subs	Fully Brand or sidised Generic
	\$	Per	 Manufacturer
Inhaled Anticholinergic agents			
IPRATROPIUM BROMIDE Aerosol inhaler, 20 μg per dose CFC-free)	200 dose OP	✔ Atrovent
on a PSO		20	✓ <u>Ipratropium</u> <u>Steri-Neb</u>
Nebuliser soln, 250 μg per ml, 2 ml – Up to 40 neb available on a PSO		20	✓ <u>Ipratropium</u> <u>Steri-Neb</u>
TIOTROPIUM BROMIDE – Special Authority see SA0872 below Powder for inhalation, 18 µg per dose		acy 30 dose	✓ Spiriva
► SA0872 Special Authority for Subsidy Initial application only from a general practitioner or relevant sp following criteria: All of the following:			
 To be used for the long-term maintenance treatment of bro 2 In addition to standard treatment, the patient has trialled a 3 Any of the following: The patient's breathlessness according to the Medi 3.1 Grade 4 (stops for breath after walking about 100 n 3.2 Grade 5 (too breathless to leave the house, or brea 4 Actual FEV₁ (litres) < 0.6 × predicted (litres); and 5 Either: 5.1 Patient is not a smoker (for reporting purposes only 5.2 Patient is a smoker and has been offered smoking of 6 The patient has been offered annual influenza immunisation Renewal only from a general practitioner or relevant specialist. criteria: All of the following: Patient is compliant with the medication; and Patient has experienced improved COPD symptom contro 3 Applicant must state recent measurement of FEV₁ (% of provide the state of the section of	dose of at leas cal Research C teters or after a thless when dro); or cessation couns on. Approvals valid I (prescriber de redicted).	t 40 µg ipratropiu ouncil (UK) dysp few minutes on sessing or undress selling; and for 2 years for a termined); and	im q.i.d for one month; and noea scale is: the level); or sing); and
Inhaled Beta-Adrenoceptor Agonists with Antic	holinergic <i>F</i>	gents	
SALBUTAMOL WITH IPRATROPIUM BROMIDE Aerosol inhaler, 100 μg with ipratropium bromide, 20 μg pe dose Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg pe vial, 2.5 ml – Up to 20 neb available on a PSO	13.50 r	200 dose OP 20	 ✓ Combivent ✓ Duolin
Mast cell stabilisers			
NEDOCROMIL Aerosol inhaler, 2 mg per dose CFC-free	23.20 (28.07)	112 dose OP	Tilade
SODIUM CROMOGLYCATE Powder for inhalation, 20 mg per dose	16.31 (17.94)	50 dose	Intal Spincaps
Aerosol inhaler, 5 mg per dose CFC-free		112 dose OP	Vicrom

	Subsidy (Manufacturer's \$		Fully Brand or sidised Generic Manufacturer
Methylxanthines			
AMINOPHYLLINE * Inj 25 mg per ml, 10 ml – Up to 5 inj available on	a PSO12.84	5	✔ Mayne
THEOPHYLLINE Tab long-acting 250 mg *‡ Oral liq 80 mg per 15 ml 		100 500 ml	✓ Nuelin-SR Nuelin
Cystic Fibrosis			
DORNASE ALFA – Special Authority see SA0611 be Nebuliser soln, 2.5 mg per 2.5 ml ampoule		HP1] 6	✓ Pulmozyme
► SA0611 Special Authority for Subsidy Special Authority approved by the Cystic Fibrosis Adv Notes: Application details may be obtained from PHA The Co-ordinator, Cystic Fibrosis Advisory Panel	RMÁC's website http://www Phone: (04) 460 4990	w.pharmac.govt.i	nz or:
PHARMAC, PO Box 10 254 Wellington Prescriptions for patients approved for treatment mus	Facsimile: (04) 916 7571 Email: CFPanel@pharma	<u> </u>	ediatricians who have experience
and expertise in treating cystic fibrosis.		physiolans of pa	
Nasal Preparations			
Allergy Prophylactics			
BECLOMETHASONE DIPROPIONATE Metered aqueous nasal spray, 50 μg per dose Metered aqueous nasal spray, 100 μg per dose		200 dose OP 200 dose OP	✓ Alanase✓ Alanase
BUDESONIDE Metered aqueous nasal spray, 50 µg per dose	2.35 (4.00)	200 dose OP	Butacort Aqueous
Metered aqueous nasal spray, 100 µg per dose .	()	200 dose OP	Butacort Aqueous
IPRATROPIUM BROMIDE Aqueous nasal spray, 0.03%		30 ml OP	✓ <u>Apo-Ipravent</u>
SODIUM CROMOGLYCATE Nasal spray, 4%		22 ml OP	✔ Rex

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully idised	Brand or Generic Manufacturer
Respiratory Devices				
MASK FOR SPACER DEVICE a) Maximum of 20 dev per WSO b) Only on a WSO c)				
 Spacer devices and masks also available to paedia by the paediatrician. Limited to one pack of 20 per 2) Only available for children aged six years and unde 3) For Space Chamber and Foremount Child's Silicon spacer device, the mask, or both are required. Distributed by Airflow Products. Forward orders to: Airflow Products Telephone: 04 499 1240 PO Box 1485, Wellington Facsimile: 04 499 1245 c 	order. Orders via a ho r. le Mask wholesale su or 0800 AIR FLOW	spital phar	macy.	
Size 2		1	✓ <u>F</u>	oremount Child's Silicone Mask
PEAK FLOW METER a) Maximum of 10 dev per WSO b) Only on a WSO Low range Normal range SPACER DEVICE		1 1		reath-Alert reath-Alert
a) Maximum of 20 dev per WSO b) Only on a WSO c)				
 Spacer devices and masks also available to paedia by the paediatrician. Limited to one pack of 20 per For Space Chamber and Foremount Child's Silicon spacer device, the mask, or both are required. 	order. Orders via a ho	spital phar	macy.	
Space Chamber distributed by Airflow Products. Forwa Airflow Products - PO Box 1485, Wellington Telephone: 04 499 1240 or 0800 AIR FLOW, Facsimile		0 323 270		
Volumatic Distributed by GlaxoSmithKline. Forward ord Telephone: 0800 877 789 Facsimile: 0800 877 785	ders to:			
230 ml (autoclavable) – Subsidy by endorsement Available where the prescriber requires a spacer device endorsed accorringly.		1 erilisation i		pace Chamber utoclave and the WSO is
230 ml (single patient) 800 ml		1 1	_	pace Chamber plumatic

	Subsidy		Fully Brand or
	(Manufacturer's I		sidised Generic
	\$	Per	 Manufacturer
Ear Droparations			
Ear Preparations			
ACETIC ACID WITH 1. 2- PROPANEDIOL DIACETATE AND BEN	IZETHONIUM		
For Vosol ear drops with hydrocortisone powder refer, page 1			
Ear drops 2% with 1, 2-Propanediol diacetate 3% and			
benzethonium chloride 0.02 %		35 ml OP	✔ Vosol
	0.97	55 III OF	VUSUI
CHLORAMPHENICOL			
Ear drops 0.5%	1.87	5 ml OP	 Chloromycetin
FLUMETASONE PIVALATE			
Ear drops 0.02% with clioquinol 1%	4 46	7.5 ml OP	✓ Locorten-Vioform
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCI		N	
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate			
2.5 mg and gramicidin 250 µg per g	3.35	7.5 ml OP	 Kenacomb
Ear/Eye Preparations			
DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN			
Ear/Eye drops 500 µg with framycetin sulphate 5 mg and			
gramicidin 50 µg per ml		8 ml OP	
		01111 01	Sofradex
	(9.27)		Solladex
FRAMYCETIN SULPHATE			
Ear/Eye drops 0.5%	4.13	8 ml OP	
	(8.65)		Soframycin
Eye Preparations			
Lyerreparations			
Anti-Infective Preparations			
Anti-Intective Treparations			
ACICLOVIR			
* Eye oint 3%		4.5 g OP	Zovirax
		- 5 -	
CHLORAMPHENICOL	0.07	4 = 00	
Eye oint 1%		4 g OP	Chlorsig
Eye drops 0.5%	1.40	10 ml OP	 Chlorsig
CIPROFLOXACIN			
Eye Drops 0.3%	12.43	5 ml OP	 Ciloxan
For treatment of bacterial keratitis or severe bacterial conju	unctivitis resistar	nt to chloramph	enicol.
FUSIDIC ACID			
Eve drops 1%	4 50	5 g OP	
	(10.68)	0 9 01	Fucithalmic
	(10.00)		r dolthainnio
GENTAMICIN SULPHATE			4.4
Eye drops 0.3%	11.40	5 ml OP	 Genoptic
PROPAMIDINE ISETHIONATE			
* Eye drops 0.1 %		10 ml OP	
,	(7.99)		Brolene
	(1.00)		Brolono
SULPHACETAMIDE SODIUM			
* Eye drops 10%	4.41	15 ml OP	Bleph 10
TOBRAMYCIN			
Eye oint 0.3%		3.5 g OP	✓ Tobrex
Eye drops 0.3%		5 ml OP	✓ Tobrex
7 · · · · · · · · · · · · · · · · · · ·			

154

SENSORY ORGANS

	Subsidy		Fully Brand or
	(Manufacturer's	Price) Sub Per	osidised Generic Manufacturer
	φ	Fei	Manufacturer
Corticosteroids and Other Anti-Inflammatory Pr	eparations		
DEXAMETHASONE			
* Eye oint 0.1%		3.5 g OP	Maxidex
* Eye drops 0.1 %	4.50	5 ml OP	Maxidex
DEXAMETHASONE WITH NEOMYCIN AND POLYMYXIN B SUI	LPHATE		
* Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin			
B sulphate 6,000 u per g		3.5 g OP	✓ Maxitrol
* Eye drops 0.1% with neomycin sulphate 0.35% and polymy-		-	
xin B sulphate 6,000 u per ml		5 ml OP	Maxitrol
DICLOFENAC SODIUM			
* Eye drops 1 mg per ml		5 ml OP	Voltaren Ophtha
FLUOROMETHOLONE			
* Eye drops 0.1%	4 05	5 ml OP	🖌 FML
	(4.30)	0 0.	Flucon
(Flucon Eye drops 0.1% to be delisted 1 December 2009)	()		
LEVOCABASTINE			
Eye drops 0.5 mg per ml		4 ml OP	
)	(10.34)		Livostin
LODOXAMIDE TROMETAMOL			
Eye drops 0.1%		10 ml OP	Lomide
PREDNISOLONE ACETATE			
* Eye drops 0.12%	4 50	5 ml OP	
	(7.53)	0 111 01	Pred Mild
* Eye drops 1%		5 ml OP	
	(9.44)		Pred Forte
SODIUM CROMOGLYCATE			
Eye drops 2%	3.95	10 ml OP	Cromolux
Glaucoma Preparations - Beta Blockers			
Giaucoma Preparations - Deta Diockers			
BETAXOLOL HYDROCHLORIDE			
* Eye drops 0.25%	11.80	5 ml OP	Betoptic S
* Eye drops 0.5%	7.50	5 ml OP	 Betoptic
LEVOBUNOLOL			
* Eye drops 0.25%	7.00	5 ml OP	Betagan
* Eye drops 0.5 %	7.00	5 ml OP	✓ Betagan
TIMOLOL MALEATE			
* Eye drops 0.25%		5 ml OP	✓ <u>Apo-Timop</u>
* Eye drops 0.25%, gel forming		2.5 ml OP	 Timoptol XE
* Eye drops 0.5%		5 ml OP	Apo-Timop
* Eye drops 0.5%, gel forming	3.78	2.5 ml OP	Timoptol XE

	Subsidy (Manufacturer's Pri \$	ce) S Per	Fully ubsidised	Brand or Generic Manufacturer
Glaucoma Preparations - Carbonic Anhydrase	Inhibitors			
Prescribing Guidelines irusopt, Cosopt and Azopt are subsidised for use as either mor irusopt, Cosopt and Azopt should not be prescribed for a per laucoma are not contraindicated unless: 1) that person has previously trialled all other such subsidis 2) those trials have indicated that that person does not resp	son in whom less e	expensive f	irst line a tartrate);	gents for the treatment of
CETAZOLAMIDE ≰ Tab 250 mg	10.40	100	✓ <u>D</u>	iamox
BRINZOLAMIDE ▲ Eye Drops 1%	9.77	5 ml OP	🗸 A	zopt
ORZOLAMIDE HYDROCHLORIDE ∉ Eye drops 2%	9.77 (13.95)	5 ml OP	Tr	usopt
ORZOLAMIDE HYDROCHLORIDE WITH TIMOLOL MALEAT Eve drops 2% with timolol maleate 0.5%	-	5 ml OP	✔ C	osopt
Glaucoma Preparations - Prostaglandin Analog	gues			
 Prescribing Guideline bimatoprost, lantanoprost and travoprost are subsidised for us djunctive agent for patients in whom prostaglandin analogue m bimatoprost, lantanoprost and travoprost should not be prescrive atment of glaucoma are not contraindicated unless: That person has previously trialled all other such subs hibitors); and Those trials have indicated that that person does not response prescribing guideline above Eye Drops 0.03% 	onotherapy has bee ibed for a person in idised agents (beta bond adequately to t	n ineffectiv whom les blockers, j	e in contro s expensi pilocarpino vith those	olling intraocular pressur ve first line agents for th e, carbonic anhydrase i
ATANOPROST – Retail pharmacy-Specialist See prescribing guideline above Eye drops 50 μg per ml, 2.5ml		2.5 ml OP	✔ X;	alatan
RAVOPROST – Retail pharmacy-Specialist See prescribing guideline above ▲ Eye drops 0.004%		2.5 ml OP	🖌 Tı	ravatan
Glaucoma Preparations - Other				
RIMONIDINE TARTRATE				

Prescribing Guidelines

Brimonidine tartrate is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Brimonidine tartrate should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless:

- that person has previously trialled all other such subsidised agents (except dorzolamide hydrochloride); and
- those trials have indicated that that person does not respond adequately to or does not tolerate treatment with those other agents.

BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE

▲ Eye drops 0.2% with timolol maleate 0.5%18.50 5 ml OP ✓ Combigan

🖌 AFT

SENSORY ORGANS

	Subsidy (Manufacturer's Pr \$	rice) Sub Per	Fully osidised	Brand or Generic Manufacturer
Prescribing Guidelines				
Combigan is subsidised for use as either monotherapy or as an	adjunctive agent fo	r the treatmer	nt of gla	ucoma.
Combigan should only be prescribed when:				
1) less expensive first line agents for the treatment of glauce	oma are contraindic	ated; or		
2) the response to such subsidised agents is inadequate; or				
the patient cannot tolerate such subsidised agents.				
PILOCARPINE				
* Eye drops 0.5%	3.19	15 ml OP	🖌 Р	ilopt
* Eye drops 1%		15 ml OP	🖌 Р	ilopt
	4.26		🖌 İs	opto Carpine S29
* Eye drops 2%	4.32	15 ml OP	🖌 Р	ilopt
	5.35		🖌 İs	opto Carpine S29
* Eye drops 4%	6.57	15 ml OP	🖌 Р	
	7.99		🖌 İs	opto Carpine S29
* Eye drops 6%	8.56	15 ml OP	🖌 Р	
* Eye drops 2% single dose - Special Authority see SA089	5			
below - Hospital pharmacy [HP3]		20 dose		
	(32.72)		M	linims
(Pilopt Eye drops 0.5% to be delisted 1 December 2009)	· /			

(Pilopt Eye drops 0.5% to be delisted 1 December 2 (Pilopt Eye drops 1% to be delisted 1 March 2010)

(Pilopt Eye drops 2% to be delisted 1 January 2010)

(Pilopt Eye drops 5% to be delisted 1 Sandary 2010) (Pilopt Eye drops 6% to be delisted 1 February 2010)

(Pliopt Eye drops 6% to be delisted 1 February 2010)

➡SA0895 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 Patient has to use an unpreserved solution due to an allergy to the preservative; or

2 Patient wears soft contact lenses.

Note: Minims for a general practice are considered to be "tools of trade" and are not approved as special authority items. **Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Mydriatics and Cycloplegics

ATROPINE SULPHATE * Eye drops 1%4.40	15 ml OP	✓ <u>Atropt</u>
CYCLOPENTOLATE HYDROCHLORIDE * Eye drops 1%8.76	15 ml OP	✔ Cyclogyl
HOMATROPINE HYDROBROMIDE * Eye drops 2%	15 ml OP	✓ Isopto Homatropine
TROPICAMIDE * Eye drops 0.5% 7.15 * Eye drops 1% 8.66	15 ml OP 15 ml OP	 Mydriacyl Mydriacyl
Preparations for Tear Deficiency	10 111 01	• myanacyi
For acetylcysteine eye drops refer, page 163 HYPROMELLOSE		
* Eye drops 0.3% 2.62 * Eye drops 0.5% 2.00	15 ml OP 15 ml OP	 Poly-Tears Methopt

SENSORY ORGANS

	Subsidy (Manufacturer's F \$	rice) Sub Per	Fully Brand or sidised Generic Manufacturer
POLYVINYL ALCOHOL * Eye drops 1.4% * Eye drops 3% TYLOXAPOL * Eye drops 0.25%	3.75	15 ml OP 15 ml OP 15 ml OP	✓ <u>Vistil</u> ✓ <u>Vistil Forte</u> ✓ Enuclene
Other Eye Preparations			
NAPHAZOLINE HYDROCHLORIDE * Eye drops 0.1%	4.15	15 ml OP	✓ Naphcon Forte
PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN * Eye oint with soft white paraffin		3.5 g OP	✓ Lacri-Lube
PARAFFIN LIQUID WITH WOOL FAT LIQUID * Eye oint 3% with wool fat lig 3%	3.63	3.5 g OP	✔ Poly-Visc
PHENYLEPHRINE HYDROCHLORIDE * Eye drops 0.12%	4.47	15 ml OP	✓ Prefrin
PHENYLEPHRINE HYDROCHLORIDE WITH ZINC SULPHATE * Eye drops 0.12% with zinc sulphate 0.25%	4.51	15 ml OP	 Zincfrin

VARIOUS

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully Brand or sidised Generic Manufacturer
Agents Used in the Treatment of Poisonings			
See also to MUSCULOSKELETAL, Anticholinesterases, page 99			
CHARCOAL			
* Tab 300 mg		100	Red Seal
 * Oral liq 50 g per 250 ml a) Up to 250 ml available on a PSO b) Only on a PSO 	43.50	250 ml OP	Carbosorb-X
DESFERRIOXAMINE MESYLATE – Hospital pharmacy [HP3]			
* Inj 500 mg		10	✓ <u>Mayne</u>
IPECACUANHA			
* Tincture		500 ml	
	(43.40)		PSM
NALOXONE HYDROCHLORIDE a) Up to 5 inj available on a PSO b) Only on a PSO			
* Inj 400 μg per ml, 1 ml		5	Mayne
SODIUM CALCIUM EDETATE			
* Inj 200 mg per ml, 5 ml		6	
	(156.71)		Calcium Disodium Versenate
Detection of Substances in Urine			
ORTHO-TOLIDINE			
* Compound diagnostic sticks	7.50 (8.25)	50 test OP	Hemastix
TETRABROMOPHENOL			
* Blue diagnostic strips	7.02 (13.92)	100 test OP	Albustix

INTRODUCTION

The following extemporaneously compounded products are eligible for subsidy:

- The "Standard Formulae".
- Oral liquid mixtures for patients unable to swallow subsidised solid dose oral formulations.
- The preparation of syringe drivers when prescribed by a general practitioner.
- Dermatological preparations
 - a) One or more subsidised dermatological galenical(s) in a subsidised dermatological base.
 - b) Dilution of proprietary Topical Corticosteroid-Plain preparations with a dermatological base (Retail pharmacy-specialist).
 - c) Menthol crystals only in the following bases:

Aqueous cream Urea cream 10% Wool fat with mineral oil lotion Hydrocortisone 1% with wool fat and mineral oil lotion Glycerol, paraffin and cetyl alcohol lotion.

Glossary

Dermatological base: The products listed in the Barrier creams and Emollients section and the Topical Corticosteroids-Plain section of the Pharmaceutical Schedule are classified as dermatological bases for the purposes of extemporaneous compounding and are the bases to which the dermatological galenicals can be added. Also the dermatological bases in the Barrier Creams and Emollients section of the Pharmaceutical Schedule can be used for diluting proprietary Topical Corticosteroid-Plain preparations. The following products are dermatological bases:

- Aqueous cream
- Cetomacrogol cream BP
- Collodion flexible
- Emulsifying ointment BP
- Glycerol with paraffin and cetyl alcohol lotion
- Hydrocortisone with wool fat and mineral oil lotion
- · Oil in water emulsion
- Oily cream
- Urea cream 10%
- White soft paraffin
- Wool fat with mineral oil lotion
- Zinc cream BP
- Zinc and castor oil ointment BP
- Proprietary Topical Corticosteroid-Plain preparations

Dermatological galenical: Dermatological galenicals will only be subsidised when added to a dermatological base. More than one dermatological galenical can be added to a dermatological base.

The following are dermatological galenicals:

- Coal tar solution BP up to 10%
- Hydrocortisone powder up to 5%
- Salicylic acid powder
- Sulphur precipitated powder

Standard formulae: Standard formulae are a list of fomulae for ECPs that are subsidised. Their ingredients are listed under the appropriate therapeutic heading in Section B of the Pharmaceutical Schedule and also in Section C.

Explanatory notes

Oral liquid mixtures

Oral liquid mixtures are subsidised for patients unable to swallow subsidised solid oral dose forms where no suitable alternative proprietary formulation is subsidised. Suitable alternatives include dispersible and sublingual formulations, oral liquid formulations or rectal formulations. Before extemporaneously compounding an oral liquid mixture, other alternatives such as dispersing the solid dose form (if appropriate) or crushing the solid dose form in jam, honey or soft foods such as yoghurt should be explored.

Subsidy for extemporaneously compounded oral liquid mixtures is based on:

Solid dose form	qs
Preservative	qs
Suspending agent	qs
Water	to 100%

Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients such as flavouring and colouring agents, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The majority of extemporaneously compounded oral liquid mixtures should contain a preservative and suspending agent. Methylcellulose 3% is considered a suitable suspending agent and compound hydroxybenzoate solution or methyl hydroxybenzoate 10% solution are considered to be suitable preservatives. Usually 1 ml of these preservative solutions is added to 100 ml of oral liquid mixture.

Some solid oral dose forms are not appropriate for compounding into oral liquid mixtures and should therefore not be used/considered for extemporaneously compounded oral liquid mixtures. This includes long-acting solid dose formulations, enteric coated tablets or capsules, sugar coated tablets, hard gelatin capsules and chemotherapeutic agents.

The following practices will not be subsidised:

- Mixing one or more proprietary oral liquids (eg an antihistamine with pholcodine linctus).
- Extemporaneously compounding an oral liquid with more than one solid dose chemical.
- Mixing more than one extemporaneously compounded oral liquid mixture.
- Mixing one or more extemporaneously compounded oral liquid mixtures with one or more proprietary oral liquids.
- The addition of a chemical/powder/agent/solution to a proprietary oral liquid or extemporaneously compounded oral mixture.

Standard formulae

A list of standard formulae is contained in this section. All ingredients associated with a standard formula will be subsidised and an appropriate compounding fee paid.

Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.


Dermatological Preparations

Proprietary topical corticosteroid preparations may be diluted with a dermatological base (see page 160) from the Barrier Creams and Emollients section of the Pharmaceutical Schedule (Retail pharmacy-Specialist). Dilution of proprietary topical corticosteroid preparations should only be prescribed for withdrawing patients off higher strength proprietary topical corticosteroid products where there is no suitable proprietary product of a lower strength available or an extemporaneously compounded product with up to 5% hydrocortisone is not appropriate. (In general proprietary topical corticosteroid preparations should not be diluted because dilution effects can be unpredictable and may not be linear, and usually there is no stability data available for diluted products).

One or more dermatological galenicals may be added to a dermatological base (including proprietary topical corticosteroid preparations). Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The addition of dermatological galenicals to diluted proprietary Topical Corticosteroids-Plain will not be subsidised.

The flow diagram on page 162 may assist you in deciding whether or not a dermatological ECP is subsidised.



Vosol Ear Drops

Standard Formulae

Glycerol

Water

ACETYLCYSTEINE EYE DROPS Acetylcysteine inj 200 mg per ml, 10 ml Suitable eye drop base	qs qs
ASPIRIN AND CHLOROFORM APPLICATI Aspirin Soluble tabs 300 mg Chloroform	ON 12 tabs to 100 ml
CODEINE LINCTUS PAEDIATRIC (3 mg pe Codeine phosphate Glycerol Preservative Water	er 5 ml) 60 mg 40 ml qs to 100 ml
CODEINE LINCTUS DIABETIC (15 mg per Codeine phosphate Glycerol Preservative Water	5 ml) 300 mg 40 ml qs to 100 ml
FOLINIC MOUTHWASH Calcium folinate 15 mg tab Preservative Water (Preservative should be used if quantity sup more than 5 days. Maximum 500 ml per pre	
MAGNESIUM HYDROXIDE MIXTURE Magnesium hydroxide paste Methyl hydroxybenzoate Water	275 g 1.5 g 770 ml
METHADONE MIXTURE Methadone powder	qs

qs

to 100 ml

METHYL HYDROXYBENZOATE 10% SOLI Methyl hydroxybenzoate Propylene glycol (Use 1 ml of the 10% solution per 100 ml of	10 g to 100 ml
mixture)	
OMEPRAZOLE SUSPENSION Omeprazole capules Sodium bicarbonate powder BP Water	qs 8.4 g to 100 ml
PHENOBARBITONE ORAL LIQUID Phenobarbitone Sodium Glycerol BP Water	1 g 70 ml to 100 ml
PILOCARPINE ORAL LIQUID Pilocarpine 4% eye drops Preservative Water (Preservative should be used if quantity sup more than 5 days.)	qs qs to 500 ml pplied is for
SALIVA SUBSTITUTE FORMULA Methylcellulose Preservative Water (Preservative should be used if quantity sup than 5 days. Maximum 500 ml per prescript	
VOSOL EAR DROPS WITH HYDROCORTISONE POWDER 1% Hydrocortisone powder	1%

to 35 ml

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturor's	Prico) C	Fully Brand or bsidised Generic
	(Manufacturer's F \$	Price) Su Per	bsidised Generic Manufacturer
Extemporaneously Compounded Preparations	and Galenica	als	
ACETYLCYSTEINE – Hospital pharmacy [HP1]-Specialist			
Inj 200 mg per ml, 10 ml		10	
	(219.75)		Martindale
			Acetylcysteine
	(255.35)		Hospira
BENZOIN			
Tincture compound BP	24 42	500 ml	
	(38.00)	000 111	PSM
	(00.00)		
CHLOROFORM – Only in combination			
Only in aspirin and chloroform application. Chloroform BP	05 50	500 ml	
	25.50	500 ml	✓ PSM
CODEINE PHOSPHATE			
Powder – Only in combination	63.09	25 g	
	(84.20)		Douglas
a) Only in extemporaneously compounded codeine linctu			ediatric.
 b) ‡ Safety cap for extemporaneously compounded oral I 	iquid preparations	S.	
COLLODION FLEXIBLE			
Collodion flexible	19.30	100 ml	✔ PSM
COMPOUND HYDROXYBENZOATE - Only in combination			
Only in extemporaneously compounded oral mixtures.			
Soln		100 ml	David Craig
GLYCEROL			5
 Liquid – Only in combination 	19.80	2,000 ml	🖌 ABM
	24.75	2,000 mi	✓ PSM
	19.80		
	(24.75)		MidWest
Only in extemporaneously compounded oral liquid prepa	()		marroot
MAGNESIUM HYDROXIDE			
Paste	22.61	500 g	🖌 PSM
	22.01	500 g	♥ F SW
METHADONE HYDROCHLORIDE			
a) Only on a controlled drug form			
b) No patient co-payment payable	raimburgad at the	rate of the ob	econect form available (methoden
c) Extemporaneously compounded methadone will only be	reimbursed at the	e rate of the ch	leapest form available (methadon
powder, not methadone tablets). Powder	7.04	1 a	🖌 AFT
Safety cap for extemporaneously compounded oral liqu		1 g	V AFI
	ויט אוכאמומנוטווס.		
	10.00	05 -	
Powder		25 g	
	(18.45)		PSM
METHYLCELLULOSE			
Powder		100 g	🖌 ABM
	(17.72)		MidWest
PHENOBARBITONE SODIUM			
Powder – Only in combination		100 g	✔ MidWest
a) Only in children up to 12 years		- 3	
b) ± Safety cap for extemporaneously compounded oral I	iquid preparations		

b) ‡ Safety cap for extemporaneously compounded oral liquid preparations.

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturer's P \$	rice) Sul Per	Fully osidised	Brand or Generic Manufacturer
PROPYLENE GLYCOL				
Only in extemporaneously compounded methyl hydroxybenzo	pate 10% solution	۱.		
Liq		500 ml	🖌 🖌	ЗМ
	17.70		🖌 PS	SM
SODIUM BICARBONATE				
Powder BP – Only in combination	9.80	500 g	🖌 🖌	ЗМ
	(11.99)		Bi	omed
	(29.50)		Da	avid Craig
Only in extemporaneously compounded omeprazole susp	ension.			
SYRUP (PHARMACEUTICAL GRADE) - Only in combination				
Only in extemporaneously compounded oral liquid preparatio	ns.			
Liq		2,000 ml	🖌 <u>Mi</u>	dwest
WATER				
Tap – Only in combination	0.00	1 ml	🖌 Ta	p water

EXPLANATORY NOTES

The list of special foods to which Subsidies apply is contained in this section. The list of available products, guidelines for use, subsidies and charges is reviewed as required. Applications for new listings and changes to subsidies and access criteria will be considered by the special foods sub-committee of PTAC which meets as and when required. In all cases, subsidies are available by Special Authority only. This means that, unless a patient has a valid Special Authority number for their special food requirements, they must pay the full cost of the products themselves.

Eligibility for Special Authority

Special Authorities will be approved for patients meeting conditions specified under the *Conditions and Guidelines* for each product. In some cases there are also limits to how products can be prescribed (for example quantity, use or duration). Only those brands, presentations and flavours of special foods listed in this section are subsidised.

Who can apply for Special Authority?

 Initial Applications:
 Only Specialists

 Reapplications:
 Specialist or general practitioner on recommendation of specialist. Reapplications by general practitioners on specialist recommendation must include the name of the specialist and the date the specialist was contacted.

All applications must be made on an official form available from the PHARMAC website www.pharmac.govt.nz. All applications must include specific details as requested on the form relating to the application. A supporting letter may be included if desired. Applications must be forwarded to:

Ministry of Health Sector Services Private Bag 3015 WHANGANUI 4540 Freefax 0800 100 131

Subsidies and manufacturer's surcharges

The Subsidies for some special foods are based on the lowest priced product within each group. Where this is so, or where special foods are otherwise not fully subsidised, a manufacturer's surcharge may be payable by the patient. The manufacturer's surcharge is the difference between the price of the product and the subsidy attached to it and may be subject to mark-ups applied at a pharmacy level. As a result the manufacturer's surcharge may vary. Fully subsidised alternatives are available in most cases (as indicated by a tick in the left hand column). Patients should only have to pay a co-payment on these products.

Where are special foods available from?

Distribution arrangements for special foods vary from region to region. Special foods are available from hospital pharmacies providing an outpatient dispensing service as well as retail pharmacies in the Northern, Midland and Central (including Nelson and Blenheim) regions.

Definitions

 Failure to thrive
 An inability to gain or maintain weight resulting in physiological impairment.

 Growth deficiency
 Where the weight of the child is less than the fifth or possibly third percentile for their age, with evidence of malnutrition

Subsidv Fully (Manufacturer's Price) Subsidised Per \$

Brand or Generic Manufacturer

V

Nutrient Modules

Carbohydrate

SA0912 Special Authority for Subsidy

Initial application — (Cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Either:

- 1 cystic fibrosis; or
- 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient.

Initial application - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 cancer in children; or
- 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 3 failure to thrive; or
- 4 growth deficiency; or
- 5 bronchopulmonary dysplasia; or
- 6 premature and post premature infant; or
- 7 inborn errors of metabolism.

Renewal — (Cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

Renewal - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

CARBOHYDRATE SUPPLEMENT - Special Authority see SA0912 above - Hospital pharmacy [HP3]

Powder		5,000 g	 Morrex Maltodextrin
	1.30	400 g OP	
	(5.29)	-	Polycal
	1.14	350 g OP	
	(7.85)	-	Polycose
	1.30	368 g OP	
	(12.00)	-	Moducal
olvcose Powder to be delisted 1 October 2009)	. ,		

(Polycose Powder to be ed 1 October 2009,

Carbohydrate And Fat

SA0581 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 infant aged four years or under; and
- 2 cvstic fibrosis.

Initial application - (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

continued...

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

continued...

Both:

- 1 infant aged four years or under; and
- 2 Any of the following:
 - 2.1 cancer in children; or
 - 2.2 failure to thrive; or
 - 2.3 growth deficiency; or
 - 2.4 bronchopulmonary dysplasia; or
 - 2.5 premature and post premature infants.

Renewal — (Cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

CARBOHYDRATE AND FAT SUPPLEMENT - Special Authority see SA0581 on the preceding page - Hospital pharmacy [HP3]

Powder (neutral)	60.31	400 g OP	Duocal Super
			Soluble Powder

Fat

➡SA0899 Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a relevant specialist. Approvals valid for 3 years where the patient has inborn errors of metabolism.

Initial application — (Indications other than inborn errors of metabolism) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 failure to thrive where other high calorie products are inappropriate or inadequate; or
- 2 growth deficiency; or
- 3 bronchopulmonary dysplasia; or
- 4 fat malabsorption; or
- 5 lymphangiectasia; or
- 6 short bowel syndrome; or
- 7 infants with necrotising enterocolitis; or
- 8 biliary atresia.

Renewal — (Inborn errors of metabolism) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

Renewal — (Indications other than inborn errors of metabolism) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

	Subsidy (Manufacturer's \$		Fully sidised	Brand or Generic Manufacturer
FAT SUPPLEMENT – Special Authority see SA0899 on the pred	eding page – H	ospital pharmac	y [HP3]	
Emulsion (neutral)		200 ml OP	V C	alogen
	30.75	500 ml OP	V C	alogen
Emulsion (strawberry)		200 ml OP	V C	alogen
Oil		250 ml OP	🖌 Li	iquigen
	30.00	500 ml OP	🗸 M	ICT oil (Nutricia)

Protein

➡SA0582 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Either:

- 1 protein losing enteropathy; or
- 2 high protein needs (eg burns).

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

Powder	 	225 g OP	Protifar 90
Powder (vanilla)	 	275 g OP	Promod

Oral Supplements

These products are to be used only as supplements to a person's dietary needs. Subsidy for up to 500 ml a day. Amounts prescribed in excess of this amount must be paid for by the patient.

➡SA0583 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years where the patient has cystic fibrosis.

Initial application — (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 cancer in children; or
- 2 inflammatory bowel disease; or
- 3 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 4 malnutrition requiring nutritional support.

Renewal — (Cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

	Subsidy (Manufacturer's F \$	Price) Sut Per	Fully osidised	Brand or Generic Manufacturer
ORAL SUPPLEMENT 1KCAL/ML - Special Authority see SA05	583 on the precedi	ing page – Hos	spital pha	armacy [HP3]
Powder (chocolate)	9.22	900 g OP		ustagen Hospital Formula
	4.75	400 g OP		
	(7.22)		E	nsure
Powder (strawberry)	4.75	400 g OP		
	(7.22)		Ei	nsure
Powder (vanilla)	9.22	900 g OP		ustagen Hospital Formula
	4.75	400 g OP		
	(7.22)	-	E	nsure

Oral Supplements/Complete Diet (Nasogastric/Gastrostomy Tube Feed)

Respiratory Products

➡SA0588 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 CORD patients who have hypercapnia; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

CORD ORAL FEED 1.5KCAL/ML - Special Authority see SA0588 above - Hospital pharmacy [HP3]

Diabetic Products

SA0594 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 Type I and II diabetics who require nutritional supplementation; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully sidised	Brand or Generic Manufacturer
DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see Liquid		preceding page 1,000 ml OP	✔ D ✔ G	ital pharmacy [HP3] iason RTH lucerna Select RTH
ORAL FEED 1KCAL/ML - Special Authority see SA0594 on the	preceding page	– Hospital phar	macy [H	HP3]
Liquid (strawberry)		200 ml OP	V D	iasip
	1.78	237 ml OP	🖌 R	esource Diabetic
Liquid (vanilla)	1.50	200 ml OP	🖌 D	iasip
	1.78	237 ml OP	🖌 R	esource Diabetic
	1.88	250 ml OP	🖌 G	lucerna Select

Fat Modified Products

➡SA0615 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The product is to be used as a complete diet; and
- 2 Either:
 - 2.1 Patient has metabolic disorders of fat metabolism; or
 - 2.2 Patient has chylothorax.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

FAT MODIFIED FEED - Special Authority see SA0615 above - Hospital pharmacy [HP3]

Powder	60.48	400 g OP	Monogen
--------	-------	----------	---------

High Protein Products

SA0589 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

1 Anorexia and weight loss; and

2 Either:

- 2.1 decompensating liver disease without encephalopathy; or
- 2.2 protein losing gastro-enteropathy; and

3 Either:

- 3.1 The product is to be used as a supplement (maximum 500 ml per day); or
- 3.2 The product is to be used as a complete diet.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

ORAL FEED 1KCAL/ML - Special Authority see SA0589 above - Hospital pharmacy [HP3] 200 ml OP

Fortimel

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Brand or Generic Manufacturer
Paediatric Products For Children Awaiting Liver	Transplant		
 SA0607 Special Authority for Subsidy Initial application only from a paediatrician. Approvals valid for 3 Both: Child (up to 18 years) who is awaiting liver transplant; and 2 Either: The product is to be used as a supplement (maximu 2.2 The product is to be used as a complete diet. Renewal only from a paediatrician. Approvals valid for 3 years for 	ım 500 ml per day); o	r	
Both: 1 The treatment remains appropriate and the patient is bene 2 Either: 2.1 The product is to be used as a supplement (maximu 2.2 The product is to be used as a complete diet. ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA06	fiting from treatment; Im 500 ml per day); o 507 above – Hospital J	and r pharmacy [HP3]	
Powder Paediatric Products For Children With Chronic F		0 g O P 🖌 G	eneraid Plus
 SA0606 Special Authority for Subsidy Initial application only from a paediatrician. Approvals valid for 3 Both: child (up to 18 years) with chronic renal failure; and Either:	years for applications	s meeting the follo	wing criteria:
Renewal only from a paediatrician. Approvals valid for 3 years for Both: 1 1 The treatment remains appropriate and the patient is bene 2 Either: 2.1 The product is to be used as a supplement; or 2.2 The product is to be used as a complete diet.		0	eria:
ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA06 Liquid			indergen
SA0896 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid All of the following:	for 1 year for applicat	tions meeting the	following criteria:

- 1 infant aged one to eight years; and
- 2 Any of the following:
 - 2.1 any condition causing malabsorption; or
 - 2.2 failure to thrive; or
 - 2.3 increased nutritional requirements; and
- 3 Either:
 - 3.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 3.2 The product is to be used as a complete diet.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

continued...

	Subsidy (Manufacturer's F \$		Sub Per	Fully sidised	
continued All of the following:					
 The treatment remains appropriate and the patient is benefit Either: 2.1. The product is to be used as a supplement (maximum 	Ū		nd		
2.1 The product is to be used as a supplement (maximur2.2 The product is to be used as a complete diet; and3 General Practitioners must include the name of the specialis					
PAEDIATRIC ENTERAL FEED 1.5KCAL/ML – Special Authority se			odina n	ane -	Hospital pharmacy [HP3]
Liquid			nl OP	۲ ا	Nutrini Energy RTH
PAEDIATRIC ENTERAL FEED 1KCAL/ML - Special Authority see	SA0896 on the	e prece	ding pag	ge – H	ospital pharmacy [HP3]
Liquid		200 r			Nutrini RTH
	2.68	500 r	nl OP		Nutrini RTH Pediasure RTH
PAEDIATRIC ORAL FEED 1.5KCAL/ML - Special Authority see S.	A0896 on the p	recedir	ng page	– Hos	pital pharmacy [HP3]
Liquid (strawberry)	1.60	200 r	nl OP		Fortini
Liquid (vanilla)	1.00	000 -			NutriniDrink Fortini
Liquid (vanilla)	1.60	200 r	nl OP		-ortini NutriniDrink
(Fortini Liquid (strawberry) to be delisted 1 November 2009) (Fortini Liquid (vanilla) to be delisted 1 November 2009)				• .	
PAEDIATRIC ORAL FEED 1KCAL/ML - Special Authority see SAG	0896 on the pre	eceding	page -	Hospi	tal pharmacy [HP3]
Liquid (chocolate)		-	nl OP		Pediasure
Liquid (strawberry)			nl OP		Pediasure
Liquid (vanilla)		237 r			Pediasure
PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special Au [HP3]	-)896 or	the pre	ceding	g page – Hospital pharmacy
Liquid (chocolate)	1.60	200 r	nl OP		Fortini Multifibre
				•	NutriniDrink Multifibre
Liquid (strawberry)	1.60	200 r	nl OP	1	Fortini Multifibre
				•	NutriniDrink Multifibre
Liquid (vanilla)	1.60	200 r	nl OP		Fortini Multifibre
				•	NutriniDrink Multifibre
(Fortini Multifibre Liquid (chocolate) to be delisted 1 November 200	,				
(Fortini Multifibre Liquid (strawberry) to be delisted 1 November 20	09)				
(Fortini Multifibre Liquid (vanilla) to be delisted 1 November 2009)					

Renal Products

➡SA0587 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both:

- 1 acute or chronic renal failure; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or

continued...

	Subsidy (Manufacturer's F \$	Price) Per	Fully Subsidised	Brand or Generic Manufacturer
ontinued				
2.2 The product is to be used as a complete diet.				
enewal only from a relevant specialist or general practitioner or	the recommend	lation of a	relevant spe	ecialist. Approvals valid fo
years for applications meeting the following criteria:				
I of the following:	(1)			
 The treatment remains appropriate and the patient is bene Either: 	fitting from treath	nent; and		
2.1 The product is to be used as a supplement (maximu	im 500 ml per de	av). or		
2.2 The product is to be used as a supplement (maxima 2.2 The product is to be used as a complete diet; and		<i>ly)</i> , 01		
3 General Practitioners must include the name of the special	list and date con	tacted.		
NTERAL FEED 2KCAL/ML - Special Authority see SA0587 on	the preceding pa	age – Hosp	oital pharma	cv [HP3]
Liquid	1 01	500 ml C		utrison
				Concentrated
ENAL ORAL FEED 2KCAL/ML – Special Authority see SA0587	on the precedir	ig page – I	lospital pha	rmacy [HP3]
Liquid	2.43	200 ml C) P 🛛 🖌 N	epro (vanilla)
	2.88	237 ml C	DP 🖌 N	ovaSource Renal
Liquid (apricot)		125 ml C		enilon 7.5
Liquid (caramel)		125 ml C		enilon 7.5

➡SA0592 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 malabsorption; or
 - 1.2 short bowel syndrome; or
 - 1.3 enterocutaneous fistulas; or
 - 1.4 pancreatitis; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet.

Notes: Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.

Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

ENTERAL/ORAL ELEMENTAL FEED 1KCAL/ML - Special Authori	ity see SA0592	2 above – Hosp	pital pharmacy [HP3]
Powder	4.40	79 g OP	Vital HN
	7.50	76 g OP	Alitraq
ORAL ELEMENTAL FEED 0.8KCAL/ML - Special Authority see SA	A0592 above -	Hospital pharr	macy [HP3]
Liquid (grapefruit)	9.50	250 ml OP	Elemental 028 Extra
Liquid (pineapple & orange)	9.50	250 ml OP	Elemental 028 Extra
Liquid (summer fruit)	9.50	250 ml OP	 Elemental 028 Extra

	Subsidy (Manufacturer's \$	Price) Subs Per	Fully sidised	Brand or Generic Manufacturer
ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see S/ Powder (unflavoured)		eceding page – 80.4 g OP		
SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML - Special Autl [HP3]	hority see SA05	592 on the prec	eding p	oage – Hospital pharmacy
Liquid	6.02 12.04	500 ml OP 1,000 ml OP		eptisorb eptisorb

Undyalised End Stage Renal Failure

►SA0586 Special Authority for Subsidy

Initial application only from a gastroenterologist or renal physician. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 undialysed end stage renal patients; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet.

Note: Where possible, the requirements for oral supplementation should be established in conjunction with assessment by a dietician.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
 - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

RENAL ORAL FEED 1KCAL/ML - Special Authority see SA0586 above - Hospital pharmacy [HP3]

Adult Products Standard

SA0702 Special Authority for Subsidy

Initial application — (Oral feed for cystic fibrosis patient) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

1 Cystic fibrosis; and

2 Either:

- 2.1 The product is to be used as a supplement; or
- 2.2 The product is to be used as a complete diet.

Initial application — (Oral feed for indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 any condition causing malabsorption; or
 - 1.2 failure to thrive; or
 - 1.3 increased nutritional requirements; and

2 Either:

- 2.1 The product is to be used as a supplement; or
- 2.2 The product is to be used as a complete diet.

continued...

Subsidy		Fully	Brand or
(Manufacturer's Price)	Sub	sidised	Generic
\$	Per	~	Manufacturer

continued...

Renewal — (Oral feed cystic fibrosis patient) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 The product is to be used as a supplement; or
 - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

Initial application — (Enteral feed) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 enteral feeding; or
 - 1.2 nasogastric; or
 - 1.3 nasoduodenal; or
 - 1.4 nasojejunal; or
 - 1.5 gastrostomy/jejunostomy; and
- 2 Either:
 - 2.1 The product is to be used as a supplement; or
 - 2.2 The product is to be used as a complete diet.

Renewal — (Enteral feed or Oral feed for indications other than cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 The product is to be used as a supplement; or
 - 2.2 The product is to be used as a complete diet; and

3 General Practitioners must include the name of the specialist and date contacted.

Notes: This group of products can be used either as a supplement or as a complete diet.

If a product is being used as a supplement, the limit is 500 ml per day.

Cystic fibrosis patients are exempt the 500 ml per day volume restriction when using Ensure Plus, Fortisip or Resource Plus as a supplement.

ENTERAL FEED 1KCAL/ML – Special Authority see SA0702 on the preceding page – Hospital pharmacy [HP3]

Liquid	1.24	250 ml OP	 Isosource HN Isosource Standard
	2.65	500 ml OP	✓ Nutrison Standard RTH
	5.29	1,000 ml OP	 Nutrison Standard RTH
			 Isosource HN RTH Isosource Standard RTH
			Osmolite RTH

	Subsidy		Fully Brand or
	(Manufacturer's		sidised Generic
	\$	Per	 Manufacturer
ENTERAL FEED WITH FIBRE 1 KCAL/ML - Special Authori	tv see SA0702 on	page 175 – Hosi	pital pharmacy [HP3]
Liquid		250 ml OP	✓ Fibersource
			Fibersource HN
	2.65	500 ml OP	✓ Nutrison Multi Fibre
	5.29	1,000 ml OP	Nutrison Multi Fibre
			Fibersource HN RTH
			Fibersource RTH
			Jevity RTH
(Fibersource Liquid to be delisted 1 December 2009)			•
(Fibersource RTH Liquid to be delisted 1 December 2009)			
ENTERAL FEED WITH FIBRE 1.5KCAL/ML - Special Autho	rity see SA0702 or	nage 175 - Ho	coital pharmacy [HP3]
Liquid		1.000 ml OP	Ensure Plus RTH
	1.75	250 ml OP	✓ Isosource 1.5
	7.00	1,000 ml OP	✓ Isosource 1.5
	7.00	1,000 111 01	✓ Nutrison Energy
			Multi Fibre
ODAL EEED & EKOAL AN Operated Asthetic and OA0700	475 11	the Large second second fill	
ORAL FEED 1.5KCAL/ML – Special Authority see SA0702 of			
Liquid (banana)		200 ml OP	✓ Fortisip
Linuid (abaaalata)	(1.45)		Ensure Plus
Liquid (chocolate)		200 ml OP	 Fortisip Resource Plus
	1.33 1.12	237 ml OP 200 ml OP	Resource Plus
		200 III OF	Ensure Plus
	(1.45) 1.33	237 ml OP	Ensure Plus
Liquid (coffee)		237 mi OP 237 mi OP	 Ensure Plus Ensure Plus
Liquid (conee)		200 ml OP	
	(1.45)	200 111 01	Ensure Plus
Liquid (strawberry)		200 ml OP	✓ Fortisip
	1.33	237 ml OP	Resource Plus
	1.12	200 ml OP	
	(1.45)	200 111 01	Ensure Plus
	1.33	237 ml OP	✓ Ensure Plus
Liquid (toffee)		200 ml OP	✓ Fortisip
Liquid (tropical fruit)		200 ml OP	✓ Fortisip
Liquid (vanilla)		200 ml OP	✓ Fortisip
1 (1.33	237 ml OP	Resource Plus
	1.12	200 ml OP	
	(1.45)		Ensure Plus
	1.33	237 ml OP	Ensure Plus
ORAL FEED WITH FIBRE 1.5 KCAL/ML - Special Authority	SEE SA0702 on na	ae 175 - Hospita	al pharmacy [HP3]
Liquid (chocolate)		200 ml OP	Fortisip Multi Fibre
Liquid (chocolate)		200 ml OP	✓ Fortisip Multi Fibre
Liquid (vanilla)		200 ml OP	 Fortisip Multi Fibre
Erquia (varinia)		200 111 01	

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

Adult Products High Calorie

SA0585 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 Cystic fibrosis; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements; and
- 4 Either:
 - 4.1 The product is to be used as a supplement; or
 - 4.2 The product is to be used as a complete diet.

Initial application — (Indications other than cystic fibrosis) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 any condition causing malabsorption; or
 - 1.2 failure to thrive; or
 - 1.3 increased nutritional requirements; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements; and
- 4 Either:
 - 4.1 The product is to be used as a supplement; or
 - 4.2 The product is to be used as a complete diet.

Renewal — (Cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted; and
- 3 Either:
 - 3.1 The product is to be used as a supplement; or
 - 3.2 The product is to be used as a complete diet.

Renewal — (Indications other than cystic fibrosis) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted; and
- 3 Either:
 - 3.1 The product is to be used as a supplement; or
 - 3.2 The product is to be used as a complete diet.

Notes: This product can be used either as a supplement or as a complete diet.

If it is being used as a supplement, the limit is 500 ml per day.

ORAL FEED 2KCAL/ML - Special Authority see SA0585 above - Hospital pharmacy [HP3]

 ✓ Two Cal HN

	Subsidy (Manufacturer's F \$	Price) Subs Per	Fully Brand or sidised Generic Manufacturer
Food Thickeners			
►SA0595 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals v swallowing disorder. Renewal only from a relevant specialist or general practitioner of			
1 year for applications meeting the following criteria: Both:			
 The treatment remains appropriate and the patient is ber General Practitioners must include the name of the spec 			
FOOD THICKENER – Special Authority see SA0595 above – H Powder		[HP3] 250 g OP	Resource Thicken Up
	4.56 (7.25)	380 g	Karicare Food Thickener
Gluten Free Foods	i .		
Initial application only from a relevant specialist. Approvals va the following criteria: Either: 1 Gluten enteropathy has been diagnosed by biopsy; or 2 Patient suffers from dermatitis herpetiformis.		Tenewai uniess	nouned for applications meeting
GLUTEN FREE BAKING MIX - Special Authority see SA0722			
Powder	(5.15)	1,000 g OP	Healtheries Simple Baking Mix
GLUTEN FREE BREAD MIX – Special Authority see SA0722 a		,. ,	-
Powder	3.93 (6.88)	1,000 g OP	NZB Low Gluten Bread Mix
	4.77		
	(8.57)		Bakels Gluten Free Health Bread Mix
			Health Bread Mix
GLUTEN FREE FLOUR – Special Authority see SA0722 above Powder	(8.57) 3.51 (10.51) e – Hospital pharm	acy [HP3] 2.000 g OP	

	Subsidy (Manufacturer's P \$		Fully Brand or dised Generic ✔ Manufacturer
LUTEN FREE PASTA - Special Authority see SA0722 on the p	receding page -	Hospital pharma	acy [HP3]
Buckwheat Spirals	2.00	250 g OP	
	(3.11)		Orgran
Corn and Spinach Rigatini	2.00	250 g OP	
	(2.92)		Orgran
Corn and Vegetable Shells	2.00	250 g OP	
	(2.92)		Orgran
Corn and Vegetable Spirals	2.00	250 g OP	
	(2.92)		Orgran
Garlic and Parsley Shells	2.00	250 g OP	
	(2.92)		Orgran
Rice and Corn Garden Herb Pasta	2.00	250 g OP	
	(2.92)		Orgran
Rice and Corn Lasagne Sheets	1.60	200 g OP	
	(3.82)		Orgran
Rice and Corn Macaroni	2.00	250 g OP	
	(2.92)		Orgran
Rice and Corn Penne	2.00	250 g OP	
	(2.92)		Orgran
Rice and Maize Pasta Spirals	2.00	250 g OP	
	(2.92)		Orgran
Rice and Millet Spirals	2.00	250 g OP	
	(3.11)		Orgran
Rice and corn spaghetti noodles	2.00	375 g OP	
	(2.92)		Orgran
Vegetable and Rice Spirals	2.00	250 g OP	
	(2.92)		Orgran
Italian long style spaghetti	2.00	220 g OP	
	(3.11)		Orgran
roran Corn and Spinach Bigatini to be delisted 1 March 2010)			

(Orgran Corn and Spinach Rigatini to be delisted 1 March 2010) (Orgran Garlic and Parsley Shells to be delisted 1 March 2010)

(Orgran Rice and Corn Garden Herb Pasta to be delisted 1 March 2010)

Foods And Supplements For Inborn Errors Of Metabolism - Other

SA0732 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either:

- 1 dietary management of homocystinuria; or
- 2 dietary management of maple syrup urine disease.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
 - 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the specialist and date contacted.

Prescribing Guideline

It can cost up to \$70,000 a year to keep an adult on protein supplements. Because protein substitutes are so expensive and because they are only effective in controlling PKU if a restricted diet is followed, adults with PKU will be required to demonstrate they are following the prescribed diet by regular blood testing. The requirement for testing applies to those aged over 16 years. Failure to follow an appropriate diet results in high blood phenylalanine levels.

The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully osidised	Brand or Generic Manufacturer
Supplements For Homocystinuria				
AMINOACID FORMULA WITHOUT METHIONINE – Special [HP3] See prescribing guideline on the preceding page Powder	,	732 on the pre- 500 g OP	01	bage – Hospital pharmacy MET Maxamum
Supplements For MSUD				
AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND IS – Hospital pharmacy [HP3] See prescribing guideline on the preceding page	OLEUCINE - Spe	cial Authority s	ee SA07	732 on the preceding page
Powder		500 g OP		SUD Maxamaid SUD Maxamum
Foods And Supplements For Inborn Errors Of	Metabolism -	PKU		

Prescribing Guideline

It can cost up to \$70,000 a year to keep an adult on protein supplements. Because protein substitutes are so expensive and because they are only effective in controlling PKU if a restricted diet is followed, adults with PKU will be required to demonstrate they are following the prescribed diet by regular blood testing. The requirement for testing applies to those aged over 16 years. Failure to follow an appropriate diet results in high blood phenylalanine levels.

The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.

Foods For PKU

SA0733 Special Authority for Subsidy

Initial application — (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1 dietary management of PKU; and

2 The patient's blood phenylalanine level is < 900 mmol/litre (average of tests over last 12 months).

Initial application — (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years where the patient requires dietary management of PKU.

Renewal — (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year where blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months).

Renewal — (Patient aged 16 or under) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both:

1 The treatment remains appropriate and the patient is benefiting from treatment; and

2 General Practitioners must include the name of the specialist and date contacted.

PHENYL FREE BAKING MIX – Special Authority see SA0733 above – Hospital pharmacy [HP3]

See prescribing gu	ideline above
--------------------	---------------

Powder	6.70	500 g OP
	(8.22)	

Loprofin Mix

SPECIAL FOODS

	Subsidy (Manufacturer's F \$		Fully Brand or dised Generic ✔ Manufacturer
HENYL FREE PASTA – Special Authority see SA0733 on the See prescribing guideline on the preceding page	preceding page -	Hospital pharma	acy [HP3]
Animal shapes	10.65	500 g OP	
	(11.91)		Loprofin
Lasagne	5.32	250 g OP	
-	(5.95)	-	Loprofin
Low protein rice pasta		500 g OP	
	(11.91)	•	Loprofin
Macaroni		250 g OP	
	(5.95)	•	Loprofin
Penne		500 g OP	
	(11.91)	5	Loprofin
Spaghetti		500 g OP	·
1.0	(11.91)	0	Loprofin
Spirals	· · · ·	500 g OP	·
- p	(11.91)		Loprofin

Supplements For PKU

SA0733 Special Authority for Subsidy

Initial application — (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 dietary management of PKU; and
- 2 The patient's blood phenylalanine level is < 900 mmol/litre (average of tests over last 12 months).

Initial application — (Patient aged 16 or under) only from a relevant specialist. Approvals valid for 3 years where the patient requires dietary management of PKU.

Renewal — (Patient aged over 16) only from a relevant specialist. Approvals valid for 1 year where blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months).

Renewal — (Patient aged 16 or under) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully sidised	Brand or Generic Manufacturer
AMINOACID FORMULA WITHOUT PHENYLALANINE - Spec macy [HP3]	ial Authority see	SA0733 on the	preced	ing page – Hospital phar-
See prescribing guideline on page 181				
Tabs		75 OP	🖌 Pł	hlexy 10
Sachets (pineapple/vanilla) 29 g		30 OP	🖌 Mi	inaphlex
Sachets (tropical)		30	🖌 Pł	hlexy 10
Infant formula		400 g OP	🖌 XF	P Analog LCP
Powder (orange)		500 g OP	🖌 XF	P Maxamaid
	320.00	0	V XF	P Maxamum
Powder (unflavoured)		500 g OP	V XF	P Maxamaid
	320.00	g	V XF	P Maxamum
Liquid (berry)		62.5 ml OP		ophlex LQ
	31.20	125 ml OP		ophlex LQ
Liquid (citrue)	• · · = •	62.5 ml OP		ophlex LQ
Liquid (citrus)	31.20	125 ml OP		ophlex LQ
Liquid (forest berries)	• · · = •			•
Liquid (forest berries)		250 ml OP		asiphen Liquid
Liquid (orange)		62.5 ml OP		ophlex LQ
	31.20	125 ml OP		ophlex LQ
Liquid (tropical)		250 ml OP	🖌 Ea	asiphen

Multivitamin And Mineral Supplements

➡SA0962 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Dietary management of phenylketonuria (PKU); or
- 2 For use as a supplement to the ketogenic diet in patients diagnosed with epilepsy.

AMINOACID FORMULA WITH MINERALS WITHOUT PHENYLALANINE – Special Authority see SA0962 above – Retail pharmacy See prescribing guideline on page 181

Powder	 	 	250

 Metabolic Mineral Mixture

a OP

Infant Formulae

For Premature Infants

➡SA0602 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 6 months where the patient is infant weighing less than 1.5 kg at birth.

PREMATURE BIRTH FORMULA - Special Authority see SA0602 above - Hospital pharmacy [HP3]

Liquid0.75	100 ml OP	S26LBW Gold RTF
------------	-----------	-----------------

For Williams Syndrome

➡SA0601 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 1 year where the patient is an infant suffering from Williams Syndrome and associated hypercalcaemia.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

	Subsidy (Manufacturer's Price) \$	Subs Per	Brand or Generic Manufacturer
LOW CALCIUM INFANT FORMULA – Special Authority see SAC Powder	1 0	page – Ho) g OP	

For Gastrointestinal And Other Malabsorptive Problems

➡SA0603 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 1 year where the patient is infant suffering from malabsorption and other gastrointestinal problems.

Renewal only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1 The treatment remains appropriate and the patient is benefiting from treatment; and

2 General Practitioners must include the name of the specialist and date contacted.

Neocate should be used only as a last resort when the infant is unable to absorb any of the below formulae. The objective with each of the formulae prescribed is to get the infant off them as soon as possible. This may take six months, it may take three years. Because of this, variation on age limit is not regarded as appropriate. These formulae will be available only from a hospital pharmacy. Vivonex Pediatric may be a suitable and less expensive alternative for many children that would otherwise be eligible for a subsidy for Neocate and should, therefore, be tried first in these cases. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.

ELEMENTAL FORMULA – Special Authority see SA0603 above – Hospital pharmacy [HP3]

Powder		450 g OP	
	(19.01)	Ũ	Pepti Junior
	63.97	400 g OP	
	(67.08)	-	Neocate
	(67.08)		Neocate LCP
	5.62	48.5 g OP	
	(6.00)		Vivonex Pediatric
Powder (tropical)		400 g OP	
	(56.00)		Neocate Advance
Powder (unflavoured)		400 g OP	
	(56.00)		Neocate Advance

For Milk Intolerance

➡SA0604 Special Authority for Subsidy

Initial application — (Lactase deficiency or disaccharide intolerance) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Patient is less than 3 years of age; and
- 2 Either:
 - 2.1 diagnosed as suffering from congenital lactase deficiency; or
 - 2.2 suffering from disaccharide intolerance.

Notes: Secondary lactose intolerance in children is usually short lasting, and can be controlled by dietary measures and by giving sufficient calories to regenerate digestive enzymes.

The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.

Initial application — (Infant with intolerance to cows' milk) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 intolerant to cows' milk; and

continued...

SPECIAL FOODS

	Subsidy (Manufacturer's Prio \$	ce) Subs Per	Fully idised	Brand or Generic Manufacturer
continued				
2 patient is less than 3 years of age.				
Note: The subsidy for these products reflects the philosophy th	at the patient incurs	s no additiona	l finan	cial burden for purchasing
specialised more expensive products.			alial fa	C months for smallesting
Renewal — (Infant with intolerance to cows' milk) only from meeting the following criteria:	a relevant specialis	t. Approvais v	alid to	6 months for applications
Both:				
 The treatment remains appropriate and the patient is ben patient is less than 3 years of age. 	efiting from treatme	nt; and		
GOATS MILK INFANT FORMULA - Special Authority see SA06	04 on the preceding	g page – Reta	il phar	macy
Powder	9.42	900 g OP		
	(22.75)		K	aricare Goats Milk Infant Formula
LACTOSE FREE INFANT FORMULA - Special Authority see S	A0604 on the prece	ding page – F	Retail p	harmacy
Powder	5.66	900 g OP		
	(17.95)		D	elact
SOYA INFANT FORMULA - Special Authority see SA0604 on t	he preceding page -	- Retail pharm	nacy	
Powder		900 g OP		
	(19.57)		S	26 Soy
Infant Formulae - Lactose Intolerance and Cow	s' Milk Protein	Intoleranc	е	
►SA0757 Special Authority for Subsidy				
Initial application only from a relevant specialist. Approvals val	id for 6 months for a	pplications me	eeting	the following criteria:
All of the following:				
1 The patient is less than 2 years of age; and				
 Intolerant to cows' milk; and Diagnosed as suffering from congenital lactase deficience 	,			
o Diagnoseu as sullening nom congenital lactase delicienc	/.			

s Diagnosed as suffering from congenital lactase deticiency. **Renewal** only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

Powder	 	7.27	900 g
		(16.35)	

Karicare Soy All Ages

Pharmaceuticals and quantities that may be obtained on a Practitioner's Supply Order

ADRENALINE ✓ Inj 1 in 1,000, 1 ml
AMINOPHYLLINE ✓ Inj 25 mg per ml, 10 ml
AMIODARONE HYDROCHLORIDE ✔ Inj 50 mg per ml, 3 ml
AMOXYCILLIN ✓ Cap 250 mg
AMOXYCILLIN CLAVULANATE Tab amoxycillin 500 mg with potassium
clavulanate 125 mg
potassium clavulanate 31.25 mg per 5 ml
5 ml
APPLICATOR Applicator – See note on page 691
ASPIRIN ✓ Tab dispersible 300 mg
ATROPINE SULPHATE ✓ Inj 600 µg, 1 ml
AZITHROMYCIN ✓ Tab 500 mg – Subsidy by endorsement – See note on page 844
BENDROFLUAZIDE ✔ Tab 2.5 mg – See note on page 54
BENZATHINE BENZYLPENICILLIN ✓ Inj 1.2 mega u per 2.3 ml
BENZTROPINE MESYLATE ✓ Inj 1 mg per ml, 2 ml
BENZYLPENICILLIN SODIUM (PENICILLIN G) ✔ Inj 1 mega u5
CEFTRIAXONE SODIUM ✓ Inj 500 mg – Hospital pharmacy [HP3] – Subsidy by endorsement – See note on
page 835 ✓ Inj 1 g – Hospital pharmacy [HP3] – Subsidy by endorsement – See note on page 835

ned on a Practitioner's Supply Order
CHARCOAL V Oral liq 50 g per 250 ml
CHLORPROMAZINE HYDROCHLORIDE 30 ✓ Tab 10 mg
CIPROFLOXACIN ✓ Tab 250 mg
 CO-TRIMOXAZOLE ✓ Tab trimethoprim 80 mg and sulphamethoxazole 400 mg
COMPOUND ELECTROLYTES Powder for soln for oral use 5 g
CONDOMS 49 mm 144 52 mm 144 52 mm extra strength 144 53 mm 144 53 mm 144 53 mm (chocolate) 144 53 mm (strawberry) 144 53 mm extra strength 144 53 mm extra strength 144 55 mm 144 55 mm 144 56 mm 144 56 mm extra strength 144 56 mm, shaped 144
DEXAMETHASONE ✓ Tab 1 mg – Retail pharmacy-Specialist
DEXAMETHASONE SODIUM PHOSPHATE ✓ Inj 4 mg per ml, 1 ml
DEXTROSE ✓ Inj 50%, 10 ml

PRACTITIONER'S AND WHOLESALE SUPPLY ORDERS

(continued)

DIAPHRAGM ✓ Diaphragm – See note on page 691
DIAZEPAM ✓ Inj 5 mg per ml, 2 ml – Subsidy by endorsement – See note on page 1135 ✓ Rectal tubes 5 mg5 ✓ Rectal tubes 10 mg5
DICLOFENAC SODIUM ✓ Inj 25 mg per ml, 3 ml
DIGOXIN ✔ Tab 62.5 µg
DOXYCYCLINE HYDROCHLORIDE Tab 50 mg
ERGOMETRINE MALEATE ✔ Inj 500 µg per ml, 1 ml
ERYTHROMYCIN ETHYL SUCCINATE Tab 400 mg
ERYTHROMYCIN STEARATE Tab 250 mg
ETHINYLOESTRADIOL WITH DESOGESTREL Tab 20 µg with desogestrel 150 µg63 Tab 20 µg with desogestrel 150 µg and 7 inert tab
ETHINYLOESTRADIOL WITH GESTODENE Tab 30 µg with gestodene 75 µg and 7 inert tab
 ETHINYLOESTRADIOL WITH LEVONORGESTREL ✓ Tab ethinyloestradiol 30 µg with levonorgestrel 50 µg (6) and tab ethinyloestradiol 40 µg with levonorgestrel 75 µg (5), and tab ethinyloestradiol 30 µg with levonorgestrel 125 µg (10) and 7 inert tab ✓ Tab 50 µg with levonorgestrel 125 µg and 7 inert tab ✓ Tab 30 µg with levonorgestrel 150 µg ✓ Tab 30 µg with levonorgestrel 150 µg and 7 inert tab

Tab 20 μg with levonorgestrel 100 μg and 7 inert tab84
 ETHINYLOESTRADIOL WITH NORETHISTERONE ✓ Tab 35 µg with norethisterone 1 mg
FLUCLOXACILLIN SODIUM ✓ Cap 250 mg
FLUPENTHIXOL DECANOATE ✓ Inj 20 mg per ml, 1 ml ✓ Inj 20 mg per ml, 2 ml ✓ Inj 100 mg per ml, 1 ml
FLUPHENAZINE DECANOATE ✓ Inj 12.5 mg per 0.5 ml, 0.5 ml ✓ Inj 25 mg per ml, 1 ml ✓ Inj 100 mg per ml, 1 ml
FUROSEMIDE ✓ Tab 40 mg
GLUCAGON HYDROCHLORIDE Inj 1 mg syringe kit5
GLYCERYL TRINITRATE ✔ Tab 600 µg 100 ✔ Oral pump spray 400 µg per dose
HALOPERIDOL ✓ Tab 500 µg
HALOPERIDOL DECANOATE ✓ Inj 50 mg per ml, 1 ml
HYDROCORTISONE ✔ Inj 50 mg per ml, 2 ml5
HYDROXOCOBALAMIN V Inj 1 mg per ml, 1 ml6
HYOSCINE N-BUTYLBROMIDE ✓ Inj 20 mg, 1 ml
continued

✓ fully subsidised brand available Please refer to Section A for a definition, and conditions of supply, of Practitioner's Supply Orders.

continued) IPRATROPIUM BROMIDE ✔ Nebuliser soln, 250 µg per ml, 1 ml40
✓ Nebuliser soln, 250 µg per ml, 2 ml
LEVONORGESTREL Tab 30 μg
LIGNOCAINE HYDROCHLORIDE ✓ Inj 0.5%, 5 ml – See note on page 108
LOPERAMIDE HYDROCHLORIDE ✓ Tab 2 mg
MEDROXYPROGESTERONE ACETATE ✓ Inj 150 mg per ml, 1 ml ✓ Inj 150 mg per ml, 1 ml syringe
METHYLERGOMETRINE ✓ Inj 200 µg per ml, 1 ml
METOCLOPRAMIDE HYDROCHLORIDE ✓ Inj 5 mg per ml, 2 ml
METRONIDAZOLE ✓ Tab 200 mg30
MORPHINE SULPHATE ✓ Inj 5 mg per ml, 1 ml – Only on a controlled drug form
drug form5
NALOXONE HYDROCHLORIDE ✓ Inj 400 µg per ml, 1 ml5
NONOXYNOL-9 ✔ Jelly 2% 108 g
NORETHISTERONE ✓ Tab 350 µg
NORETHISTERONE WITH MESTRANOL Tab 1 mg with mestranol 50 µg and 7 inert tab84
OXYTOCIN ✓ Inj 5 iu per ml, 1 ml

PARACETAMOL	00
 ✓ Tab 500 mg ✓ Oral lig 120 mg per 5 ml 	
✓ Oral liq 250 mg per 5 ml	
PETHIDINE HYDROCHLORIDE	
✓ Inj 50 mg per ml, 1 ml – Only on a controlle drug form	
✓ Inj 50 mg per ml, 1.5 ml – Only on a	
controlled drug form	
✓ Inj 50 mg per ml, 2 ml – Only on a controlle drug form	ed 5
PHENOXYMETHYLPENICILLIN (PENICILLII	
✓ Cap potassium salt 250 mg	
 Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml 	200 ml 200 ml 200 ml
PHENYTOIN SODIUM	200
✓ Inj 50 mg per ml, 2 ml	
✓ Inj 50 mg per ml, 5 ml	5
PHYTOMENADIONE V Inj 2 mg per 0.2 ml	5
 Inj 2 mg per 0.2 mi Inj 10 mg per ml, 1 ml 	
PIPOTHIAZINE PALMITATE	
 ✓ Inj 50 mg per ml, 1 ml ✓ Inj 50 mg per ml, 2 ml 	
PREDNISOLONE SODIUM PHOSPHATE	
✓ Oral lig 5 mg per ml – See note on	
page 75	30 ml
PREDNISONE	
✓ Tab 5 mg	
PROCAINE PENICILLIN ✓ Inj 1.5 mega u	5
PROCHLORPERAZINE	
✓ Tab 5 mg	
✓ Inj 12.5 mg per ml, 1 ml	5
PROMETHAZINE HYDROCHLORIDE ✓ Inj 25 mg per ml, 2 ml	5
SALBUTAMOL	
✓ Inj 500 µg per ml, 1 ml	5
✓ Aerosol inhaler, 100 µg per dose CFC free	1000 doso
Nebuliser soln, 1 mg per ml, 2.5 ml	
✓ Nebuliser soln, 2 mg per ml, 2.5 ml	30
SALBUTAMOL WITH IPRATROPIUM BROM	
Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml	20
	continued

✓ fully subsidised brand available

Please refer to Section A for a definition, and conditions of supply, of Practitioner's Supply Orders.

(

PRACTITIONER'S AND WHOLESALE SUPPLY ORDERS

(continued)

SILVER SULPHADIAZINE
✓ Crm 1% with chlorhexidine digluconate 0.2%
SODIUM BICARBONATE ✓ Inj 8.4%, 50ml ✓ Inj 8.4%, 100 ml
SODIUM CHLORIDE ✓ Inf 0.9% – See note on page 43

✓ Inj 0.9%, 10 ml......5

TRIMETHOPRIM ✓ Tab 300 mg
VERAPAMIL HYDROCHLORIDE ✓ Inj 2.5 mg per ml, 2 ml
WATER ✓ Purified for inj 5 ml – See note on page 435 ✓ Purified for inj 10 ml – See note on page 435 ✓ Purified for inj 20 ml – See note on page 435
ZUCLOPENTHIXOL DECANOATE ✓ Inj 200 mg per ml, 1 ml

Pharmaceuticals that may be obtained on a Wholesale Supply Order

INTRA-UTERINE DEVICE

MASK FOR SPACER DEVICE ✓ Size 2

PEAK FLOW METER

✓ Low range

Normal range

PREGNANCY TESTS - HCG URINE Cassette

SPACER DEVICE

✓ 230 ml (autoclavable)

✓ 230 ml (single patient)

🖌 800 ml

Rural Areas for Practitioner's Supply Orders

NORTH ISLAND

Northland DHB

Dargaville Hikurangi Kaeo Kaikohe Kaitaia Kawakawa Kerikeri Mangonui Maungaturoto Moerewa Naunauru Paihia Rawene Ruakaka Russell Tutukaka Waipu Whangaroa

Waitemata DHB

Helensville Huapai Kumeu Snells Beach Waimauku Warkworth Wellsford

Auckland DHB

Great Barrier Island Oneroa Ostend

Counties Manukau DHB Tuakau Waiuku

Waikato DHB Coromandel Huntly Kawhia Matamata Morrinsville Ngatea Otorohanga Paeroa Pauanui Beach Putaruru Raglan

Tairua Taumarunui Te Aroha Te Kauwhata Te Kuiti Tokoroa Waihi Whangamata Whitianga

Bay of Plenty DHB

Edgecumbe Katikati Kawerau Murupara Opotiki Taneatua Te Kaha Waihi Beach Whakatane

Lakes DHB Mangakino

Turangi

Tairawhiti DHB **Ruatoria** Te Araroa

Te Karaka Te Puia Springs Tikitiki Tokomaru Bay Tolaga Bay

Taranaki DHB

Eltham Inglewood Manaia Oakura Okato Opunake Patea Stratford Waverley

Hawkes Bay DHB

Chatham Islands Waipawa Waipukurau Wairoa Whanganui DHB

Bulls

Marton Ohakune Raetihi Taihape Waiouru MidCentral DHB Dannevirke

Foxton Levin Otaki Pahiatua Shannon Woodville

Wairarapa DHB

Carteron Featherston Grevtown Martinborough

SOUTH ISLAND

Nelson/Marlborough DHB Havelock

Mapua Motueka Murchison Picton Takaka Wakefield

West Coast DHB

Dobson Grevmouth Hokitika Karamea Reefton South Westland Westport Whataroa

Canterbury DHB

Akaroa Amberlev Amuri Cheviot Darfield Diamond Harbour Hanmer Springs Kaikoura

Leeston I incoln Methven Oxford Rakaia Rolleston **Rotherham** Templeton Waikari

South Canterbury DHB

Fairlie Geraldine Pleasant Point Temuka Twizel Waimate

Otago DHB

Alexandra Balclutha Cromwell Kurow I awrence Milton Oamaru Outram Owaka Palmerston Ranfurly Roxburgh Tapanui Wanaka

Southland DHB

Gore Lumsden Mataura Ohan Otautau Queenstown Riverton Te Anau Tokonui Tuatapere Winton

SECTION F: PART I

A Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule:

a) is exempt from any requirement to dispense in Monthly Lots;

b) will only be subsidised if it is dispensed in a 90 Day Lot unless it is Close Control.

A Community Pharmaceutical that is an oral contraceptive and that is identified with a * within the other sections of the Pharmaceutical Schedule:

a) is exempt from any requirement to dispense in Monthly Lots;

b) will only be subsidised if it is dispensed in a 180 Day Lot unless it is Close Control.

SECTION F: PART II: CERTIFIED EXEMPTIONS AND ACCESS EXEMPTIONS TO MONTHLY DISPENSING

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule, may be dispensed in a 90 Day Lot if:

- a) the Community Pharmaceutical is identified with a ▲ within the other sections of the Pharmaceutical Schedule and the prescriber has endorsed the Prescription item(s) on the Prescription to which the exemption applies "certified exemption". In endorsing the Prescription items for a certified exemption, the prescriber is certifying that:
 - i) the patient wished to have the medicine dispensed in a quantity greater than a Monthly Lot; and
 - ii) the patient has been stabilised on the same medicine for a reasonable period of time; and

iii) the prescriber has reason to believe the patient will continue on the medicine and is compliant.

b) a patient, who has difficulty getting to and from a pharmacy, signs the back of the Prescription to qualify for an Access Exemption. In signing the Prescription, the patient or his or her nominated representative must also certify which of the following criteria they meet:

i) have limited physical mobility;

- ii) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
- iii) are relocating to another area;
- iv) are travelling extensively and will be out of town when the repeat prescriptions are due.

The following Community Pharmaceuticals are identified with a A within the other sections of the Pharmaceutical Schedule and may be dispensed in a 90 Day Lot if endorsed as a certified exemption in accordance with paragraph (a) in Section F Part II above.

ALIMENTARY TRACT AND ME INSULIN ASPART	ETABOLISM
INSULIN GLARGINE	
INSULIN ISOPHANE	
INSULIN ISOPHANE WITH	INSULIN NEUTRAL
INSULIN LISPRO	
INSULIN LISPRO WITH INS	ULIN LISPRO PROTAMINE
INSULIN NEUTRAL	
CARDIOVASCULAR SYSTEM AMIODARONE HYDROCHL Tab 100 mg Tab 200 mg	Cordarone-X Cordarone-X
DISOPYRAMIDE PHOSPHA	ΤE
FLECAINIDE ACETATE Tab 50 mg Tab 100 mg Cap long-acting 100 mg Cap long-acting 200 mg	
MEXILETINE HYDROCHLORIDE	
PROPAFENONE HYDROCH	ILORIDE

MUSCULOSKELETAL SYSTEM PYRIDOSTIGMINE BROMIDE

NERVOUS SYSTEM AMANTADINE HYDROCHLORIDE

APOMORPHINE HYDROCHLORIDE

ENTACAPONE

GABAPENTIN

GABAPENTIN (NEURONTIN)

LAMOTRIGINE

LISURIDE HYDROGEN MALEATE

PERGOLIDE

ROPINIROLE HYDROCHLORIDE

TOLCAPONE

TOPIRAMATE

VIGABATRIN

SENSORY ORGANS

BIMATOPROST

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

DESMOPRESSIN Nasal drops 100 µg per Minirin ml Nasal spray 10 µg per Desmopressin-PH&T dose BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE

BRINZOLAMIDE

LATANOPROST

TRAVOPROST

SECTION G: SAFETY CAP MEDICINES

Pharmacists are required, under the Code of Ethics of the Pharmacy Council of New Zealand, to endeavour to use safety caps when dispensing any of the medicines listed in Section G in an oral liquid formulation pursuant to a prescription or Practitioner's Supply Order. This includes all proprietary and extemporaneously compounded oral liquid preparations of those pharmaceuticals listed in Section G of the Pharmaceutical Schedule. These medicines will be identified throughout Section B of the Pharmaceutical Schedule with the symbol '‡'.

Exemptions

Oral liquid preparations of the pharmaceuticals listed in Section G of the Pharmaceutical Schedule will be dispensed in a container with a safety cap unless:

- the practitioner has endorsed the Prescription or Practitioner's Supply Order, stating that, the Pharmaceutical is not to be dispensed in a container with a safety cap; or
- the Contractor has annotated the Prescription or Practitioner's Supply Order stating that, because of infirmity of the particular
 person, the Pharmaceutical to be used by that person should not be dispensed in a container with a safety cap; or
- the Pharmaceutical is packaged in an Original Pack so designed that on the professional judgement of the Contractor, transfer to a container with a safety cap would be inadvisable or a retrograde procedure.

Reimbursment

Pharmacists will be reimbursed according to their agreement. Where an additional fee is paid on safety caps it will be paid on all dispensings of oral liquid preparations for those pharmaceuticals listed in Section G of the Pharmaceutical Schedule unless the practitioner has endorsed or the contractor has annotated the Prescription or Practitioner's Supply Order that a safety cap has not been supplied.

Safety Caps (NZS 5825:1991)

20 mm	. Clic-Loc, United Closures & Plastics PLC, England
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
24 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Clic-Loc, ACI Closures under license to Owens-Illinois
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
28 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Clic-Loc, ACI Closures under license to Owens-Illinois
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
	PDL Squeezlok
	PDL FG

SAFETY CAP MEDICINES

FERROUS SULPHATE Oral liq 150 mg per 5 ml Ferodan

CARDIOVASCULAR SYSTEM

AMILORIDE Oral liq 1 mg per ml Biomed

CAPTOPRIL Oral liq 5 mg per ml Capoten

CHLOROTHIAZIDE	
Oral liq 50 mg per ml	Biomed

DIGOXIN Oral liq 50 µg per ml Lanoxin FUROSEMIDE Oral liq 10 mg per ml Lasix

SPIRONOLACTONE Oral liq 5 mg per ml Biomed

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES LEVOTHYROXINE

 Tab 50 μg
 Eltroxin

 Goldshield
 Synthroid

 Tab 100 μg
 Eltroxin

 Goldshield
 Synthroid

 Tab 25 μg
 Synthroid

 (Extemporaneously compounded oral liquid preparations)

MUSCULOSKELETAL SYSTEM

IBUPROFEN Oral liq 100 mg per 5 ml Fenpaed

QUININE SULPHATE Tab 200 mg Q 200 Tab 300 mg Q 300 (Extemporaneously compounded oral liquid preparations)

NERVOUS SYSTEM

ALPRAZOLAM Tab 250 µg Arrow-Alprazolam Tab 500 µg Arrow-Alprazolam Tab 1 mg Arrow-Alprazolam (Extemporaneously compounded oral liquid preparations)

CARBAMAZEPINE Oral lig 100 mg per 5 ml Tegretol

CLOBAZAM Tab 10 mg Frisium (Extemporaneously compounded oral liquid preparations) CLONAZEPAM Oral drops 2.5 mg per Rivotril ml DIAZEPAM Tab 2 mg Pro-Pam Arrow-Diazepam Tab 5 mg Pro-Pam Arrow-Diazepam Tab 10 mg Pro-Pam (Extemporaneously compounded oral liquid preparations) FTHOSUXIMIDE Oral lig 250 mg per 5 ml Zarontin LORAZEPAM Tab 1 mg Ativan Tab 2.5 mg Ativan (Extemporaneously compounded oral liquid preparations) I ORMFTAZEPAM Noctamid Tab 1 mg (Extemporaneously compounded oral liquid preparations) METHADONE HYDROCHLORIDE Oral lig 2 mg per ml Biodone **Biodone Forte** Oral liq 5 mg per ml Oral lig 10 mg per ml Biodone Extra Forte MIDAZOLAM Tab 7.5 mg Hypnovel (Extemporaneously compounded oral liquid preparations) MORPHINE HYDROCHLORIDE Oral lig 1 mg per ml **RA-Morph** Oral liq 2 mg per ml **RA-Morph** Oral lig 5 mg per ml RA-Morph Oral lig 10 mg per ml **RA-Morph**

NITRAZEPAM

Tab 5 mg Nitrados (Extemporaneously compounded oral liquid preparations)

OXAZEPAM

Tab 10 mg Ox-Pam Tab 15 mg Ox-Pam (Extemporaneously compounded oral liquid preparations)

SAFETY CAP MEDICINES

OXYCODONE HYDROCHLORIDE Oral liq 5 mg per 5 ml OxyNorm

PARACETAMOL Oral liq 120 mg per 5 ml Paracare Junior Oral lig 250 mg per 5 ml Paracare Double Strength

PHENYTOIN SODIUM Oral liq 30 mg per 5 ml Dilantin

SODIUM VALPROATE Oral liq 200 mg per 5 ml

Epilim S/F Liquid Epilim Syrup

TEMAZEPAM

Tab 10 mg Normison (Extemporaneously compounded oral liquid preparations)

TRIAZOLAM

Tab 125 μg Hypam Tab 250 μg Hypam (Extemporaneously compounded oral liquid preparations)

RESPIRATORY SYSTEM AND ALLERGIES

CETIRIZINE HYDROCHLORIDE Oral liq 1 mg per ml Cetirizine - AFT

CHLORPHENIRAMINE MALEATE Oral liq 2 mg per 5 ml Histafen DEXTROCHLORPHENIRAMINE MALEATE Oral liq 2 mg per 5 ml Polaramine

PROMETHAZINE HYDROCHLORIDE Oral liq 5 mg per 5 ml Phenergan

SALBUTAMOL Oral liq 2 mg per 5 ml Salapin

THEOPHYLLINE Oral lig 80 mg per 15 ml Nuelin

TRIMEPRAZINE TARTRATE Oral liq 30 mg per 5 ml Vallergan Forte

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

CODEINE PHOSPHATE Powder Douglas (Extemporaneously compounded oral liquid preparations)

METHADONE HYDROCHLORIDE Powder AFT (Extemporaneously compounded oral liquid preparations)

PHENOBARBITONE SODIUM Powder MidWest (Extemporaneously compounded oral liquid preparations)

- Symbols - 3TC93	
- A -	
A-Lices64	
Abacavir sulphate92	
Abacavir sulphate with	
lamivudine92	
Abilify120	1
Acarbose	
ACB51	
Accu-Chek Performa31, 32	
Accupril49	1
Accuretic 1049	
Accuretic 2049	
Acebutolol	
Acetazolamide156	
Acetic acid with 1, 2- propanediol	
diacetate and	
benzethonium154	
Acetic acid with hydroxyquinoline	
and ricinoleic acid73	
Acetylcysteine164	
Aci-Jel73	
Aciclovir	
Infection91	
Sensory154	
Acidex	,
Acipimox44	
Acitretin65	,
Actigall	1
Actos	í.
Actrapid28	
Actrapid Penfill28	
Acupan108	,
Adalat 1053	,
Adalat Oros53	,
Adalimumab101	
Adefin XL53	,
Adefovir dipivoxil89	
Adrenaline56	
Advantan62	
AFT-Pyrazinamide88	
Agents Affecting the	
Renin-Angiotensin System48	
Agents Used in the Treatment of	
Poisonings159	
Agrylin136	
Alanase152	
Albay147	
Albustix159	
Aldara67	
Alendronate sodium106	i

Alendronate sodium with
cholecalciferol 106
Alfacalcidol
Alginic acid25
Alitraq174
Alkeran
Allersoothe148
Allopurinol107
Alpha Adrenoceptor Blockers48
Alpha tocopheryl acetate
Alpha-Bromocriptine119
Alpha-Keri Lotion64
Alprazolam124
Alu-Tab25
Aluminium hydroxide25
Amantadine hydrochloride119
Amiloride
Amiloride with frusemide54
Amiloride with
hydrochlorothiazide54
Aminophylline152
Amiodarone hydrochloride50
Amirol
Amisulpride120
Amitrip111
Amitriptyline111
Amizide
Amlodipine52
Amorolfine
Amoxycillin85
Amoxycillin clavulanate85
Amphotericin B
Amsacrine
Amsidyl136
Amyl nitrite
Anabolic Agents75
Anaesthetics108
Anagrelide hydrochloride136
Analgesics
Anastrozole142
Anastrozole-DP142
Andriol Testocaps76
Androderm
Antabuse129
Antacids and Antiflatulants25
Anten111
Anthelmintics83
Anti-inflammatory Non Steroidal
Drugs (NSAIDs)
Antiacne Preparations
Antiallergy Preparations147
Antianaemics

Antiandrogen Oral
Contraceptives72
Antiarrhythmics50
Antibacterials83
Antibacterials Topical59
Anticholinesterases
Antidepressants111
Antidiarrhoeals25
Antiepilepsy Drugs113
Antifibrinolytics, Haemostatics
and Local Sclerosants
Antifungals
Antifungals Topical
Antihaemorrhoidals
Antihistamines
Antihypotensives
Antimalarials
Antimigraine Preparations117
Antinaus118
Antinausea and Vertigo
Agents 117
Antiparkinson Agents
Antipruritic Preparations
Antipsychotics
Antiretrovirals
Antiretrovirals - Additional
Antiretrovirais - Additional
Therapies
Antirheumatoid Agents100 Antispasmodics and Other
Agents Altering Gut
Motility
Antithrombotic Agents40
Antithymocyte globulin
(equine)
Antitrichomonal Agents
Antituberculotics and
Antileprotics
Antiulcerants
Antivirals
Anusol
Anxiolytics
API60
Apo-Allopurinol107
Apo-Amlodipine52
Apo-Amoxi85
Apo-Ascorbic Acid36
Apo-B-Complex
Apo-Bromocriptine119
Apo-Captopril48
Apo-Cimetidine27
Apo-Clopidogrel40
Apo-Diclo99

Apo-Diclo SR99
Apo-Doxazosin48
Apo-Folic Acid
Apo-Gliclazide
APO-go119
Apo-Ipravent152
Apo-Moclobemide112
Apo-Nadolol
Apo-Nicotinic Acid44
Apo-Oxybutynin
Apo-Prazo
Apo-Prednisone
Apo-Primidone
Apo-Pyridoxine
Apo-Selegiline
Apo-Terazosin
Apo-Terbinafine
Apo-Thiamine
Apo-Timol
Apo-Timop
Apo-Zopiclone
Apomine
Apomorphine hydrochloride119
Applicator
Apresoline
Aquasun 30+67
Aquasun Oil Free Faces
SPF30+
SPF30+
SPF30+
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120 Aristocort 62 Aromasin 142
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120 Aristocort 62 Aromasin 142 Arrow-Alprazolam 124
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120 Aristocort 62 Aromasin 142 Arrow-Alprazolam 124 Arrow-Azithromycin 84
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120 Aristocort 62 Arrow-Alprazolam 142 Arrow-Alprazolam 124 Arrow-Alprazolam 84 Arrow-Cabergoline 81
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120 Aristocort 62 Arrow-Alprazolam 142 Arrow-Alprazolam 124 Arrow-Cabergoline 81 Arrow-Citalopram 112
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120 Ariotocort 62 Aromasin 142 Arrow-Alprazolam 124 Arrow-Cabergoline 81 Arrow-Citalopram 112 Arrow-Clopidogrel 40
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120 Arrow-Alprazolam 142 Arrow-Alprazolam 124 Arrow-Cabergoline 81 Arrow-Citalopram 112 Arrow-Clopidogrel 40 Arrow-Diazepam 125
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120 Ariotocort 62 Arrow-Alprazolam 142 Arrow-Alprazolam 124 Arrow-Cabergoline 81 Arrow-Citalopram 112 Arrow-Clopidogrel 40 Arrow-Lamotrigine 115
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120 Aristocort 62 Arrow-Alprazolam 142 Arrow-Alprazolam 124 Arrow-Cabergoline 81 Arrow-Citalopram 112 Arrow-Citalopram 125 Arrow-Lizepam 125 Arrow-Lamotrigine 115 Arrow-Lisinopril 49
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120 Aristocort 62 Aromasin 142 Arrow-Alprazolam 124 Arrow-Cabergoline 81 Arrow-Citalopram 112 Arrow-Diazepam 125 Arrow-Lisinopril 49 Arrow-Metformin 30
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120 Aristocort 62 Arrow-Alprazolam 142 Arrow-Alprazolam 124 Arrow-Cabergoline 81 Arrow-Cialopram 112 Arrow-Clopidogrel 40 Arrow-Lisinopril 49 Arrow-Metformin 30 Arrow-Nifedipine XR 53
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120 Aristocort 62 Arrow-Alprazolam 142 Arrow-Alprazolam 142 Arrow-Cabergoline 81 Arrow-Citalopram 112 Arrow-Clopidogrel 40 Arrow-Lizepam 125 Arrow-Lamotrigine 115 Arrow-Lamotrigine 155 Arrow-Lamotrigine 30 Arrow-Lostopril 49 Arrow-Netformin 30 Arrow-Norfloxacin 98
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120 Aristocort 62 Arrow-Alprazolam 142 Arrow-Alprazolam 142 Arrow-Cabergoline 81 Arrow-Citalopram 112 Arrow-Clopidogrel 40 Arrow-Lamotrigine 115 Arrow-Lamotrigine 115 Arrow-Lamotrigine 115 Arrow-Lamotrigine 153 Arrow-Metformin 30 Arrow-Norfloxacin 98 Arrow-Ranitidine 27
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120 Aristocort 62 Aromasin 142 Arrow-Alprazolam 124 Arrow-Clabergoline 81 Arrow-Citalopram 112 Arrow-Clopidogrel 40 Arrow-Lisinopril 49 Arrow-Metformin 30 Arrow-Netformin 30 Arrow-Norfloxacin 98 Arrow-Raintidine 27 Arrow-Raintidine 27
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120 Aristocort 62 Arrow-Alprazolam 142 Arrow-Alprazolam 124 Arrow-Alprazolam 124 Arrow-Cabergoline 81 Arrow-Clopidogrel 40 Arrow-Liapopril 49 Arrow-Listopril 49 Arrow-Nifedipine XR 53 Arrow-Norfloxacin 98 Arrow-Ranitidine 27 Arrow-Ranitidine 27 Arrow-Sinva 10mg 46
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120 Aristocort 62 Aromasin 142 Arrow-Alprazolam 124 Arrow-Alprazolam 124 Arrow-Alprazolam 124 Arrow-Alprazolam 124 Arrow-Cabergoline 81 Arrow-Clopidogrel 40 Arrow-Cialopram 112 Arrow-Lisinopril 49 Arrow-Logine XR 53 Arrow-Norfloxacin 98 Arrow-Ranitidine 27 Arrow-Roxithromycin 85 Arrow-Simva 10mg 46 Arrow-Simva 20mg 46
SPF30+ 67 Aquasun Sensitive SPF 30+ 67 Aqueous cream 63 Aratac 50 Arava 100 Arimidex 142 Aripiprazole 120 Aristocort 62 Arrow-Alprazolam 142 Arrow-Alprazolam 124 Arrow-Alprazolam 124 Arrow-Cabergoline 81 Arrow-Clopidogrel 40 Arrow-Liapopril 49 Arrow-Listopril 49 Arrow-Nifedipine XR 53 Arrow-Norfloxacin 98 Arrow-Ranitidine 27 Arrow-Ranitidine 27 Arrow-Sinva 10mg 46

Arrow-Sumatriptan117 Arsenic trioxide137
Arthrexin100
Asacol
Ascorbic acid
Aspec 300108
Aspen Adrenaline56
Aspirin
Blood40
Nervous108
Asthalin150
Atacand49
Atazanavir sulphate93
Atenolol51
ATGAM144
Ativan125
Atomoxetine127
Atorvastatin45
Atropine sulphate
Alimentary
Sensory
Atropt
Atrovent
Augmentin85
Augmentin
Avomine
Avonex
Azamun144
Azatadine maleate147
Azathioprine144
Azithromycin84
Azol82
Azopt156
AZT93
- B -
- B -
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine
- B - B-D Micro-Fine

treatment147
Bendrofluazide54
Benhex64
Benzathine benzylpenicillin85
Benzoin164
Benztrop120
Benztropine mesylate
Benzydamine hydrochloride
Benzylpenicillin sodium (penicillin
G)
Beta Adrenoceptor Blockers
Beta Cream61
Beta Ointment
Beta Scalp
Beta-Adrenoceptor Agonists150
Betadine
Betadine Skin Prep64
Betaferon
Betagan
Betahistine dihydrochloride117
Betaloc
Betaloc CR
Betanethasone dipropionate61
Betamethasone sodium
phosphate with
betamethasone acetate
Betamethasone valerate
Betamethasone valerate with
clioquinol
Betamethasone valerate with
fusidic acid
Betaxolol hydrochloride155
Betnovate
Betnovate-C
Betoptic
Betoptic S
Bezafibrate
Bezalip Retard44
Bicalox
Bicalutamide
Bicillin LA85
BiCNU
Bimatoprost156
Biodone
Biodone Extra Forte109
Biodone Forte
Bisacodyl
BK Lotion
Blenoxane
Bleomycin sulphate
Bleph 10154
Blood glucose diagnostic test

Blood glucose diagnostic test
strip
Bonjela
Bosentan
Breath-Alert153
Brevinor 1/2171
Brevinor 1/2871
Brevinor 2171
Bricanyl Turbuhaler
Brimonidine tartrate
Brimonidine tartrate with timolol
maleate
Brinzolamide
Brolene
Bromocriptine mesylate119
Brufen
Brufen Retard99
Buccastem118
Budesonide
Alimentary25
Respiratory148, 152
Budesonide with
eformoterol
Bumetanide54
Bupivacaine hydrochloride108
Buprenorphine
hydrochloride
Bupropion hydrochloride
Burinex54
Buscopan27
Buserelin acetate80
Buspirone hydrochloride124
Busulphan133
Busulphan
Butacort Aqueous152
- C -
Cabergoline81
Cafergot117
Cal-d-Forte
Calamine60
Calci-Tab 50037
Calci-Tab 60037
Calcipotriol65
Calcitonin107
Calcitriol
Calcitriol-AFT
Calcium
Calcium carbonate37
Calcium carbonate with
aminoacetic acid
Calcium Channel Blockers
Calcium Disodium
Versenate 159

Calcium folinate134


Calcium Folinate Ebewe	37 05
sulphonate	43
Calcium Resonium	43
Calogen1	69
Calsource	37
Camptosar1	26
Campiosal	
Canesten	
Capadex1	
Capecitabine1	34
Capoten	48
Capsaicin	
Captopril	48
Carafate	28
Carbamazepine1	
Carbimazole	
Carboplatin1	33
Carboplatin Ebewe1	33
Carbosorb-X1	59
Cardinol	
Cardinol LA	
Cardizem CD	
Carmustine1	
Carvedilol	
Catapres	54
Catapres-TTS-1	53
Catapres-TTS-2	53
Catapres-TTS-3	53
CeeNU1	33
Cefaclor monohydrate	
Cefazolin sodium	83
Cefoxitin sodium	
Ceftriaxone sodium	
Cefuroxime axetil	
Cefuroxime sodium	83
Celestone Chronodose	75
Celiprolol	51
Cellcept1	44
Celol	51
Cerezyme	35
Cerezyme1 Cetirizine - AFT1	47
Cetirizine hydrochloride1	47
Cetomacrogol	63
Charcoal1	59
Chemotherapeutic Agents1	33
Chlorambucil1	33
Chloramphenicol1	
Chlorhevidine aluconate	
Alimentary	35
Dermatological	62
Donnatological	00

Chloroform164
Chloromycetin154
,
Chlorothiazide
Chlorpheniramine maleate147
Chlorpromazine
hydrochloride121
Chlorsig154
Chlorthalidone
Chlorvescent
Cholecalciferol36
Cholestyramine with
aspartame
Choline salicylate with
cetalkonium chloride
Ciclopiroxolamine
Cilazapril48
Cilazapril with
hydrochlorothiazide
Cilicaine
Cilicaine VK86
Ciloxan154
Cimetidine27
Ciprofloxacin
Infection86
Sensory154
Cisplatin
Cisplatin Ebewe133
Citalopram hydrobromide112
Cladribine
Clarithromycin84
Clexane41
Climara 10077
Climara 5077
Clindamycin86
Clinistix
Clinitest
Clinoril100
Clobazam113
Clobetasol propionate61, 66
Clobetasone butyrate61
Clomazol
Dermatological59
Genito-Urinary
Clomiphene citrate81
Clomipramine hydrochloride111
Clonazepam113
Clonidine53
Clonidine hydrochloride
Cardiovascular
Nervous117
Clopidogrel40
Clopine121
Clopixol122, 123

Clopress111
Clotrimazole
Dermatological59
Genito-Urinary73
Clozapine121
Clozaril
Co-Renitec49
Co-trimoxazole87
Coal tar
Coal tar with allantoin, menthol,
phenol and sulphur
Coal tar with salicylic acid and
sulphur
Coco-Scalp
Codalgin110
Codeine phosphate
Extemporaneous164
Nervous109
Cogentin
Colaspase (L-asparaginase)137
Colchicine107
Colestid44
Colestipol hydrochloride44
Colgout107
Colifoam26
Colistin sulphomethate87
Colistin-Link87
Collodion flexible164
Colofac27
Coloxyl
Combigan156
Combivent151
Combivir93
Compound electrolytes43
Compound
hydroxybenzoate
Comtan
Concerta131
Condoms
Condyline67
Contraceptives - Hormonal
Contraceptives - normonal
Non-hormonal
Copaxone127
Copper
Corangin
Cordarone-X
Corticosteroids and Related
Agents for Systemic Use
Corticosteroids Topical61
Cosmegen137
Cosopt156
Cotazym ECS

Coumadin42	2
Coversyl49	
Cozaar	0
Creon 1000033	
Creon Forte	
Crixivan	
Cromolux155	
Crotamiton60	
Crystacide	
Cyclizine hydrochloride117	7
Cyclizine lactate117	
Cycloblastin133	3
Cyclogyl157	(
Cyclopentolate	_
hydrochloride 15	7
Cyclophosphamide133	3
Cyclosporin A146	6
Cyklokapron40	0
Cyproheptadine	
hydrochloride147	7
Cyproterone acetate	6
Cyproterone acetate with	
ethinyloestradiol	2
Cystic Fibrosis	2
Cytarabine13	5
Cytotec2	
Cytoxan133	
- D -	
- D - D-Penamine	0
- D - D-Penamine	0 2
- D - D-Penamine	0 2
- D - D-Penamine	0 2 3
- D - D-Penamine	0 2 3 7
- D - D-Penamine	0 2 3 7 0
- D - D-Penamine	0 2 3 7 0
- D - D-Penamine	0 2 3 7 0 7
- D - D-Penamine	0 2 3 7 0 7
- D - D-Penamine	0 2 3 7 0 7 5
- D - D-Penamine	0 2 3 7 0 7 5 5
- D - D-Penamine	
- D - D-Penamine	
- D - D-Penamine	
- D - D-Penamine	02370 75 50627
- D - D-Penamine	02370 75 506277
- D - D-Penamine	
- D - D-Penamine	02370 75 50627708
- D - D-Penamine	02370 755062770 80
- D - D-Penamine	02370 755062770 807
- D - D-Penamine	02370 7550627708072
- D - D-Penamine	
- D - D-Penamine	02370 75 5062770 807235
- D - D-Penamine	02370 75 50627708072355
- D - D-Penamine	02370 75 50627708072355

Depo-Medrol with lidocaine75
Depo-Provera72
Depo-Testosterone
Deprim87
Derbac-M64
Dermol61, 66
Desferrioxamine mesylate159
Desmopressin81
Desmopressin81 Desmopressin-PH&T81
Detection of Substances in
Urine 159
Dexamethasone
Hormone
Sensory155
Dexamethasone sodium
phosphate
Dexamethasone with framycetin
and gramicidin
Dexamethasone with neomycin
and polymyxin b sulphate155
Dexamphetamine sulphate
Dextrochlorpheniramine
maleate 148
Dextropropoxyphene with
paracetamol 109
Dextrose43
Dextrose with electrolytes43
DHC Continus
Diabetes
Diabetes Management
Diabur 5000
Diamox156
Diaphragm
Diasip
Diason RTH
Diastix
Diastop
Diazepam113, 125
Dibenyline
Diclofenac sodium
Musculoskeletal System
Sensory155
Didanosine [DDI]92
Didronel107
Difflam
Diflucortolone valerate61
Digestives Including
Enzymes 33
Digoxin50
Dihydrocodeine tartrate109
Dilantin115
Dilantin Infatab115
Dilatrend51



Diltiazem hydrochloride	53
Dilzem	53
Dimetriose	
Dipentum	
Diphemanil methylsulphate	
Diphenoxylate hydrochloride with	00
Diprierioxylate nyurochionue with	0.5
atropine sulphate	
Diprosone	61
Diprosone OV	61
Dipyridamole	41
Disinfecting and Cleansing	
Agents	63
Disipal	120
Disopyramide phosphate	120
Disopyramide prospriate	50
Disulfiram	
Dithranol	
Diuretics	54
Diurin 40	
Diurin 500	54
Dixarit	
DM Ject	
Docetaxel	
Docusate sodium	
Docusate sodium with	0+
sennosides	04
sennosides	34
Domperidone	
Dopergin	
Dopress	
Dornase alfa	152
Dorzolamide hydrochloride	156
Dorzolamide hydrochloride with	
timolol maleate	. 156
Dostinex	81
Dothiepin hydrochloride	111
Doxazosin mesylate	
Dovazosini mesylate	40
Doxepin hydrochloride	
Doxine	
Doxorubicin	138
Doxorubicin Ebewe	
Doxy-50	86
Doxycycline hydrochloride	
DP Lotion	64
DP Lotn HC	
DP-Anastrozole	
Dr Reddy's Omeprazole	28
Dr Reddy's Pantoprazole	
Dulcolax	
Duicolax Duocal Super Soluble	34
	100
Powder	
Duolin	
Duphalac	
Duphaston	
Durex Confidence	69

Durex Extra Safe	69
Durex Select Flavours	69
Duride	
Durogesic	109
Dusting Powders	
Dydrogesterone	
Dynacirc-SRO	
-E-	
E-Mycin	84
Ear Preparations	
Ear/Eye Preparations	
Easiphen	
Easiphen Liquid	
Econazole nitrate	
Efavirenz	
Efexor XR	
Eformoterol fumarate	
Efudix	
Egopsoryl TA	
Elemental 028 Extra	
Eligard	
Elocon	
Eloxatin	
Eltroxin	
EMLA	
Emtricitabine	93
Emtriva	90 93
Emulsifying ointment	00 63
Enalapril	

Eltroxin	79
EMLA	108
Emtricitabine	93
Emtriva	
Emulsifying ointment	63
Enalapril	
Enalapril with	
hydrochlorothiazide	49
Enbrel	
Endocrine Therapy	142
Endoxan	
Enerlyte	43
Enfuvirtide	93
Enoxaparin sodium	41
Ensure	
Ensure Plus	
Ensure Plus RTH	
Entacapone	119
Entecavir	
Entocort CIR	25
Enuclene	158
Enzymes	
Epilim	115
Epilim Crushable	115
Epilim IV	115
Epilim S/F Liquid	115
Epilim Syrup	
Epirubicin	
Epirubicin Ebewe	

Eprex	39
ERA	85
Ergometrine maleate	73
Ergotamine tartrate with	
caffeine	117
Erythrocin IV	
Erythromycin ethyl succinate	
Erythromycin lactobionate	
Erythromycin stearate	85
Erythropoietin alpha	39
Erythropoietin beta	39
Estelle 35-ED	72
Estraderm TTS 100	
Estraderm TTS 25	
Estraderm TTS 50	77
Estrofem	
Etanercept	
Ethambutol hydrochloride	
Ethics Aspirin	
Ethics Aspirin EC	40
Ethics Ibuprofen	
Ethinyloestradiol	78
Ethinyloestradiol with	
desogestrel	70
Ethinyloestradiol with gestodene	
gestodene	70
Ethinvloestradiol with	
levonorgestrel	71
Ethinyloestradiol with	
norethisterone	71
Ethosuximide	113
Etidrate	
Etidronate disodium	107
Etopophos	138
Etoposide	138
Etoposide phosphate	138
Eumovate	61
Eurax	
Exemestane	142
Extemporaneously Compounded	
Preparations and	
Galenicals	164
Eye Preparations	154
Ezetimibe	46
Ezetimibe with simvastatin	47
Ezetrol	46
-F-	
Famotidine	27
Famox	27
Felo 10 ER	
Felo 5 ER	53
Felodipine	53
Femara	142

	INDEX
Generic Chemicals and	Brands

Femodene 2870
Femtran 10077
Femtran 5077
Fenpaed99
Fentanyl
Fentanyl citrate109
Ferodan
Ferro-F-Tabs
Ferro-Gradumet38
Ferro-tab
Ferrograd-Folic
Ferrous fumarate
Ferrous fumarate with folic
acid
Ferrous gluconate with ascorbic
acid
Ferrous sulphate
Ferrous sulphate
Ferrous sulphate with folic
acid
Ferrum H38
Fexofenadine hydrochloride148
Fibalip44
Fibersource177
Fibersource HN177
Fibersource HN RTH177
Fibersource RTH177
Fibro-vein40
Finasteride73
Fintral73
Flagyl88
Flagyl-S88
Flecainide acetate51
Fleet
Fleet Phosphate Enema
Flixotide149
Flixotide Accuhaler149
Florinef
Fluanxol
Fluarix
Flucloxin86
Flucon155
Fluconazole87
Fludara135
Fludara Oral135
Fludarabine phosphate135
Fludrocortisone acetate
Fluids and Electrolytes43
Flumetasone pivalate
Fluocortolone caproate with
fluocortolone pivalate and
cinchocaine
Fluorometholone155

Fluorouracil Ebewe135
Fluorouracil sodium
Dermatological68
Oncology135
Fluox112
Fluoxetine hydrochloride112
Flupenthixol decanoate123
Fluphenazine decanoate
Flutamide142
Flutamin142
Fluticasone149
Fluticasone with salmeterol150
Fluvax
FML155
Foban
Folic acid
Food Thickeners
Foods And Supplements For
Inborn Errors Of Metabolism -
Other 180
Foods And Supplements For
Inborn Errors Of Metabolism -
PKU
Foradil
Foremount Child's Silicone
Mask 153
Fortimel171
Fortini173
Fortini Multifibre173
Fortisip177
Fortisip Multi Fibre177
Fosamax106
Fosamax Plus106
Framycetin sulphate154
FreeStyle Lite
Frisium113
Frumil54
Fucicort62
Fucidin87
Fucithalmic154
Fungilin35
Furosemide54
Fusidic acid
Dermatological59
Infection
Sensory154
Fuzeon
- G -
Gabapentin113
Gabapentin (Neurontin)113
Gabapentin (Neurontin)
hexachloride
Gastrosoothe27

Gaviscon	25
Gaviscon Double Strength	25
Gaviscon Infant	25
Gemcitabine Ebewe	135
Gemcitabine hydrochloride	135
Gemzar	135
Generaid Plus	172
Genoptic	154
Genotropin	80
Genox	144
Gentamicin sulphate	
Infection Sensory	87
Sensory	154
Gestrinone	82
Glatiramer acetate	
Gliben	30
Glibenclamide	30
Gliclazide	
Glipizide	
Glivec	
Glucagen Hypokit	
Glucagon hydrochloride	28
Glucerna Select	171
Glucerna Select RTH	171
Glucobay	29
Glucose oxidase	20
Gluten Free Foods	
Glycerol	
Alimentary	34
Extemporaneous	
Glycerol with paraffin and cetyl	
alcohol	
Glyceryl trinitrate	
Gold Knight	69
Goldshield	79
Gopten	
Goserelin acetate	81
Goserelin acetate Growth hormone biosynthetic	
human	
Gutron	51
Gynaecological	
Anti-infectives	73
Gynol II	69
· - H -	
Habitrol	55
Haldol	
Haldol Concentrate	
Haloperidol	
Haloperidol decanoate	
Haloperidol decanoate	
healthE	
healthE Fatty Cream	00
	n.s
Healtheries Iron with Vitamin	63

С
Healtheries Multi-vitamin
tablets37
Healtheries Simple Baking
Mix
Hemastix159
Heparin sodium42
Heparinised saline
Hepsera89
Herceptin145
Hexamine hippurate
Hiprex
Histafen147
Holoxan
Homatropine hydrobromide
Horleys Bread Mix179
Horleys Flour
Hormone Replacement Therapy -
Systemic76
Humalog29
Humalog Mix 2529
Humalog Mix 5029
Humira101
HumiraPen101
Humulin 30/7028
Humulin NPH28
Humulin R28
Hyalase107
Hyaluronidase107
Hybloc
Hydralazine
Hydrea138
Hydrocortisone
Dermatological61
Hormone
Hydrocortisone acetate
Hydrocortisone butyrate
Hydrocortisone butyrate with
chlorquinaldol
Hydrocortisone with
miconazole
Hydrocortisone with natamycin
and neomycin62
Hydrocortisone with wool fat and
mineral oil62
Hydroderm Lotion64
Hydrogen peroxide
Alimentary
Dermatological 59.68
Dermatological
Hydroxychloroquine sulphate88
Hydroxyurea138
Hygroton54

Hyoscine (scopolamine)118Hyoscine hydrobromide118Hyoscine N-butylbromide27Hypam127Hyperuricaemia and Antigout107Hypnovel127Hypromellose157
Hytrin48
Hytrin Starter Pack48
Hyzaar50
-1-
lbiamox85
Ibuprofen99
Idarubicin hydrochloride138
Ifosfamide133
lloprost57
Imatinib mesylate141
Imiglucerase
Imigran117
Imipramine hydrochloride111
Imiquimod67
Immune Modulators94
Immunosuppressants144
Imuran
Indapamide
Indinavir
Indomethacin
Infant Formulae
Influenza vaccine
agents 151
Inhaled Corticosteroids
Inhaled Long-acting
Beta-adrenoceptor
Agonists 149
Inhibace
Inhibace Plus
Insulin aspart
Insulin glargine
Insulin isophane
Insulin isophane with insulin

Interieron alpha-za with
ribavirin
Interferon alpha-2b95
Interferon beta-1-alpha127
Interferon beta-1-beta127
Intra-uterine device69
Intron-A95
Invirase
Ipecacuanha159
Ipratropium bromide151–152
Ipratropium Steri-Neb151
Irinotecan
Iron polymaltose
Ismo 2055
Isogel
Isoniazid88
Isoprenaline hydrochloride
Isoptin
Isopto Carpine157
Isopto Homatropine157
Isosorbide mononitrate55
Isosource 1.5177
Isosource HN176
Isosource HN RTH176
Isosource Standard176
Isosource Standard RTH176
Isotane 1058
Isotane 2058
Isotretinoin
Isradipine53
Isuprel56
Itraconazole87
- J -
Janola63
Jevity RTH177
,
- K -
Kaletra93
Karicare Food Thickener179
Karicare Goats Milk Infant
Formula 185
Karicare Soy All Ages185
Kemadrin120
Kenacomb154
Kenacort-A76
Kenacort-A4076
Keppra115
Keto-Diabur 500031
Keto-Diastix
Ketoconazole
Dermatological
Infection
Ketone blood beta-ketone

- La la -

. 31
.99
.31
.37
.37
.31
172
.92
.84
.84
.78
.78
.40
.40
.33

	-

-L-	
LA-Morph110	i
Labetalol	
Lacri-Lube158	1
Lactulose	
Lamictal115	,
Lamivudine90, 93	6
Lamotrigine	,
Lanoxin	1
Lanoxin PG50	1
Lansoprazole27	
Lantus	
Lantus SoloStar29	1
Lanvis	
Largactil121	
Lasix	
Latanoprost156	í
Lax-Tabs	
Laxatives	i
Laxsol	
Leflunomide100	
Lemnis Fatty Cream63	6
Lemnis Fatty Cream HC61	
Letrozole	
Leukeran FC133	6
Leunase137	
Leuprorelin81	
Leustatin	,
Levetiracetam115	,
Levlen ED71	
Levobunolol155	,
Levocabastine155	,
Levodopa with benserazide119	l
Levodopa with carbidopa119	l
Levonorgestrel	
Genito-Urinary72	
Hormone	

Levothyroxine79	9
Lifestyles Flared69	9
Lignocaine hydrochloride108	3
Lignocaine with	
chlorhexidine 108	3
Lignocaine with prilocaine108	3
Lipid Modifying Agents44	1
Lipitor45	
Liquigen169	
Lisinopril49	9
Lisuride hydrogen maleate119	
Litak	
Lithicarb121	
Lithium carbonate12	
Livostin	
Locasol	-
Loceryl	
Locoid	
Locoid C62	
Locoid Crelo62	
Locoid Lipocream62	
Locorten-Vioform154	1
Lodoxamide trometamol155	
Loette	
Logem115	
Lomide	
Lomustine133	
Loperamide hydrochloride25	
Lophlex LQ	3
Lopinavir with ritonavir93	
Lopresor	
Lopressor	
Loprofin	
Loprofin Mix181	
Loraclear Hayfever Relief148 Lorapaed148	3
Loratadine148	
Lorazepam125	
Lormetazepam127	
Losartan)
Lovir91	
Loxamine	
Lucrin Depot81	1
Lucrin Depot PDS81	1
Ludiomil	
Lumigan156	-
Lycinate	
Lyderm65	נ
- M -	
m-Enalapril49	
m-Eslon110)

m-Hydrocortisone61
Mabthera144
Macrogol 335034
Madopar 125119
Madopar 250119
Madopar 62.5
Madopar Dispersible
Madopar HBS
Magnesium hydroxide
Magnesium sulphate
Alimentary
Dermatological68
Dermatological
Malathion
Maprotiline hydrochloride111
Marcain Heavy108
Marcain Isobaric108
Marevan42
Marine Blue Lotion SPF 30+67
Marquis Black69
Marquis Conforma69
Marquis Protecta69
Marquis Selecta69
Marquis Sensolite
Marguis Supalite
Marquis Titillata69
MarquisTantiliza69
Marvelon 2170
Marvelon 2870
Mask for spacer device153
Mast cell stabilisers
Maxalt Melt
Maxidex
Maxitrol
MCT oil (Nutricia)169 MDS Quick Card73
Mebendazole
Mebeverine hydrochloride27
Madeal
Medrol
Medroxyprogesterone acetate
Genito-Urinary72
Hormone77, 79
Mefenamic acid99
Megace143
Megestrol acetate143
Melphalan133
Menthol60
Mercaptopurine136
Mercilon 2170
Mercilon 2870
Mesalazine26
Mesna139
Mestinon
Metabolic Disorder Agents35



Metabolic Mineral Mixture
Metamide118
Metamucil
Metformin hydrochloride30
Methadone hydrochloride
Extemporaneous164
Nervous109
Methatabs109
Methoblastin136
Methopt
Methotrexate
Methotrexate Ebewe
Methotrimeprazine
Methyl hydroxybenzoate164
Methylcellulose
Methyldopa54
Methylergometrine
Methylphenidate
hydrochloride
Methylphenidate hydrochloride
extended-release
Methylprednisolone
Methylprednisolone aceponate
aceponate
Methylprednisolone acetate
Methylprednisolone acetate with
lignocaine
Methylprednisolone sodium
succinate
Methylxanthines152
Metoclopramide
hydrochloride 118
Metoclopramide hydrochloride
with paracetamol 117
Metopirone
Metoprolol succinate52
Metoprolol tartrate52
Metronidazole88
Metyrapone82
Mexiletine hydrochloride51
Mexitil
Miacalcic107
Mianserin hydrochloride111
Micanol
Micelle E
Miconazole35
Miconazole nitrate
Dermatological60
Genito-Urinary73
Micreme73
Micreme H62
Microgynon 20 ED71

Microgynon 3071
Microgynon 30 ED71
Microgynon 50 ED71
Microlax
Microlut
Midazolam
Midodrine
Minaphlex
Minerals
Minidiab
Minirin81
Mino-tabs86
Minocycline hydrochloride86
Minomycin
Minor Skin Infections64
Mirena78
Misoprostol27
Mitomycin C139
Mitomycin-C
Mitozantrone
Mitozantrone Ebewe
Mixtard 30
Moclobemide
Modecate123
Moducal167
Mogine115
Mometasone furoate62
Monofeme71
Monogen171
Morphine hydrochloride110
Morphine sulphate110
Morphine tartrate110
Morrex Maltodextrin167
Motilium117
Mouth and Throat35
Movicol
MSUD Maxamaid
MSUD Maxamum
Mucilaginous laxatives
Mucilaginous laxatives with
stimulants
Mucilax
Multiload Cu 37569
Multiload Cu 375 SL69
Multiparin42
Multiple Sclerosis
Treatments
Multivitamins37
Mupirocin59
Mupirocin59 Muscle Relaxants107
Muscle Relaxants107
Muscle Relaxants
Muscle Relaxants107


Mycostatin	60
Mydriacyl	157
Mylan	
Mylanta P	25
Myleran	
Myocrisin	
Myometrial and Vaginal Hormone	
Preparations	73
- N -	
Nadolol	52
Nalcrom	
Naloxone hydrochloride	.159
Naltrexone hydrochloride	.131
Nandrolone decanoate	75
Napamide	55
Naphazoline hydrochloride	.158
Naphcon Forte	.158
Naprosyn SR 1000	.100
Naprosyn SR 750	.100
Naproxen	.100
Naproxen sodium	.100
Nardil	.112
Nasal Preparations	.152
Natulan	
Nausicalm	.117
Navelbine	
Navoban	
Nedocromil	
Nefopam hydrochloride	
Neo-B12	36
Neo-Mercazole	
Neo-Naclex	
Neocate	
Neocate Advance	
Neocate LCP	
Neoral	
NeoRecormon	
Neostigmine	
Neotigason	65
Nepro (vanilla)	
Nerisone	
Neulactil	
Neurontin Nevirapine	
Nicotine	
Nicotinell	
Nicotinic acid	
Nifedipine	
Nifuran	
Nilstat	
Alimentary	35
Genito-Urinary	
Infection	

Nipent139
Nitrados127
Nitrates55
Nitrazepam127
Nitroderm TTS55
Nitrofurantoin98
Nitrolingual Pumpspray55
Nizoral
Dermatological60
Infection
Noctamid127
Nodia25
Noflam 250100
Noflam 500100
Nonoxynol-969
Nordette 2871
Norditropin SimpleXx 10mg80
Norditropin SimpleXx 15mg80
Norditropin SimpleXx 5mg80
Norethisterone
Genito-Urinary72
Hormone
Norethisterone with
mestranol71
Norflex107
Norfloxacin
Noriday 2872
Norimin
Norinyl-1/2871
Normacol
Normacol Plus
Normison127
Norpress111
Nortriptyline hydrochloride111
Norvir
Noten51
NovaSource Renal174
NovoFine
NovoRapid29
NovoRapid Penfill29
Nozinan121
Nuelin
Nuelin-SR152
Nupentin113
Nutraplus63
Nutrient Modules
Nutrini Energy RTH173
Nutrini RTH173
NutriniDrink173
NutriniDrink Multifibre
Nutrison Concentrated174
Nutrison Energy Multi Fibre
Nutrison Multi Fibre

Nutrison Standard RTH1	
Nuvelle	78
Nyefax Retard	53
Nystatin	
Alimentary	35
Dermatological	
Genito-Urinary	
Infection	88
NZB Low Gluten Bread Mix1	79
- 0 -	
Octreotide (somatostatin	
analogue) 1	43
Oestradiol	77
Oestradiol valerate	77
Oestradiol with levonorgestrel	78
Oestradiol with	
norethisterone	78
Oestriol	
Genito-Urinary	73
Hormone	
Oestrogens	
Oestrogens with	
medroxyprogesterone	78
Oil in water emulsion	63
Oily cream	63
Olanzapine121, 1	22
Olbetam	23 11
Olsalazine	
Oneprazole	
Omeprazole, amoxycillin and	20
clarithromycin	70
Ondansetron1	
One-Alpha	10
One-Alpha1	
	39
Optium 5 second test Optium Blood Ketone Test	32
Optium Blood Ketone Test	0 4
Strips Optium Xceed	31
Orabase	35
Oracort	
Oral Supplements1	69
Oral Supplements/Complete Diet	
(Nasogastric/Gastrostomy	
Tube Feed)1	
Oratane	
Orgran1	
Ornidazole	
Orphenadrine citrate1	
Orphenadrine hydrochloride1	
Ortho	69
Ortho All-flex	
Ortho Coil	69
Ortho-tolidine1	59

Oruvail 100	99
Oruvail 200	
Osmolite RTH	
Ospamox Paediatric Drops	85
Other CNS Agents	
Other Endocrine Agents	
Other Oestrogen	
Preparations	
Other Progestogen	
Preparations	78
Other Skin Preparations	
Ovestin	00
Genito-Urinary	73
Hormone	
Ox-Pam	
Oxaliplatin	
Oxazepam	
Oxis Turbuhaler	
Oxybutynin	
Oxycodone hydrochloride	
OxyContin	
OxyNorm	
Oxypentifylline	
Oxytocin	73
- P -	
Pacifen	107
De l'éta De la la la la la la la la la la la la la	

Pacifen	
Pacific Buspirone	124
Paclitaxel	139
Paclitaxel Ebewe	139
Paediatric Seravit	37
Pamidronate disodium	107
Pamisol	107
Panadol	
Pancreatic enzyme	33
Pancrex V	
Pancrex V Forte	33
Panteston	76
Pantocid IV	28
Pantoprazole	28
Panzytrat	33
Papaverine hydrochloride	56
Paracare	
Paracare Double Strength	108
Paracare Junior	
Paracetamol	108
Paracetamol with codeine	110
Paradex	109
Paraffin	64
Paraffin liquid with soft white	;
paraffin	158
Paraffin liquid with wool fat	
liquid	158



Paraldehyde113
Paramax117
Parasiticidal Preparations64
Parnate112
Paroxetine hydrochloride112
Paxam113
Peak flow meter153
Pedialyte - Bubblegum44
Pedialyte - Fruit44
Pedialyte - Plain44
Pediasure173
Pediasure RTH173
Pegasys95
Pegasys RBV Combination
Pack95
Pegatron Combination
Therapy
Pegylated interferon alpha-2a95
Pegylated interferon alpha-2b
with ribavirin97
Penicillamine100
PenMix 3028
PenMix 4028
PenMix 5028
Pentasa26
Pentostatin
(deoxycoformycin)139
Pepti Junior184
Peptisoothe27
Peptisorb175
Pergolide119
Perhexiline maleate53
Periactin147
Pericyazine122
Perindopril49
Permax
Permethrin65
Persantin41
Pethidine hydrochloride111
Pevaryl60
Pexsig53
Pharmacare108
Phenate
Phenelzine sulphate112
Phenergan148
Phenobarbitone115
Phenobarbitone sodium164
Phenoxybenzamine
hydrochloride 48
Phenoxymethylpenicillin
(Penicillin V)
Phentolamine mesylate48
Phenylephrine

hydrochloride15	58
Phenylephrine hydrochloride with	
zinc sulphate 15	58
Phenytoin sodium113, 1	15
Phlexy 1018	33
Phosphate-Sandoz	44
Phytomenadione	
Pilocarpine15	57
Pilopt18	57
Pimafucort	
Pindol	
Pindolol	
Pinetarsol	
Pioglitazone	
Piportil	23
Piram-D10	
Piroxicam10	
Pizaccord	
Pizotifen1	
Plaquenil	
Plavix	
Plendil ER	
Podophyllotoxin	
Polaramine14	48
Polaramine Colour-Free	
Repetab14	48
Polaramine Repetab14	48
Poloxamer	
Poly-Tears15	
Poly-Visc15	58
Polycal16	67
Polycose16	67
Polytar Emollient	36
Polyvinyl alcohol18	50
Ponstan	
Postinor-1	
Potassium bicarbonate	
Potassium chloride	
Povidone iodine	
Prantal	
Pravachol	
Pravastatin	
Prazosin hydrochloride	
Pred Forte15	
Pred Mild15	
Prednisolone acetate15	55
Prednisolone sodium	
phosphate	75
Prednisone	76
Prefrin1	58
Pregnancy tests - HCG urine	
Premarin	77

Premia 2.5 Continuous	70
Premia 5 Continuous	70
Priadel12	21
Primidone1	15
Primolut N	79
Pro-Pam12	25
Probenecid10)7
Procaine penicillin8	36
Procarbazine hydrochloride1	39
Prochlorperazine1	18
Procyclidine hydrochloride12	20
Prodopa	54
Prograf14	46
Progynova	77
Promethazine hydrochloride14	48
Promethazine theoclate1	18
Promod16	39
Pronafenone hydrochloride	51
Propafenone hydrochloride	54
Propranolol	50
Propylene glycol16	20
Protamine sulphate	10
	+2
Protaphane	28
Protaphane Penfill	28
Protifar 9016	59
Provera77, 7	79
PSO186–18	39
Psoriasis and Eczema	
Preparations	65
Pulmicort Turbuhaler14	48
Pulmocare17	70
Pulmozyme15	52
Purinethol1	36
Pyrazinamide	38
Pyridostigmine bromide	99
Pyridoxine hydrochloride	36
Pytazen SR	11
-Q-	
- Q - Q 2001(
)/
Q 30010)7
Questran-Lite	
Quetapel12	22
Quetiapine12	22
Quinapril	19
Quinapril with	
hydrochlorothiazide	49
Quinine sulphate10)7
	53
- B -	
RA-Morph1	10
Ranbaxy Amoxicillin	25
	J
-lanhavy-(Cotaclor	zγ
Ranbaxy-Cefaclor	33

Ranitidine hydrochloride27
Rapamune
Recombinant human growth
hormone
Redipred75
Regitine
Renilon 7.5174
Resonium-A
Resource Diabetic
Resource Plus
Resource Thicken Up179
Respigen
Respiratory Devices153
Retrovir
ReVia131
Reyataz
Rheumacin100
Rheumacin SR100
Ridal122
Ridaura100
Rifabutin88
Rifadin88
Rifampicin88
Rifinah88
Riodine64
Risperdal122
Risperdal Consta123
Risperdal Quicklet124
Risperidone122-124
Ritalin129
Ritalin LA131
Ritalin SR129
Ritonavir93
Rituximab144
Rivotril113
Rizatriptan benzoate117
Rocaltrol solution
Roferon RBV Combination
Pack95
Roferon RBV Combination Pack
Starter Kit95
Roferon-A95
Ropin119
Ropinirole hydrochloride119
Roxithromycin85
Rubifen
Rubifen SR129
Rythmodan50
Rytmonorm51
- S -
- 5 - S26 Soy
S26 S0y
Sabril

Salamol150
Salapin150
Salazopyrin26
Salazopyrin EN
Salbutamol150
Salbutamol with ipratropium
bromide 151
Salicylic acid66
Salmeterol149
Sandomigran117
Sandostatin143
Sandostatin LAR143
Sandoz
Saquinavir93
SC Profi-Fine
Scalp Preparations
Scopoderm TTS118
Sebizole
Sedatives and Hypnotics
Selegiline hydrochloride119
Senna
Senokot
SensoCard32
Serenace121
Seretide150
Seretide Accuhaler150
Serevent149
Serevent Accuhaler149
Seroquel122
Sevredol110
Sex Hormones Non
Contraceptive
Shield 49
Shield Blue
Shield XL
Sildenafil
Silvazine
Silver sulphadiazine
Simethicone25
Simvastatin46
Sindopa119
Sinemet119
Sinemet CR119
Sirolimus146
Siterone76
Slow-Lopressor
Smoking Cessation55
Sodium acid phosphate
Sodium alginate25
Sodium auginate
Sodium bicarbonate
Blood43
Extemporaneous165

Sodium calcium edetate159 Sodium
carboxymethylcellulose
Carboxymethylcellulose
Sodium chloride
Sodium citrate with sodium lauryl
sulphoacetate
Sodium citro-tartrate74
Sodium cromoglycate
Alimentary
Respiratory151-152
Sensory155
Sodium fluoride37
Sodium hypochlorite63
Sodium nitroprusside31
Sodium polystyrene sulphonate
sulphonate 44
Sodium tetradecyl sulphate40
Sodium valproate115
Sofradex154
Soframycin154
Solian
Solox27
Solu-Cortef75
Solu-Medrol75
Sonaflam100
Sotacor
Sotalol
Space Chamber153
Spacer device
Span-K
Spiriva151
Spironolactone
Spirotone
Sporanox
Sprycel
Staphlex
Stavudine [d4T]93
Stelazine
Stemetil
Stesolid
Stocrin
Stomahesive
Strattera
Sucralfate
Sulindac
Sulphacetamide sodium
Sulphasalazine
Sulphur
Sumagran
Sumatriptan
Sunscreens
Sunscreens, proprietary67
Suplena175



Suprefact80
Surgam100
Sustagen Hospital Formula
Sustanon Ampoules76
Symbicort Turbuhaler 100/6150
Symbicort Turbuhaler 200/6150
Symbicort Turbuhaler
400/12
Symmetrel119
Sympathomimetics
Synacthen76
Synacthen Depot76
Synermox85
Synflex100
Synthroid79
Syntocinon73
Syntometrine73
Syrup (pharmaceutical
grade)
- T -
-
Tacrolimus146
Tambocor51
Tambocor CR51
Tamoxifen citrate144
Tamoxifen Sandoz144
Tap water165
Tar with cade oil66
Tar with triethanolamine lauryl
Tar with triethanolamine lauryl sulphate and fluorescein
Tar with triethanolamine lauryl
Tar with triethanolamine lauryl sulphate and fluorescein
Tar with triethanolamine lauryl sulphate and fluorescein
Tar with triethanolamine lauryl sulphate and fluorescein 120 Taxotere 137
Tar with triethanolamine lauryl sulphate and fluorescein 66 Tasmar 120 Taxotere 137 Tegretol 113 Tegretol CR 113 Telfast 148
Tar with triethanolamine lauryl sulphate and fluorescein 66 Tasmar 120 Taxotere 137 Tegretol 113 Tegretol CR 113 Telfast 148
Tar with triethanolamine lauryl sulphate and fluorescein 66 Tasmar 120 Taxotere 137 Tegretol 113 Tegretol CR 113
Tar with triethanolamine lauryl sulphate and fluorescein66Tasmar120Taxotere137Tegretol113Tegretol CR113Telfast148Temazepam127
Tar with triethanolamine lauryl sulphate and fluorescein66Tasmar120Taxotere137Tegretol113Tegretol CR113Telfast148Temazepam127Temgesic109
Tar with triethanolamine lauryl sulphate and fluorescein66Tasmar120Taxotere137Tegretol113Tegretol CR113Telfast148Temazepam127Temgesic109Temozolomide139
Tar with triethanolamine lauryl sulphate and fluorescein66Tasmar120Taxotere137Tegretol113Tegretol CR113Telfast148Temazepam127Temgesic109Temozolomide139Teniposide139
Tar with triethanolamine lauryl sulphate and fluorescein66Tasmar120Taxotere137Tegretol113Tegretol CR113Telfast148Temazepam127Temgesic109Temozolomide139Teniposide139Tenofovir disoproxil fumarate93
Tar with triethanolamine lauryl sulphate and fluorescein66Tasmar120Taxotere137Tegretol113Tegretol CR113Telfast148Temazepam127Temgesic109Temozolomide139Teniposide139Tenosvir disoproxil fumarate93Tenoxicam100
Tar with triethanolamine lauryl sulphate and fluorescein66Tasmar120Taxotere137Tegretol113Tegretol CR113Telfast148Temazepam127Temgesic109Temozolomide139Tenosoide139Tenosvir disoproxil fumarate93Tenoxicam100Terazosin hydrochloride48
Tar with triethanolamine lauryl sulphate and fluorescein66Tasmar120Taxotere137Tegretol113Tegretol CR113Telfast148Temazepam127Temgesic109Temozolomide139Tenjoside139Tenosicam100Terazosin hydrochloride48Terbinafine88
Tar with triethanolamine lauryl sulphate and fluorescein
Tar with triethanolamine lauryl sulphate and fluorescein
Tar with triethanolamine lauryl sulphate and fluorescein
Tar with triethanolamine laurylsulphate and fluoresceinfasmar120Taxotere137Tegretol113Tegretol CR113Telfast148Temazepam127Temgesic109Temodal139Tenozolomide139Tenoside139Tenosicam100Terazosin hydrochloride48Terbutaline sulphate150Testosterone76Testosterone esters76
Tar with triethanolamine laurylsulphate and fluoresceinfasmar120Taxotere137Tegretol113Tegretol CR113Teffast148Temazepam127Temgesic109Temodal139Tenozolomide139Tenoside139Tenosicam100Terazosin hydrochloride88Terbutaline sulphate150Testosterone76Testosterone esters76Testosterone undecanoate76
Tar with triethanolamine lauryl sulphate and fluorescein
Tar with triethanolamine lauryl sulphate and fluorescein 66 Tasmar 120 Taxotere 137 Tegretol 113 Tegretol CR 113 Temazepam 127 Temgesic 109 Temozolomide 139 Temozolomide 139 Tenosciam 100 Terazosin hydrochloride 48 Terbutaline sulphate 150 Testosterone 76 Testosterone cypionate 76 Testosterone undecanoate 76 Tetrabenazine 132 Tetrabenophenol 159
Tar with triethanolamine lauryl sulphate and fluorescein
Tar with triethanolamine lauryl sulphate and fluorescein 66 Tasmar 120 Taxotere 137 Tegretol 113 Tegretol CR 113 Temazepam 127 Temgesic 109 Temozolomide 139 Temozolomide 139 Tenosciam 100 Terazosin hydrochloride 48 Terbutaline sulphate 150 Testosterone 76 Testosterone cypionate 76 Testosterone undecanoate 76 Tetrabenazine 132 Tetrabenophenol 159

Thalidomide Pharmion139	
Theophylline152	-
Thiamine hydrochloride	
Thioguanine136	5
Thioprine144	
Thiotepa134	ŀ
Thymol glycerin	6
Thyroid and Antithyroid	
Agents)
Tiaprofenic acid100)
Tiberal88	3
Tilade151	
Tilcotil100)
Timolol maleate	
Cardiovascular52)
Sensory155	5
Timoptol XE155	
Tiotropium bromide151	
Titralac25	
TMP87	
Tobramycin	
Infection	7
Sensory154	
Tobrex154	
Tofranil111	
Tolcapone120	
Tolvon111	
Topamax116	
Topiramate116	
Total parenteral nutrition	,
(TPN)	ł
TPN	Ś
Tracleer	
Trandate	
Trandolapril49	2
Tranexamic acid40	ý
Tranylcypromine sulphate	,)
Trastuzumab145	
Travatan	
Travoprost156	
Trental 40056	
Tretinoin140	
Triamcinolone acetonide	'
Alimentary	
Dermatological62	,)
Hormone	
Triamcinolone acetonide with)
gramicidin, neomycin and nystatin	
Dermatological62)
Sensory154	-
	ŀ
Triamterene with hydrochlorothiazide54	
nyurochiorothiazide	ŀ

Triazolam127
Trichozole
Trifeme71
Trifluoperazine
hydrochloride 122
Trimeprazine tartrate148
Trimethoprim87
Trimipramine maleate112
Tripress112
Triquilar ED71
Trisequens78
Trisul
Trophic Hormones79
Tropicamide157
Tropisetron118
Trusopt156
Two Cal HN178
Tyloxapol158
- U -
Ultraproct26
Ural74
Urea63
Urinary Agents73
Urinary Tract Infections98
Uromitexan139
Ursodeoxycholic acid
,
- V -
- V - Vaccines

		INDEX
Generic Chemicals	and	Brands

Vincristine sulphate Vinorelbine Vinorelbine Ebewe Viramune Viramune Suspension Viread Vistil	140 140 92 92 93
Vistil Forte	
Vitadol C	
Vital HN	174
Vitamin A with vitamins D and C	36
Vitamin B complex	36
Vitamins3	6–37
Vivonex Pediatric	184
Vivonex TEN	175
Voltaren	99
Voltaren D	99
Voltaren Ophtha	155
Volumatic	
Vosol	154
Vumon	139
Vytorin	47
- W -	
Warfarin sodium Wart Preparations	

Wasp venom allergy
treatment147
Water
Blood43
Extemporaneous165
Wholesale Supply Order189
Wool fat with mineral oil64
- X -
Xalatan156
Xeloda134
Xenazine 25132
XMET Maxamum181
XP Analog LCP183
XP Maxamaid183
XP Maxamum183
Xylocaine108
- Z -
Zadine147

Zadine	147
Zantac	27
Zarontin	113
Zavedos	138
Zeffix	90
Zeldox	122
Zerit	93
Zetop	147
Ziagen	92
•	

Zidovudine [AZT] Zidovudine [AZT] with	.93
lamivudine	03
Zinacef	
Zinder	
Zinc and castor oil	
Zinc oxide	
Zinc sulphate	
Zincaps	
Zincfrin	
Zinnat	.83
Ziprasidone	
Zofran	118
Zofran Zydis	118
Zoladex	
Zopiclone	
Zostrix HP	
Zovirax	
Zuclopenthixol decanoate	
Zuclopenthixol	120
hydrochloride	100
Zyban	
Zyprexa	
Zyprexa Zydis	123

Dear Pharmacist

Where I refer in a prescription to a medicine by its trade mark or trade name (brand), or by the name of its manufacturer, I give authority to substitute an alternative brand of the same medicine in the following situations:

Sole Supply Products

Where PHARMAC has entered into sole supply arrangement for the medicine you may substitute the sole supply brand, except if the patient chooses to pay for the non-sole supply brand.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

Other subsidised products

Where PHARMAC has listed one or more brands of the medicine on the Pharmaceutical Schedule (and the brand that I have prescribed is not listed or has a Manufacturer's Price that is greater than the Subsidy) you may substitute with a listed brand, except if the patient specifically requests the brand prescribed.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

Exceptions

I do not want substitution to occur for the following chemical entities, unless I am contacted verbally in each specific case.

This authority to substitute replaces all previous authorities relating to these particular pharmaceuticals which I may have provided previously.

This authority to substitute is valid unless I have indicated on the prescription an instruction not to substitute.

This authority is valid whether or not there is a financial implication for the Funder.

Please inform my patient that I have authorised substitution.

Name:	NZMC:
Signature:	Date:
	to change a prescribed medicine in this way is

Dear Pharmacist

Where I refer in a prescription to a medicine by its trade mark or trade name (brand), or by the name of its manufacturer, I give authority to substitute an alternative brand of the same medicine in the following situations:

Sole Supply Products

Where PHARMAC has entered into sole supply arrangement for the medicine you may substitute the sole supply brand, except if the patient chooses to pay for the non-sole supply brand.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

Other subsidised products

Where PHARMAC has listed one or more brands of the medicine on the Pharmaceutical Schedule (and the brand that I have prescribed is not listed or has a Manufacturer's Price that is greater than the Subsidy) you may substitute with a listed brand, except if the patient specifically requests the brand prescribed.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

Exceptions

I do not want substitution to occur for the following chemical entities, unless I am contacted verbally in each specific case.

This authority to substitute replaces all previous authorities relating to these particular pharmaceuticals which I may have provided previously.

This authority to substitute is valid unless I have indicated on the prescription an instruction not to substitute.

This authority is valid whether or not there is a financial implication for the Funder.

Please inform my patient that I have authorised substitution.

Name:	NZMC:
Signature:	Date:
	to change a prescribed medicine in this way is

Dear Pharmacist

Where I refer in a prescription to a medicine by its trade mark or trade name (brand), or by the name of its manufacturer, I give authority to substitute an alternative brand of the same medicine in the following situations:

Sole Supply Products

Where PHARMAC has entered into sole supply arrangement for the medicine you may substitute the sole supply brand, except if the patient chooses to pay for the non-sole supply brand.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

Other subsidised products

Where PHARMAC has listed one or more brands of the medicine on the Pharmaceutical Schedule (and the brand that I have prescribed is not listed or has a Manufacturer's Price that is greater than the Subsidy) you may substitute with a listed brand, except if the patient specifically requests the brand prescribed.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

Exceptions

I do not want substitution to occur for the following chemical entities, unless I am contacted verbally in each specific case.

This authority to substitute replaces all previous authorities relating to these particular pharmaceuticals which I may have provided previously.

This authority to substitute is valid unless I have indicated on the prescription an instruction not to substitute.

This authority is valid whether or not there is a financial implication for the Funder.

Please inform my patient that I have authorised substitution.

Name:	NZMC:
Signature:	Date:
	to change a prescribed medicine in this way is

Dear Pharmacist

Where I refer in a prescription to a medicine by its trade mark or trade name (brand), or by the name of its manufacturer, I give authority to substitute an alternative brand of the same medicine in the following situations:

Sole Supply Products

Where PHARMAC has entered into sole supply arrangement for the medicine you may substitute the sole supply brand, except if the patient chooses to pay for the non-sole supply brand.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

Other subsidised products

Where PHARMAC has listed one or more brands of the medicine on the Pharmaceutical Schedule (and the brand that I have prescribed is not listed or has a Manufacturer's Price that is greater than the Subsidy) you may substitute with a listed brand, except if the patient specifically requests the brand prescribed.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

Exceptions

I do not want substitution to occur for the following chemical entities, unless I am contacted verbally in each specific case.

This authority to substitute replaces all previous authorities relating to these particular pharmaceuticals which I may have provided previously.

This authority to substitute is valid unless I have indicated on the prescription an instruction not to substitute.

This authority is valid whether or not there is a financial implication for the Funder.

Please inform my patient that I have authorised substitution.

Name:	NZMC:
Signature:	Date:
	to change a prescribed medicine in this way is

Dear Pharmacist

Where I refer in a prescription to a medicine by its trade mark or trade name (brand), or by the name of its manufacturer, I give authority to substitute an alternative brand of the same medicine in the following situations:

Sole Supply Products

Where PHARMAC has entered into sole supply arrangement for the medicine you may substitute the sole supply brand, except if the patient chooses to pay for the non-sole supply brand.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

Other subsidised products

Where PHARMAC has listed one or more brands of the medicine on the Pharmaceutical Schedule (and the brand that I have prescribed is not listed or has a Manufacturer's Price that is greater than the Subsidy) you may substitute with a listed brand, except if the patient specifically requests the brand prescribed.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

Exceptions

I do not want substitution to occur for the following chemical entities, unless I am contacted verbally in each specific case.

This authority to substitute replaces all previous authorities relating to these particular pharmaceuticals which I may have provided previously.

This authority to substitute is valid unless I have indicated on the prescription an instruction not to substitute.

This authority is valid whether or not there is a financial implication for the Funder.

Please inform my patient that I have authorised substitution.

Name:	NZMC:
Signature:	Date:
	to change a prescribed medicine in this way is

Dear Pharmacist

Where I refer in a prescription to a medicine by its trade mark or trade name (brand), or by the name of its manufacturer, I give authority to substitute an alternative brand of the same medicine in the following situations:

Sole Supply Products

Where PHARMAC has entered into sole supply arrangement for the medicine you may substitute the sole supply brand, except if the patient chooses to pay for the non-sole supply brand.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

Other subsidised products

Where PHARMAC has listed one or more brands of the medicine on the Pharmaceutical Schedule (and the brand that I have prescribed is not listed or has a Manufacturer's Price that is greater than the Subsidy) you may substitute with a listed brand, except if the patient specifically requests the brand prescribed.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

Exceptions

I do not want substitution to occur for the following chemical entities, unless I am contacted verbally in each specific case.

This authority to substitute replaces all previous authorities relating to these particular pharmaceuticals which I may have provided previously.

This authority to substitute is valid unless I have indicated on the prescription an instruction not to substitute.

This authority is valid whether or not there is a financial implication for the Funder.

Please inform my patient that I have authorised substitution.

Name:	NZMC:
Signature:	Date:
	to change a prescribed medicine in this way is

Dear Pharmacist

Where I refer in a prescription to a medicine by its trade mark or trade name (brand), or by the name of its manufacturer, I give authority to substitute an alternative brand of the same medicine in the following situations:

Sole Supply Products

Where PHARMAC has entered into sole supply arrangement for the medicine you may substitute the sole supply brand, except if the patient chooses to pay for the non-sole supply brand.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

Other subsidised products

Where PHARMAC has listed one or more brands of the medicine on the Pharmaceutical Schedule (and the brand that I have prescribed is not listed or has a Manufacturer's Price that is greater than the Subsidy) you may substitute with a listed brand, except if the patient specifically requests the brand prescribed.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

Exceptions

I do not want substitution to occur for the following chemical entities, unless I am contacted verbally in each specific case.

This authority to substitute replaces all previous authorities relating to these particular pharmaceuticals which I may have provided previously.

This authority to substitute is valid unless I have indicated on the prescription an instruction not to substitute.

This authority is valid whether or not there is a financial implication for the Funder.

Please inform my patient that I have authorised substitution.

Name:	NZMC:
Signature:	Date:
	to change a prescribed medicine in this way is